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Abstract 
The practical work described in this thesis is concerned with the design, synthesis and 
biological evaluation of a series of substituted pyrimidines. The overall objective of 
the work was to discover compounds that were potentially useful in the treatment of 
malignant diseases. In this regard cyclin-dependent kinase 9 (CDK9) or aurora kinase 
A (AK-A) were selected as relevant targets and the reason for their selection is 
presented in the introductory chapters. At the outset a relatively non-specific 'lead 
pharmacophore' for both kinases, a 2-am ino-4-(thiazol-5-yl)pyri midine, was 
identified and systematic structure-driven modification of its structure was undertaken 
to enhance either CDK9 or AK-A selectivity over CDK2 and other selected kinases. 
The rationale and outcome of this modification process is presented separately in the 
results and discussion sections, reporting advances towards the discovery of a 
selective CDK9 inhibitor and a selective AK-A inhibitor. 
In order to facilitate this work the design and synthesis of a library of 183 novel 2-
amino-4-(thiazol-5-yl)pyrimidines (III) was carried out and all compounds were 
appropriately characterised. As a result of the gradually increasing number of active 
molecules against either CDK9 or AK-A, an evolving structure activity and binding 
orientation of this series of analogues was established. This knowledge was used to 
direct further synthesis in order to enhance the selectivity of the pyrimidines towards 
the respective kinases. 
A number of potent and selective inhibitors of both CDK9 and AK-A were identified 
representing an achievement of the overall goals of the project. The discovery 
chemistry lead to the provision of a significant focussed library of substituted 
pyrimidines that has and will prove valuable in the search for selective and multiple 




1.0 General Introduction 
Cancer is defined as uncontrolled cell division and can develop from a single cell that 
has undergone one or more mutations in its DNA. If mutations occur in genes that are 
capable of transforming cells, and these escape the natural DNA repair mechanisms 
that exist within the cell, uncontrolled cell division can result. Such genes can be 
divided into two categories. 
The first group are known as oncogenes and are mutated forms of normal cellular 
genes involved in cell proliferation. In their regulated state in non-transformed cells 
these genes are classified as proto-oncogenes. The activity of a proto-oncogene can 
become deregulated in several ways. One method involves increasing the amount of 
the transforming gene product, either by over-expression or amplification of the gene, 
or by increasing the stability of the gene product. Alternatively, mutation can lead to 
expression of a more active gene product, either by circumventing the need for 
activation, or by blocking points of inactivation or degradation. These events are 
frequently the result of acquired mutations, and the mutated gene is normally 
dominant. Therefore only one of the two existing cellular copies of the proto-
oncogene need be mutated for the abnormal cellular characteristics associated with 
transformation to be manifested. 
The second group encompasses the tumour suppressor genes. Mutations of these 
genes results in a loss of their ability to protect the cell from entering uncontrolled cell 
division'. They are normally recessive, i.e. both the existing cellular copies of the 
gene must be mutated to eliminate their regulatory control  (Figure 1). 
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Many proto-oncogenes and tumour suppressor genes are involved in the regulation of 
the cell cycle. In their regulated State they are responsible for maintaining the integrity 
of DNA replication and cell division, via various pathways and cellular checkpoints, 
and are therefore critical for cancer prevention. The mechanisms by which 
transforming mutations escape repair are often associated with their ability to override 
the regulatory pathways and checkpoints in the cell, which they are involved in 
controlling. The selective inhibition of these transformed genes (or their products), 
and hence the prevention of their disruption of cell cycle control, therefore represents 
a possible means of preventing the uncontrolled cell division that is characteristic of 
tumour cells. For this reason cell cycle proto-oncogenes and tumour suppressor genes 
have been identified as an important class of oncology drug-development targets 3 . 
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Chapter 2 
Cyclin-Dependent Kinases (CDKs 
2.0 Cycl in -Dependent Kinases (CDKs) 
2.01 Introduction to CDKs 
In the last decade research into the control of cell cycle progression has hugely 
intensified and a reasonable understanding of the complex pathways governing this 
cycle now exists. Many groups working in oncology have focussed on a series of 
serine/threonine protein kinases, known as cyclin-dependent kinases (CDKs), and the 
study of their roles in the overall control of cell division and DNA replication. The 
interaction of CDKs with both oncogenes and tumour suppressor genes and the 
discovery that they are commonly downregulated in tumour cells 45 has identified 
CDKs as possible chemotherapeutic targets in cancer research. 
2.02 CDKs and the Cell Cycle 
CDKs are mostly involved in the control of cell cycle progression. This term is used 
to describe the events involved in the replication and division of the genetic and 
cellular material contained within each cell 6. The cycle is divided into four key stages, 
each of which is controlled by numerous regulatory pathways involving the CDKs 
(Figure 2). One complete cycle involves the replication of the chromosomes during 
which DNA is synthesised (S-phase or synthesis), and the segregation of the 
chromosomes and cellular material to create two new identical daughter cells (M-
phase or mitosis). Between each of these stages are resting intervals (G, and G2) 8 ; G 1 , 
S, and G2 are collectively known as interphase and account for approximately 23 
hours of a traditional 24-hour cycle leaving one hour during which mitosis takes 
place'. 
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Figure 2: The biological functions of CDKs. (a) The CDKs responsible for progression through the 
various phases of the cell cycle are shown. CDK7 (also known as CDK-activating kinase, CAK) is 
involved in activation through phosphorylation of both CDKs I and 2. (b) Several CDKs are involved 
in promoting efficient RNA elongation by phosphorylating the C-terminal domain (CTD) of RNA 
polymerase II (RNA Pol LI). 
CDKs are inactive monomers that become activated in two steps. The first involves 
the non-covalent binding of an appropriate cyclin subunit to form a partially activated 
complex. The levels of individual cyclins fluctuate during the cell cycle whereas the 
CDK levels do not. The transient nature of the cyclins is therefore critical to cell cycle 
control as they ensure that each CDK is only activated during the appropriate stage of 
the cell cycle. The second stage of CDK activation is the phosphorylation of the 
CDKJcyclin complex at a specific threonine residue by various CDK-activating 
kinases (CAKs) 4 . Activated CDKIcyclin complexes are then responsible for the 
subsequent phosphorylation of numerous tumour suppressor genes, transcription 
factors and other proteins that are necessary for controlled cell cycle progression 6 . 
Additional control of CDK activation is achieved through the action of CDK 
inhibitors (CKIs) that exert their effects through negative control pathways and 
include the INK (pI6t4A  and pJ8INK4C)  and Cip/Kip (p27' and p21C1P)  protein 
families9 ' ° . The functions of known CDK-cyclin complexes are summarised in Figure 
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Figure 3: Functions of Known CDK-cyclin Complexes" 
CDK 	Cyclin partner or other 	Functions in: 
activator 
Cell cycle (G2, G2/M, M), NS 
Cell cycle (GI, GI/S, M), apoptosis, 
RNA transcription 
Cell cycle (GO/GI, 01, G/S) 
Cell Cycle (G I), NS, cell differentiation 
Apoptosis, NS, various tissue-specific 
functions 
Cell cycle (01), NS, cell differentiation 
Cell cycle (CAK), RNA transcription 
RNA transcription 
RNA transcription, differentiation, 
apoptosis 
Cell cycle (G2IM) 
Cell cycle (M), RNA transcription, 
apoptosis, NS 
CDKI Cyclins A and B 
CDK2 Cyclins E, A and B 
CDK3 Cyclins C and E 
CDK4 Cyclin D 
CDK5 p35 (p25)  and p39 (p 29) 
CDK6 Cyclin D 
CDK7 Cyclin H 
CDK8 Cyclin C 
CDK9 Cyclins T and K 
CDKIO Unknown 
CDKI I Cyclin L 
Gap phases prior to cell cycle entry (G 0: quiescent state); preceding G and following 02 the DNA-
synthesis phase (S); mitosis (M). CAK: Cyclin-dependant kinase-activating kinase: CDK Cyclin-
dependent kinase; G: Gap: M: Mitosis; NS: Nervous system: RNA: Ribonucleic acid: S: Synthesis. 
Most cells in multicellular organisms are found in the resting stage Go,  during which 
the CDKs are in a deactivated state. Extracellular signalling pathways respond to 
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stimuli such as mitogens (numerous growth factors and other proteins), by stimulating 
the cell to enter the cycle and begin the process of cell division. Passage of cells from 
G0 through the early G, phase of the cycle is under the control of the D-type cyclins 
(Dl, D2, and D3), which are responsible for the activation of CDK6 and CDK4 1213 . 
Cyclin Dl is an oncogene that is overexpressed in greater than 50% of all breast 
cancers ' 4 ; its primary function is in the control of cellular progression from G0 to G1. 
Mitogenic stimuli promote increased expression of cyclin D, which then binds to and 
activates CDK6 and CDK4. Once assembled the CDK4/cyclin D or CDK6/cyclin D 
complexes are activated by CAKs via phosphorylation 15  enabling them to 
phosphorylate the retinoblastoma tumour suppressor protein pRb and two Rb related 
proteins p107 and p136' 6. The Rb (retinoblastoma) protein in its hypophosphorylated 
state is tightly bound to E2F transcription proteins and its phosphorylation results in 
the release of E2F, which in turn promotes the transcription of certain proteins that are 
required for DNA synthesis' 3 . Retinoblastoma protein is regarded as the gene most 
responsible for the regulation of the G ,/S phase restriction checkpoint and ineffective 
pRb phosphorylation will result in cells remaining in the G, phase of the cell cycle 
until the cause has been identified and repaired 16 . 
Progression of cells through the latter part of G, and the restriction checkpoint is 
regulated by the expression of the cyclin E proteins (El and E2) that associate with 
CDK2. Phosphorylation of pRb by CDK4 and CDK6/cyclin D complexes promotes 
the release of E2F resulting in the increased expression of cyclin E. Binding of these 
complexes to the Kip inhibitory proteins prevents their association with CDK2/cyclin 
E complexes, ensuring they are free to undergo subsequent phosphorylation and 
activation 1719 . Phosphorylation of CDK2/cyclin E facilitates the phosphorylation of a 
number of targets including pRb leading to the expression of cyclin A that is needed 
for the next phase of the cell cycle. These complexes are also involved in the 
downregulation of CKIs such as p21 and p27' 5 . Phosphorylated CDK2/cyclin E 
complexes are found late in G, and are known to be essential for the progress of cells 
through the G,/S restriction checkpoint. Cyclin E is then rapidly destroyed by 
ubiquitination once the cells have progressed into S-phase 20 . 
Cyclin A complexes with CDK2 and the subsequent activation of this complex 
facilitates the activating phosphorylation of a number of targets that include various 
transcription factors 21-22  and the expression of cyclin H. The regulation of 
CDK2/cyclin A activity is, as with the other CDKs, additionally regulated by CKTs 
and tumour suppressor proteins. 
CDK7/cyclin H activated complexes promote the expression of B cyclins (B I and 132) 
that in turn form complexes with CDKI during the final stage of the cell cycle. The 
progression of cells through the G2/M checkpoint requires CDK7/cyclin H activation 
but the primary role of CDK7 is in the control of transcription 23 . The final stage of the 
cell cycle is M-phase or mitosis and this stage is commonly subdivided into six 
separate steps. The progression of cells through each step is closely monitored by the 
activity of numerous kinases including CDKI (Figure 4)24• 
Figure 4: Stages of Mitosis 24 
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Stages of Mitosis: 
Interphase: Cell is preparing for mitosis. 
Prophase: The nuclear material begins to condense in the nucleus and the centrioles start to 
move towards opposite ends of the cell. 
Pronietaphase: The nuclear membrane dissolves and the chromosomes begin to move towards 
the centre of the cell. 
Metaphase: Spindle fibres attached to the chromosomes ensure they are aligned correctly in 
the centre of the cell. This ensures that efficient chromosome separation occurs. 
Anaphase: The paired chromosomes separate and are moved towards the poles of the cell via 
the mitotic spindle fibres and the kinetochores. 
Telophase: The chromatids reach the opposite poles of the cell and the partitioning of the cell 
into two new daughter cells begins. The spindle fibres diffuse. 
Cytokinesis: A ring of protein around the cell contracts. This forms two new identical 
daughter cells, each having one nucleus. 
The primary role of the activated CDKI/cyclin B complexes is in the controlled 
expression of various proteins, including condensins and microtubule binding proteins 
that are essential for proper chromosomal condensation and separation respectively 25 . 
Degradation of cyclin B by ubiquitination marks the end of mitosis and concludes a 
complete cell cycle with the formation of two identical daughter cells. The cells then 
either remain at rest in G0 or enter into another cycle. 
2.03 CDKs and Transcription 
CDKs are also involved in the transcription of RNA. CDKs 7, 8 and 9 are not 
considered to be cell cycle CDKs as their primary role is in the control of 
transcription, which is the process by which a template strand of DNA is utilized by 
specific RNA polymerases to generate one of three different classes of RNA. In 
eukaryotes there are three distinct RNA polymerases and each is primarily responsible 
for the synthesis of one or other of mRNAs, tRNAs or rRNAs 26. RNAPII (RNA 
polymerase II) is a 12-subunit DNA dependent RNA polymerase and is involved 
mostly in the synthesis of mRNAs. These are the genetic coding templates used 
during translation to determine the order in which amino acids are incorporated into a 
polypeptide during the elongation phase of translation 26 . The largest subunit of 
RNAPH has a unique domain at its carboxyl terminus known as the CID (carboxy 
terminal domain), which is comprised of 52 repeats of a heptapeptide with the 
sequence Tyr l-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 27 . The CTD is required for mRNA 
processing in vivo and binds to processing factors in vitro 28 . The CTD is rich in 
potential phosphoacceptor amino acid residues and is subject to reversible 
phosphorylation during the transcription cycle. Initiation of transcription requires a 
hypophosphorylated CTD and this step is regulated by the phosphorylation of the 
Ser5 residue in the heptapeptide sequence. The CTD is hyperphosphorylated during 
transcription and the phosphorylation of Ser2 is implicated in this 2930 . To date three 
different CDKs (CDK7, CDK8 and CDK9) have been implicated in the control of 
transcription via their role in CTD phosphorylation. CDK7 and CDK8 have been 
shown to be active in the initiation of transcription, with CDK8 acting as a negative 
regulator 30,  whereas CDK9 is a component of the P-TEFb (positive transcription 
elongation factor b) and is involved in the regulation of transcription elongation 28.31 
(Figure 5)32 
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Figure 5: Assembly of the Activated CTD 32 
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CTD: Carboxy-Terminal Domain 
GTF's: General Transcription Factors 
P-TEFb: Positive Transcription Elongation Factor b 
PlC: Pre-Initiation Complex 
TFIIH: Transcription Factor IIH 
CTD-P: Phosphorylated Carboxy-Terminal Domain 
After assembly of GTFs and RNA Pol LI with its associated mediator complex at the promoter, the 
RNA Pol II CTD is phosphorylated. This results in severing connections to promoter-associated GTFs 
and at the same time in promoting associations with elongation-specific factors and RNA processing 
factors. 
During transcription the unphosphorylated CTD forms a pre-initiation complex (PlC) 
with transcription factors (lID, HB, hF and lIE) and this is responsible for the 
positioning of RNAPII on specific nuclear gene promoters often called initiation 
factors. CDK7 (part of the TFIIH complex) phosphorylates Ser5 in the CTD and this 
is responsible for the activation of the PlC 33 . 
To overcome the negative regulators of transcription (N-TEF; Negative-Transcription 
Elongation Factors) and facilitate progression to elongation, positive transcription 
elongation factors are recruited, which include P-TEFb. This is a multisubunit 
complex and contains numerous cyclin T subunits that are all associated with CDK9. 
CDK9/cyclin Ti activation is responsible for the phosphorylation of Ser2 in the CTD 
resulting in the subsequent binding of elongation factors and mRNA processing 34 . 
Tumour cells require the rapid synthesis of small anti-apoptotic proteins, such as McI- 
I and Bcl-2 35 , to ensure that they are not identified as abnormal by cellular control 
mechanisms and thereby directed into the apoptotic pathway. The expression of these 
anti-apoptotic genes is under the control of RNA polymerase H. Therefore, the 
inhibition of the CDKs responsible for the control of RNA polymerase H, represents a 
potential chemotherapeutic target. The precise roles of CDKs 7, 8 and 9 in the 
regulation of RNA polymerase II are still not fully understood, nor has the specificity 
of CDK7 and CDK9 for each serine residue in the CTh been determined absolutely. 
There is also evidence to suggest that certain other CDKs (1, 2 and I I) play some 
part, as yet undetermined, in transcriptional regulation 36 . For these reasons, this area 
of cancer research is still relatively novel and only a few transcriptional inhibitors 
have been identified to date. 
2.04 Activation of CDKs 
The crystal structure of CDK2 was the first to be published 37  and almost all research 
into the design of small molecule CDK inhibitors is based on structural information 
relating to this kinase. Crystal structures have since been published showing the 
conformational changes to the CDK2 ATP-binding domain that occur when it is 
activated by the binding of its associated cyclin subunit, cyclin A 3839 . The crystal 
structure of CDK2 shows that the protein is divided into two lobes, a C-terminal lobe 
consisting mostly of (x-helices and a smaller N-terminal lobe comprised of mainly 
antiparallel 3-strands 38 . The ATP-binding site lies between the two lobes and contains 
an amino-acid sequence that is common to all CDKs, called the PSTAIRE helix 40, and 
the activation T-loop in which the activating phosphorylation site (Thrl60) is 
situated 11.31  (Figure 6) 40 . 
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Fiure 6: Crvt1 Struturc of CDK2 
A ribbon representation of the Cyclin A-CDK2 complex is shown. CDK2 is shown in cyan, with the 
helix containing the CDK sequence motif (PSTAIRE) in red and the activation loop in yellow. Cyclin 
A is shown in purple. 
Binding of cyclin A to CDK2 results in two major conformational changes that are 
responsible in part for CDK2 activation. First is the rotation of the PSTAIRE helix 
through 900,  which correctly positions the necessary residues in the active site to 
facilitate catalysis 39. The T-loop is also moved away from the active site, which 
creates an unobstructed pathway for the 'y-phosphate of ATP to phosphorylate the 
appropriate residue (Thrl6O) and complete CDK2 activation 3941 . Phosphorylation of 
the CDK2/cyclin A complex is responsible for further conformational changes 
including additional folding of the T-loop and stabilisation of the phosphate group. 
These latter changes ensure the catalytic binding domain is in the optimal 
conformation to readily accept substrates (Figure 7) 3941 . 
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Fiurc : Acli\ tion i CDK2 
A ribbon representation of the Cycliri A-CDK2 complex is shown. CDK2 is shown in cyan. with the 
helix containing the CDK sequence motif (PSTAIRE) in red and the activation loop in yellow. Cyclin 
A is shown in purple. In the first activation step the PSTAIRE region is rotated through 900  and the 1- 
loop is moved away from the active site. In the second stage of activation the CDK2/cyclin A complex 
is phosphorylated resulting in further changes to the T-loop and active site conformation. 
The CDKs have extensive sequence homology 37 (40-75%). The design of selective 
inhibitors is therefore very challenging as small molecules that are designed to inhibit 
a particular CDK are highly likely to inhibit the others to some extent (Figure 8)42. 
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Figure 8: Sequence alignment of CDKs 1, 2, 4, 6, 7 and 942 
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COK1 	45 ?STA:FEIU LKELR---. 1::I:LQ  LM --------- --RLYL:F: 33 
CDK2 45 FSTARE•U LKELN---I N:IL' 	T-----EN-- -FL71FU: 33 
CDK4 	50 	:srvRE.?I LRRLEAFEI N'1RL 1t'c :SRTDREI-- -?vTLIF1:.;6 
CDN6 55 PLSTIREYAV LRHLETFE NVURLFFCT 
'F
-- 	TLIF1: 01 
CDK7 56 MRTALREIYI LQELS ---1 N::GLI4AFG HKSN ------ --- 3 1 
CDK9 60 PITALREJ  LQLLK --- HE NVLLIEICR  TKASPYNRCK oo:Y 	1 106 
CDK1 	84 3DL:: 45 IP-PGQYMDS SLVKS?LYI: LG:: CHSR F;LHRDKg. - 32 
CDK2 	84 HQDLKKFt4 SA-LTG-IPL PLf<S1'LFIL L:_ GW.E- 	P - :HRDg. 131 
CDK4 97 DQDLRTYI4 AP-PPG-LPA ETcLLLr LRGLILHA: :  :::HRDIKL .44 
CDK6 102 DQDLTTYLIK  VP-EPG-VPT E D 	LR •LHLH  r.HRD 	49 
CDK7 	95 ETDLEVIIKD NS-LV--LTP SHY MT LQ 	YLHQN NILHRD 	I 41 
CDK9 107 EHDLAGLLSN VL-VK--FTL SE RI ML LNGIYY  :HPN KILHRDMK:A 3 
CDK1 133 NLLIDDK-GT IKLADFGLAj AFr------: RvYTHE1 1c::E: 	177 
cDK2 132 NLLINTE-GA IKLADFGLIJ AFG----VPV RTYTHEVV wYr EL 76 
CDK4 145 NILVTSG-GT VKLADFGL?I  :YS----YQM AL-TPVVV WY EYLIc 168 
CDK6 150 NILVTSS-GQ IKLADFGL IYS ---- FQM AL - TSVVV1 WYRWE:LL 193 
CDK7 142 NLLLDEN-GV LELADFGLAK SFG ---- SPN RAYTHQWTR WYRIPELLF  186 
CDK9 154 NVL:TRD-M,' LKLADFGLI AFSLAKNSQP  NRYTNRvv1 WYP.,: PE LLd 202 
CDK1 178 sARYsD: W§:GTIlAFL ATKK, NGD 	LLFP.I FJkLG 'NEV 227 
CDK2 177 cKlY:IJo:  N GI EI VTRA 10 LLFFJ RTLGT jvv 226 
CDK4 189 ST- .:.::: NF:i:U;1 . -I: 	jcL1F1: :L:GLIr•D 237 
CDK6 194 SS-.1D1 WIGI:$AEI  13-RGS •VILGKIL DV:GL$CD 242 
CDK7 187 AR1:1::IIo> NAlGI:LAEL I1L FLP GD UL1OLTRII ETLGTIT•Q 236 
cDK9 203 ERDl:I:zL WIOGI:MAEI WTISI:MQCI; TLHQLALIS QLCGS:TPE, 252 
CDK1 228 WP 	 IN-TFKNRF GSLASHVKNL DEN-- LIL ILSKIYDP - 274 
CDK2 227 WPt-SU 	rp-o KNAR QDFSKVVPPL DED-- SLSQ -YDPN 273 
CDK4 238 WPI P,G- PRGP RPVQSVVPEM EES-- QLE FNp:i 282 
cDK6 243 WF3 IR-- RQ-HSKSA QPIEKFVTDI DEL-- IN L ILKCITFNPI  287 
CDK7 237 WP:::::1 1-TFKSFPGIP --LHHIFSAA GDD--LL L IQGLFLFNPCA 282 
CDK9 253 WPNV1:-:I•1:: IKLELVKGQK RKVKDRLKAY VRDPYA L IDKLIVLDPAQ  302 
CDK1 275 RI KMALN PNDLDNQ- IKKM 	 297 
CDK2 274 RI KAAL PFLDVTKP- \TPNLRL 298 
CDK4 283 R:FRALQ  S LEKDEGN- FE 	 303 
CDK6 288 r: ISALSI P DLERC- KENLDSHLPP SQNTSELNTA 	 326 
CDK7 283 0:: :QALKN K SNRPG?- TP--GCQLPR PNCFVETLKE QSNFALAIKR 329 





CDK7 330 KRTEALEQGG LPKKLIF 	 346 
CDK9 352 QSTNQSRNPA TTNQTEFERV F 	 372 
Key 
0 Residues common to all CDKs 
Residues common to five CDKs 
Residues common to four CDKs 
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These sequences are used in the construction of accurate homology models, which 
allow minor structural differences in the binding regions of individual CDKs to be 
identified. These can then be exploited in the design of selective CDK inhibitors. 
2.05 Existing Inhibitors of CDKs 
The most widely known CDK inhibitors are flavopiridol 43 [1] (alvocidib, 
AventislNCl) and R-roscovotine445 [3] (seliciclib, Cyclacel), which are both known 
to inhibit several CDKs. 
Flavopiridol is a semisynthetic flavone, chemically related to a plant native to India, 
which is currently undergoing numerous clinical trials for a variety of cancers 43 . 
Chemically flavopiridol is a rohitukine analogue in which the 2-methyl substituent 
has been replaced by an o-chlorophenyl moiety (Figure 9)45• 
Figure 9: Structure of Flavopiridol [I] and Rohitukine [2] 




HO O 1 HO 	0 
OH 	 OH 
Flavopiridol (11 	 Rohitukine [2] 
Flavopiridol [II causes transformed cells to arrest at both the G 1 /S and G2/M 
checkpoints as a result of its low nM inhibitory activity against CDKs 1, 2, 4 and 746, 
However, more recently it has been determined that flavopiridol also induces 
apoptosis in tumour cells via its ability to inactivate the P-TEFb complex and 
subsequently block the RNA pol ymerase-control led transcription 478 of anti-apoptotic 
proteins such as MC-I 45 . This is achieved in part by low nM inhibition of CDK9 47 . 
R-roscovitine [3], a 2,6,9-trisubstituted purine (Figure 10)44  , has been shown to be a 
potent and selective inhibitor of CDKs 2, 7 and 9 (ICo values of 100, 360 and 810 
nM respective] Y)49 . It induces cell cycle arrest in both the G 1 /S and G2/M phases of 
the cell cycle, which can be attributed to its potent inhibition of CDKs 2 and 750• 
1r1 
Recent studies have additionally shown that it is capable of selectively inducing 
apoptosis in transformed cells, preventing the transcription of anti-apoptotic proteins 51 
via its inhibitory activity against the transcriptional CDKs 7 and 9. This suggests that 
its anticancer properties are achieved by a combined inhibition of both cell cycle 
CDKs and RNA polymerase II activity. 
Figure 10: Structure of R-roscovitine 13 ]51 
9 
HOJN N N 
Roscovitine [31 
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2.06 Objective - The Synthesis of a Selective CDK9 Inhibitor 
It will be noted from the introduction that a CDK9 inhibitor would be useful in cancer 
chemotherapy as many human cancers are caused by the overexpression of cyclins. 
This approach to the control of cancer has been partially validated by the discovery of 
flavopiridol and R-roscovitine. However, the recent observation that many 
transformed cells, which lack cyclin E or CDK2, continue to proliferate 52 , introduces 
the possibility that the selective inhibition of cell cycle CDKs is not the most efficient 
therapeutic strategy in cancer treatment. The ability of tumour cells to divide in the 
absence of these key players in cell cycle control has led researchers to look for 
alternative and more effective pharmacological targets. The understanding that 
flavopiridol and R-roscovitine exert some of their anti-cancer activity via their effects 
on transcription, and the role of CDK9 in this process has led to the hypothesis that a 
specific CDK9 inhibitor would yield valuable information in the search for a new 
anti-cancer agent. 
The role of CDK9 in the control of RNA polymerase II activity, suggests that a 
specific CDK9 inhibitor would have the ability to selectively inhibit RNA polymerase 
II activity in transformed cells, thus preventing the rapid synthesis of the anti-
apoptotic proteins they require to avoid detection by the normal checkpoints of the 
cell cycle. Compounds capable of selectively inhibiting CDK9, and hence RNA 
polymerase II activity, would potentially be capable of inducing apoptosis in tumour 
cells at any stage of their cell cycle, whereas molecules inhibiting the cell cycle CDKs 
are capable of inducing cell death in transformed cells only during the individual 
stages of the cell cycle that these CDKs control. 
Molecular modelling has facilitated the development of more or less specific cell 
cycle CDK inhibitors. Therefore, I propose that a detailed comparative analysis of the 
binding domains of the cell cycle CDKs with that of CDK9 should enable existing 
sites of similarity and divergence to be identified, which could potentially be 
exploited in the design of selective CDK9 inhibitors. Although it is appreciated that 
the extensive sequence homology of the CDKs illustrates the potential difficulties 
associated with the design of a selective CDK9 inhibitor, some differences are 
apparent and we propose that these can be investigated as possible sites at which to 
introduce CDK9 selectivity to an existing CDK active pyrimidine scaffold. 
IN 
2.07 Lead Identification 
Initial work on the design and synthesis of small molecule CDK9 inhibitors was based 
on the crystal structure of CDK2 bound to a known CDK2 inhibitor, Staurosporine [4] 
(Figure 11). 




The specific hydrogen bond pattern of ATP in the hinge region of CDK2 is conserved in the 
Staurosporine complex facilitating the use of this template in the virtual screening of a library to 
identify potential CDK2 inhibitors. 
Staurosporine [4] is a microbial alkaloid that was first characterised in 1986 and has 
since been shown to be a potent CDK2/cyclinA inhibitor 4 . Virtual screening 
(LIDAEUSTM, Edinburgh University) 55 was used in the automated docking of small 
ligands into the active site of CDK2. The program generated different binding 
orientations of small molecules into a homology model of the CDK2 catalytic binding 
domain, based on the crystal structure of the CDK2/Staurosporine complex. Each 
ligand was evaluated using a scoring system designed to account for predicted 
interactions with the catalytic domain including hydrogen bonding, hydrophobic and 
Van der Waals interactions. This program enabled the virtual screening of a large 
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commercially available library of drug-like molecules and a series of potential hits 
was identified and screened in vitro using CDK2/cyclin E and CDK4/cyclin Dl 
protein kinase assays 55. This process generated a number of hits, which included a 
series of 2-amino-4-heteroaryl-pyrimidines. A rational approach was then used in the 
development of a lead pharmacophore (Figure 12) 56 . 
Figure 12: Structure of Lead Pharmacophore 56 
CYC1 	CYC2 	CYC3 
CI 	 R1 






N NH2 	N NH2 	N NOH  N N 	R3 
H 	 H 
In silico screening hits 	 Lead Pharmacophore 
CYCI was identified using the LIDAEUS screen as a potential CDK2 inhibitor (IC ."() > 15 j.M). 
Structural modifications were undertaken: introduction of a thiazole ring to the 4-position of the 
pyrimidine (CYC2) and alkylation of the amine on the pyrimidine 2-position (CYC3) were identified 
as favourable. Finally, introduction of an aniline moiety to the pyrimidine 2-position presented the lead 
pharmacophore. 
A number of potent and selective CDK2 inhibitors have been synthesised to date. The 
binding orientation of these compounds within the CDK2 catalytic domain was 
initially predicted using computational docking and then later confirmed by 
crystallography (Figure 13). 
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Favourable interactions with the CDK2 binding domain identified on the left. Hydrogen bond 
interactions between the anilino-NH and the N of pyrimidine and Leu83 are shown as dotted lines on 
the right. 
The catalytic domains of CDK2 and CDK9 share a number of common residues 42 
suggesting that they are similar in size and shape. It was proposed that the lead 
pharmacophore would therefore bind in a similar orientation to the catalytic domain 
of CDK9 and hence form similar interactions. However, a number of significant 
structural differences exist between the catalytic domains of CDK2 and CDK9 and it 
was proposed that the lead pharmacophore could be modified accordingly to enhance 
CDK9 potency and selectivity, simultaneously reducing CDK2 activity. Therefore it 
should be possible to synthesise a potent and selective CDK9 inhibitor derived from 
this pharmacophore by introducing alternative substituents on both the thiazole and 
aniline rings. 
2.08 Rational Approach to the Design of a Selective CDK9 Inhibitor 
In sequence terms the catalytic domains of CDK2 and CDK9 share a number of 
common residues (Figure 14)42.  This homology in itself suggests that three-
dimensionally they will be similar in size and shape. It was proposed that a 
comparative analysis of the crystal structure of CDK2 and the homology model of 
CDK9 would yield valuable information concerning the design of CDK9 selective 
inhibitors. 
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Figure 14: The Amino Acid Sequence Alignment of CDK2 and CDK9 42 
MAX QYDSVECPFC 13 
CDK2 	1 	MENFQKVE KIGEGTYGVV YKARN-KLTG EVVALKKIRL DTETEG --- V 44 
CDK9 14 ::YEKLA KIGQGTFV FKA-RKTG QKVALIVLM ENE---KEGF 59 
cDK2 4 	sTAIRE:.: LKELN --- t NIVKLLDVIN T-----EN-- -KLYLVFEFL 83 
cDK9 60 ?:TALRE:: LQLLX --- }IE NVVNLEICR TKASPYNRCK GSIYLVFDFC :06 
CDK2 84 	DLi:FDA SA-LTG-IPL PLIKSYLFQL LQGLAFCRSH RVLHRDLKPQ :31 
CDK9 107 EHDLAGLLSN VL-VK—FTL SEIKRVMQML LNGLYYIHRN KILHRDMKAA 153 
CDK2 132 NLMNTE-GA IKLADFGLAR AFG ---- VPV RTYTNEVVTL WYRAPEILLG 176 
CDK9 154 NVLITRD-GV LKLADFGLAR AFSLAKNSQP NRYTNRVVTL WYRPPELLLG 202 
CDK2 177 CKYYSTAVDI WSLGCIFAEM VTRRALFPGD SEIDQLFRIF RTLGTFDEVV 226 
CDK9 203 ERDYGPPIDL WGAGCINAEM WTRSPIMQGN TEQiQLAUS QLCGSITPEV 252 
CDK2 227 WPGVTSMPDY KP-SFPKWAP. QDFSXVVPPL DED—GRSL LSQMLHYDPNK 273 
CDK9 253 WPNVDNYELY EKLELVKGQK RKVKDRLKAY VRDPYALDL IDKLLVLDPAQ 302 
CDK2 274 RISAKAALAH PEFQDVTKP- VPHLRL 	 298 
CDK9 303 RIDSDDALNH DFFWSDPMP- SDLKGMLSTH LTSMFEYLAP PRRKGSQITQ 351 
CDK2 
CDK9 352 QSTNQSRNPA TTNQTEFERV F 	 372 
Key 
El Residues common to both CDKs 
DI PSTAIRE (CDK2) / PLTALRE (CDK9) region 
The CDK9 sequence (Swiss-Prot P50750) 42 was aligned with that of CDK2 (Swiss-
Prot P24941) 42 and a homology model of CDK9 was built, modelled on a CDK2 
crystal structure (PBD code I FVV) 57 . To facilitate comparative analysis the CDK9 
homology model was overlaid on the CDK2 crystal structure (Figure 15). This 
enabled the identification of structural differences that could potentially be exploited 
in the design of CDK9 selective inhibitors. It was proposed that the lead pyrimidine 
pharmacophore could be docked into each of the 3D-models to facilitate the design of 
novel molecules having preferable interactions with CDK9 while simultaneously 
reducing favourable contacts with CDK2. 
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The CDK2 and CDK9 homology models are overlaid to illustrate their conformational similarities. 
Significant residues have been identified to show corresponding residues that account for this and 
highlight differences that could potentially be exploited in the design of CDK9 selective compounds. 
The catalytic domains of CDK2 and CDK9, whilst similar in both size and 
conformation, nonetheless exhibit some differences. The hinge region of CDK2 is 
comprised of residues 80-85 whereas that of CDK9 is made up of residues 103-108. 
Despite having different sequences, the backbone of the hinge region in the two 
proteins has a broadly similar conformation. However, the way the terminal residues 
in the hinge region (G1n85 in CDK2 and His 108 in CDK9) interact with the rest of the 
protein results in slightly different positioning of the adjacent aspartic acid residues 
(Asp86 in CDK2 and Asp109 in CDK9) and other conformational differences 
between the ATP-binding sites of the two kinases. The aniline ring component of the 
lead pharmacophore interacts with the ATP-binding domain in this region and it was 
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postulated that modifications to this part of the pharmacophore represented a potential 
route to the synthesis of selective small molecule CDK9 inhibitors. 
In CDK2, the hinge region of the ATP-binding domain includes a phenylalanine 
residue (Phe80), with which the methyl substituent on the 4-position of the thiazole 
ring is thought to form a hydrophobic interaction. In CDK9. the hinge region includes 
a corresponding phenylalanine residue (Phe 103), which can be overlaid directly onto 
the Phe80 of CDK2. This suggested that the thiazole ring methyl substituent would 
form similar hydrophobic interactions with both kinases in this region and any 
alterations to this part of the pharmacophore would not preferentially enhance CDK9 
selectivity. The thiazole ring nitrogen can function as a hydrogen bond acceptor and it 
is located in close proximity to a lysine residue (Lys33) in the ATP-binding domain of 
CDK2, which can act as a hydrogen bond donor. There is an analogous lysine residue 
(Lys48) in the CDK9 binding domain and, as before, it was decided that 
modifications to this part of the pharmacophore were not likely to enhance CDK9 
selectivity over CDK2. 
The N I nitrogen of the pyrimidine ring and the anilino NH in the lead pharmacophore 
form two hydrogen bonds with the backone of a leucine residue (Leu83) in the CDK2 
binding domain. The corresponding residue in CDK9 is a cysteine residue (Cys 106). 
It was proposed that similar hydrogen bond interactions were possible with the 
corresponding region on the CDK9 catalytic domain. These interactions were 
considered very favourable for potency and it was decided to leave these 
functionalities intact. 
2.09 Proposed Synthetic Route to a Selective CDK9 Inhibitor 
In summary, the comparative modelling carried Out suggested that the most likely 
means of enhancing CDK9 selectivity would be through the design and synthesis of 
compounds with alternative substituents on the aniline ring component of the lead 
pharmacophore. A number of functions, which favourably influenced the binding to 
either CDK2 or CDK9, had to be retained. These included the preservation of a small 
alkyl or alkylamino substituent on the 2-position of the thiazole ring, a pyrimidine 
ring substituted on the 4-position with the aforementioned thiazole and an aniline ring 
functionality on the 2-position (Figure 16). In order to reach the objective of 
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discovering a novel CDK9 selective agent, it was decided that new pyrimidines 
should be synthesised, variously substituted in the aniline position, but retaining these 
advantageous features. 








• : Part of Lead Pharmacophore to be Retained (R 1 = Me, NH2, NHMe, NHEt or Thiazolone) 
• : Part of Lead Pharmacophore to be Modified in Order to Enhance CDK9 Selectivity 
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Chapter 3 
Results and Discussion 
CDKs 
17111 
3.0 Results and Discussion 
3.01 Compounds with an Acetamide Aniline Substituent 
Previous work had been restricted to the study of the effects on CDK potency and 
selectivity of direct substitution of the aniline ring by small substituents including, for 
example, Me, F, NI-1 2  and NO2. Initial compounds synthesised in my studies 
incorporated an acetamide substituent on either the 3- or 4-position of the aniline ring. 
This was to investigate effects of additional substituents attached to the aniline ring 
(Figure 17). 
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K, (nM) 72h MTT 
(III) No. Type R1  (.tM) 
CDK 1K CD K CDK CDK CDK MES- A278 
2A 2E 4 7 9 SA 0 
(111)5 1 Me ND 	NI) 	0.5 	ND I NI) ND ND 
±0.6  
(111)6 1 NHMe 122 45 24 	241 313 18 ND ND 
±8 ±11 ±28 ±94 ±17 ±7  
(111)7 1 NI-lEt 148 18 30 109 209 14 0.13 0.07 
±124 ±16 ±4 ±68 ±37 ±5 ±0.06 ±0.02 
(111)8 3 3- 578 221 	- 34 	767 377 19 ND ND 
CH2NHAc ±267 ±15 
278 
±17 ±3 ±283 ±6  
(III) 9 2 Me 166 96 365 828 243 ND ND 
±59 ±67 ±43 ±28 ±203 ±153  
(III) 10 2 NI-1 2  317 343 	71 246 851 78. 0.76 0.38 
±179 ±93 ±31 ±6 ±437 ±35 ±0.20 ±0.03 
(111)11 2 NHMe 149 162 	20 7 400 27 0.29 0.09 
±112 ±87 ±8 ±6 ±233 ±18 ±0.05 ±0.01 
(111)12 2 NHEt 213 133 31 36 103 11 0.26 0.10 
±173 ±47 ±12 ±22 ±7 ±4  ±0.02 
(III) 13 3 4- 85 158 	- 2 97 212 7 0.25 0.11 
CH,NHAc ±80 1 ±29  ±48 1 ±163 ±6  ±0.06 
Key 
MES-SA: Uterine tumour cell line A2780: Ovarian tumour cell line 
Assay results below 50 nM with individual CDKs 
0 CDK2A 	 • CDK2E 	 0 CDK4 	 0 CDK9 
Assay results from this initial series of pyrimidines were very encouraging. Analogues 
with a methylamino or ethylamino substituent on the 2-position of the thiazole ring or 
with a thiazolone pyrimidine 4-substituent (type 3 analogues) remained very potent 
inhibitors of a number of the kinases they were screened against and showed some 
signs of selective inhibition. Pyrimidines that were 3-substituted with an acetylamino 
moiety (Type 1) were more selective for CDK2A and CDK2E when compared with 
the 4-substituted analogues (Type 2) that were more selective for CDK2E and CDK4. 
These analogues all possessed some CDKI activity (K 1 values of 85-578 nM) but 
were much more selective for the other CDKs mentioned. Several analogues 
highlighted in Figure 17, that were potent inhibitors of CDK9, were much less potent 
inhibitors of the other transcriptional kinase CDK7 (K1 values of 103-851 nM), 
indicating that it may be possible to increase CDK9 selectivity over CDK7 with some 
structural modifications, although most of the molecules retained significant CDK2E 
activity. Pyrimidines with a methyl or amine substituent on the 2-position of the 
thiazole ring were much less potent against the CDK panel than those with 
alkylamino substituents or thiazolones at this position. This suggested that the 
acetylated amine was interacting more favourably with the kinase binding domains 
than the other substituents. In order to understand and elaborate on these results. 
compound (III) 7 was selected for molecular modelling studies. This compound was a 
potent inhibitor of CDKs 2A (Ki 18 nM). 2E (Ki 30 nM) and 9 (K, 14 nM), and was 
subsequently docked with CDKs 2 and 9 to show possible interactions with the 





Figure 18: Computational Docking of (III) 7 with CDK2 and CDK9 
CDKF Compound 7 
CflI(C/ Compound 7 
Compound (III) 7 bound to both CDK2 and CDK9 in the same orientation identifying several common 
favourable interactions. The acetamide functionality of (111)7 resulted in the twisting of the aniline ring 
towards the CDK2 and CDK9 catalytic domains and may account for the increased potency of this 
analogue compared with its 4-acetylated analogue (III) 12. 
The compound bound to both proteins in the same orientation, and as a result a 
number of comparable interactions formed with both of the kinase binding domains. 
These included a number of hydrogen bonds. Hydrogen bonds formed between the 
anilino-NH and the NI of the pyrimidine ring with residues in the kinase hinge region 
(Leu83 in CDK2 and Cys 106 in CDK9). An additional hydrogen bond is formed 
between the thiazole ring nitrogen and adjacent lysine residues (Lys33 in CDK2 and 
Lys48 in CDK9). The ethylamino substituent did not appear to form any additional 
interactions with either kinase binding domain, and hence did not explain the 
increased potency of analogues with this type of substitution when compared with 
those with either methyl or amino thiazole substituents. The acetamide functionality 
appeared to be capable of forming an additional three hydrogen bonds with other 
residues in the CDK2 kinase domain (Asp86 and Lys89). Comparable interactions 
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with the CDK9 kinase domain were not apparent but the CDK9 potency of (111) 7 
suggested that similar interactions were being formed nevertheless. The 4-substituted 
analogue (III) 12 was equipotent and it was assumed that this would form similar 
interactions with both proteins. 
3.02 Compounds with a Methylamine Aniline Substituent 
Having observed the possible effect of the CONHCOCH 3 group, it was interesting to 
determine the effects on CDK activity of removing the acetamide group. Results 
obtained form an evaluation of these primary amines and although not 
comprehensive, those presented indicate that the removal of the acetate group was 
associated with a marked decrease in CDK activity when compared to the equivalent 
N-acetamido compound (Figure 19). 
Figure 19: Compounds with Methylamine Aniline Substituents 
R 1 	 0 





NN R3 	 NN R3 
Type I 	 Type 2 
K, (nM)  
CDK2 C CDK7 (III) No. Type R 1 R2 R3 
E 
(111)14 1 Me H CH,NH1 211 ND ND 
±33  
(III) 15 1 NHMe H CH 2NH2 207 127 ND 
±4 ±32  




(III) 17 2 N/a CH.,NH, H 30 	ND 	- 
±12 1 
MES-SA: Uterine tumour cell line A2780: Ovarian tumour cell line 
Assay results below 50 nM with individual CDKs 
• CDK2E 	 D 
The only primary amino analogue with CDK activity below 50 nM is (Ill) 17 and this 
analogue was 18 times less potent at inhibiting CDK2E and three times less potent at 
inhibiting CDK7 than its acetate-protected analogue (Ill) 13. Despite this decrease in 





corresponding pair of primary amino and acylamino compounds was carried out 
(Figure 20). 
Figure 20: Computational Docking of an Acetamide-substituted Compound (III) 7 
Compared with its Deprotected Analogue (HI) 16 
CDKZI O:mo.n7 FCornpcuid 1E 
%Aspl45 
The acetamide functionality of (LII) 7 extended further towards the CDK2 catalytic binding domain, 
which may account for the increased potency of this compound compared to its deacetylated analogue 
(LII) 16. 
Both compounds bound to CDK2 in the same orientation and subsequently hydrogen 
bonds were, as before, predicted to form between both the anilino-NH and the 
pyrimidine NI and Leu83 in the hinge region of the CDK2 binding domain. An 
additional hydrogen bond was predicted to form between the thiazole nitrogen and an 
adjacent lysine residue (Lys33). The acetamide functionality appeared to be in a 
position that facilitated additional interactions with other hinge region residues (G1n85 
and Lys89). These interactions were not possible in the deprotected analogue, 
explaining the associated decrease in CDK2 potency with acetate-removal. 
32 
3.03 Compounds with a Sulfonamide Aniline Substituent 
The successful synthesis of potent CDK inhibitors with acetamido aniline substituents 
prompted synthesis of compounds with larger but electronically similar groups to 
determine the size of substituent that could be tolerated in each of the CDKs (Figure 
21). 








N 	N R2 
H 00 
Type 2 
K, (nM) 72h MTT 
(III) Type R 1 R2   (PM)  
No. CDKI 	CDK2 	CDK2 I CDK 	CDK7 	CDK MES- A278 
A 	E 	4 	9 SA 0 
(III) 1 Me Me 734 41 11512 ND 88 ND ND 
18 ±25 ±11 ±0.4 	±105  ±21  
(111) 1 NH, Me 326 	105 	i 	51 107 63 2 0.17 0.04 
19 ±88 ±26 ±17 	±54 
161 	41 	47 	- 350 
±14 ±1 ±0,02 ±0.02 
(III) I NHMe Me 173 28 ND ND 
20 ±71 ±14 ±0.0 ±84 ±89 ±5  
(III) 1 NHEt Me 410 60 INI I 	93 106 4 0.10 0.04 
21  ±109 ±17 ±3 ±65 ±58 ±0.2 ±0.01 ±0,02 
(111) 2 N/a Me 163 42 39 106 108 2 0.30 0.13 
22 ±52 ±2 ±4 ±54 ±2 ±0.3 ±0.01 ±0.02 
(III) I Me CF3 529 386 74 748 327 393 ND ND 
23 ±64 ±165 ±40 ±242 ±88 ±203  
(111) 1 NH2 CF3 225 129 34 353 91 31 ND ND 
24 ±64 -  ±30 ±16  
(111) 1 NHMe C173 902 341 348 1228 1410 11 ND ND 
25 ±121 ±52 ±150 ±187 ±572 ±6  
(111) 1 NHEt CF3 > 1895 872 > 2793 94 ND ND 
26 10000 ±211 1000 ±1917 ±63 
0 
(111) 2 N/a CF3 1054 600 1010 5095 96 6 ND ND 
27 ±1030  ±96  ±61 ±1 
MES-SA: Uterine tumour cell line A2780: Ovarian tumour cell line 
Assay results below 50 riM with individual CDKs 
LI CDK2A 	 U CDK2E 	 0 CDK9 
Many of the pyrimidines synthesised (70%) in this series were potent inhibitors of 
CDK9 regardless of the substituent on the 2-position of the thiazole. Analogues with 
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selective for this kinase over other kinases tested, indicating that introduction of a 
sulfonamide moiety to the 3-position on the aniline ring was a viable means of 
increasing CDK9 potency and selectivity. Compounds with a methylsulfonamide 
substituent were in general more potent CDK9 inhibitors than their trifluoromethyl-
substituted analogues, although they were frequently less selective. In order to 
understand this significant observation two analogues, (III) 21 and 26, were selected 
for molecular modelling with the CDK9 homology model (Figure 22). 
Figure 22: Comparison of (III) 21 and (III) 26 Interactions with the Homology Model 
of CDK9 
CDK9 I Cornpuid 21  
Compounds (III) 21 and 26 bound to the CDK9 homology model in the same orientation. Modelling 
did not suggest any obvious interactions that could account for the differences in CDK9 potency 
observed for these two analogues. 
The compounds both interacted with the CDK9 homology model in the same manner. 
They formed hydrogen bond interactions and were in the same orientation within the 
kinase-binding domain. The methylsulfonamide moiety appeared to be sitting in the 
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binding domain in a position that allowed for the direct overlay of the 
trifluoromethylsulfonamide moiety and it was not possible to suggest a structural 
reason for the differences in potency recorded. Four distinct hydrogen bonds were 
identified between both small molecules and the CDK9 binding domain, partially 
accounting for the low nM inhibitory activity of both analogues. In order to 
investigate further the influence of sulfonyl substituents on CDK9 activity and 
selectivity, a series of compounds with an alternative sulfonamide moiety on the 
aniline ring was subsequently designed and synthesised (Figure 23). 
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Figure 23: Compounds with Alternative Sulfonamide Substituents on the 3-position 













(111) Type R 1 R2   (IIM) 
No. CDK CDK CDK CDK4 CDK7 CDK MES A278 
1 2A 2E  9 -SA 0 
(111) 1 Me OH 662 594 173 251 636 53 1.74 2.05 
28  ±298 ±220 ±55.0 ±8 ±132 ±22  ±0.34 
(III) 1 NI-I 2 01-1 318 247 60 67 168 7 0.60 1.81 
29  ±7.0 ±34 ±43 ±3 ±368 ±1 ±0.17 ±0.29 
(III) I NHMe OH 414 401 165 58 410 18 0.48 0.91 
30  ±222 ±72 ±57 ±1 ±229 ±6 ±0.07 ±0.14 
(III) I NHEt OH 370 346 103 60 166 18 0.18 0.57 
31  ±37 ±17 ±4 ±29 ±92 ±6 ±0.14 ±0.05 
(III) 2 N/a OH 618 411 377 150 369 10 1.77 2.05 
32  ±233 ±6 ±133 ±53 ±44 ±5 ±0.59 ±0.34 
(III) I Me OMe 1089 2201 141 3.02 3.71 
33  ±351  ±1653 ±89 ±0.58 ±2.14 
(III) 1 NH, OMe 971 579 134 830 291 9 0.21 0.35 
34  ±124 ±50 ±45 ±255 ±99 ±6 ±0.04 ±0.13 
(III) 1 NHMe OMe 50 120 413 6 0.25 0.29 
35  ±40 ±52 ±166 ±0.2 ±0.07 ±0.01 
(III) I NHEt OMe 709 582 191 88 81 29 0.31 
36  ±324 ±5 ±86 ±5 ±9 ±6  ±0.14 
(III) 2 N/a OMe > 1307 1387 360 5 0.69 0.86 
37 1000 ±5 ±1046 ±50 ±1 ±0.19 ±0.14 
0 
MES-SA: Uterine tumour cell line A2780: Ovarian tumour cell line 
Assay results below 50 nM with individual CDKs 1J CDK9 
80% of the compounds with 3-sulfonamide substituents were very potent inhibitors of 
CDK9. In this series only the compounds with a methyl substituent on the 2-position 
of the thiazole ring had K1 values of> 50 nM. These compounds were also selective 
for this CDK being much less potent inhibitors of CDKs 1, 2A, 2E, 4 and 7. 
In comparison, the 4-substituted analogues were somewhat less potent and selective 
CDK9 inhibitors, but interestingly were low nM inhibitors of CDKs 1, 2A and 2E, 
and one analogue, (III) 41, was also a low nM CDK4 inhibitor (Figure 24). 
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Figure 24: Compounds with Analogous Sulfonamide Substituents on the 4-position of 













N 	 SNR2 
H 
LNN) )  
Type 2 
K (nM)  72h MTT (lAM) 
(III) Type R 1 R2 CDK CDK ('DK - CDK CDK CDK MES- A278 
No. 1 2A 2E 4 7 9 SA 0 
(III) I Me OH 3 5 5 	526 877 134 0.27 0.49 
38 ±1 ±1 ±3 :827 ±133 ±50. ±0.10 ±0.19 
2 
(III) 1 NI-1 2  OH 7 6 4 010 940 62 1.74 2.44 
39  ±2 ±4 ±3 614 ±292 ±22 ±0.76 ±0.06 
(III) I NHMe OH 16 4 3 245 2045 0.37 0.94 
40  ±6 ±1 ±2 i50 ±840  ±0.09 ±0.10 
(III) I NHEt OH 18 29 8 7 103 0.15 
41  ±11 ±1 ±1 ±3 ±36  ±0.40  
(III) 2 N/a OH 5 3 1 828 1148 11 0.30 0.70 
42  ±1 ±0.1 ±0.3 4-467 ±669 ±1 ±0.19 ±0.55 
(III) I Me OMe 54 1 6 1353 167 0.22 
43  ±9 ±0.4 ±0.4 10000 ±238 ±44  ±0.03 
(III) 1 NH, OMe 35 3 2 - 720 42 0.31 0.36 
44  ±17 ±1 ±1 10000 ±201 ±1 ±0.03 ±0.06 
(III) 1 NHMe OMe 14 5 1 1765 74 0.09 0.12 
45 	1  ±3 ±3  10000 ±1031 ±31 ±0.05 ±0.01 
(111) 1 NHEt OMe 15 4. 27 322 86 36 0.08 0.08 
46  ±6 ±3 ±2 :40 ±21 ±4 ±0.02 ±0.02 
(III) 2 N/a OMe 4 2 0.1 940 14 0.02 0.11 
47  ±1 ±2 10000 ±55 ±2 ±0.08 ±0.01 
Key 
MES-SA: Uterine tumour cell line A2780: Ovarian tumour cell line 
Assay results below 50 aM with individual CDKs 
U CDKI 	 0 CDK2A 	 • CDK2E 
U CDK4 	 U CDK9 
The change in selectivity associated with the positioning of the aniline substituent was 
investigated further using the molecular modelling of selected analogues (Ill) 35 and 
(Ill) 45, having the same substituent on either the 3- or 4-position with both CDK2 
(Figure 25) and CDK9 (Figure 26). 
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Figure 25: Computational Docking of (Ill) 35 and (111) 45 with CDK2 





The 3-sulfonamide .substituent of (III) 35 appeared to be colliding with the residues in the CDK2 
homology model situated adjacent to the aniline ring, whereas the 4-sulfonamide substituent of (III) 45 
did not. This may account for the decreased CDK2 potency of the 3-substituted analogue. 
The compounds both bound to the CDK2 homology model in the same orientation 
and comparable hydrogen bonds were noted between the anilino-NH and the N I on 
the pyrimidine ring with Leu83 in the hinge region of the binding domain. The 4-
substituent of compound (III) 45 is located in the binding domain adjacent to an 
aspartic acid residue (Asp86) and it appears that this interaction is favourable as the 
model predicted hydrogen bond formation at this site. There was also the possibility 
of further hydrogen bond formation between the sulfonamide nitrogen in the 4-
substituent and an adjoining lysine residue (Lys89). The 3-sulfonamide substituent 
was also in a position to form this interaction. However, the 3-substituent appeared to 
be colliding with the predicted CDK2 hinge region positioning and the hydrogen bond 
with the aspartic acid residue (Asp86) was not formed. This would account for the 
observed decrease in CDK2 potency of the 3-substituted analogue (III) 35 in 
comparison to the 4-substituted derivative (III) 45. 
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Figure 26: Computational Docking of (HI) 35 and (HI) 45 with CDK9 Homology 
Model 
CDKS/ Comoon 45 / Uc -Ti Un : 
The 3-sulfonamide substituent was situated in close proximity to Hisl08 and Lys35 in the CDK9 
homology model. This suggested that the 3-substituent is forming a favourable interaction with these 
residues in the CDK9 homology model. The 4-substituent was directed away from the binding domain 
and did not form comparable interactions thus accounting for its loss of CDK9 inhibitory activity. 
The 3-substituted analogue (III) 35 was selective for CDK9 and, in addition to the 
usual hydrogen bond interactions, a further interaction was noted between the 
methoxy group of this sulfonamide substituent and an adjacent lysine residue (Lys35) 
in the CDK9 binding domain. The sulfonamide nitrogen was also in close proximity 
to a histidine residue (Hisl08) in the hinge region where an additional interaction 
could potentially form. The 4-sulfonamide substituent appeared to extend away from 
the hinge region of the CDK9 binding domain but two potential interactions were 
observed between the sulfonamide nitrogen and G1u109, and between one of the 
sulfonamide oxygens and HislO8. These alternative hydrogen bonds could possibly 
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be either less stable or weaker than those forming between the 3-substituent and the 
kinase domain, accounting for the lower CDK9 potency of the 4-substituted analogue. 
To further investigate the CDK9 selectivity of 3-substituted compounds more 
analogues with alternative aniline substituents on this position were synthesised 
(Figure 27). 
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K, (nM) 72h MIT 
(III) Type R1 R2  (JIM)  
No. CDK CDK CDK CDK CDK CDK MES- A278 
1 - 2A 2E 4 7 9 SA 0 
(III) I NHMe H 67 44 2 9 25 1 0.08 0.01 
48 ±11 - ±12 ±1 ±3 ±7 ±1  ±0.01 
(III) I NHEt H 691 54 4(i3 	32 56 5 1.61 0.67 
49 ±81 ±134 ') 53 24 ±1 ±0.24 ±0.10 
(III) 2 N/a H 21 21 3 22 39 0.3 0.04 0.15 
50 ±1 ±1 ±1 ±1 ±8 ±0.2 40.01 ±0.01 
(III) I Me Me 174 51 23 112 54 3 0.25 0.25 
51 ±28 ±11 ±6 77 ±24 ±2  ±0.13 
(111) 1 NI-1 2  Me 233 120 26 163 128 4.3 0.21 0.43 
52 ±32 ±29 ±3 ±73 ±48 ±2 ±0.06 ±0.05 
(III) 1 NHMe Me 334 200 33 20 107 4. 0.28 0.18 
53 ±3 ±55 ±1 ±7 ±71 ±2 ±0.08  
(III) I NHEt Me 320 152 	54 3 74 27 0.08 0.03 
54 ±153 ±49 ±31 ±2 1 ±66 ±1 ±0.01 ±0.04 
(III) 1 NH, Et 660 243 47 391 193 6 ND ND 
55 ±352 ±44 ±16 ±50 ±13 ±2  
(III) I NHMe Ft 1763 499 7 792 1380 17 0.34 0.37 
56 ±979 ±30 ±8 ±215 ±656 ±12  ±0.03 
(III) I NHEt Et > > 127 346 268 22 0.32 0.46 
57 10000 10000 ±25 ±34 ±51 ±2  ±0.09 
(III) 2 N/a Et 427 606 352 334 1068 5 ND ND 
58 ±49 ±6 ±115 ±23 ±302 ±3  
(III) I NHMe Bn ND ND 350 ND > 25 0.15 0.08 
59  ±128  10000 ±8  
(111) 1 NHEt Bn ND ND > ND > - 77 0.18 0.12 
60  10000  10000 ±5 ±0.03 ±0.08 
(III) I N/a Bn > ND > 174 > 23 1.36 1.28 
61 10000  10000 ±108 10000 ±4 ±0.11 ±0.25 
Key 
MES-SA: Uterine tumour cell line A2780: Ovarian tumour cell line 
Assay results below 50 nM with individual CDKs 
O CDKI 	 0 CDK2A 	 • CDK2E 
0 CDK4 	 0 CDK7 	 0 CDK9 
These compounds were almost all potent CDK9 inhibitors and in addition six [(II 1) 51 
and 56-61] were also CDK9 selective. The latter group, with only one exception, 
EE 
contained either an ethyl- or a benzyl-sulfonamide substituent on the 3-position of the 
aniline ring. Compounds with smaller 3-substituents (free sulfonamides or 
met hylsulfonamides) were much less selective for CDK9, as they were also potent 
inhibitors of CDKI, CDK2A, CDK2E, CDK4 and CDK7. The loss of selectivity 
incurred by the smaller 3-substituents suggested that while the larger groups 
(ethylamine and benzylamine) are capable of forming favourable interactions with the 
CDK9 binding domain, they are too large to be favourably contained in the more 
closed domain of CDK2. Interestingly, four of the compounds with smaller 
sulfonamide substituents were low nM CDK4 inhibitors and one (III) 54 was 
reasonably selective for this CDK. 
To further expand the existing SAR, 4-substituted analogues of the 
benzylsulfonamide compounds above were synthesised and assayed to facilitate 
further investigation into the effects on selectivity of switching the aniline ring 
substituent from the 3-position to the 4-position (Figure 28). 
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(N 	;III S ' N __- a, ,-, 
H 
LNN, )  
Type 2 
\ 0 
CX N)z:J l 
Type 3 
K, (nM) 72h MTT 
( 1 II)No. Type R1 ________ _____  (PM)  
CDK CDK CDK CDK CDK CDK9 MES- A278 
1 2A 2E 4 7  SA 0 
(III) 59 1 NHMe ND NI) 350 ND > 25 ND ND 
±128  10000 ±8  
(111)60 1 NHEt ND ND > ND > 77 ND ND 
10000  10000 ±5  
(III) 61 3 3- > ND > 174 > 23 > ND 
SO,NHBn 10000  10000 ±108 10000 ±4 1000  
(III) 62 2 Me > 536 	188 	> > > > 536 
10000 ±175 10000 10000 10000 1000 ±175 
(III) 63 2 NH 2 33 10 7 	> 523 52 33 10 
±22 ±8 ±2 10000 ±57 ±10 ±22 ±8 
(111) 64 2 NHMe 243 308 80 > 1866 243 308 
±4 ±103 ±37 10000 10000 ±1383 ±4 ±103 
(111)65 2 NHEt > 763 285 4275 > 182 > 763 
10000 ±253 ±1 ±888 10000 ±5 2000 ±253 
(111)66 3 4- 1134 654 80 > > 376 1134 654 
SO,NHBn ±652 ±375 ±55 10000 10000 ±145 ±652 ±375 
Key 
MES-SA: Uterine tumour cell line A2780: Ovarian tumour cell line 
Assay results below 50 nM with individual CDKs 
El CDK2A 	 U CDK2A 	 G CDK9 
The results concurred with those previously recorded for 4-substituted compounds, 
with large aniline substitutions on this position of the aniline ring inducing a 
significant loss of potency against all CDKs. 
A further series of analogues that were di-substituted on the aniline ring were 
designed and synthesised to determine if CDK9 selectivity could be increased further 
by combining a large 3-substituent (associated with CDK9 potency and selectivity) 
with a small 4-substituent (some favourable interactions with CDK9 binding domain). 
The corresponding mono-substituted analogues were synthesised for comparison 
(Figure 29). 
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Figure 29: Compounds with Di-substituted Aniline Rings Compared with Their 
Corresponding Mono-Substituted Analogues 
R 1 
N=< 




N 	R2 ro 
N '_J'  N J~)(S' N 
H 
Type 2 
K, (nM) 72hMTT 
(111) Type R 1 R2  (l.tM)  
No. CDK CDK CDK CDK CDK7 CDK9 MES- A278 
2A 2E 4  SA 0 
(III) 1 NH2 H > > 1647 > 2762 > 5.67 5.26 
67 10000 10000 ±186 10000 ±119 10000  ±0.72 
(111) 1 NHMe H > > > > > 
68 10000  10000 10000 10000 10000  
(111) 1 NHEt H > > I > > 
69 10000  10000  1000 10000  
(III) 2 N/a H > > 1472 > 3816 55 
70 10000 10000 ±783 10000 ±258 ±20  
(III) 1 Me Me > > 2134 > 1942 115 2.02 1.98 
71 10000 10000 ±38 10000 ±34 ±51  ±0.49 
(III) 1 NH, Me > > > > 304 9 0.17 0.69 
72 10000 10000 10000 10000 ±87 ±1 ±0.04 ±0.04 
(III) 1 NHMe Me > > > > 3469 7 0.37 0.50 
73 10000 10000 10000 10000 ±1525 3 ±0.04 ±0.38 
(III) 1 NHEt Me > > > > 541 13 0.37 0.43 
74 10000 10000 10000 10000 ±201 ±10  ±0.26 
(III) 2 N/a Me > > 2081 > 1172 27 
75 10000 10000 ±225 10000 ±286 ±3  
Key 
MES-SA: Uterine tumour cell line A2780: Ovarian tumour cell line 
Assay results below 50 nM with Individual CDKS 
0 CDK9 
Whilst this research is very much in its early stages with only a small number of 
analogues synthesised to date, the assay results were very encouraging as CDK9 
selectivity was hugely increased with no associated loss of potency. It was observed 
that most of the analogous compounds with no 4-methyl substituent (III) 67-69 were 
completely inactive against CDK9 and molecular modelling of (III) 67 and its bis-
substituted analogue (III) 72 was carried out to investigate the effects of an additional 
4-methyl moiety on kinase binding using a CDK9 homology model (Figure 30). 
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Figure 30: Computational Docking of (HI) 67 and (III) 72 with CDK9 Homology 
Model 
CDK3 I Cor-ptiiid 7? / 	 : u  -icl 
The methyl group of (III) 72 appeared to twist the aniline ring slightly which resulted in a change to the 
positioning of the morpholine ring compared to the mono-substituted analogue (III) 67. This moved the 
morpholine ring closer to HisI 08 in the CDK9 homology model and may account for the observed 
potency of (III) 72 compared to the inactive (III) 67. 
Interestingly, the methyl group appeared to twist the aniline ring into a position where 
the morpholine ring was in close proximity to a histidine residue (His] 08) in the hinge 
region, facilitating a potentially favourable interaction. The 4-methyl substituent was 
also situated close to the nitrogen of an aspartic acid residue (Asp 109) in the hinge 
region and an extra interaction could occur at this location. Although the model 
suggested that there was a hydrogen bond with the morpholine-ring oxygen of the 
compound without a 4-methyl substituent (III) 67, this ring appeared to have 
insufficient space in the binding domain when compared to the morpholine ring of the 




In summary, potent and selective CDK9 molecules were successfully synthesised as a 
result of detailed SAR analysis of this pyrimidine series. It was concluded that the 
most effective means of inducing CDK9 selectivity, over other CDKs, was via 
introduction of a bulky sulfonyl-morpholino substituent on the 3-position of the 
aniline ring coupled with an additional methyl substituent on the 4-position. Removal 
of this additional 4-methyl substituent resulted in a complete loss of CDK9 potency 
and selectivity (Figure 31). 
Figure 31: Favourable Contacts with CDK9 Homology Model [R I = Me, NHMe, 
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Interactions favourable to both CDK2 and CDK9 inhibitory activity i.e. areas where CDK9 
• 	selectivity over CDK2 has been shown to be unsuccessful due to conformational similarities 
between the kinase active sites at residues indicated. 
Interactions favourable to CDK9 inhibitory activity but unfavourable for CDK2 activity i.e. 
. 	 areas where CDK9 selectivity over CDK2 has been successful due to conformational 
differences between the kinase active sites at residues indicated. 
Another outcome of the achievement of the "in vitro" goals of this project was that, 
based on their selective kinase inhibitory properties, a number of molecules presented 
themselves as potential candidates for further development. The cellular activity of 
the molecules has been presented in tables in previous sections but not commented 
upon, as the major goals were "in vitro" based. Nevertheless, molecules having the 
sought for "in vitro" properties did have the anticipated cellular activity and further 
WO 
pharmacological studies were undertaken to assess their potential as drug candidates. 
The biological results of selected compounds are summarised below. 
3.05 Mechanism of Action Studies 
To determine the cellular effects of the compounds that were potent inhibitors of 
CDK9 in vitro, a series of experiments designed to determine their mode of action, 
were carried out. CDK9 is known to be responsible for the activating phosphorylation 
of the Ser-2 residue in the CTD region of RNA polymerase H, and hence CDK9 
inhibitors should block this activation step. Inhibition of RNA polymerase II in turn 
prevents expression of small anti-apoptotic genes, such as McI-I, required by 
transformed cells for their continued proliferation 35 . Two compounds, identified as 
potent and selective CDK9 inhibitors underwent a series of biological tests to 
determine their cellular effects (Figure 32). 
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Figure 32: Compounds (111) 72 and (III) 73 Significantly Reduce Phosphorylation of 
RNA Polymerase II at Ser-2 (and Ser-5) and Reduce Mci-i Protein Levels in A2780 
Cells. 
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Compounds (III) 72 and 73 significantly reduced the phosphorylation of Ser2 and Ser5 (located in the 
CTD of RNAPII), a response indicative of RNAPII inhibition. Both compounds resulted in increased 
p53 and decreased Mcl-1 (an anti-apoptotic protein). Both these responses are indicative of cytotoxic 
agents. 
Both compounds produced cellular effects consistent with inhibition of transcription. 
The circulating levels of RNA polymerase II were not affected but phosphorylation of 
both Ser-2 and Ser-5 in the CTD was notably reduced in tumour cells treated with 
compounds (III) 72 and (III) 73. Levels of the tumour suppressor protein p53 were 
increased whereas cellular levels of the anti-apoptotic protein Mci-I were 
significantly decreased. This suggested that the tumour cell proliferation was being 
blocked and instead cells were entering the apoptotic pathway. Apoptosis is 
frequently associated with the activation of a class of proteins known as the caspases 















pathways including apoptosis. A common method of detennining the cellular 
selectivity of potential anticancer agents utilises this pathway. Compounds (III) 72 
and (III) 73 were both shown to selectively induce apoptosis in transformed cells via 
caspase 3/7 induction (Figures 33 and 34). 
Figure 33: Compounds (III) 72 and (III) 73 Induce Apoptosis in Transformed Cells 
via Caspase 3/7 Induction (A2780 cells, 24h treatment) 
Figure 34: Compounds (Ill) 72 and (III) 73 Did Not Induce Apoptosis in 
Untransformed Cells via Caspase 3/7 Induction (W 138 cells, 24h treatment) 
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Chapter 4 
Aurora Kinases (AKs 
cl 
4.0 Aurora Kinases (AKs) 
4.01 Introduction to Aurora Kinases (AKs) 
Aurora kinases are a family of serine/threonine protein kinases that are involved in the 
control of various stages of mitosis. The original aurora allele was first identified in 
1995 during a screen for Drosophila inelanogaster mutants that illustrated defects in 
spindle-pole behaviour 59 and was subsequently named aurora after the polar night sky 
phenomenon 60 . The aurora kinase of Saccha rorn ces cerevisiae (Increase-in-ploidy I, 
Ipl I) was first noted during a screen for mutants that were defective in chromosome 
segregation 61-62.  It is now known that there are two distinct Aurora kinases in 
Drosophila and one in yeast. It has also been determined that in humans there are 
three types of Aurora kinases which are now commonly known as aurora A (Aur-A) 
aurora B (Aur-B) and aurora C (Aur-C) 60. A number of different names for each exist, 
deriving from their diverse routes of discovery but these have mostly been replaced 
by the nomenclature used above. 
The three Aurora kinases share extensive sequence homology and each has a short 
carboxy-terminal catalytic domain 60. They differ, however, in the length and sequence 
of their amino-terminal domains. Vertex were the first to solve the crystal structure of 
the Aur-A protein 63 , and to date a further seven structures have been published 67 . 
There are currently two published crystal structures of the Aur-B protein 68 . The 
crystal structure of Aur-C is as yet undetermined. Despite some obvious similarities 
the three Aurora kinases differ in their expression patterns, subcellular localisation 
and timing of activity6970 suggesting there is some potential for selective inhibition. 
4.02 Aurora A (Aur-A) 
The primary role of Aur-A (also known as Aurora-2, STK6, ARK! and aurorallpll-
related kinase) is in regulation of mitotic spindle formation and hence in the efficient 
control of chromosome segregation during mitosis. Aur-A is concentrated in the 
pericentriolar material (PCM) around the centrosomes during their separation in the 
late S/early G2 phases of the cell cycle 60. The centrosome is also known as the 
microtubule organising centre and contains a pair of small organelles known as 
centrioles, each consisting of a ring of nine microtubules including three fused in each 
group. The centrosome is responsible for the organisation of the microtubules into a 
51 
bipolar spindle during mitosis. The process begins with the division of the centrosome 
and the replication of the centrioles resulting in a pair of centrosomes each containing 
two centrioles. This is followed by migration of the centrosomes to opposite poles of 
the cell from which spindle fibres begin to extend. Kinetochores are then formed by 
the attachment of various proteins to the specialised condensed regions of the dividing 
chromosomes known as centromeres and it is to these that the spindle fibres extend 
and attach. The spindle fibres align the dividing chromosomes along the metaphasal 
plate in the middle of the cell, ensuring efficient distribution of the chromosomes 
during cell division as the separated chromosomes move along the spindle towards the 
poles of the cell, ultimately ensuring each daughter cell receives one exact copy of the 
nuclear material. Spindle formation is a process that includes the recruitment of a 
number of different proteins including y-tubulin that are essential for centrosome 
maturation 71 . 
Studies using GFP-tagged Aur-A have determined the location of the kinase during 
mitosis. In GI, as expected, Aur-A levels are low but increase significantly around the 
PCM during prophase as the nuclear envelope is dissociated. As the cell progresses 
through metaphase and anaphase, Aur-A is found mostly in the microtubules at the 
spindle poles and the polar microtubules, respectively. The GFP-tagged Aur-A signal 
fades after telophase suggesting that it is effectively degraded in late mitosis 62.71 
(Figure 35 )60.  
52 
a 
Centrb4e 	 A 








Spincle pole C,iniornere 
° 
/ Aurora D 
1 







• 14  





Figure 35: Localisation of the Aurora kinases 6° 
a) The relative location of Aur-A and Aur-B in mitotic cells is shown. The level of both kinases is 
substantially reduced in GI cells. By prophase, Aur-A (green boxes) is concentrated around the 
centrosomes, whereas Aur-B (red circles) is nuclear. In metaphase, Aur-A is on the microtubules near 
the spindle poles, whereas Aur-B is located in the inner centroniere. In anaphase, most Aur-A is on the 
polar microtubules, but some might also be located in the spindles midzone. Aur-B is concentrated in 
the spindles midzone and the cell cortex at the site of cleavage-furrow ingression. In cytokinesis, both 
kinases are concentrated in the rnidbody. 
Cells known to be deficient in Aur-A have been shown to contain centrosomes that 
are incapable of complete maturation due to a lack of y-tubulin, resulting in spindles 
of significantly decreased mass and hence effectiveness 62. Conversely, cells designed 
to overexpress Aur-A are shown to contain extra centrosomes and are 
multinucleated 71 . 
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Aur-A kina.se activity is induced by phosphorylation and three phosphorylation sites 
in the human form of the kinase have now been identified via mass spectrometry 62 . 
The first is a conserved Thr288 residue found in the activation loop (Figure 36)63. 
Figure 36: Overall structure of the Aur-A-adenosine complex 63 
Hinge (green), giycine-rich loop (red), and activation loop (purple) are key features of the protein 
kinase fold involved in binding adenosine. The position of a conserved threonine residue, Thr-288, 
which 	is phosphorylated during activation of Aur-A is indicated by a star. 
Other sites have been identified in human Aur-A as Ser5 I in the amino-acid terminal 
A Box and Ser342. To determine the individual roles of each of these sites, single 
mutations have been made at each. Replacement of the three residues with both 
alanine and aspartic acid has been carried out on Xenopus oocytes. Mutation at Ser53 
(Xenopus oocyte equivalent to Ser5 I in human Aur-A) did not induce a significant 
effect on Aur-A activity 61 . This suggests that phosphorylation of this site is not 
involved in activation of the kinase. It is thought that Ser53 may play a role in 
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degradation of the kinase 6° as replacement of the serine residue with aspartic acid, a 
residue that can potentially simulate the effects of phosphorylation, prevented Aur-A 
breakdown in vitro during mitotic exit 6271 . Mutations at Thr295 (Thr288 in human 
Aur-A) resulted in a complete loss of kinase activity. This residue in the published 
crystal structure is shown to be located in the activation loop, suggesting that 
phosphorylation at this site is essential for kinase activity. Results obtained regarding 
Ser349 differed depending on the mutation. When this residue was mutated to an 
alanine there was very little effect on kinase activity. However, when an aspartic acid 
was inserted at this position, kinase activity was abolished suggesting that this residue 
also plays an important regulatory role in Aur-A activation71.  Indeed it has now been 
shown that in the crystal structure of human Aur-A this phosphorylation site is in a 
position that could be responsible for conformational changes in the kinase, 
suggesting that it plays a critical part in determining whether or not the kinase is in its 
active form 63 . 
Human Aur-A can be mapped to the chromosomal region 20q 13.272.  This region is 
associated with increases in chromosomal copy numbers in many cancer cell lines 
including breast, colorectal and ovarian. It is unsurprising therefore that recent studies 
have shown that the over-expression of Aur-A results in centrosome amplification, 
aneuploidy and transformation in a transfected breast cancer cell line 73 , and is 
amplified in a variety of other cancer cell lines including ovarian carcinoma and 
hepatoblastoma7475 . 
4.03 Aurora B (Aur-B) 
Aur-B kinase (also known as Aurora-I) is often called the equatorial aurora. The 
human homologue was first identified in a polymerase chain reaction screen for 
kinases that were over-expressed in tumour cell lines 60. Aur-B is known to be a 
chromosomal passenger protein, a term used to describe proteins that relocate to 
different subcellular locations during the later stages of mitosis 76 . This aurora kinase 
functions by forming a complex with a number of chromosomal passenger proteins, 
including INCENP (inner centromere protein) 7778 and survivin/BIR-1 7981 , and is 
primarily involved in the control of chromosomal segregation and cytokinesis 80 . The 
passenger proteins initially associate with the arms of the newly forming 
chromosomes during prophase when the nuclear chromatin is beginning to condense. 
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They then relocate to the centromeres during prometaphase and metapha.se, the 
midzone of the mitotic spindle during anaphase and finally the midbody during 
telophase just prior to cytokinesis 8 ' (Figure 35 )60.  
The protein survivin has been shown to interact with both INCENP and Aur-B 82 and 
may play some part in targeting Aur-B to the histone3(H3)-bound INCENP 
molecules 83.  It has been proposed that INCENP targets the Aur-B complex to the 
microtubules during anaphase, enabling Aur-B to initiate the necessary microtubule 
activity for efficient cytokinesis 77 . Extensive research has been carried out to identify 
the individual roles of the three complex components in this intricate pathway, and it 
has been shown by numerous groups that they are entirely dependent on each other 
for targeting and function. In cells that lack functional INCENP it has been shown 
that Aur-B is prevented from properly localising to the both the centromere and 
spindle midzone, and survivin localisation to the centromere is also prevented 82. Such 
abnormalities result in improperly segregated chromosomes and cells that are 
incapable of completing cytokinesis 7781 . Aur-B has been mapped to the human 
chromosome region 17p 13. 1, which encodes for the tumour suppressor gene p53 and 
represents a region that is frequently mutated in a variety of cancers 8485 . 
4.04 Aurora C (Aur-C) 
Aur-C is the most recently discovered aurora kinase and little is known about its 
cellular function. Aur-C shows extensive sequence homology with Aur-B and it is 
thought that consequently it has a similar role in the control of efficient chromosome 
segregation and cytokinesis 83 . New studies have identified Aur-C as a passenger 
protein akin to Aur-B, which is first localised to the centromeres and then travels to 
the central mitotic spindles during cytokinesis 8687 . This aurora kinase also functions 
by complexing with INCENP but with a much lower affinity than Aur-B and its 
cellular expression has been shown to closely correlate with that of cyclin B, further 
implicating it as a regulator of mitosis 88.  Aur-C has been mapped to human 
chromosome 19q 13.43, a region that is transformed in several tumour types 89 . 
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4.05 Aurora Kinases as Anti-Cancer Targets 
The key roles played by the aurora family of kinases in the control of mitosis have 
identified them as possible cancer therapeutic targets. Aur-A has been identified as a 
potential marker of tumour progression and prognosis. Overexpression of Aur-A 
kinase contributes to genetic instability and tumourigenesis by disrupting proper 
assembly of the mitotic checkpoint complex. In addition. Aur-A kinase is a key 
regulatory component of the p53 pathway and its overexpression leads to increased 
p53 degradation, which facilities oncogenic transformation. Aur-A has been identified 
as a colon cancer-associated kinase that is overexpressed in more than 50% of 
primary colorectal cancers 909 , and amplification or overexpression has been detected 
in breast and ovarian tumours and in multiple tumour cell-lines 9294. A recent 
systematic analysis of expression levels of AKs A, B and C mRNA in multiple 
primary tumour samples using microarray technology, revealed that Aur-A and Aur-B 
were significantly overexpressed when compared with normal controls 92 . Repression 
of Aur-A expression by RNA interference delays mitotic entry in human cancer 
cells95 while overexpression of wild-type Aur-A compromises spindle checkpoint 
function and inhibits cytokinesis leading to centrosome amplification, a characteristic 
feature of many cancer cells 70. Exogenous over-expression of Aur-B kinase in 
Chinese hamster embryo cells caused chromosome separation defects during mitosis 
and increased invasiveness of cells in vivo, while an inhibitory antibody prevented 
efficient chromosome separation, allowing cells to escape spindle checkpoint arrest in 
the presence of microtubule inhibiting drugs and to exit mitosis without completing 
anaphase or cytokinesis 95 . 
4.06 Existing Aurora Inhibitors 
Given the potential relevance of aurora kinases to cancer aetiology, a number of 
companies are currently working on the development of aurora kinase inhibitors as 
potential anti-cancer agents, and a few compounds have entered clinical trials. The 
lead compounds in this area are Hesperadin [76]96,  ZM44739 [77J97  and, most 
recently, VX-680 [781 98 . 
Hesperadin [761 is a substituted indoline (Figure 37), which inhibits Aur-B by 
preventing the association of the kinase with H3 and by blocking the subsequent 
phosphorylation of SerlO necessary for Aur-B localisation to the centromere. The 
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molecule also interferes with the localisation of survivin to the centromere suggesting 
that it blocks Aur-B targeting to H3. It requires 250 nM Hesperadin [76] to half-
maximally inhibit Aur-B in HeLa cells, preventing the development of a properly 
functioning spindle pole96 . 
Figure 37: Structure of Hesperadin [76] 96  
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The specificity of Hesperadin [76] was determined using a panel of 25 other kinases 
and the compound was shown to be relatively selective for Aur-B kinase, although the 
results were not published in fu11 96 . The Aur-A and Aur-C kinase activity of 
Hesperadin [76] were not included. 
AstraZeneca have introduced a joint inhibitor of Aur-A and Aur-B kinases known as 
ZM447439 [77]97•  This compound is a quinazoline derivative with an aniline 
substituent and an ether linked morpholine group (Figure 38). It inhibits Aur-A and 
Aur-B with IC 50 values of 110 and 130 nM, respectively, and is inactive against a 
number of other cell cycle kinases including cyclin-dependent kinases 1, 2, 4 and 
Polo-like kinase I (IC ,()  >10 pM)97 . 
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Cells treated with ZM447439 [77] do not show any affect on the localisation of Aur-A 
or Aur-B, but they nevertheless exhibit cellular defects characteristic of both Aur-A 
and Aur-B inhibition, as the chromosomes are not correctly aligned along the spindle 
(Aur-A function) and are improperly segregated (Aur-B kinase function) 97 . This 
suggests that ZM447439 [771  is interfering with the cellular targets of these kinases. 
Vertex has developed a potent and selective aurora inhibitor that is known as VX-680 
[ 78]. It has been shown to inhibit Aur-A, Aur-B and Aur-C with K, values of 0.6. 18 
and 4.6 nM, respectively, 98 and to have greater than 100-fold selectivity for the 
Aurora kinases over a panel of 55 other closely related kinases. The only other kinase 
against which it is known to be significantly active is Frns-related tyrosine kinase-3 
(FLT-3), which it inhibits with a Ki value of 30 nM. VX-680 [78] is a tn-substituted 
pyrimidine ring with a phenyl-linked cyclopropyl moiety on the 2-position, a pyrazole 
substituent on the 4-position and a piperazine on the 6-position (Figure 39)98 





The cellular effects of VX-680 [78] include the accumulation of polyploid cells, 
preventing the proliferation of a range of tumour cells, with IC 50 values between 15 
and 113 nM98 indicating the pharmacological potential of this compound in anti-
cancer therapy. VX-680 [78] was described as having in vivo anti-tumour activity. 
Although not orally bioavailable, by iv or ip administration, VX-680 [78] was able to 
inhibit tumour growth in a number of leukaemia and solid tumour animal models. The 
anti-tumour activity of VX-680 [78] is thought to be due to the combination of 
inhibitory activities toward Aur-A, Aur-B and Fms-like tyrosine kinase 3 (F1t3) 99 . 
Subsequent preliminary Phase I clinical studies have suggested that this compound is 
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capable of prolonging survival and inducing remission in acute myeloid leukaemia 
(AML)98°° . 
Nerviano has identified a series of 3-aminopyrazole derivatives [79] as potent Aurora 
kinase inhibitors (Figure 40)67. 
Figure 40: General structure of the Nerviano compounds [79 j67 
NJ 
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These compounds were shown to inhibit Aur-A with IC50 values of between 5 and 
130 nM and prevented tumour cell proliferation with IC 50 values from 0.22 - 3.00 
LM67 . The publication did not include any data on the ability of these compounds to 
inhibit other kinases including Aur-B or Aur-C. 
4.07 Objective - The Synthesis of an Aurora Inhibitor 
The pharmacological significance of a selective aurora inhibitor to the role of these 
enzymes in tumour aetiology and, eventually, to the potential treatment of cancer is 
clear, given that Aur-A and Aur-B are overexpressed in a number of cancer types. The 
selective inhibition of Aur-A activity in transformed cells could potentially promote 
inefficient chromosome separation in tumour cells, preventing their replication and 
resulting ultimately in tumour cell death. In parallel, we have observed that a number 
of compounds with a core pyrimidine structure, initially synthesised as potential CDK 
inhibitors, have significant Aurora activity alongside their primary CDK activity. We 
proposed to use comparative analysis of the CDK2 and Aur-A catalytic binding 
domains to identify regions of similarity and diversity, and to investigate the possible 
exploitation of the differences in the design and synthesis of Aurora inhibitors of 
varying selectivity. 
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4.08 General Modelling Considerations 
The catalytic domains of CDK2 and the three aurora kinases are each comprised of 
approximately 250 residues 42" 01 , many of which are the same, resulting in the 
domains being of similar size and shape. Therefore, the lead pharmacophore should 
form similar, but not identical, interactions with both CDK2 and Aur-A. However, the 
residues lining the ATP-binding site of Aur-A and CDK2 differ more significantly 
(see Figures 42 and 43), with 23 differences within the amino acid sequences (21 for 
CDK2 and Aur-B and Aur-C). These differences are manifested structurally in the 
ATP-binding sites of the individual proteins and present an opportunity for the design 
of selective Aur-A inhibitors. The lead pharmacophore, it was hypothesised, could be 
rationally modified to enhance Aur-A potency and selectivity and reduce or abolish 
CDK2 inhibitory activity, with the objective of discovering a selective Aur-A 
inhibitor. 
4.09 Rational Approach to the Design of a Selective Aurora Inhibitor 
In order to facilitate the design and synthesis of selective aurora inhibitors, the 
catalytic binding domains of the three aurora kinases and CDK2 were modelled and 
compared in order to reveal sites of similarity and divergence, that could account for 
structural parameters contributing to the binding of each of these with the different 
kinase binding domains. The similarities and differences could then potentially be 
exploited in the design of more selective and potent aurora inhibitors (Figure 41). 
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Figure 41: Amino Acid Sequences of CDK2 (Swiss-Prot P24941), Aur-A (Swiss-Prot 
014965), Aur-B (Swiss-Prot Q96GD4) and Aur-C (Swiss-Prot Q9UQB9) 42 
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U Amino acid residues common to all four proteins 
0 Amino acid residues common to two or three of the proteins 
• Amino acid residues common to the aurora proteins 
• Amino acid residues lining the ATP-binding site 
The sequences of the three aurora proteins were extracted from Swiss-Prot and aligned using 
Multalign. The alignment is shown above along with that of CDK2. Residue numbering is according to 
the full-length sequences (full-length human Aurora A, B. and C have 403. 342, and 309 residues 
respectively). 
The catalytic domains of CDK2 and the three aurora kinases are each comprised of 
258 residues. Of these 258 residues, there were 66 differences identified between Aur-
A and Aur-B, and 68 between Aur-A and Aur-C. There were only 38 differing 
residues between Aur-B and Aur-C. A number of differences between CDK2 and the 
aurora kinases were noted and a more detailed analysis of the residues that form the 
ATP-binding site was carried out (Figure 42). 
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U Amino acid residues common to all four proteins 
Ei Amino acid residues common to two or three of the proteins 
• Amino acid residues common to the aurora proteins 
The differences in the residues lining the ATP-binding sites of Aur-A and CDK2 are 
manifested structurally in the proteins. A homology model of Aur-A, compared with 
an existing model of CDK2 was used to identify regions in the ATP-binding site that 
were structurally different and hence represented areas where selectivity could 
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potentially be introduced by modifying the lead pharmacophore appropriately (Figure 
43). 
Figure 43: Significant Residues in the Catalytic Domains of CDK2 (green) and Aur-A 
102 
The homology model of Aur-A is based on the structure of Pdkl (PDB code IUU3) 1112  with which 
Aurora A shares 35.7% sequence similarity. The glycine insertion in the hinge region (G1y216) results 
in a bulge in the catalytic binding domain enlarging this region in comparison with the CDK2 binding 
domain. 
Although the ATP-binding sites are very similar in both size and shape some 
differences do exist. The most obvious is the bulge in the hinge region of Aur-A that 
is due to a single glycine insertion (G216). This results in a conformational change in 
the Aur-A protein that expands this region in size, and facilitates the accommodation 
of larger ligands than those that would interact favourably with CDK2. The hinge 
region of Aur A is hydrophobic and composed of residues 210-217, of which Glu-2 I I 
and Ala-213 take part in ATP binding. They are assisted in ATP binding by the side 
chain of residue Trp-277 located in the activation loop through the formation of 
hydrogen bonds. In CDK2 the hinge region consists of residues 80-85 among which is 
a phenylalanine residue (F80). The corresponding residue in Aur-A is a smaller 
leucine residue (L210) resulting in a slight increase in available ligand space at this 
location in the binding pocket. 
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4.10 Hit Identification 
A number of compounds synthesised in the early stages of the CDK discovery 
program were found, when cellular studies were carried out, to have a different mode 
of action than anticipated. CDK inhibitors commonly cause cell cycle arrest in the 
early stages of the cell cycle (GUS phase) whereas a number of compounds were 
shown to cause cell cycle arrest during mitosis. This suggested that such compounds 
were perhaps interacting with different cellular targets to CDK2, and they were 
subsequently screened against a panel of kinases to identify possible alternative 
targets. The compounds, each with the same core pyrimidine structure, were identified 
as joint inhibitors of the aurora kinases Aur-A and Aur-B (Figure 44)103• 















(III) 80 NHEt OMe OMe OMe 0.44 2.97 239.00 
(111)81 NHMe OMe OMe OMe 0.71 2.65 256.00 
(III) 82 NH, H Morph H 2.34 2.85 1 	81.30 
(III) 83 Me H N(Me)2 H 3.81 1.47 251.00 
A1084 NHEt H H Piperaz-4-Ac 3.00 2.69 1257.00 
(111) 85 Me OMe OMe OMe 3.37 6.51 463.00 
(III) 86 Me H Morph H 1.35 42.00 2697.00 
(111) 7 NHEt H H CH,NHCOMe 4.67 2.39 215.00 
(III) 	12 NHEt H CH,NHCOMe H 5.00 4.10 32.00 
(111)87 NMeEt H Morph H 5.10 4.91 357.00 
(111)88 NH OMe - OMe OMe 5.42 4.22 	1 191.00 
(III) 46 NHEt H S02NH(CH 2 ) 2 
OMe  
H 5.93 2.09 81.00 
(111)21 NHEt H H CHNHSOMe 2.25 1.32 83.90 
Compounds (III) 80-88 were synthesised by colleagues at Cyclacel and are not included in the 
experimental section. All compounds listed above have significantly higher inhibitory activity against 
the AKs than against CDK2. 
The lead pharniacophore (with a 3-nitro aniline substituent) was then fitted into the 
homology models of both Aur-A and CDK2 to identify its orientation within their 
ATP-binding domains (Figure 45). 
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Figure 45: Computational Docking of Lead Pharmacophore with Aur-A (green) and 
CDK2 (blue) 
N=( 
N 0L NO2 
/ 
The aniline ring of the lead pharmacophore is located in a region where the binding domains of AK-A 
and CDK2 have notable conformational differences suggesting that structural modifications here could 
potentially introduce Aur-A selectivity over CDK2. 
The pyrimidine ring of the lead pharmacophore is located in an area where the two 
proteins have no significant domain differences. This suggested that modifications to 
the pyrimidine ring did not represent a viable means of introducing Aur-A selectivity. 
The aniline ring however, appeared to interact with the hinge region where the bulge 
in Aur-A due to a glycine insertion (G216) is located. This indicated that larger 
substituents on the aniline ring could fit into this additional space in the Aur-A 
binding domain, but that such substitutions would not be well tolerated by the smaller 
CDK2 binding domain and hence CDK2 potency would be reduced. The substituted 
thiazole ring also appeared to interact with the hinge region at an area where the 
binding domains of the two proteins differed. It docked into the region where there is 
either a leucine residue (1-210, Aur-A) or a phenylalanine residue (1780, CDK2) and 
suggested that the resulting additional space in Aur-A would accommodate large 
substituents on the 2-position of the thiazole whereas the smaller CDK2 binding 
domain might not. Such substitutions would therefore potentially increase Aur-A 
selectivity. Recently, the first crystal structure of Aur-A bound to a small molecule 
inhibitor was published and a new pocket in the binding domain was identified 
(Figure 46)67.  It was postulated that this would be situated adjacent to the thiazole of 
the lead pharmacophore and suggested that any large thiazole substituents introduced 
would have adequate space. 
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Figure 46: Aurora-A Homology Model Indicating the Position of the Additional 
Binding Pocket67 
The location of the additional pocket, present in the Aur-A binding domain but not in that of CDK2, is 
marked in yellow. Structural modifications to the lead pharmacophore, such as the introduction of 
bulky substituents to the 2-position of the thiazole ring, would extend into this additional pocket and 
represent a potential site for the introduction of Aur-A selectivity over CDK2. 
4.11 Proposed Synthesis of a Selective Aurora Inhibitor 
It was proposed that the synthesis of compounds with larger substituents on both the 
2-position of the thiazole and on the 3- and 4- positions of the aniline ring represented 
the most likely means of introducing Aur-A selectivity over CDK2 (Figure 47). A 
number of appropriate enaminone and guanidine intermediates were subsequently 
designed and synthesised to facilitate the synthesis of novel pyrimidines. 










• Part of Lead Pharmacophore to be Retained 
• : Part of Lead Pharniacophore to be Modified in Order to Enhance Aurora Selectivity 
Chapter 5 
Results and Discussion 
(AKs) 
5.0 Results and Discussion 
5.01 Synthesis of Compounds with a Methylthiazole Substituent 
The lead compounds (Figure 43), without exception, had small amino, alkylamino or 
alkyl substituents on the 2-position of the thiazole ring whereas the aniline ring 
substituents encompassed a variety of groups ranging in size and reactivity. The most 
potent and selective compound for Aur-A over CDK2, compound (III) 86, contained a 
4-morpholine moiety on the aniline ring and a methyl substituent on the 2-position of 
the thiazole. A series of analogues with the same thiazole substituent and alternative 
aniline substituents of varying size were subsequently designed and synthesised to 
determine the size of aniline substituent that the larger Aur-A binding domain could 
tolerate without potency being significantly reduced (Figure 48). 
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(III) 86 H Morph H 0.014 0.042 2.697 ND ND ND 
(111)89 H Thiomorph H 0.031 0.018 2.286 >10 >10 ND 
(111)90 H Piperidine H 0.034 0.043 >10 >10 1.312 ND 
(111)91 H Pyrrolidine H 0.111 ND ND ND ND ND 
(111)92 1 H Morph Me 0.007 1 0.012 0.611 1 >30 1.721 0.024 
(111)93 H Piperidine Me 0.067 ND ND ND ND ND 





0.002 0.377 ND ND ND 
(III)95 H H CO-morph 022 
_______ 
0.009 0.221 ND ND ND 
The newly synthesised compounds were all reasonably potent inhibitors of Aur-A, 
suggesting that the alternative aniline substituents were capable of forming similar 
interactions with the Aur-A kinase domain to those that existed with the morpholine 
ring. Replacement of the morpholine ring with either a thiomorpholine or a piperidine 
ring induced a slight decrease in potency but these analogues were equally as 
selective for Aur-A over the other CDKs when compared with the lead compound 
(III) 86. The compound with a 4-pyrrolidine ring, (III) 91, was significantly less 
potent than the other analogues suggesting that this substituent was perhaps too small 
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to interact as efficiently with the kinase-binding domain. Introduction of an additional 
3-methyl substituent produced different assay results depending on the 4-substituent. 
Compound (III) 93 (with a 4-piperidine ring) lost potency whereas the compound with 
a 4-morpholine ring (III) 92 gained potency and retained reasonable selectivity, 
indicating that this type of his-substitution warranted further investigation. Analogues 
with ring substituents on the 3-position were potent inhibitors of Aur-A, but were also 
significantly more potent CDK2 inhibitors than those with ring substituents on the 4-
position. 
5.02 Synthesis of Compounds with an Aminothiazole Substituent 
These observations were explored further by the synthesis of compounds with other 
small thiazole substituents, analogous to the lead compounds, coupled with the same 
aniline substituents as above (Figure 49). 
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(111)82 H Morph H 0.002 0.003 0.081 ND ND ND 
(111)96 H Thiomorph H 0.011 0.005 0.742 >10 0.540 0.073 
(111)97 H Piperidine H 0.007 0.006 0.418 0.759 0.110 0.035 
(III) 98 H Pyrrolidine H 0.030 0.215 1.302 >10 0.522  
(III) 99 H Morpholine Me 0.010 0.008 0.651 1 >10 0.521 0.012 
(III) 100 H Piperidine Me 0.026 0.013 0.649 ND ND ND 
(111) 101 H Morpholine OMe 0.007 0.004 0.365 1.137 0.274 ND 
(III) 102 H OMe Me 0.007 ND 0.119 ND ND ND 
(III) 103 OMe H OMe 0.018 0.045 0.074 ND ND ND 
(III) 104 H H CO-morph 0.022 0.009 0.221 ND ND ND 
(III) 105 H H CH,- ND ND 
 thiomorph  
0.004 0.034 ND ND 
(111) 106 1 H OCH,O 0.013 0.057 0.536 ND ND ND 
The lead compound (III) 82 was a very potent inhibitor of both Aur-A and Aur-B but 
was also a potent CDK2 inhibitor. The new compounds were almost all more 
selective for the aurora kinases by comparison. The thiomorpholine and piperidine 
derivatives, with no 3-substituents, were equipotent aurora inhibitors but were 
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significantly more selective than the lead compound over the other CDKs tested. 
Pyrrolidine derivative (III) 98 was, as with the 2-methyl substituted thiazole, less 
potent for Aur-A but was surprisingly seven times less active against Aur-B. This was 
the first analogue to show some selectivity between the aurora kinases. The docking 
of selected analogues into a homology model of Aur-A was carried out to compare the 
predicted interactions and explain the loss of potency induced by the pyrrolidine ring 
(Figure 50). 
Figure 50: Molecular Docking of Compounds (ifi) 82, 97 and 98 with Aur-A 
Homology Model 
Airora Al Compound 82 
Auiota Al CrruriJ 97 





The compounds each appeared to bind with the Aur-A homology model in the same 
overall orientation. The NI of the pyrimidine ring and the anilino-NH form hydrogen 
bonds with A1a213 in the hinge region of the kinase-binding domain. The morpholine 
and piperidine rings are planar with the aniline ring and interact with both the 
additional glycine residue (G1y216), that is absent in CDK2, and a threonine residue 
(Thr217) in the hinge region of the ATP-binding domain. The piperidine ring is 
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marginally further away from both these residues, which may account for the five-
fold loss in potency between compounds (III) 82 and (III) 97. The pyrrolidine ring has 
moved the molecule slightly so that it is no longer planar in comparison to the other 
analogues and the smaller size of this substituent has moved it slightly further from 
the threonine residue (Thr217) at the end of the hinge region. This small structural 
change may explain the associated loss of Aur-A potency. 
Compounds with additional small 3-substituents have lost some Aur-A potency but 
are more selective than the lead (III) 82 over the other CDKs. This suggested that 
CDK2 inhibition could be decreased using this type of bis-substitution. Once again, 
the compounds with ring substituents on the 3-position were potent Aurora inhibitors 
but were also reasonably potent CDK2 inhibitors, highlighting this type of structural 
modification as unlikely to produce selective aurora inhibitors. Computational 
docking of (III) 104 with both Aur-A and CDK2 was carried out to explain the lack of 
selectivity of compounds with substituents on the 3-position (Figure 5 I). 
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Figure 51: Computational Docking of (Il) 104 with Aur-A and CDK2 
Aura A I Compoun 1 ,14  
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Compound (III) 104 bound to both the Aur-A and CDK2 homology models in a similar orientation 
with the most notable differences in the conformation of the aniline ring component. 
Compound (III) 104 bound to both kinases in the same orientation and therefore 
formed a number of common interactions with each. The N  of the pyrimidine ring 
and the anilino NH form hydrogen bonds with A1a213 (Aur-A) and Leu213 (CDK2); 
the amine on the 2-position of the thiazoie ring forms another hydrogen bond with 
either the lysine residue (Lys33 in CDK2 and Lys-162 in Aur-A) or the aspartic acid 
residue (Asp274 in Aur-A and Asp-145 in CDK2) adjacent to it. The hinge region of 
Aur-A is slightly larger than that of CDK2 due to the glycine insertion (G1y216) and 
the carbonyl group of the R 4 substituent is located in the resultant additional space. 
The morpholine ring is thus positioned to facilitate an interaction with an adjacent 
threonine residue (Thr217) or an arginine residue (Arg220) in close proximity to it. 
Absence of the additional glycine residue (Gly216) in CDK2 reduces the available 
space next to the hinge region and as a result the 3-substituent is twisted away from it 
slightly. This has marginally increased the distance between the morpholine ring and 
an aspartic acid residue (Asp86) at the end of the hinge region. The result is a loss of 
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CDK2 potency in comparison with Aur-A but sufficient interaction is occurring to 
retain some CDK2 inhibitory activity. 
5.03 Synthesis of Compounds with an Ethylaminothiazole Substituent 
The first analogue with fused substituents on the 3- and 4-positions gave an 
encouraging result, as it was reasonably potent and selective for both Aur-A and Aur-
B over CDK2. Further analogues of (III) 106 were subsequently synthesised with an 
ethylamino substituent on the 2-position of the thiazole ring to expand existing SAR 
(Figure 52). 
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(III) 107 H Morph H 0.016 0.014 0.469 ND ND ND 
(III) 108 H Thiornorph H 0.021 0.012 0.941 >10 0.866 ND 
(III) 109 H Piperidine H 0.014 0.015 0.394 ND ND ND 
(III) 110 H Morph Me 0.012 0.019 0.476 >10 1.04 0.066 
(111) 	III H I Piperidine Me 0.081 1 ND ND I ND ND ND 
(111) 	112 H Morph OMe 0.005 0.008 0.12 ND ND ND 
(III) 	113 H Morph CI 0.024 ND 0.106 ND ND ND 
(111)1 14 Cl Morph CI >1 ND ND ND ND ND 
(111)1 	5 H OMe Me 0.02 0.03 0.414 ND ND ND 
(111)1 16 OMe H OMe 0.16 ND ND ND ND ND 
(111)] 17 H OCH,O 0.028 ND 0.093 ND ND ND 
(111)] 18 H O(CH2)20 0.041 0.034 0.243 ND ND ND 
Assay results concurred with the existing SAR. Replacement of the 4-morpholine ring 
with a thiomorpholine or a piperidine ring has no effect on either aurora potency or 
selectivity over CDK2. Introduction of an additional 3-methyl substituent with a 4-
piperidine ring resulted in a loss of potency and had no effect on either potency or 
selectivity when the 4-substituent was a morpholine ring. The effects on kinase 
binding of additional 3-substituents were probed further with the synthesis of 
analogues with 3-methoxy and 3-chloro groups. A single additional 3-substituent 
resulted in a loss of selectivity and the introduction of 3,3-dichloro functionalities 
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abolished all Aur-A inhibitory activity. Compounds with fused 3- and 4-substituents 
were potent aurora inhibitors but they also had reasonable CDK2 inhibitory activity. 
The compound with no 4-substituent (III) 116 was markedly less potent against Aur-
A than all the other analogues, confirming the need for 4-substituents on the aniline 
ring in order to have Aur-A inhibition. 
5.04 Synthesis of Compounds with a 4-Morpholine Substituent 
The successful synthesis of a number of potent and selective Aur-A inhibitors with 
small thiazole substituents coupled with a morpholine moiety on the 4-position on the 
aniline ring, led to the synthesis of analogues with alternative thiazole substituents to 
determine the effects on kinase inhibition. The region surrounding the thiazole in the 
Aur-A binding domain is hydrophobic and slightly larger in Aur-A than in CDK2. 
This is due to the existence of a smaller residue (Leu210) in Aur-A resulting in more 
space that could potentially accommodate larger thiazole substituents. Such 
substituents would not interact favourably with the smaller CDK2 binding domain 
and hence, this represented a possible site at which to introduce additional Aur-A 
selectivity over CDK2. A number of compounds with larger thiazole substituents 
were synthesised to test this hypothesis (Figure 53). 
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(III) 	119 NHMe 0.007 0.018 0.009 0.011 >10 4.654 0.047 
(III) 107 NHEI ND 0.016 0.014 0.469 ND ND ND 
(111) 120 CHOH ND 0.013 0.017 0.837 >10 1.210 0.155 
(III) 	121 2-thiophene 0.209 >10 0.800 ND ND ND ND 
(III) 122 2-thiazole ND 0.217 ND ND ND ND ND 
(III) 123 CH-,S02-2- ND 0.009 
thiophene  
0.024 2.078 1.366 >10 ND 
(111)124 3-pyridinyl 0.055 0.05 0.085 >10 ND ND ND 
(111)125 N 0.276 ND ND ND ND ND ND 
(III) 126 I 0.116 ND ND ND ND ND ND 
(III) 127 NMe- ND 0.024 
3-pyridinyl  
0.086 1.654 >10 0.965 ND 
(III) 128 NMe- ND 0.155 
2-pyridinyl  
ND ND ND ND ND 
(III) 129 CI 0.925 ND ND ND ND ND ND 
(III) 130 C1 	C1 0.080 ND ND ND ND ND ND 
Dm AK-A: Drosophila AK-A 
Compounds with sulphur-containing ring substituents, (III) 121 and (III) 122, attached 
directly to the 2-position of the thiazole were not potent Aur-A inhibitors suggesting 
that a hydrogen bond donor at this position, such as the methylamino substituent in 
(III) 119, was necessary for activity. However, the compound with a sulfonamide-
linked thiophene substituent (III) 123 had significant Aur-A and Aur-B inhibitory 
activity and was more selective than both the lead compounds. This compound had a 
very high molecular weight (MW 513.66), which suggested that it may not be a good 
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drug candidate, but it was modelled with the Aur-A homology model to investigate 
the reason for its potency (Figure 54). 
Figure 54: Molecular Docking of (III) 123 
The sulfonamide-linked thiophene appeared to extend into the region of the Aur-A homology model 
where the additional pocket is located, suggesting that this functionality is forming favourable 
interactions with this region of the Aur-A binding domain. The hydrogen bond interactions (marked 
with broken line) that exist between the anilino NH and the N 1 of the pyrimicline ring have also been 
indicated. 
Molecular docking of this compound with the Aur-A homology model indicated that 
the sulfonamide-linked thiophene was in close proximity to the aspartic acid residue 
(Asp274) in the Aur-A binding pocket, suggesting a favourable interaction is taking 
place here. The large thiazole substituent is obviously accommodated by the 
additional pocket of space present in Aur-A and not in CDK2, accounting for the loss 
of CDK2 inhibitory activity. Although this observation presented an interesting 
insight regarding the binding of the molecule, and in particular its Aur-A/CDK2 
specificity, the lack of potency of the other analogues with alternative sulphur-
containing thiazole substituents meant that this line of investigation was not pursued 
further. 
Compounds with substituted pyridinyl rings attached directly to the 2-position of the 
thiazole ring (III) 125 and (lU) 126 were much less potent inhibitors of Aur-A than 
NMI 
the lead analogues (III) 107 and (III) 119. Alkyl-substituted pyridinyl rings appeared 
to be too large to facilitate favourable interactions with the increased space in this 
region in the Aur-A binding domain. However, compound (HI) 124, which contained 
an unsubstituted 3-pyridinyl ring attached directly to the 2-position of the thiazole (K1 
0.05 tM) was both Aur-A potent and selective, as it had no significant CDK2 
inhibitory activity (K1 >10 j.tM). The increased selectivity of this compound over 
CDK2 suggested that the additional space in the Aur-A binding domain around the 
thiazole was accommodating the larger thiazole substituent, whereas the smaller 
CDK2 binding domain could not. 
5.05 Synthesis of Compounds with a 3-Pyridinyl Thiazole Substituent 
The potency and selectivity of the analogue with a 3-pyridinyl thiazole substituent 
prompted the synthesis of a series of analogues with alternative aniline substituents to 
a 4-morpholine ring, to further determine the effects of this type of thiazole 
substituent on Aur-A selectivity over CDK2 (Figure 55). 
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Figure 55: Compounds with a Thiazole 3-Pyridinyl Substituent 
(N
R3 
N N,& R4 
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(111)124 H Morph H 0.055 0.085 0.050 >10 ND ND 
(111)131 H SO,NH H 1.127 
(CH 2OMe  
ND ND ND ND ND 
(III) 132 H CH2NHAc H 0.024 ND ND 1.252 1.184 1.447 
(III) 133 H H CH, 0.024 0.021 
NHAc  
0.023 0.611 1.783 1.397 
(111)134 H H CH 2 NH 2 0.213 ND ND ND ND ND 
(111)135 OMe OMe OMe ND 0.016 0.083 >10 >10 >10 
(III) 136 OMe H OMe ND >10 ND ND ND ND 
(111)137 H OMe Me ND 0.081 ND 2.40 ND ND 
(111)138 H Morph Cl 0.037 ND 0.315 >10 >10 >10 
(111)139 Cl Morph Cl >10 ND ND ND ND ND 
(111)140 H Morph OMe ND 0.019 0.206 >10 >10 >10 
(111)141 H Pip-4-Ac H 0.080 ND ND ND ND ND 
(111)142 H Thioniorph H ND 0.099 ND ND NI) ND 
(111)143 H Pyrrolidine H ND 0.334 ND ND ND ND 
(III) 144 H Piperidine H ND 0.169 ND ND ND ND 
(III) 145 H Piperidine Me ND 0.193 ND ND ND ND 
(III) 146 H OCH2O ND 0.328 ND ND ND ND 
(III) 147 H O(CH2)20 I ND 1 0.260 1 ND I ND ND ND 
The aniline substituents encompass a range of sizes and are located on the 2-, 3- and 
4-positions. Analogues (III) 132 and (III) 133 have an acetamide in the 3- and 4-
positions respectively and both are effective and equipotent inhibitors of DmAK-A. 
They were also shown to inhibit CDKs 7 and 9 with relatively similar values and 
differed only in their CDK2 activity with (III) 133 (K, 0.611 .tM) being twice as 
effective as (III) 132 (K1 1.25 tiM). Alkylamino aniline substituents were known from 
previous studies to induce low nM CDK2 inhibition when coupled with small 
alkylamino substituents, such as ethylamino and methylamino groups, on the 2- 
position of the thiazole ring, whereas these analogues showed 20-50 fold selectivity 
for AK-A over CDK2 and (III) 124 was completely inactive against CDK2. This 
prompted the docking of analogues (UT) 124 and (III) 133 into CDK2 to better 
understand these results (Figure 56). 
Figure 56: Comparison of (III) 124 and (HI) 133 Interactions with CDK2 
CDK2/ Corrp:und 124 
CDK2/ Compound 1 ,17 3 
Leu83 	
- 	 0lu81 
kpAspGG 	 PheO 
LysaS 
Both compounds bound to CDK2 in a similar orientation with the different aniline substituents 
representing the only notable conformational differences. The niorpholine ring of (III) 124 was located 
very close to Asp86 in the catalytic binding domain and may not represent a site of favourable 
interaction whereas the acetamide moiety on the 3-position of (III) 133 appeared to be better 
accommodated in this region. 
These analogues both bound to CDK2 in the same orientation. In both compounds the 
anilino-NH and the NI of the pyrimidine form hydrogen bonds with Leu83. An 
additional hydrogen bond is formed between the nitrogen in the thiazole ring and the 
adjacent lysine residue (Lys33). These interactions are common to both analogues and 
do not explain the differences in their selectivity over CDK2. Further analysis 
indicated that the morpholine ring of (III) 124 is very close to the aspartic acid residue 
(Asp86) in the hinge region and this may impede efficient binding. In Aur-A this 
residue is further away from the morpholine ring due to a single glycine insertion 
(G1y216) suggesting that the absence of this residue alone is responsible for 
abolishing the CDK2 activity of this compound. Analogue (III) 133 has no large 
morpholine substituent on the 4-position of the aniline ring to interfere in this way 
E;Jj 
with the CDK2 binding domain but has a 3-methylacetamide substituent instead. This 
is in close proximity to the hinge region of CDK2 enabling an additional interaction to 
form. This substituent also appears to be better accommodated than the morpholine 
ring of (III) 124, possibly explaining the slight increase in the CDK2 activity of this 
analogue in comparison. Further analysis of the Aur-A binding domain, suggested 
that the 3-pyridinyl substituent was being accommodated by a tryptophan residue 
(Trp277) in the binding pocket of AK-A. and that this interaction was part of a 
significant W277 loop interaction with the ligand. It was speculated that this 
interaction was in part responsible for the stabilisation of these analogues in a CDK2-
like binding mode with AK-A. 
5.06 Synthesis of Compounds with Alternative Aniline Substituents 
Replacement of the morpholine ring with either piperidine or thiomorpholine resulted 
in a significant loss of Aur-A potency in this series, indicating that this type of aniline 
substitution coupled with a 3-pyridinyl thiazole group was not a viable route to 
developing potent Aur-A inhibitors. A similar loss of Aur-A potency was recorded 
using compounds with fused 3- and 4-substituents. Once again, absence of a 4-
substituent was not consistent with Aur-A inhibitory activity as seen previously with 
compound (III) 116. 
One compound in this series (III) 140 was a potent Aur-A inhibitor that was selective 
over CDKs 2, 7 and 9 and showed a ten-fold selectivity over Aur-B. This compound 
was structurally similar to (III) 124 but contained an additional methoxy group on the 
3-position on the aniline ring. It was docked into the Aur-A homology model to 
identify possible additional interactions that were forming (Figure 57). 
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Figure 57: Molecular Docking of (HI) 140 with Aur-A Homology Model 
?urorA/ Compound 140 
Pro2 14 







The additional methoxy group appeared to twist the morpholine ring so it was no longer planar with the 
aniline ring. This may account for the increased potency of this compound when compared with its 
mono-substituted analogue (III) 124, which did not have an additional aniline 3-methoxy substituent. 
This compound inserted into the catalytic domain of Aur-A very efficiently forming a 
number of favourable interactions. The anilino-NH and NI of the pyrimidine ring are 
in the correct orientation to form the expected hydrogen bonds with the alanine 
residue (A1a2 13) in the hinge region. The methoxy substituent on the 3-position of the 
aniline ring is twisting the morpholine ring out of planarity with the aniline ring and is 
consequently facilitating a favourable interaction with the glycine residue (G1y216) at 
the end of the hinge region. The 3-pyridinyl substituent is, as expected. acting as a 
hydrogen bond acceptor and forming an interaction between its nitrogen and the 
adjacent lysine residue (Lys62). This interaction is preferable to a possible alternative 
that could exist with a neighbouring aspartic acid residue (Asp274). 
The di-chlorine compound (III) 139 had no Aur-A potency whereas the compound 
with only one 3-chlorine group (Ell) 138 had reasonable Aur-A inhibitory activity. 
These results concurred with those obtained from the structurally similar analogues 
(III) 113 (mono-chloro) and (HI) 114 (bis-chloro), which have an ethylamino moiety 
on the 2-positon of the thiazole (Figure 58). 
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(III) 138 3-pyridinyl H Cl 0.037 ND 0.315 >10 >10 >10 
(III) 113 NHEt H CI 0.006 ND 0.024 0.106 ND ND 
(III) 148 2-thiazole H Cl ND >10 ND ND ND ND 
(111) 149 CKçJ...CI H Cl 0.127 ND ND ND ND ND 
(III) ISO Ph-morph I H I Cl ND I >10 ND I ND I ND ND 
(III) 139 3-pyridinyl Cl Cl >10 ND ND ND ND ND 
(III) 	114 NHEt Cl Cl >10 ND ND ND ND ND 
(III) 	151 2-thiazole Cl Cl ND >10 ND ND ND ND 
The analogues with two chlorine substituents were completely inactive against Aur-A. 
Monosubstituted analogues generally exhibited greater potency (there were a few 
exceptions), which suggested that the additional chlorine was responsible for the loss 
of Aur-A inhibitory activity. Compound (III) 151 was selected for molecular 
modelling to determine the effects on Aur-A inhibition of this type of aniline 




Figure 59: Molecular Modelling of (III) 151 with Aur-A Homology Model 
Aurcia A / L:mo.n: 151 
Overlap of the two chlorine residues resulted in the rotation of the morpholine ring and may account 
for the lack of potency observed for all compounds with two chlorine substituents on the aniline ring. 
It appeared that the overlap of the two chlorine residues resulted in the rotation of the 
morpholine ring so that it was no longer coplanar with the aromatic aniline ring. The 
model did not indicate, however, that this distortion was sufficient to prevent the 
hydrogen bond interaction between the anilino-NH and the sidechain of Ala2l3, but 
binding to Arg220 could potentially be affected. The loss of activity could be due to 
the ability of the chlorine groups to affect other favourable interactions and they could 
potentially interfere with the anilino-NH interaction via an inductive effect. 
5.07 Synthesis of Compounds with Amine-Linked Thiazole Substituents 
A number of compounds with phenyl rings amine-linked to the 2-position of the 
thiazole ring and a 4-morpholine substituent on the aniline ring were noted to be 
reasonably potent Aur-A inhibitors, also exhibiting partial selectivity for this kinase 
over other CDKs. The additional space around the thiazole substituent that existed in 
the Aur-A binding domain in comparison to that of CDK2, suggested that it would be 
beneficial to synthesise additional analogues with this type of thiazole substitution as 
they would be potentially inactive against CDK2 (Figure 60). 
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(III) 152 OMe OMe OMe 0.013 0.021 1.262 >10 >10 0.009 
(III) 153 OMe H OMe 0.150 ND ND ND ND ND 
(III) 154 H Morph H 0.036 ND ND ND ND ND 
(III) 155 1 H Pip-Ac H 0.011 0.024 0.689 1.216 0.207 0.055 
(111)156 H Pip- H >10 
CH 2Ph  
ND ND ND ND ND 
(III) 157 H O(CH2 )10 ND 0.231 ND ND ND ND 
(III) 158 H H Me 0.438  ND ND ND ND 
(III) 159 H H CO-Morph 0.026 10.016 ND ND ND ND 
The results for this series of compounds were very interesting as they indicated that 
the Aur-A binding domain accommodated the bulky thiazole substituent whereas the 
CDK2 binding domain did not. The most potent compound (III) 155, was found to be 
as potent as the lead compounds (Ki 0.011 nM) and was also more selective against 
CDK2. This analogue had an acetate-protected piperazine ring on the 4-position of the 
aniline ring and was three times more potent than the analogous morpholine 
derivative. This compound was docked into the Aur-A homology model to further 




Figure 61: Docking of (ifi) 155 with the Aur-A Homology Model 
Aurora Al Compound 155  
The 4-acetylpiperazine moiety on the 4-position of the aniline ring extended towards Arg220 in the 
predicted Aur-A binding domain suggesting that a favourable interaction existed between the 
compound (III) 155 and this residue. 
The anilino NH and N 1 in the pyrimidine ring are forming hydrogen bonds with the 
hinge region of the catalytic binding domain with lengths of 2.19 and 1.87 A, 
respectively. These interactions are, however, common to all pyrimidines synthesised 
and did not explain the increased potency of this analogue. The piperazine ring with 
an acetate moiety on the 4-position is orientated in such a manner that allows the 
carbonyl group of the acetate to form a favourable interaction with an arginine residue 
(Arg220) in the Aur-A active site. The long chain on the 2-position of the thiazole 
ring places the phenyl ring in close proximity to the aspartic acid residue (Asp274) 
facilitating effective hydrogen binding at this position that may not be possible with a 
smaller substituent. The complete loss of potency recorded for the compound in 
which the acetate group on the piperazine was replaced with a larger benzyl group, 
suggests that the space adjacent to the arginine residue (Arg220) was insufficient in 
size to accommodate a substituent of this size favourably. 
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To investigate the possible optimisation of the proposed favourable interaction 
between the phenyl ring and Asp274, additional compounds with varying lengths of 
alkylamino chains were prepared (Figure 62). 
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(III) 160 NHPh Pip-Ac 0.045 ND ND ND ND ND 
(III) 161 NH(CH 2 Ph Pip-Ac 0.044 0.031 1.020 ND ND ND 
(III) 155 NH(CH 2 )2Ph Pip-Ac 0.011 0.024 0.689 1.216 0.207 0.055 
(III) 162 NHPh I Morph j >10 IND ND ND ND ND 
(M) 163 NHCH2Ph Morph 0.028 0.032 >10 0.760 0.750 ND 
(III) 154 NH(CH2 ) 2Ph Morph 0.036 ND ND ND ND ND 
Results indicate that the optimal chain length for Aur-A potency in the first series of 
compounds (those with a 4-piperazine moiety) is indeed two carbons long as 
compound (III) 155 was the most active. However, it was not as selective as 
compound (III) 161 over CDK2. The potency and selectivity for the lower series of 
compounds (those with a 4-morpholine aniline substituent) represented a similar 
trend. The analogue with a benzylamine thiazole substituent (III) 163 was less potent 
than its phenylethyl analogue (III) 154 but it was very selective for the aurora kinases 
over the CDKs. Lack of CDK activity of the selected analogues screened against this 
kinase indicated the potential value of this type of thiazole substitution in the future 
design of selective Aur-A inhibitors. 
A number of the methylated analogues of these compounds were prepared somewhat 
opportunistically (see Chemistry Section 6.0). Activities of the methylated and 
unmethylated analogues were compared to expand the SAR from the compounds 
above (Figure 63). 
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(III) 160 Ph H Pip-Ac 0.045 ND ND ND ND ND 
(III) 164 Ph Me Pip-Ac 0.228 ND ND ND ND ND 
(III) 162 Ph H Morph >10 ND ND ND ND ND 
010 165 Ph Me Morph 0.182 0.308 >10 >10 >10 ND 
(III) 161 CH 2Ph H Pip-Ac 0.044 0.031 1.02 ND ND ND 
(III) 166 CH 2Ph Me Pip-Ac 0.033 10.017 1 0.97 10.758 10.359 1 ND 
Methylated analogues produced mixed results: the methylated analogue of (III) 162 
[compound (III) 1651 was reasonably potent against Aur-A whereas its unmethylated 
analogue was completely inactive. The methylated analogue of (III) 161 [compound 
(Ill) 166] was also marginally more potent against Aur-A and was equally selective 
for this kinase over CDK2. However, the methylated analogue of (III) 160 [compound 
(III) 164] was five times less potent than its unmethylated counterpart. Additional 
compounds based on this series would have to be synthesised, before any firm 
conclusions can be reached on how the methylation of the amine-linker affects Aur-A 
inhibitory activity. 
5.08 Summary of Compounds with Significant Aurora Activity 
All compounds with an IC50 of less than 200 nM (K 1 <36.36 nM) against AK-A were 
deemed to have significant inhibitory activity to warrant further analysis. These 
compounds were subjected to a series of additional tests designed to eliminate 
analogues that would be unsuitable lead candidates, and identify those that were 
potentially suitable for further development (Figure 64). 
Figure 64: Screening Cascade for Aur-A Inhibitors 
SCREENING CASCADE 
MEDINAL CHEMISTRY 	
________ Cellular screening 
In vitro screening 
Urn AK-A c 	
CDK2 I5O> 5iM 	CDK4 1050> 5M 	Transcriptional inhibition - Reporter gene 
GSK3 IC50> 5 iM assay- nonh 
1050<200nM 
CDK7 1050>5 tM 	CDK1 1050> 5 M 	
ion at 20MM 
Cellomics screen 
CDK9 1050> 0.2 pM F1t3  
hAK-A and 6<20 nM 	 Inhibition ofphospho-htstoneH3 at 
Kinase selectivity - In house panel 
Microsomal stability - clearance > 30 mm 
Log 0 <2.5 
Compound characterization 
ADME screening in vitro 
In vitro selectivity - kinase and non-kinase panel 
PK in rodents 
suomicromoiar comceniraiion 
Induction of polyploidy at 	sub- 
micromolar concentration 
Cytotoxicity - 96h MIT 
No killing of normal non-proliferating 
cells (LC50>100iM) 
Cytotoxicity against sensitive tumour 
cell lines (1050 < 1 iiM) 
MOA 
Cell cycle analysis 
Inhibition of AK-A and B in cells (Western blot analysis 
of phospho-AK-A and B, CDK1 etc) 
Cell death type and kinetics 
Selectivity cell line panel - incl. 3D cultures etc. 
In vivo efficacy 	 LTP 
P388 and solid tumour xenografts 	===> LEAD COMPOUND 
Compounds with an ICS( ) of less than 200 nm against Aur-A or Aur-B were consequently screened 
against a panel of kinases, including CDKs 2, 7 and 9, to determine their selectivity for the AKs. 
Compounds with a CDK2 inhibitory activity of> 200 nm were then additionally screened against other 
kinases including GSK3 and F1t3. If the compounds were observed to be selective they underwent 
cellular screening, followed by MOA and ADME studies to determine their drug-like properties. 
Finally compounds that exhibited good pharmaceutical properties would be selected for in vivo studies 
and ultimately be identified as potential lead clinical candidates. 
Ell 
A total of 44 compounds inhibited AK-A with a K, value of< 0.036 tM (Figure 65). 






K. (iM)  
(III) R R- R., R AK-A AK-13 ('DK2 ('DK7 CDK9 F1t3 
No 
(Ill) ML II pipmi 	II 1 	0 134 	0 (I4 I 
90 10.004 	±0.))! 9 	10000 	10000 ±11.40 
(11I) Me H morph Me 0.007 0.012 0.611 > 1.721 0.024 
92 ±0.003 ±0.001 ±0.120 10000 ±0.360 ±0.010 
(Ill) Me F! Thio II 0.031 0.018 2.286 > > 
93  morph  ±0.005 ±0.010 ±1.090 10000 10000 
(Ill) Me II IT ('IL.- 0.008 0.002 0.177 
94  thiomorph ±0.001 ±0.00 ±0.03  
(III) Ni!. F! Thjo 11 0.011 0.005 0.742 > 0.540 0.073 
96  morph  ±0.004 ±0.003 ±0.114 10000 ±0.050 ±0.020 
(III) NH , F! piperid 111 0.007 0.006 0.419 0.759 0.110 0.035 
97 ±0.002 ±0.000 ±0.07 ±0.000 ±0.050 ±0.010 
(III) Nil. H pyrrol 11 0.030 0.215 1.302 > 0.522 
98 ±0.008 ±0.003 ±0.150 10000 ±0.100  
(111) N11 2 H morph Me 0.010 0.008 0.651 > 0.521 0.012 
99 ±0.001 ±0.002 ±0.210 10000 ±0.060 ±0.002 
(ill! N11 2 H piperid Me 0.026 0.013 0.649 
00 ±0.012 ±0.004 ±0.140  
(Ill) NH 2 H morph OMe 0007 0.004 0.365 1.137 0.274 
101 10.000 10.01)1 10.140 .±0.20 1 0.010 
(III! Nfl. I-I OMe Mc 0.007 0.119 
02 ±0.002  ±0.03  
(III) NFl- OMe H OMe 0.018 0.045 0.1174 0.003 
03 ±0.005 ±0.000 ±0.020  ±0.001 
(Ill) NH. II II Co- 0.022 0.009 0.221 
104  morph ±0.006 ±0.002 ±0.043  
(III) NfIEt H morph H 0.016 0.014 0.469 
07 ±0.007 ±0.008 ±0.197  
(III) NILEt U Thiom 1-1 0.021 0.012 0.941 > 0.866 
06  orph  ±0.006 ±0.000 ±0.180 10000 ±0.050  
1110 NilEt II piperid 1-! 0.014 0.015 0.394 
109 ±0.003 ±0.001 ±0.030  
(III) NlIEt U morph Me 0.012 0.019 0.476 > 1.040 0.006 
110 ±0.001 ±0.002 ±0.160 10000 ±0.250 1  ±0.002 
(III) NIlEt If morph OMe 0.005 0.008 0.120 
112 ±0.001 ±0.001 ±0.030  
(III) NIIEt If morph CI 0.024 0,106 
13 "11.1)1(1 1).006 
(Ill) NHF.t H OMe Me 0020 0.030 0.414 
115 ±0.009 ±0.012 ±0.210  
(III) N I I F.1 I! ()(C l.hO 11.034 0.243 
118 ±11.1)! 5 ±0.036  
(III) NIIMe H morph Fl 0.019 0.009 0.011 > 4.654 0.047 
119 ±0.005 ±0.00! ±0.010 10000 ±0.690 ±0,020 
I 	1111) '1 120H U morph H 0.013 0.017 0.837 > 1.210 0.155 
120 ±0.005 ±0.004 ±0.280 10000 ±0.280 ±0.000 
(III) thiaz H morph H *0149 0.592 1.318 > 
122  ±0.034  ±0.180 ±0.310 10000 
91 
Till 	(11:S0' 11 morph 1-1 0.009 0.024 2.078 1.366 > 
123 thioph  ±0.002 ±0.009 ±0.230 ±0.120 10000 
(III) 	3-pyrid H morph H 0.050 0.085 
124 4--0.020 ±0.004  
K, (MM)  
1111) 	R R2 R, R4 AK-A AK-B CDK2 CDK7 CDK9 1710 
No. 
(Iii) '1 Cl-! )- H morph H 0.024 0.086 1.654 > 0.965 0.034 
27 3pyrid  ±0.002 ±0.004 1-0.950 10000 ±0.060 ±0.010 
(Ill) 3-pyrid H CH:NHAc H 0.023 0.021 0.611 1.783 1.397 0017 
32 ±0.002 ±0.007 ±0.130 ±0.190 ±0.004 ±0.080 
11111 3-pyrid H U (IT: *0.023 1.252 1.184 1.447 
33 NHAc ±0.001 ±0360 ±0.170 ±0.670  
(III) 	3-pvrid OMe OMe OMe U ()I( I.03 0.053 
35 ±0.005 ±0.001 10000 10000 10000 ±0.020 
(III) 3-pyrid H morph CI *0.037 0.315 > > 
138 ±0.022 ±0.10 10000 10000 10000 
I 	(Tll) 	1 .pyrid H morph OMe 0.019 0.206 > > > 0.049 
40 ±0.004 ±0.002 10000 10000 10000 ±0.010 
(Ill) 	\11(CH.) 2 OMe OMe OMe 0.013 0.021 1.262 > > 0.010 
152 Ph ±0.0001 ±0.002 ±0.760 10000 10000 ±0.001 
1II1 Nl1(CH)2 H Pip-Ac H 0.0112 0.024 0.689 1.216 0.207 0.055 
55 l'h ±0.002 ±0.002 ±0.042 ±0.230 ±0.080 ±0.030 
(Ill) \Fl(CI-1 2 ) H H CO-morph 0.026 0.016 
1 59 Ph ±0.012 ±0.001  
(Ill) NMeBn Fl Pip-Ac 1-I 0.033 0.017 0.970 0.758 0.359 
66 ±0.003 ±0.004 ±0.180 ±0.060 ±0.140  
(Ill) thioph H H Cf!2 0.026 0.014 0.412 0.026 
67 NIIAc ±0.004 ±0.001 ±0.010  ±0.004 
Ill) thioph H Pip-Ac H 0.050 0.015 1.234 0.696 0.749 
168 ±0.01 ±0.002 ±0.450 ±0.330 ±0.064  
(III) (11 20H H piperid H 0.016 0.020 1.174 3.894 1.019 0.123 
70 ±0.002 ±0.001 ±0.134 ±0.370 ±0.041 ±0.030 
(1I!) (11 2011 H morph OMe 0.008 0.012 0.966 > > 0.028 
171 ±0.002 ±0.002 ±0.110 1 	10000 10000 ±0.010 
(III) (11 20H H piperid OMe 0.012 0.010 0.860 0.735 0.211 0.033 
172 ±0.001 ±0.003 ±0.170 ±0.05 ±0.001 ±0.004 
(Ill) (lIOI! H morph Me 0.008 0.009 0.650 3.429 1.233 0.030 
73 ±0.001 ±0.001 ±0.03 ±0.47 ±0.04 ±0.010 
(Ill) N(CH)- H Pip-Ac H 0.006 0.049 0.188 1.742 0.612 0.013 
174 3pyrid  ±0.001 ±0.005 ±0.030 ±0.190 ±0.180 ±0.001 
(Ill) NUMe H OMe Me 0.010 0.067 
175 ±0.001  40.02  
Table Colour Key 
Compounds with a cyclic 4-substituent on the aniline ring 
Compounds with a cyclic 3-substituent on the aniline ring 
• Compounds with small alkyl substitutions on the 3- and/or 4-position of the aniline ring 
F1 Compounds with an acetate-protected alkylamine on the 3- or 4-position of the aniline ring 
0 Compounds with tris-OMe substituents on the 3- and 4-positions on the aniline ring 
* K, values for Dm AK-A (not AK-A) 
5.09 SAR Analysis of Aurora Active Compounds 
Of the 44 compounds listed above, 32 have an aryl substituent on the 4-position of the 
aniline component of the pyrimidine. These substituents include a morpholine ring 
(17 compounds), a thiomorpholine ring (3 compounds), an acetate-protected 
piperazine ring (4 compounds), a piperidine ring (6 compounds), a pyrrolidine ring (I 
compound) and a fused 3- and 4-cyclic ether (1 compound). These analogues were 
potent inhibitors of both Aur-A and Aur-B, and showed good selectivity for these two 
aurora kinases over CDKs 2, 7 and 9. Twelve of these 32 compounds (37.5%) also 
contained an additional 3-substituent that was relatively small in comparison to the 
aryl ring moieties. These included a methyl group (5 compounds), a methoxy group (5 
compounds) and a chlorine atom (2 compounds). Assay results prove conclusively 
that the introduction of large aryl substitutions to the 4-position of the aniline ring is 
an effective means of inducing aurora potency and selectivity. Introduction of 
additional small 3-substituents does not interfere with this potency and selectivity, and 
additional combinations of this nature should now be explored as a means of 
improving the pharmacokinetics of these analogues. 
Three of the analogues have a cyclic substituent on the aniline 3-position and are 
unsubstituted on the 4-position. These analogues have either a carbonyl- or alkyl-
linked morpholine ring on the 3-position, and although they were found to be 
remarkably potent inhibitors of both Aur-A and Aur-B, they also inhibited CDK2 
with low Ki values (177-221 nM). Therefore, in general the results show that while 
aryl substituents on the 3-position do induce Aur-A and Aur-B potency they do not 
reduce CDK2 activity sufficiently to be deemed pharmacologically significant in this 
study. 
The remaining nine analogues do not have either a 3- or 4-aryl substituent but have 
only alkyl substituents including acetamides, methyl or methoxy functional ities. 
These pyrimidines were all potent inhibitors of both Aur-A and Aur-B and many were 
selective for these kinases over CDK2. The most selective analogues included the tn-
methoxy derivatives, suggesting that these should be pursued as a viable lead series. 
Analogues with small 3- and 4-anilino substituents that also contained small 
methylamino substituents on the 2-position of the thiazole component of the 
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pyrimidine, were found to be equipotent inhibitors of both the aurora kinases and 
CDK2. Hence these were discarded as potential Aur-A and Aur-B inhibitors. 
The three final analogues included in Figure 65 each have either a 3- or 4-acetamide 
substituent on the aniline ring, and although substitutions of this nature were expected 
to favour CDK2 activity (based on assay results of all analogues), they are reasonably 
potent and selective aurora inhibitors. They are therefore worthy of further 
investigation to determine why they lack CDK2 activity. 
There appears to be no distinct correlation between the size of the substituent on the 
2-position of the thiazole ring and aurora potency, as the analogues in Figure 65 
represent a very diverse selection of thiazole substituents, yet they are all good 
inhibitors of both Aur-A and Aur-B. However, by analysing their aurora selectivity 
relative to CDK2 the effects of substitution size become more apparent. Analogues 
with small alkylamino or free thiazole amino substitutions are much less selective for 
aurora than those with bulky ring substituents that are either directly or amine-linked 
to the thiazole ring. Comparison of the assay results obtained from analogues with 
similar aniline substituents, but very different thiazole substituents such as (III) 107, 
with compounds (III) 123 and (III) 127, highlight this observation. These three 
compounds all contain a morpholine moiety on the 4-position of the aniline ring but 
have different thiazole substitutions. Compound (III) 107 has an ethylamino group on 
the 2-position of the thiazole ring and is only thirty times more potent at inhibiting 
Aur-A over CDK2. On the other hand compounds (III) 123 and (III) 127 have an 
sulfonamide-linked 2-thiophene and a methylamino-linked 3-pyridinyl, respectively, 
on the 2-position of the thiazole ring and are 231 and 69 times more potent inhibitors 
of Aur-A over CDK2. The data suggest therefore, that introduction of large aryl 
substituents to the 2-position of the thiazole ring is an effective means of inducing 
aurora selectivity over CDK2 without the loss of aurora potency (Figure 66). 
Figure 66: Favourable interactions for AK-A selectivity over CDK2 
LyS33 	Asp145 	 Lys162 	Ar9138 
(NH2 ) (NH2 ) 
PheSO N 	
Asp86 P021 	
OLeuM N--< R, 
Ar22O Lys89 NH2 
E8 1 	H 	 H ) LQ1 E2 1) I NNCt:R3 01P1 %08  (NH) 	 (NH) (CC)  
Leu83 
(CC) 	 A1a213 
Glycine insertion (additional space) 
CDK2 	 Aur-A 
Key 
• 	Interactions favourable to both CDK2 and Aur-A inhibitory activity i.e. areas where Aur-A 
selectivity over CDK2 has been shown to be unsuccessful due to conformational similarities 
between the kinase active sites at residues indicated. 
Areas where the introduction of Aur-A selectivity over CDK2 has been successful due to 
conformational differences between the kinase active sites dictated by the different residues at 
the locations indicated. 
The impressive activity revealed in the work carried out to discover a new aurora 
kinase inhibitor lacking CDK activity, has yielded a number of compounds for further 
evaluation as drug candidates for the treatment of cancer. Although not the topic of 
this thesis, all of the compounds synthesised were evaluated in cell biology to gauge 
their activity in cyctotoxic tests predictive of their potential use in this field. These 
results were sufficiently encouraging to warrant further in vivo kinetic and efficacy 
evaluation of several of the most promising molecules, and to date one of these 
molecules has been selected for preclinical development with a view to undertaking 
clinical evaluation in the coming year. 
Chapter 6 
Chemical Synthesis 
(CDKs and AKs) 
Mol 
6.0 Chemical Synthesis 
6.01 Introduction to Synthesis 
Based on the similarities that exist between the cycl in -dependent kinase (CDK) and 
aurora kinase (AK) catalytic binding domains, established structure-activity data 
available and molecular modelling considerations, we proposed that structural 
modifications to the lead pyrimidine pharmacophore would be a viable synthetic 
means of enhancing either CDK9 or Aurora kinase inhibitory activity depending on 
the site and nature of the substitution. Novel compounds would all have the 
pyrimidine nucleus as the central structural scaffold and would be modified at specific 
sites depending on the design objective. 
The search for potential CDK9 selective compounds involved the introduction of a 
variety of 3- and 4-substituted anilines to the 2-position of the pyrimidine scaffold. 
The substituent on the 2-position of the thiazole remained as either a small amino, 
alkyl or alkylamino moiety as dictated by molecular modelling. The pursuit of novel 
and selective Aurora kinase inhibitory molecules, in addition to aniline substituent 
modification, involved the introduction of alternative substituents to the 2-position of 
the thiazole (Figure 67). 







Pyrimidine Scaffold to be Retained 
U 	Modification Site in Search for Selective CDK9 Molecule 
ITI U : Modification Sites in Search for Selective Aurora Kinase Molecule 
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The chemistry concerned with the synthesis of both potential CDK9 and Aurora 
selective molecules is presented as a combined entity (Chapter 6.0), whereas the 
emerging structure-activity data, biology and selection of compounds for further 
analysis has been addressed in two separate chapters (Chapters 3.0 and 5.0), one 
relating to CDK9 and the other Aurora. 
6.02 Potential Synthetic Routes to the Required Pyrimidines 
A literature survey of the approaches to the synthesis of substituted pyrimidines 
reveals a number of synthetic strategies. 
A number of pyrimidines that are substituted on the 2- and 4-positions, by a thiazole 
and an aniline respectively, have been prepared from 2,4-dichloropyrim i dine [A] in 
two synthetic steps (Figure 68)104. 
Figure 68: Two-step Synthesis of 2,4-Disubstituted Pyrimidines' °' °5 
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The first step involves the introduction of a thiazole, via palladium chemistry, to the 
pyrimidine 4-position' 0105 . There is precedent for this reaction to be carried out 
successfully using microwave chemistry ' °6 ' °7 , and the R,-substituted thiazole will 
react preferentially at the pyrimidine ring 4-position' 08 . Poor solubility of the starting 
2,4-dichloropyrimidine ultimately results in low yields, however, and the limited 
availability of the boronic acids presented some synthetic disadvantages. The second 
step, involving introduction of the aniline functionality to the pyrimidine 2-position 
under either basic' 09  or acidic' 10 conditions, can also be carried out using microwave 
chemistry" enabling a relatively large number of compounds to be synthesised with 
short reaction times. 
An alternative to the first and somewhat problematic step described above is to use a 
more soluble starting material such as 2-chloropyrimidine. The 5-position of the 
starting thiazole [B] can be deprotonated using butyl lithium' 12,  enabling thiazole 
coupling, in conjunction with a DDQ oxidation step, to give the required 4-substituted 
pyrimidine in reasonable yield' 12  The synthesis could then proceed by the route 
previously outlined" 0 (Figure 69), where the acid-catalysed removal of the 
trimethylsilyl protecting group on the 2-position of the thiazole occurs 
simmultaneously' 12 











1. n-BuLi, D20, 30°C 	
N 	CI 
HcI, MeCN, 1400C 
2-chioropyrimidine, D20,  30°C 
[B] 	2. 
3. DDQ, THF, rt (''I) 
A different synthetic route involving the conversion of a trisubstituted thiazole [C] to 
the required 2,4-disubstituted pyrimidine in two synthetic steps has been reported. 
This 5-iodothiazole can be converted to the corresponding alkynone by treatment with 
TMS-acetylene in the presence of a suitable palladium catalyst' 3 The product can be 
reacted with a substituted guanidine, under basic conditions, to furnish the 
appropriately substituted pyrimidine (ifi) (Figure 70)11 3 . This route, although efficient 
for the compounds reported, potentially lacks scope due to the limited availability of 
the necessary starting materials. 
Figure 70: Synthesis of 2,4-Disubstituted Pyrimidines from Trisubstituted Thiazole 
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A series of 2,4-disubstituted pyrimidines was prepared using 2-methylsulfanyl-
pyrimidin-4-ol [D] as a starting material (Figure 71)105.  The starting pyrimidine [D] 
was treated with an appropriately substituted amine in the presence of DMEU (1,3-  
dimethylimidazolidin-2-one) to obtain the corresponding 2-substituted pyrimidine. 
The hydroxy group on the pyrimidine 4-position was then converted to chioro by 
treatment with P0C13 105" 4 This chioro-compound could then undergo a Suzuki 
coupling reaction with suitably substituted boronic acids' 04 . 
Figure 71: Synthesis of 2,4-Di substituted Pyrimidines from 2-Methylsulfanyl-

























By far the most attractive and flexible route to the pyrimidines envisaged at the outset 
of this work was that outlined by Bredereck" 5 involving the condensation of an 
enaminone (I) and a guanidine (II) (Figure 72). This general route, as well as offering 
wide diversity by variation of the enaminone and the guanidine, was also amenable to 
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the use of microwave chemistry, enabling a large number of investigative compounds 
to be synthesised efficiently. 
6.03 Synthesis of Pyrimidines 
In the preparation of the compounds required to reach the objectives of this thesis, 
183 novel 2-amino-4-(thiazol-5-yl)pyrimidines (III) were synthesised by condensation 
of the appropriate guanidine with a corresponding enaminone following the methods 
outlined by Bredereck" 5 and summarised below (Figure 72). Two sets of starting 
materials, the enaminoketones (I) and the guanidines (II), were proposed and their 
preparation is discussed below. 
Figure 72: Synthetic Route used for Pyrimidine Synthesis 115 
R1 
N'S 





(') 	 (I') 
R 1 
a 
N 	 R3 
(I'') 
a) NaOH (leq), 2-methoxyethanol, MW 1900C, 20 mm 
6.04 Synthesis of Enaminoketone Intermediates 
The enaminone intermediates (I) [226-248] were synthesised from commercially 
available thiourea starting materials. A total of twenty-three (2E)-l-(2-alkyl-4-methyl-
I ,3 -thiazol-5-yI)-3 -(dimethylamino)prop-2-en- I -ones were synthesised using the 
general procedure described by Wang et al (Figure 73)56.116  The R 1 groups were 
selected to include a range of sizes and electronic properties designed to optimise the 
CDK9 or aurora kinase inhibitory activity depending upon the phase of the project. 
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Figure 73: General Synthetic Route to Enaminones (I) 
cl 
la 	NS 




a) pyridine (1 .5eq), MeOH, reflux 80900C,  4-16h; b) neat 
N,N-dimethylformamide dimethylacetal (6eq) or neat 
N,N-dimethylformamide diethylacetal (6eq), ref lux 110 °C, 16h. 
6.04.1 Synthesis of 2-Substituted (2E)-3-(Dimethylamino)- 1-(4-methyl- 1,3-
thiazol-5-yl)prop-2-en-1-ones (I) [218-221] 
The first series of enaminones to be synthesised contained substituents on the 2-
position of the thiazole ring {R 1 = N=CN(Me)2 (I) [218], NHMe (I) [219], NHEt (I) 
[220], CH20H [221]}. These enaminones were obtained in two steps from the 
appropriately substituted and commercially available thioureas (Figure 72)56.  In 
general, the thiourea was solubilised in warm methanol with an excess of pyridine and 
the solution cooled to 0°C before the addition of 3-chloro-2,4-pentanedione 
(exothermic addition). The mixture was allowed to warm to room temperature and the 
thiourea intermediates [197-200] were obtained as milky white precipitates in 
excellent yields (87-89%). The thiazoles thus obtained were heated in an excess of 
neat NN-dimethylformamide dimethylacetal to give the enaminones (I) [218-221] in 
good yields (6773%)56h16.  Enaminones were used in cyclisation reactions without 
further purification as HPLC analysis indicated that this was unnecessary. 
6.04.2 Synthesis of 5-acetyl-3,4-dimethyl-1,3-thiazol-2(3H)-one (I) [222] 
Synthesis of 5-acetyl-3,4-dimethyl-1 ,3-thiazol-2(3H)-one (I) [222] was carried out 
using a slightly different synthetic route (Figure 74). Commercially available 
ammonium thiocyanate was treated with sulfuric acid and water to generate 
carbonyl sulfide, which was then reacted with methylamine to give the intermediate 
isothiocyanate as a precipitate in good yield (61%)". The isolated material was 
stirred with 3 -chl oro-2,4-pentanedi one in basic methanol to give the thiazolone 
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intermediate [201] which was converted to the required thiazolinone (I) [222] using 
standard procedures 56 . 
Figure 74: Synthetic Route to 5-acetyl-3 ,4-dimethyl- 1 ,3-thiazol-2(3H)-one (I) [222] 117 
0 i-NH3Me 
NH4SCN + H2SO4 	am Cos 	
a 
+H20 	 H 
[201] 
I b 
0 	 0 
—N 	 (I)[2221 
\ 
a) MeNH2 ; b) 3-chloro-2,4-pentanedione (leq), pyridine (1.5eq), MeOH, rt 
4-6h; C) neat NN-dimethylformamide dimethylacetal (6eq), reflux 110 °C 16h. 
6.04.3 Synthesis of Pyridinyl-Substituted (2E)-3-(Dimethylamino)-1-(4-methyl-
1,3-thiazol-5-yI)prop-2-en-1-ones (I) [223-228] 
Synthesis of enaminones with heteroaryl substituents on the 2-position of the thiazole 
(I) [223-228] was carried out using a similar synthetic route 16,116  A series of thioureas 
with substituted and unsubstituted pyridinyl-ring moieties underwent conversion to 
their corresponding thiazoles [202-207] by the methods previously discussed. The 
starting materials were less soluble in comparison to thioureas with amino or 
alkylamino substituents, and consequently the first step required heating to reflux to 
proceed and longer reaction times to reach completion. Thiazoles [202-207] 
precipitated out of the reaction solvent on cooling as white or yellow solids (34-83%) 
and were used in the next step without purification. They were then converted to their 
corresponding enaminones [223-228] in reasonable yields (54-87%) by refluxing in 
neat NN-dimethylformamide dimethylacetal (Figure 75)56,116.  
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Figure 75: Comparative Yields of Pyridinyl-Substituted Thiazoles 
Thiazole 	 Enaminoketone 
Compound No. R 1 Thiazole Yield Enaminoketone 
(I) Yield (%) 
and 74 81  
(I) [2231 
and 83 69  
(I) [2241 
CF3 
and 34 54 
(I) [225] 
and N 82 87 
(I) [2261 
(R=H) and N 51 71 
(I) [227] (R = Me) NR 
-' -- S 
(R = H) and 72 69 
(I) [228] (R = Me) 
'-. NR - 5 
The lowest yield was obtained in the synthesis of the disubstituted enaminone (I) 
[225]. This thiourea contained chioro and trifluoromethyl substituents on the 
pyridinyl-ring, which resulted in a slower conversion of the thiourea starting material 
to the appropriate thiazole [204]. With the exception of (I) [227] and (I) [228], all the 
enaminones precipitated out of the reacting solvents as orange crystalline solids. In 
the case of the attempted preparation of these two enaminones, isolation by 
evaporation of the solvent gave enaminone products having a molecular weight 15 
AMU higher than expected and an additional singlet, corresponding to three protons, 
in the proton NMR spectrum. This evidence suggested that, in the presence of the neat 
N,N-dimethylformamide dimethylacetal, the secondary amino group had been 
methylated to give N-methylated analogues (I) [227] and (I) [228]. Such N- 
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methylation in the presence of NN-dimethylformamide dimethylacetal has been 
previously reported" "", thus supporting the structural assignment of these products. 
6.04.4 Synthesis of (2E)-3-(Dimethylamino)- 1-{4-methyl-2-[(2-phenyl)amino]-  1,3-
thiazol-5-yljprop-2-en-1-ones (I) [229-233] 
In light of this observed methylation, a number of phenylamino-substituted thiazoles 
were subsequently synthesised. Thiourea starting materials were heated to refiux in 
basified methanol with 3-chloro-2,4-pentanedione and the resulting thiazoles [208-
212] were collected as precipitates in excellent yields (77-93%). The thiazoles 
obtained were heated to reflux in neat NN-dimethylformamide dimethylacetal and the 
expected methylated enaminones" 8 " 9 (I) [229-232] were obtained in reasonable 
yields (40% - quant.) as orange residues (Figure 76). 
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a) pyridine (1 .5eq), MeOH, reflux 80 - 90 °C, 10-1 6h; b) neat NN-dimethylformamide 
dimethylacetal (6eq), reflux 110°C, 16h; C) neat NN-dimethylformamide diethylacetal 
(6eq), reflux 110°C, 16h 
Given the ease of N-methylation using this reagent the synthesis of the required 
primary amino-analogues was investigated using an alternative procedure. In place of 
105 
N,N-dimethylformamide dimethylacetal, thiazoles [208 and 211] were heated to 
reflux in neat NN-dimethylformamide diethylacetal, which would not be expected to 
undergo the corresponding ethylation reaction, and the required enaminones (I) [239-
240] were isolated in good yield and high purity (Figure 76). The methylated and 
unmethylated enaminones (where synthesised) have been summarised for comparison 
(Figure 77). 
Figure 77: Summary of Methylated (I) [237-241] and Unmethylated Phenyl-
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6.04.5 Synthesis of Enaminones Containing Heteroatoms Other Than Nitrogen 
(I) [234-237] 
Synthesis of sulphur- and oxygen-containing enaminones (I) [234-237] was achieved 
by the conversion of thiophene-, thiazole- or morpholine-ring substituted thioureas, 
using similar procedures to those previously described 56 . The thioureas were heated to 
reflux in basified methanol with 3 -chi oro-2,4-pentanedione and after reaction times of 
16 - 20 h, the corresponding thiazoles [214-217] were collected in good yield (63-
80%). The corresponding enaminones (I) [234-237] were also obtained in good yield 
(60-83%) as yellow or orange solids, by treating with neat NN-dimethylformamide 
dimethylacetal at reflux (Figure 78). 
Figure 78: Comparative Yields 
R1 
Compound No.  Thiazole Enaminoketone (I) 
and (I) [234] Y--S- 77 83 
9 and (I) [235] 0 
r_ 	O 
63 60 
and (I) [236] 80 69 
and (I) [237] N 80 79 
Synthesis of (2E)-3-(dimethylamino)- I -[2-(2,4-dimethylphenyl)-4-methyl- I ,3-thiazol- 
5 -yl]prop-2-en- I -one (I) [238], from the appropriate starting material (2,4- 
dimethylphenylthiourea), was carried out using similar conditions to give the required 
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thiazole [213] as an off-white solid and the corresponding enaminone (I) [238] as an 
orange oil, both in reasonable yields (38% and 64%, respectively). 
6.05 Synthesis of Guanidine Intermediates (II) [291-318] 
Twenty-eight guanidine intermediates (II) [291-398] were synthesised by the 
synthetic route outlined by Zimmerman 120 , from commercially available substituted 
nitro- or amino-benzene starting materials (Figure 79). 






R3 	 NH 	R3 
(I') 
a) Pd/C, H 2, EtOH, rt 16-24h; b) HNO3(2eq), cyanamide (2eq); DOH, reflux 110 °C, 16-24h. 
6.05.1 Synthesis of Guanidines with an Acetamide Moiety 
N-(3- { [Amino(imino)methyl]aminojbenzyl)acetamide (II) [291] and 
N-(4-{[Amino(imino)methyl]amino}benzyl)acetamide (II) [292] 
Synthesis of phenylguanidine intermediates with an acetamide functionality on the 3- 
or 4-position was achieved from the appropriate nitrobenzylamine starting materials 
(Figure 80). 
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a) acetyl bromide (1 .5eq), pyridine, rt 4-16h; b) Pd/C, H 2 , EtOH, rt, 16-24h; C) HNO3 , cyanamide, EtOH, 
ref lux 110°C, 16-24h. 
The free amines were acetylated using an excess of acetyl bromide under basic 
conditions ' 21 . The acetamido nitrobenzenes [242-243] were obtained in good yield 
(80-85 %) and purified using flash chromatography. Nitro groups were then reduced 
using catalytic hydrogenation' 22  to obtain the required aniline derivatives [266-267] in 
good yield (75-83%) as pure crystalline solids or residues (purity 93-100%) 
eliminating the need for further purification. The final step involved the reaction of 
the anilines with an excess of 50 % w.w. cyanamide in acidic ethanol to afford the 
required guanidines (H) [291-292]. 56,120,123  
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6.05.2 Synthesis of Guanidines with a Sulfonamide Moiety 
N-(3- { [Amino(imino)methyl]amino}benzyl)methanesulfonamide (II) [293] and 
N-(3-{ [Amino(imino)methyl]amino}benzyl) -1 ,1 ,1-trifluoromethanesulfonamide 
(II) [294] 
The appropriate nitrobenzylamine was methanesulfonylated using an excess of either 
methanesulfonyl chloride or trifluoromethanesulfonyl chloride in dichioromethane 
(Figure 81)124. 


















a) methanesulfonyl chloride or tifluoromethanesulfonyl chloride (1.5 eq), DCM, rt 2-6h; b) Pd/C, H2, EtOH, rt 
16-24h; c) HNO3 (2eq), cyanamide (2eq); EtOH, reflux 110 °C, 16-24h. 
R = Me [244, 268 and 293] or CF 3 [245, 269 and 294]. 
The sulfonylated nitrobenzenes [244-245] were obtained in short reaction times (2 - 6 
h) as white solids (78-97%) purified by flash chromatography. Nitro-groups were 
reduced to the corresponding aniline derivatives [268-269] in good yield (91-97%) 
using catalytic hydrogenation ' 2 ' and were subsequently converted to the 
corresponding guanidines (H) [293-294] in reasonable yield (72-82%) using 
established procedures 56" 20" 23 . 
6.05.3 Synthesis of Additional Guanidines with a Sulfonamide Substituent (II) 
[295-3051 
Introduction of sulfonamide substituents to the 3- and 4-positions on the aniline ring 
was investigated using either 3- or 4-nitrobenzenesulfonamide as a starting material. 
Alkylation of the free benzenesulfonamide moiety using methyl iodide and ethyl 
iodide' 25  proved quite problematic (Figure 82). 
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Figure 82: Synthetic Route to Sulfonamide Alkylation 
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a) acetyl bromide (1 .2eq), pyridine, rt 16h; b) alkyl iodide (6- 12 eq), KOH, DMF, reflux 110 °C, 24h; c) 
alkyliodide (Seq), KOH, DMF, sealed tube 550C, 8-1 Oh; d) alkyl iodide (6eq), KOH, DMF, MW 220 0C, 20 mm; 
e) Pd/C, H 2, EtOH, rt 16-24h; f) HNO3 (2eq), cyanamide (2eq); EtOH, reflux 110 °C, 16-24h. 
R = Me [247, 272 and 296], R = Et [248, 272 and 297] 
Routes b and d were unsuccessful 
Alkylation of the sulfonamide moiety could only be achieved using sealed tube 
conditions, where the overall yield was relatively low (4655%)125.  Alkylated 
intermediates [247-248] were separated from the starting material using flash 
chromatography and underwent conversion to the corresponding guanidines (II) [296-
297] using standard conditions. 
Synthesis of sulfonamide analogues with benzyl substituents was unsuccessfully 
attempted using equivalent procedures 121  (Figure 83). 






a)benzyl bromide (1.5eq), pyridine, rt 16h. 
benzy bromide (1 .5eq), DCM, rt 16h. 
benzyl bromide (1 .5eq), KOH, DMF, reflux 110 °C, 16h 
benzyl bromide (1 .5eq), KOH, DMF, MW 200 0C, 20mm. 
Consequently the required N-benzenesulfonamides were synthesised from the 
corresponding nitrobenzene sulfonyl chlorides, by reaction with benzylamine in 
DCM' 26 . The benzylsulfonamide intermediates [249-250] were reduced to give the 
corresponding anilines [273-274] (90%) and finally converted to the desired 
guanidines [298-299], being obtained as oily residues (70-100% purity) (Figure 84). 
Figure 	84: 	Synthetic 	Route 
	to 	3-{[Amino(imino)methyl] amino) -N- 
ben zylbenzenesulfon amide (II) [298] and 4-{[Amino(imino)methyl] amino) -N-







0 	 [273] 	
H2N— 	\ 0 
NH 	S 




	 b 	C 'T> 0 10 	 10 	 HN 
CI 	 NH 	 [2741 	H2N— 	-" NH 
NH 
(II) [299] 
a) benzylamine (1.2eq), DCM, rt 16h; b) Pd/C, H2, EtOH, rt 16-24h; C) HNO3 (2eq), cyanamide (2eq); EtOH, reflux 
110°C, 16-24h. 
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Synthesis of additional guanidines with either a methoxyethyl-sulfonamido' 27 or a 
hydroxyethyl-sulfonamido' 28 moiety on either the 3- or 4-positions (H) [300-303] was 
carried out under similar reaction conditions using 2-methoxyethylamine and 
ethanolamine respectively. The morpholine-sulfonamido guanidines (H) [304-305] 
were prepared in a comparable manner in quantitative yield 56" 27 . 
6.05.4 Synthesis of Ethyl ( 3-{[Amino(imino)methyl]amino}phenyl)acetate (II) 
[306] 
Replacement of the sulfonamide substituent with an acid-containing substituent was 
attempted using a commercially available starting material (Figure 85). 
Figure 85: Synthesis of Ethyl 3-1 [amino(imino)methyl]amino } benzoate 
a 	
HN H2N_4ç 	
H2N — 	-e 
NH 	) 
°=K 
OH 	 0 
(II) [306] 
a) HNO3 (2eq), cyanamide (2eq); EtOH, reflux 110 °C, 16-24h 
3-Aminophenylacetic acid was reacted with cyanamide in acidic ethanol under 
standard reaction conditions 56" 20" 23 . Under these conditions the acid, as expected, 
underwent conversion to its corresponding ester during the course of the reaction and 
the guanidine derivative of the ester (II) [306] was isolated from the reaction mixture 
quantitatively. 
6.05.5 Synthesis of Guanidines with Ring Substituents 
1-(4-Piperidin-1-ylphenyl)guanidine (II) [307], 
1-(4-Pyrrolidin-1-ylphenyl)guanidine (II) [308] and 
1-(4-Thiomorpholin-4-ylphenyl)guanidine (II) [309] 
A number of guanidine intermediates with saturated ring-substituents in the 4-position 
on the aniline ring (II) [307-309] were synthesised. These compounds were obtained 
using 4-fluoronitrobenzene as a starting material, followed by the standard guanidine 
synthesis 56,120,123 (Figure 86). 
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(257-2581 	 [281-2821 	







[259] 	 [2831 	
NH 	(II) [309] 
a) arylamine (leq), K2CO3,  DMSO, retlux 1000C, 16h; b) Pd/C, H 2 , EtOH, rt 16-24h; c) HNO 3 (2eq), cyanamide (2eq), EIOH, reflux 
110°C, 16-24h. 
X = H [257, 281 and 307] or S [258, 282 and 308]. 
The appropriate amino-substituent was introduced to the 4-position using the 
appropriate amine under basic conditions in DMSO 129, furnishing the desired 
substituted nitrophenyl derivatives in good yields (72-99%) [257-259]. Nitro 
compounds were reduced using catalytic hydrogenation 122  producing the desired 4-
substituted amines (73-93%) [281-283], that were converted to their corresponding 
guanidines (5 1-74%) using standard conditions 56,120,123.  The guanidines (H) [307-309] 
were obtained quantitatively as oils and were used in further steps without additional 
purification. 
6.05.6 Synthesis of Disubstituted Guanidines 
1-(3-Methyl-4-piperidin-1-ylphenyl)guanidine (II) [310], 
1-(3-Methoxy-4-piperidin-1-ylphenyl)guanidine (II) [311], 
1-(3-Methyl-4.morpholin-4-ylphenyl)guanidine (II) [312] and 
1-(4-Methoxy-3-methylphenyl)guanidine (II) [313] 
A number of di-substituted guanidine intermediates (II) [310-313] were synthesised 
using an equivalent synthetic route from the appropriately substituted 
fluoronitrobenzene starting materials (Figure 87). Guanidine (II) [313] was 
synthesised in one-step from its corresponding aniline starting material 56" 20" 23 . 
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Figure 87: Synthesis and Comparative Yields of Disubstituted Guanidines 





R4 	 [293-295] 	 NH 	R4 
[268-270] 	 (II) [310-313] 
a) arylamine (1 eq), KOH, DMSO, reflux 100 0C, 1 6h; b) Pd/C, H 2, EtOH, rt 1 6-24h; c) HNO3 (2eq), cyanamide 
(2eq); EtOH, reflux 110°C, 16-24h. 
Compound (II) No. R3 K4 Yield (%) 
(II) 310 Piperidine Me 59 
(II) 311 Pipendine OMe 67 
(II) 312 Morpholine Me 63 
-
(11) 313 OMe Me 77 
6.05.7 Synthesis of 1-(1,3-Benzodioxol-5-yI)guanidine (II) [314] and 1-(2,3-
Dihydro-1,4-benzodioxin-6-yI)guanidine (II) [315] 
Synthesis of guanidines containing 3,4-methylenedioxy substituents (II) [314-315] 
was also achieved using standard conditions from commercially available aniline 
starting materials 56,120,123.  The products (TI) [314-315] were obtained in good yield 
(74-83%) as purple precipitates from the cooled reaction mixtures (Figure 88). 







a) HNO3 (2eq), cyanamide (2eq); EtOH, reflux 110 °C, 
16-24h. 
n = 1 [314] or 2 13151. 
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6.05.8 Synthesis of Guanidines with Cyclic Substituents on the 3-Position of the 
Aniline Ring 
1-[3- (Thiomorpholin-4-ylmethyl)phenyl]guanidine (II) [316], 
1-{ 3- [(4-Methylpiperazin-1-yl)methyl]phenyl}guanidine (II) [317] and 
1-[3- (Morpholin-4-ylcarbonyl)phenyl]guanidine (II) [318] 
Guanidines substituted in the 3-position with either a thiomorpholinomethyl (II) 
[316], a piperazinomethyl (II) [317] or a morpholino-amide functionality (II) [318], 
were prepared by analogous routes (Figure 89)130. 
Figure 89: Synthesis of 3-Substituted Guanidines 
CI 
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a) thiomorpholine (X = S) or methylpiperazine (X = NMe) (1 .2eq), DCM, 0 °C - rt, 16h; b) morpholine (1.5 eq), DCM, 
0°C - rt, 16h; c) Pd/C, H2, DOH, rt 16-24h; d) HNO3 (2eq), cyanamide (2eq), DOH, reflux 110 °C, 16-24h. 
X = S [263, 287 and 316] or We [264, 288 and 317] 
Starting from the acid chloride or chloromethyl derivatives, heterocyclic rings were 
introduced in good yields (71-74%) by reaction with thiomorpholine [263], 
methylpiperazine [264] or morpholine [265], respectively' 30 . Reduction of the nitro 
group using palladium-catalysed hydrogenation' 22  produced the desired anilines [287-
289] in good yields (80-97%). Guanidines (II) [316-318] were obtained quantitatively 
from reaction of the amines with HNO 3 and cyanamide in ethanol 56" 20" 23 . The 
reaction mixtures were dried and washed with ether and purity of the resulting 
residues was determined by HPLC (100%). The guanidines were used in subsequent 
cyclisation reactions without purification. 
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Attempts were made to synthesise a number of other di- and tn-substituted 
phenylguanidines by direct chiorosulfonation of 4-morpholinonitrobenzene, 4-
morpholinophenylacetamide or 4-fluorophenylacetamide 131 . None of these reactions 
gave the intermediates required for the synthesis of the corresponding guanidine 
analogues and the attempted synthesis of these compounds was abandoned. 
6.06 Preparation of 2-Amino-4-(thiazol-5-yI)pyrimidines 
Using the procedures described in the previous sections, a series of twenty-two 
enaminoketones (I) [218-240] and twenty-eight guanidines (II) [291-318] were 
prepared. This collection of reagents gave the opportunity to prepare 666 pyrimidines, 
of which 183 are reported in this thesis. The selection of pyrimidines for synthesis 
was directed by structure-activity considerations relative to the objectives of the 
project. In addition, however, the project yielded a diverse and valuable library of 
molecules useful for probing kinase activity in areas parallel to, but not directly linked 
with, the subject of this thesis. 
In general, cyclisation reactions of this type had been previously carried out under 
standard reflux conditions in 2-methoxyethanol at 140 °C for 14 - 16 h. This greatly 
limited the speed at which a significant number of investigative compounds could be 
synthesised, and alternative conditions were sought utilising microwave chemistry. 
The suitability of microwave chemistry was first established through the successful 
resynthesis of a number of existing compounds. A series of experiments was therefore 
designed to determine optimal reaction conditions including time, temperature and 
solvent. The first parameter to be optimised was time and it was determined that 20 
min reaction time resulted in the optimum yield. Secondly, reaction temperature was 
explored with an optimal temperature of 190 °C being determined. Higher 
temperatures increased by-product formation, while lower temperatures resulted in 
lower yields. Finally, the solvent used in the reaction was examined. The previous 
method utilised 2-methoxyethanol and resulted in purification difficulties. The 
cyclisation reactions were performed in a range of solvents including methanol, 
ethanol, DMSO, DMF and acetonitrile. It was determined that while acetonitrile was 
the most effective of these it was still not as effective as 2-methoxyethanol. The lower 
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volume of solvent required in microwave reactions (< 5 mL) reduced the purification 
difficulties slightly. This combined with the shortened reactions times necessary in 
microwave synthesis resulted in significantly reduced by-product formation, 
eliminating many of the purification issues previously encountered. This new route 
was then used to synthesise 183 novel pyrimidines. As reported in the experimental 
section, all the intermediate enaminoketones (I) and guanidines (H) were 
characterised by the available range of analytical techniques including 'H-NMR and 
MS, and their purity determined using HPLC. The final pyrimidine compounds have 
been characterised using 'H-NMR, 13C-NMR, HRMS and mp and their purity 
determined via HPLC. A complete analysis of one of the final pyrimidines (Ill) is 
discussed below. Although this depth of data for each of the final compounds is not 
included here, that recorded, is presented in the experimental section and can be 
interpreted largely by analogy with the data discussed below for pyrimidine (III) [73] 
(Figures 90-92). 
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Compound (III) 73 was assessed to be pure as the HPLC trace showed only one peak 
and the FIRMS correlated with the calculated value. 
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'H NMR (DMSO-d6): 8 2.77 (s, 3H, CH3), 3.16 (d, J= 4.5 Hz, 3H, CH3), 3.36 (dd, JA 
= JB = 4.5 Hz, 4H, morph-H), 3.61 (s, 3H, CH3), 3.93 (dd, JA = JB = 4.5 Hz, 4H, 
morph-H), 7.24 (d,J= 5.5 Hz, 1H, pyr-R), 7.65 (d,J= 8.5 Hz, 1H, phe-If), 8.30 (d,J 
= 8.5 Hz, 1H, phe-H), 8.34 - 8.37 (m, 1H, NH), 8.53 (s, 1H, phe-H), 8.65 (d, J= 5.5 
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13C NMIR (DMSO-d6): 19.38 (CR 3), 20.38 (CH3), 31.61 (CH3), 46.03 (2 x morph-
CR2), 66.30(2 x morph-CR 2), 108.02 (CH), 118.29 (QC), 119.89 (CH), 123.51 (CH), 
129.75 (QC), 133.71(QC), 135.34 (CH), 139.74 (QC), 153.47 (QC), 158.27 (CH), 
159.50 (QC), 159.94 (QC), 170.38 (QC). 
A.hIv.SIr.th,y: 
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(111)73 	
4 	 2 Wgnah ..  
rP 
IH 	 • 
I'.ac 
• 	 .2 	 6*d7 
it Ii J L 
160 	 140 	 120 	 100 	 80 	 66 	 - 	46 	 10 pp. 
0.2 arboaS 
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The analytical data confirm the structure of compound (ifi) [73]. It was decided that 
all compounds submitted for biological analysis should have a purity of> 90%, with 
their purity determined by HPLC analysis. A gradient solvent system using H20 and 
MeCN (each containing 0.1% TFA) was used over 25 mm (Figure 90). The proton 
NMR of compound (III) [73] has two signals in the aromatic region of the spectra 
common to all final compounds in this library. These correspond to two pyrimidine 
protons and are observed as two doublets, each having a coupling constant of 
approximately 5.5 Hz (Figure 91). The carbon NMR of compound (III) [73] has 18 
signals corresponding to 20 carbons. The four morpholine carbons are observed as 
two equivalent highfield signals, and their corresponding aromatic signals were 
identified using DEPT analysis (Figure 92). IR analysis of this series of compounds 
did not prove particularly useful as a confirmative tool in their structural analysis due 
to the lack of functional moieties with characteristic signals. Nevertheless, spectra of 
all final compounds were determined but have not been presented in the experimental 
section. 
A complete list of the 183 novel compounds synthesised is presented (Figure 93). 






Number R 1 
(HI)  
R2 R3 
5 Me H H CH2NHAc 
6 NHMe H H CH2NHAc 
7 NHEt H H CH2NHAc 
8 Thiaz H H CH2NHAc 
9 Me H CH2NHAc H 
0 NH2 H CH2NHAc H 
11 NITMe H CH2NHAc H 
12 NHEt H CH2NHAc H 
13 Thiaz H CH2NHAc H 
14 Me H H CH2NH2 
15 NHMe H H CH2NH2 
16 NHEt H H CH2NH2 
17 Thiaz H CH2NH2 H 
18 Me H H CH2NHS02Me 
19 NH2 H H CH2NHS02Me 
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Number R 1 R2 R3 R4 
20 NHMe H H CH2NHS02Me 
21 NHEt H H CH2NHS02Me 
22 Thiaz H H CH2NHS02Me 
23 Me H H CH2NHS02CF3 
24 NH2 H H CH2NHS02CF3 
25 NHMe H H CH2NHS02CF3 
26 NHEt H H CH2NHS02CF3 
27 Thiaz H H CH2NHS02CF3 
28 Me H H S02NH(CH2) 20H 
29 NH, H H S02NH(CH2)20H 
30 NHMe H H S02NH(CH2)20H 
31 NHEt H H S02NH(CH2)20H 
32 Thiaz H H S02NH(CH2)20H 
33 Me H H S02NH(CH2)2OMe 
34 NH2 H H S02NH(CH2) 2OMe 
35 NHMe H H S02NH(CH2)2OMe 
36 NHEt H H S02NH(CH2)2OMe 
37 Thiaz H H S02NH(CH2)2OMe 
38 Me H S02NH(CH2) 20H H 
39 NH2 H S02NH(CH2 ) 20H H 
40 NHMe H S02NH(CH2) 20H H 
41 NHEt H S02NH(CH2) 20H H 
42 Thiaz H S02NH(CH2)20H H 
43 Me H S02NH(CH2)2OMe H 
44 NH2 H S02NH(CH2) 2OMe H 
45 NHMe H S02NH(CH2)2OMe H 
46 NHEt H S02NH(CH2) 2OMe H 
47 Thiaz H S02NH(CH2) 2OMe H 
48 NHMe H H S02NH2 
49 NHEt H H S02NH2 
50 Thin H H S02NH2 
51 Me H H S02NHMe 
52 NH2 H H S02NHMe 
53 NHMe H H S02NHMe 
54 NHEt H H S02NHMe 
55 NH2 H H S02NHEt 
56 NHMe H H S02NHEt 
57 NHEt H H S02NHEt 
58 Thiaz H H S02NHEt 
59 NHMe H H S02NHBn 
60 NHEt H H S02NHBn 
61 Thin H H S02NHBn 
62 Me H S02NHBn H 
63 NH2 H S02NHBn H 
64 NI{Me H S02NHBn H 
65 NHEt H S02NHBn H 
66 Thiaz H S02NHBn H 
67 NH2 H H S02-morpholine 
68 NHMe H H S02-morpholine 
69 NHEt H H S02-morpholine 
70 Thiaz H H S02-morpholine 
71 Me H Me S02-morpholine 
72 NH2 H Me S02-morph line 
73 NHMe H Me S02-morph line 
74 NI-JEt IH Me I S02-morpholine 




R2 R3 R4 
89 Me H Thiomorpholine H 
90 Me H Piperidine H 
91 Me H Pyrrolidine H 
92 Me H Morpholine Me 
93 	1 Me H Piperidine Me 
94 Me H H CH2-thiomorpholine 
95 Me H H CO-morpholine 
96 NH2 H Thiomorpholine H 
97 NH2 H Piperidine H 
98 NH2 H Pyrrolidine H 
99 NH2 H Morpholine Me 
100 NH2 H Piperidine Me 
101 NH2 H Morpholine OMe 
102 NH2 H OMe Me 
103 NH2 OMe H OMe 
104 NH2 H H CO-morpholine 
105 NH2 H H CH2-thiomorpholine 
106 NH2 H OCH20 
107 NHEt H Morpholine H 
108 NHEt H Thiomopholine H 
109 N1-{Et H Piperidine H 
110 NHEt H Morpholine Me 
11 - NHEt H Piperidine Me 
12 - NHEt H Morpholine OMe 
13 - NHEt H Morpholine Cl 
14 - NHEt Cl Morpholine Cl 
15 - NHEt H OMe Me 
16 NHEt OMe H OMe 
117 NHEt H OCH20 
118 NHEt H O(CH2) 20 
119 NHMe H Morpholine H 
120 CH20H H Morpholine H 
121 Thiophene H Morpholine H 
122 Thiazole H Morpholine H 
123 CH2SO2-Thiophene H Morpholine H 
124 3-Pyridinyl H Morpholine H 
125 3 -Ethyl -4-pyridinyl H Morpholine H 
126 4-Methyl-3-Pyridinyl H Morpholine H 
127 N(Me)-3-Pyridinyl H Morpholine H 
128 N(Me)-2-Pyridinyl H Morpholine H 
129 N(Me)-4- H 
Chlorophenyl  
Morpholine H 
130 N(Me)-3,5- H 
Dichlorophenyl  
Morpholine H 
131 3-Pyridinyl H S02NH(CH2) 2OMe H 
132 3-Pyridinyl H CH2NHAc H 
133 3-Pyridinyl H H CH2NHAc 
134 3-Pyridinyl H H CH2NH2 
135 1 3-Pyridinyl OMe OMe OMe 
136 3-Pyridinyl OMe H OMe 
137 3-Pyridinyl H OMe Me 
138 3-Pyridinyl H Morpholine Cl 
139 3-Pyridinyl Cl Morpholine Cl 
140 3-Pyridinyl H Morpholine OMe 
141 3-Pyridinyl H 4-Acetylpiperazine H 
142 3-Pyridinyl H Thiomorpholine H 
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Number R 1 
(HI)  
R2 R3 
143 3-Pyridinyl H Pyrrolidine H 
144 3-Pyridinyl H Piperidine H 
145 3-Pyridinyl H Piperidine Me 
146 3-Pyridinyl H OCH20 
147 3-Pyridinyl H O(CH2)20 
148 Thiazole H Morpholine Cl 
149 N(Me)-3,5- H 
Dichiorophenyl  
Morpholine Cl 
50 - 4-Morpholinophenyl H Morpholine Cl 
151 Thiazole Cl Morpholine Cl 
152 NH(CH2)2Ph OMe OMe OMe 
53 NH(CH2 )2Ph OMe H OMe 
154 NH(CH2 )2Ph H Morpholine H 
155 NH(CH2 )2Ph H 4-Acetylpiperazine H 
156 NH(CH2 )2Ph H 4-Benzylpiperazine H 
157 NH(CH2)2Ph H O(CH2) 20 
158 NH(CH2 ) 2Ph H H Me 
159 NH(CH2) 2Ph H H CO-Morpholine 
160 NHPh H 4-Acetylpiperazine H 
61 - NH(CH2)Ph H 4-Acetylpiperazine H 
62 NHPh H Morpholine H 
63 NH(CH2)Ph H Morpholine H 
64 NH-Phenyl H 4-Acetylpiperazine H 
65 N(Me)-Phenyl H Morpholine H 
66 N(Me)CH2-Phenyl H 4-Acetylpiperazine H 
167 Thiophene H H CH2NHAc 
168 Thiophene H 4-Acetylpiperazine H 
169 N(Me)-3-Pyridinyl H 4-Acetylpiperazine H 
170 CH20H H Piperidine H 
171 CH20H H Morpholine OMe 
172 CH20H H Piperidine OMe 
173 CH20H H Morpholine Me 
174 CH20H H Piperidine Me 
175 NHMe H OMe Me 
176 3-Ethyl-4-pyridinyl H H CH2NHAc 
177 3-Ethyl-4-pyridinyl H S02NH(CH2)20H H 






180 4-Trifluoromethyl-6- H 
chloro-2-pyridinyl  
H CH2NHAc 
181 4-Methyl-3-pyridinyl H H CH2NHAc 
182 N(Me)CH2Ph H H CH2NHAc 
183 N(Me)-3,5- H 
Dichiorophenyl  
H CH2NHAc 
184 1 CH2SO2-Thiophene H 4-Acetylpiperazine H 
185 2,4-Dimethylphenyl H Morpholine H 
186 4-Morpholinophenyl H Morpholine H 
187 4-Morpholinophenyl H 4-Acetylpiperazine H 
188 NH-Phenyl OMe H OMe 
189 NH-Phenyl H 4-Benzylpiperazine H 
190 NHEt H H Me 
191 NHMe H H Me 
192 NH2 H H CH2COO(CH 2) 2 
OMe 
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Number R 1 R2 R3 
(III)  
193 NHMe H H CH2COO(CH2)2 
OMe 
194 NHEL H H CH2COO(CH2 ) 2 
OMe 
195 Thiaz H CH2NHCO-2- 
Pyridinyl  
196 Me H H CH2NHCO-2- 
Pyridinyl 
Some post-cyclisation modifications of the pyrimidine products were carried out and 
are described below. 
6.07 Synthesis of Products with an Acetamide Functionality and Their Cleavage 
(III) [5-13] 
Synthesis of 2-amino-4-(thiazol-5-yl)pyrimidines with a 3 -ethyl acetam ido aniline 
substituent was carried out using both standard reflux conditions and microwave 
chemistry. Cyclised products (III) [5-7] were isolated using flash chromatography, 
with microwave chemistry producing slightly higher yields than standard refluxing. 
The free amino compounds (HI) [14-16] were prepared by hydrolysis of the 
corresponding acetamides (III) [5-7] under acidic conditions (Figure 94)I32 






L JLNH2 Nc  NN 
H H 0 
(111) 5-7 	 (111) 14-16 
a) HCl/MeOH (4:1), retlux 125 0C, 8h. 
A1 = Me, NHMe, NHEt 
6.08 Sulfonamide-Bond Formation (III) [20 and 25] 
Introduction of a methylsulfonyl functionality to the free ethylamine substituent on 
the 3-position of the aniline ring in the cyclised pyrimidine structure, using 
alkylsulfonyl chlorides under basic conditions, was successfully carried out to 
produce the sulfonamide-protected derivatives (III) [20 and 25] albeit in very low 
yield (10 - 15%). The reaction was carried out using sodium hydride and DMF 
(Figure 95)133 
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Figure 95: Sulfonamide-Bond Formation 
	
R 	 R 1 
N=' N=< 
a S 
(N 	 (N 
N N 	 N N"f::) 	
S., R' 
(111) 18-19 
a) methanesulfonyt chloride or trifluoromethanesulfonyl chloride (leq), 
NaH (leq), DMF, 0°C - it 16h. R 1 = NHMe, R'= CH3 or CF3 
The low yield of these reactions prompted investigation of an alternative synthetic 
route to facilitate the synthesis of additional analogues. Introduction of the 
methanesulfonyl or trifluoromethanesulfonyl moiety to the appropriate nitrobenzene 
starting material, prior to the cyclisation step, was successfully carried out using the 
standard guanidine synthetic route 120 . The resulting cyclisation reactions afforded the 
desired sulfonamide-protected products (III) [18-27] in slightly higher yields (19-
32%) and in shorter reaction times (Figure 96). 
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a) Guanidines [293-294], NaOH, 2-methoxyethanol, MW 190 0C, 20 min. 
R 1 = Me, NH2, NHMe, NHEI. and R'= Me(II) [18-22] or CF3 [23-27] 
(III) No. Type R 1 R' Yield (%) Purity (%) 
(III) [18] 1  Me Me 32 100 
(III) [19] 1  NH2 Me - 26 92 
(III) [20] 1  NHMe Me 26 96 
(III) [21] 1  NHEt Me 25 92 
(III) [22] 2 Thiazolone Me 29 100 
(III) [23] 1 Me CF3 22 100 
(III) [24] 1 NH2 CF3 29 82 
(III) [25] 1 NHMe CF3 21 81 
(III) [26] 1 NHEt CF3 22 100 
(III) [27] 2 Thiazolone CF3 19 90 
6.09 Amide-Bond Formation (III) [195-196] 
Synthesis of 2-amino-4-(thi azole-5 -yl)pyrim i dines with a free ethylamine moiety 
facilitated additional reactions at this position. Introduction of an amide bond under 
standard conditions 134  was successfully carried out albeit in very low yields (2 and 
24%) to give pyrimidines (III) [195-196] (Figure 97). 
128 






L N IOLNH2 
N={ 
a 










A diverse library of 183 pyrimidines (30% of the possible combinations) was 
prepared and each of the individual molecules characterised and submitted for 
biological evaluation. The library was generated along lines guided by SAR 
considerations and facilitated the achievement of the expressed medicinal chemistry 
objectives of this thesis. The lead pharmacophore was structurally modified at various 
positions, allowing the identification of different sites in this structure at which kinase 
selectivity could be introduced. 
It was determined that CDK9 selectivity over other CDK's was best achieved, in this 
series of analogues, by having a small alkylamino substituent on the 2-position of the 
thiazole and a disubstituted aniline component. The most selective analogues were 
shown, via various MOA studies, to behave in vivo as expected. They inhibited 
polymerisation of Ser-2 and Ser-5 in the CTD of RNAPII and were shown to 
selectively induce apoptosis in tumour cells. These analoges represent a valuable 
insight into the design of selective CDK9 anti-tumour agents. 
Aur-A kinase selectivity over the CDK's was possible through the introduction of 
large bulky substituents on the 2-position of the thiazole and a disubstituted aniline 
component which, included a methyl or methoxy group on the anilino 3-position and 
a cyclic moiety on the 4-position. A number of compounds that were selective for 
Aur-A in comparison to the other CDK's tested were successfully synthesised and 
many have shown to be active in vivo. 
In addition this accumulated collection of pyrimidines comprises a valuable collection 
of molecules, which can be realistically classified as a focused kinase library, and be 
used in a chemical genetics approach to understanding kinase function and control. 
Indeed certain molecules emanating from this library have been identified as potent 
inhibitors of other kinases, although these were not the subjects of this thesis and are 





Melting points were determined with a LEICA testo-720 electrothermometer and are 
uncorrected. Analytical and preparative RP-HPLC was carried out using Vydac 
218TP54 (250 x 4.6 mm) and 218TP1022 (250 x 22 mm) columns, respectively, using 
Dionex instruments. Linear gradient elution using H 20IMeCN systems (containing 
0.1 % CF3COOH) at flow rates of I mL/min (analytical) and 9 mLlmin (preparative) 
was used. Purity was assessed by integration of chromatograms (? = 254 nm). NMR 
spectra were obtained using a Varian INOVA-500 instrument. Molar mass 
measurements were determined using a Waters Micromass ZQ 2000 single 
quadropole LCMS and Fast Atom Bombardment (FAB) high-resolution mass spectra 
(HRMS) were obtained using a Kratos MS50TC instrument. IR spectra were 
performed on a Jasco FTIIR-460plus instrument. Thin layer chromatography (TLC) 
was performed on Kieselgel 60 F 624 (Merck) with detection by UV light. Flash 
chromatography (FC) was carried out on silica gel 60 (200-400 mesh, Merck) and 
solid phase extraction (SPE) was performed on 20g pre-packed Isolute cartridges 
(Argonaut). 
Anhydrous solvents were obtained from Aldrich Chemical Company Ltd. and 
petroleum ether (PE) refers to the fraction having a boiling point of 40-60 °C, unless 
otherwise indicated. 
Physical Data 
In NMR spectra, chemical shifts are reported in parts per million (ppm) relative to an 
internal tetramethylsilane (Me 4Si) standard. The following abbreviations are used: s-
singlet; d-doublet; t-triplet; q-quartet; m-multiplet; dd-doublet of doublets; dt-doublet 
of triplets; bs-broad singlet; pyr-pyrimidine; pyrid-pyridine; phe-phenyl; morph-
morpholine; piperaz-piperazine; piper-piperidine; thiaz-thiazole; thiomorph-
thiomorpholine; pyrrol-pyrrolidine; J-coupling constant (Hz). The symbols JA  and JB 
are used to differentiate between coupling constants that are either equal (JA = JB) or 
unequal and do not represent an AB spin system pattern. 
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Molecular Modelling 
The amino acid sequences used to construct the homology models of CDK9 and Aur-
A were obtained from Swiss-Pro t 42. The building of the homology models was 
performed by Dr. M. Thomas and Dr. C. McInnes at Cyclacel, with the quality of the 
final models being assessed by commonly used measures (e.g. Ramachandran plot, 
number of deviations from ideal values for bond lengths, angles and torsions etc.) and 
will not be discussed in the experimental section. 
Biological Data 
Kinase Assays. Cellular assays against CDKs 1, 2A, 2E, 4, 7 and 9 were carried out 
by the general procedures described by Wang et a156' 116  IC50 values for Aur-A and 
Aur-B (human) kinases were obtained by measurement of incorporation of radioactive 
phosphate from ATP into Kemptide substrate (LRRASLG), upon phosphorylation by 
commercially obtained Aur-A and Aur-B (Upstate, Dundee). Assays were performed 
using 96-well plates and appropriate buffers (20mM Tris, 25mM -glycerophosphate, 
5mM EGTA, 1mM DTT, 1mM sodium vanadate, pH 7.5), into which were added 2-
5ng of active enzyme with 500 pM substrate (Kemptide). The reactions were initiated 
by addition of MgATP mix (15mM MgCl2 + lOOIiM ATP with 15-25 kBq per well of 
[y-32P]-ATP) and mixtures incubated for either 30 mm (Aur-A) or 60 mm (Aur-B) at 
30°C. Reactions were stopped by addition of an equal volume of 75 mM aq 
orthophosphoric acid, followed by filtration through p81 filterplates (Whatman 
Polyfiltronics, Kent, UK). After washing 4 times with 75 mM aq. orthophosphoric 
acid, plates were dried, scintillant added and incorporated radioactivity measured in a 
scintillation counter (TopCount, Packard Instruments, Pangbourne, Berks, UK). 
Compounds for kinase assay were made up as 10 mM stocks in DMSO and diluted 
into 10 % DMSO in assay buffer. Data was analysed using curve-fitting software 
(XLfit version 4.0.2, IDBS, Guildford, Surrey, UK) to determine IC 50 values (where 
the IC50 is the concentration of test compound which inhibits kinase activity by 50%). 
F1t3 kinase assay was obtained by measurement of incorporation of radioactive 
phosphate from ATP into myelin basic protein (MBP) substrate, upon 
phosphorylation by commercially obtained F1t3 (Upstate, Dundee, UK). Assays were 
performed using 96-well plates and appropriate assay buffers (20mM Tris, 25mM - 
glycerophosphate, 5mM EGTA, 1mM DTT, 1mM sodium vanadate, pH 7.5), into 
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which were added 5ng of active enzyme with 0.4 mg/ml substrate (MBP). The 
reactions were initiated by addition of MgATP mix (15mM M902 + 100pM ATP 
with 15-25 kBq per well of [y-32P]-ATP)  and mixtures incubated for 30 min at 30°C. 
Reactions were stopped by addition of an equal volume of 75 mM aq orthophosphoric 
acid, followed by filtration through p81 filterplates (Whatman Polyfiltronics, Kent, 
UK). After washing 4 times with 75 mM aq orthophosphoric acid, plates were dried, 
scintillant added and incorporated radioactivity measured in a scintillation counter 
(TopCount, Packard Instruments, Pangbourne, Berks, UK). Compounds for kinase 
assay were made up as 10 mM stocks in DMSO and diluted into 10% DMSO in assay 
buffer. Data was analysed using curve-fitting software (XLfit version 4.0.2, IDBS, 
Guildford, Surrey, UK) to determine IC 50 values. 
MiT cytotoxicity assays. Cells were seeded in Dulbeccos Modified Eagles Medium 
supplemented with 10% foetal calf serum and IOOU/mL streptomycin at 2000 
cells/well in 96-well plates. Plated were incubated overnight at 37 °C, 5% CO2. Drug 
candidates were made up as a stock of 10 mM in 100% DMSO and diluted to a 
concentration of 10 tM (final) in media. A 1:3 dilution series was prepared from this. 
All media used for dilutions contained 0.1% of DMSO as a control. 100 tL of 
dilution series were added to the appropriate wells and incubated for 72 h at 37 °C. 
After 72 h, media was carefully aspirated from wells and 50 j.tL of 2 mg/mL (w/v) 
MTT was added and the cells incubated in the dark at 37 °C. After 3 h the MTT 
solution was removed and the dye in the cells solubilised with 50 tL/well 100% 
DMSO. Plates were shaken gently to mix before the absorbance was read at 562 or 
595 nm depending on the intensity of the dye. Data was analysed using ActivityBase 
to determine IC 50 values. 
Western Blot Analysis. Total protein cell lysates (10 rig) were run on SDS-PAGE (4 - 
12% gradient) gels (Novartis) under reducing conditions. The separated proteins were 
transferred to membranes and were probed with antibodies specific for RNAP-II, 
RNAP-H Ser2, RNAP-II Ser-5 (Covance), p53 (Oncogene ab-6), McI- 1 (Santa Cruz) 
and actin (Sigma). 
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Determination of Apoptosis. Apoptosis was determined by caspase-3.7 assay 
(Caspase-Glo 3/7 assay, Promega), following manufacturer's instructions, with cells 
seeded at 10,000 per well of a 96-well plate in a total volume of 100 jtL medium per 
well. Assays were performed 24 h after test compound addition. Detection reagent 
(100 tL) was added directly to each 100-pt sample and readings were taken after a 




General Procedure for the Synthesis of Enaminone Intermediates (I) [218-240] 








General Procedure for the Synthesis of Thiazol-2-yls [197-200] 
The appropriate thiourea (1 eq) was solubilised in warm MeOH (25 mL) and pyridine 
(1.5 eq) added. The solution was cooled to 0 °C in an ice-water bath before drop-wise 
addition of 3 -chloro-2,4-pentanedi one (I eq) [caution: exothermic addition]. Once 
addition was complete, the reaction mixture (RM) was allowed to warm to 11 and 
stirred for 3 h. The resultant precipitate was isolated by suction filtration, washed with 
Et20 (1 x 5 mL) and further dried in vacuo56 . 
1-(2-Amino-4-methyl-1,3-thiazol-5-yl)ethanone [197] 
Synthesised from thiourea (10.00 g, 0.13 mol). 
NH2 
Colourless solid (17.85 g, 87%): mp 183-185 °C; anal. RP-HPLC: tR 6.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.32 (s, 3H, CH3), 2.40 (s, 3F1, Cl?3), 
7.89 (bs, 2H, NH2); ' 3C NMR (DMSO-d6): ö 18.81, 30.12, 121.91, 157.77, 171.09, 
188.97; MS (ESI) m/z: 157.13 [M+H]. 
1- [4-Methyl -2- (methylamino) -  1,3-thiazol-5-yl] ethanone [198] 




Colourless solid (20.18 g, 89%): mp 201-203 °C; anal. RP-HPLC: tR 7.5 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): ö 2.44 (s, 3H, CH3), 2.56 (s, 3H, CH3), 
138 
3.01 (s, 3H, CH3), NH missing; ' 3C NMR (DMSO-d6): 8 19.16, 30.05, 31.54, 49.28, 
121.78, 158.54, 188.81; MS (ESI) m./z: 171.17 [M+H]. 
1- [2-(Ethylamino) -4-methyl -1 ,3-thiazol-5-yl]ethanone [199] 




Off-white solid (17.23 g, 80%): anal. RP-HPLC: tR 9.6 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 8 1.19 (t, J = 7.5 Hz, 3H, CH2CH3), 2.43 (s, 3H, Cl!3), 
2.55 (s, 3H CH3), 3.43 - 3.44 (m, 2H, CH2CH3), NH missing; MS (ESI) m/z: 185.21 
[M+H] . 
1- [2- (Hydroxymethyl) -4-methyl -  1,3-thiazol-5-yI]ethanone [200] 
Synthesised from 2-hydroxyethanethioamide (5.05 g, 0.06 mol). 
OH 
Pale yellow solid (8.44 g, 89%): anal. RP-HPLC: tR 9.3 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 8 2.56 (s, 3H, CH3), 3.28 (s, 3H, CH3), 4.65 (d, J = 6.0 
Hz, 2H, Cl!2), 6.18 (t, J = 6.0 Hz, I H, OH); MS (ESf) mlz: 171.94 [M+H]t 
Synthesis of 5-acetyl-3,4-dimethyl-1,3-thiazol-2(3H)-one [201] 
NA S 
Conc. sulphuric acid (70 mL) was added slowly in small portions to water (100 mL), 
with cooling using an ice-water bath. Once addition was complete, the mixture was 
allowed to cool to rt before the drop-wise addition of a solution of ammonium 
thiocyanate (10.00 g, 0.131 mol) in water (10 mL) at such a rate as to maintain the 
internal temperature of the mixture at approx. 35 °C. The mixture effervesced gently 
due to the evolution of carbonyl sulfide gas, which was collected using a tube and frit 
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into ethanol (50 mL) and cooled to < 5 °C using an ice-water bath. When addition of 
the ammonium thiocyanate solution was complete, the RM was heated at 30 - 40 °C 
for an additional 2 - 3 h. Methylamine (33 wt % in EtOH, 100 mL) was added to the 
OCSIEtOH solution at a rate that maintained the internal temperature < 5 °C. On 
completion of methylamine addition, the resultant white suspension was stirred for an 
additional 2 - 3 h. The precipitate was collected by filtration, washed with Et 20 (50 
mL) and the product [201] (9.20 g, 40%) stored in the freezer until required' 17  Anal. 
RP-HPLC: tR 6.5 mm (10-70% MeCN, purity 100 %); 'H NMR (CDCI3): 8 2.34 (s, 
3H, CH3), 2.59 (s, 3H, CH3), 3.33 (s, 3H, CH3); MS (ESI) m/z: 172.91 (M+H). 
General Procedure for the Synthesis of Thiazole Intermediates with Pyridinyl-
Substituents [202-207], Phenyl-Substituents [208-213] or Heteroaryl-Substituents 
[214-217] 
1-[2-(2-Ethylpyridin-4-yI)-4-methyl-1,3-thiazol-5-yl]ethanone [202] 
Ethionamide (1.84 g, 0.01 mol) was partially solubilised in warm MeOH and the 
mixture basified with pyridine (1.34 ml, 0.02 mol, 1.5 eq) before cooling to 0 °C 
using an ice-water bath. 3 -Chloro-2,4-pentanedi one (1.33 mL, 0.01 mol) was added 
drop-wise to the solution [caution: exothermic addition]. Once addition was complete, 
the RM was allowed to warm to rt and heated at reflux for 6 - 10 h. Progress of the 
reaction was monitored by HPLC (0-60% MeCN). When no starting material 
remained the RM was allowed to cool to rt. The resultant precipitate was collected by 
suction filtration, washed with MeOH (1 x 10 mL), Et 20 (1 x 10 mL) and further 
dried in vacuo. The off-white thiazole product (2.01 g, 74%) was used in the next 
synthetic step without further purification 56 . Anal. RP-HPLC: tR 11.5 mm (0-60% 
MeCN, purity 75%); 'H NMR (CD30D): ö 1.34 (t, J = 7.5 Hz, 3H, CH2CH3); 2.60 (s, 
3H, CH3), 2.76 (s, 3H, CH3), 2.89 (q, J = 7.5 Hz, 2H, CH2CH3), 7.76 (dd, J = 1 .5 and 
5.5 Hz, IH, pyrid-H), 7.85 (d, J = 1.5 Hz, IH, pyrid-H), 8.55 (d, J = 5.5 Hz, IH, 
pyrid-H); MS (ESI) m/z: 247.03 [M+H]t 
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1-(4-Methyl-2-pyridin-3-yI-1,3-thiazol-5-yl)ethanone [203] 
Synthesised from thionicotinamide (7.59 g, 0.05 mol). 
(N 
Off-white solid (10.01 g, 83%): anal. RP-HPLC: tR 11.3 mm (0-60% MeCN, purity 
84%); 'H NMR (CD 30D): ö 2.58 (s, 3H, CH3), 2.74 (s, 3H, CH3 ), 7.54 (dd, J = 5.0 
and 8.0 Hz, I H, pyrid-H), 8.36 (dd, J = 2.0 and 8.0 Hz, 1H, pyrid-H), 8.65 (dd, J = 2.0 









Off-white solid (0.50 g, 34%): anal. RP-HPLC: tR 21.4 mm (10-70% MeCN, purity 
65%); 'H NMR (DMSO-d6): ö 2.59 (s, 3H, CH3), 2.71 (s, 3H, CH3), 9.02 (d, J = 1.0 
Hz, 1 H, pyrid-H), 9.62 (d, J = 1.0 Hz, IH, pyrid-H); MS (ESI) m/z: 321.12 [M+H]. 
1-[4-Methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]ethanone [205] 
Synthesised from 6-methylpyridine-3-carbothioamide (0.97 g, 0.64 mmol). 
L N 
Colourless solid (1.21 g, 82%): anal. RP-HPLC: tR 10.0 mm (0-60% MeCN, purity 
100%); 'H NMR (CD 30D): 8 2.59 (s, 3H, CH3), 2.60 (s, 3H, CH3 ), 2.75 (s, 3H, CH3), 
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7.43 (d, J = 8.0 Hz, IH, pyrid-H), 8.27 (dd, J = 2.5 and 8.0 Hz, IH, pyrid-H), 9.02 (d, 
J= 2.5 Hz, IH, pyrid-H); MS (ESr)nilz: 233.17 [M+H]. 
1- [4-Methyl -2- (pyridin -2-ylamino) - 1 ,3-thiazol-5-yJ]ethanone [206] 
Synthesised from 2-pyridyithiourea (1.04 g, 0.68 mmol). 
NH 
Yellow solid (0.81 g, 51%): anal. RP-HPLC: tR 13.3 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 8 2.45 (s, 3H, CH3), 2.55 (s, 311, CH3), 7.00- 7.02 (m, 
III, pyrid-H), 7.09 (d, J = 8.0 Hz, 1H, pyrid-H), 7.76 (dd, JA = JB = 8.0 Hz, IH, 
pyrid-R), 8.38 (d, J = 5.0 Hz, IH, pyrid-H), NH missing; MS (ESI) m/z: 234.08 
[M+H]t 
1- [4-Methyl -2-(pyridin-3-ylamino) -  1,3-thiazol-5-yI]ethanone [207] 
Synthesised from 3 -pyridyl thiourea (1.82 g, 1.19 mmol). 
Off-white solid (2.00 g, 72%): anal. RP-HPLC: tR 9.4 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 2.40 (s, 3H, CH3), 2.52 (s, 3H, CH3), 7.34- 7.36 (m, 
IH, pyrid-H), 8.12 (d, J = 8.5 Hz, IH, pyrid-H), 8.20 (d, J = 4.5 Hz, IH, pyrid-H), 
8.74 (bs, IH, pyrid-H), NH missing; MS (ESr) nilz: 234.23 [M+H]t 
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1- [2- (Benzylamino)-4-methyl -  1,3-thiazol-5-yl]ethanone [208] 
Synthesised from benzylthiourea (5.93 g, 0.04 mol). 
YN H 
NS 
Off-white solid (7.64 g, 87%): anal. RP-HPLC: tR 14.0 mm (0-60% MeCN, purity 
95%); 'H NMR (CD30D): 8 2.40 (s, 3H, CH3), 2.52 (s, 3H, CH3), 4.53 (s, 2H, CH2), 
7.98 (dd, JA = .18 = 8.0 Hz, 2H, phe-H), 8.49 (t, J = 8.0 Hz, 1H, phe-H), 8.82 (d, J = 
8.0 Hz, 2H, phe-H), NH missing; MS (ESr) m/z: 247.10 [M+H]t 
1- { 2-[(4-Chlorophenyl)amino] -4-methyl-1 ,3-thiazol-5-yI}ethanone [209] 




Off-white solid (3.74 g, 81%): anal. RP-HPLC: tR 18.2 mm (0-60% MeCN, purity 
34%); 'H NMR (DMSO-d 6): 8 2.42 (s, 3H, CH3 ), 2.54 (s, 3H, CH3), 7.39 (d, J = 9.0 
Hz, 2H, phe-J1), 7.65 (d, J = 9.0 Hz, 2H, phe-H), NH missing; MS (ESIF)  m/z: 267.04 
[M-i-H]. 
1-{2-[(3,5-Dichlorophenyl)amino]-4-methyl- 1,3-thiazol-5-yl }ethanone [210] 




Off-white solid (6.06 g, 80%): anal. RP-HPLC: tR 24.8 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d 6): 5 2.39 (s, 3H, CH3 ), 2.51 (s, 3H, CH3), 7.46-7.48 (m, 
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IH, phe-H), 7.51 - 7.53 (m, IH, phe-H), 7.98 (d, J = 2.0 Hz, IH, phe-H), NH 
missing; MS (ESr) m/z: 301.20 [M+H]. 
1-(2.Anilino-4.methyl- 1,3-thiazol-5-yl)ethanone [211] 
Synthesised from phenylthiourea (5.12 g, 0.03 mol). 
Il 
NH 
Off-white solid (6.00 g, 77%): anal. RP-HPLC: tR 17.6 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 2.42 (s, 3H, CH3), 2.54 (s, 3H, CH3 ), 7.04 (t, J = 8.0 
Hz, 1H, phe-H), 7.35 (dd, JA = JB = 8.0 Hz, 2H, phe-H), 7.60 (d, J = 8.0 Hz, 2H, phe-
H), NH missing; MS (ESF) in/z: 233.06 [M+H]t 
1- 1 4-Methyl -2- [(2-phenylethyl)amino] -1 ,3-thiazol -5-yl }ethanone [212] 




Off-white solid (4.41 g, 93%): anal. RP-HPLC: tR 14.5 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 8 2.29 (s, 3H, CH3), 2.40 (s, 3H, CH3 ), 2.82 (t, J = 7.0 
Hz, 2H, CH2), 3.43 (m, 2H, NHCH2), 7.15-7.25 (m, 5H, phe-H), 8.50 (bs, IH, NH); 
MS (ESI) m/z: 261.10 [M+H]. 
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1-[2-(2,4-Dimethylphenyt)-4-methyl- 1,3-thiazol-5-yI]ethanone [213] 
Synthesised from 2,4-dimethylphenylthiourea (1.06 g, 0.59 mmol). 
Colourless solid (0.55 g, 38%): anal. RP-HPLC: tR 17.5 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 5 2.25 (s, 3H, CH3), 2.34 (s, 3H, CH3), 2.40 (s, 3H, 
CH3), 2.53 (s, 3H, CH3), 7.11 (d, J = 8.0 Hz, IH, phe-H), 7.17 (bs, IH, phe-J1), 7.42 
(d, J = 8.0 Hz, IH, phe-H). MS (ESI) m,/z: does not fly. 
1-[4-methyl-2-(2-thienyl)- 1,3-thiazol-5-yI]ethanone  [214] 
Synthesised from thiophene-2-thiocarboxamide (1.13 g, 0.79 mmol). 
Off-white solid (1.35 g, 77%): anal. RP-HPLC: tR 20.0 mm (20-70% MeCN, purity 
100%); 'H NMR (CD30D): ö 2.55 (s, 3H, CH3), 2.69 (s, 3H, CH3), 7.16 (dd, JA = JB 
= 4.5 Hz, 1H, thio-H), 7.66 (d, J = 4.5 Hz, IH, thio-H), 7.72 (d, J = 4.5 Hz, IH, thio-
H); MS (ESI) m/z: 224.00 [M+H]. 
1-{4-Methyl -2- [(2-thienylsulfonyl)methyl] -1 ,3-thiazol-5-yI}ethanone [215] 
Synthesised from 2-(2-thienylsulfonyl)ethanethioamide (1.01 g, 0.46 mmol). 
y— 
os 
Yellow solid (0.87 g, 63%): anal. RP-HPLC: tR 15.6 mm (20-70% MeCN, purity 
100%); 'H NMR (CD30D): 8 2.49 (s, 3H, CH3), 2.53 (s, 3H, CL!3), 5.29 (s, 2H, CH2), 
7.24 (dd, JA = JB = 4.5 Hz, IH, thio-H), 7.70 (d, J = 4.5 Hz, IH, thio-H), 8.09 (d, J = 
4.5 Hz, IH, thio-H). 
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1-(2',4-dimethyl-2,4'-bi- 1,3-thiazol-5-yl)ethanone [216] 
Synthesised from 2-methyl-1,3-thiazole-5-carbothioamide (1.26 g, 0.79 mmol). 
N 
Off-white solid (1.51 g, 80%): anal. RP-HPLC: tR 17.5 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): 8 2.52 (s, 3H, CH3), 2.65 (s, 3H, CH3), 2.69 (s, 3H, CH3 ), 
8.21 (s, 1H, thiaz-H); MS (ESI) mlz: 239.21 [M+H] 4 . 
1- [4-methyl-2- (4-morpholin-4-ylphenyl) -  1,3-thiazol-5-yI]ethanone [217] 
Synthesised from 4-morpholinobenzenecarbothioamide (0.95 g, 0.43 mmol). 
(0) 
Yellow solid (1.04 g, 80%): anal. RP-HPLC: tR 20.3 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 2.53 (s, 3H, CH3), 2.66 (s, 3H, CH3), 3.25 (dd, JA = 
JB = 4.5 Hz, 4H, morph-H), 3.74 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 7.02 (d, J = 9.0 
Hz, 2H, phe-H), 7.84 (d, J = 9.0 Hz, 2H, phe-H); MS (ESI) m/z: 303.36 [M+H]. 
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General Procedure for the Synthesis of Enaminonketones (I) [218-221] 
The appropriate thiazol-2-yl (1 eq) was added to NN-dimethylformamide 
dimethylacetal (6 eq) and the mixture heated to 110 °C for 16 h. On cooling the 
solution was evaporated to dryness under reduced pressure. The residue was 
crystallised from EtOAc to afford the enaminoketones as orange crystalline solids that 
were further dried in vacuo56 . 
(2E)- 1-(2-Amino-4-methyl-i,3-thiazol-5-yl)-3-(dimethylamino)prop-2-en- 1-one 
(I) [218] 




Orange solid (13.70 g, 67%): mp 198-199 °C; anal. RP-HPLC: tR 9.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD 3OD): ö 2.54 (s, 3H, CL!3), 3.08 (s, 6H, CH3 ), 
3.17 (s, 6H, CH3), 5.42 (d, J= 12.0 Hz, 111, CH), 7.17 (d, J= 12.0 Hz, IH, CH), 8.13 
(s, 1H, CH); MS (ESI) m/z: 267.21 [M + H]. 
(2E)-3-(Dimethylamino)- i - [4-methyl -2- (methylamino) - i,3-thiazol -5-yI]prop-2-
en-i-one (I) [219] 




Orange solid (13.73 g, 68%): mp 209-211 °C; anal. RP-HPLC: tR 9.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.38 (s, 3H, CH3), 2.75 (d, J = 4.5 Hz, 
3H, CH3), 3.08 (s, 6H, CR)),  5.16 (d, J = 12.0 Hz, 1H, CH), 7.46 (d, J = 12.0 Hz, IH, 
CH), NH missing; ' 3C NMR (DMSO-d6): 8 18.94, 31.41, 54.99, 94.32, 122.05, 
152.96, 153.83, 169.41, 179.89; MS (ESI) rn/v 225.80 [M+H]. 
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(2E)-3-(Dimethylamino)- 1-[2-(ethylamino)-4-methyl-  1,3-thiazol-5-yl]prop-2-en-
1-one (I) [220] 
Synthesised from [199] (15.00 g, 0.08 mol). 
L NH 
NS 
Orange solid (13.54 g, 69%): anal. RP-HPLC (0-60% MeCN, purity 100%): tR 9.1 
mm (0-60% MeCN, purity 89%); 'H NMR (CD30D): 8 1.25 (t, J = 7.5 Hz, 3H, 
CH2CH3), 2.49 (s, 3H, Cu3), 3.21 (s, 6H, CH3), 3.31 (q, J = 7.5 Hz, 2H, CH2CH3), 
5.35 (d, J = 12.0 Hz, IH, Cl]), 7.66 (d, J = 12.0 Hz, IH, Cl]), NH missing; MS (ESI) 
m/z: 240.23 [M+H]. 
(2E)-3-(Dimethylanilno) -1- [2-(hydroxymethyl) -4-methyl -  1,3-thiazol-5-yl]prop-2-
en-i-one (I) [221] 
Synthesised from [200] (2.11 g, 0.01 mol). 
HO 
'1 
Orange solid (2.04 g, 73%): anal. RP-HPLC: tR 8.8 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 5 2.46 (s, 3H, CH3), 2.82 (s, 3H, CH3), 3.09 (s, 3H, 
CH3), 4.61 (d, J = 6.0 Hz, 2H, CH2), 5.33 (d, J = 12.0 Hz, IH, Cl]),  6.02 (t, J = 6.0 
Hz, IH, OH), 7.60 (d, J= 12.0 Hz, IH, Cl]); MS (ESI) m/z: 227.10 [M+H]. 
W. 
5- [(2E)-3- (Dimethylamino)prop -2-enoyl] -3 ,4-dimethyl -  1,3-thiazol-2(3H)-one (I) 
[222] 
Synthesised from [201] (5.05 g, 0.03 mol). 
NA 
S 
Orange solid (4.74 g, 71%): anal. RP-HPLC: tR 11.2 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d o): 6 2.51 (bs, 3H, CH3), 2.82 (s, 3H, CH3), 3.11 (s, 3H, 
CH3), 3.21 (bs, 3H, CH3), 5.09 (d, J = 12.0 Hz, 1H, CM), 7.60 (d, J = 12.0 Hz, IH, 
CM); MS (ESJ) m/z: 227.10 [M+H]t 
(2E) -3-(Dimethylamino) -1- [2- (2-ethylpyridin-4-yl)-4-methyl -  1,3-thiazol-5-
yl]prop-2-en-1-one (I) [223] 
Synthesised from [202] (2.00 g, 0.81 mmol). 
Orange solid (1.98 g, 81 %):  anal. RP-HPLC: tR 10.8 mm (0-60% MeCN, purity 
100%); 'H NMR (CD 3OD): 6 1.32 (t, J = 7.5 Hz, 3H, CH2CH3), 2.69 (s, 3H, CH3), 
2.86 (q, J = 7.5 Hz, 2H, CH2CH3), 2.97 (s, 3H, CM)),  3.21 (s, 3H, CM)),  5.51 (d, J = 
12.0 Hz, IH, CM),  7.68 (dd, J = 1.5 and 5.0 Hz, IH, pyrmd-H), 7.76-7.79 (m, 2H, CH 
and pyrid-H), 8.50 (d, J = 5.0 Hz, IH, pyrid-H); MS (ESf') m/z: 301.41 [M+H]. 
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(2E)-3-(Dimethylamino)-1-(4-methyl-2-pyridin-3-yI-1,3-thiazol-5-yI)prop-2-en-1-
one (I) [224] 
Synthesised from [203] (10.00 g, 0.05 mol). 
'1 
Orange solid (8.64 g, 69%): anal. RP-HPLC: tR 10.3 mm (0-60% MeCN, purity 
100%); 'H NMR (CD 30D): ö 2.73 (s, 3H, Cl-I3), 3.00 (s, 3H, CH3), 3.23 (s, 3H, Cl-I3), 
5.57 (d, J = 12.0 Hz, IH, CH), 7.55 (dd, J = 5.0 and 8.0 Hz, IH, pyrid-H), 7.82 (d, J = 
12.0 Hz, IH, CH), 8.35 (dd, J = 1.5 and 8.0 Hz, IH, pyrid-H), 8.62 (dd, J = 1.5 and 
5.0 Hz, IH, pyrid-H), 9.12 (dd, JA = JB = 1.5 Hz, IH, pyrid-H); MS (ESf') m/z: 
275.17 [M+H]. 
(2E)-1-{2-[5-Chloro-3-(trifluoromethyl)pyridin-2-yl]-4-methyl- 1,3-thiazol-5-yl}-
3-(dimethylamino)prop-2-en-1-one (I) [225] 




Orange solid (0.32 g, 54%): anal. RP-HPLC: tR 23.0 mm (0-60% MeCN, purity 
55%); 'H NMR (CD 30D): 8 2.70 (s, 3H, Cl-I3), 2.91 (s, 3H, CH3), 3.17 (s, 3H, CH3), 
5.49 (d,J= 12.0 Hz, 1H,CH),7.73 (d,J= 12.0 Hz, 1H, CH), 8.61 (d,J= 1.0 Hz, IH, 
pyrid-H), 9.01 (d, J= 1.0 Hz, 1H, pyrid-H); MS (ESI) m/z: 376.18 [M+H]. 
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(2E)-3-(Dimethylamino). 1-[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5- 
yl]prop-2-en-1-one (I) [226] 
Synthesised from [205] (1.20 g, 0.52 mmol). 
(( N 
Orange solid (1.29 g, 87%): anal. RP-HPLC: tR 10.0 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): 5 2.53 (s, 3H, CH3), 2.67 (s, 3H, CH3), 2.89 (s, 3H, CH3), 
3.16 (s, 3H, CH3), 5.45 (d, J = 12.0 Hz, 1H, CH), 7.39 (d, J = 8.0 Hz, IH, pyrid-H), 
7.72 (d, J = 12.0 Hz, 1H, CM), 8.18 (dd, J = 2.5 and 8.0 Hz, IH, pyrid-H), 8.99 (d, J = 
2.5 Hz, IH, pyrid-H); MS (ESI) m/z: 288.05 [M+H]t 
(2E)-3-(Dimethylamino) -1- {4-methyl-2- [methyl(pyridin -2-yl)amino] -  1,3-thiazol-
5-yI}prop-2-en-1-one (I) [227] 
Synthesised from [206] (1.43 g, 0.61 mmol). 
Orange oil (1.31 g, 71 %):  anal. RP-HPLC: tR 18.1 mm (0-60% MeCN, purity 100%); 
MS (ESI) m/z: 303.17 [M+H]. 
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(2E)-3-(Dimethylamino)- 1 -{4-methyl- 2-[methyl(pyridin -3-yI)amino] -1 ,3-thiazol -
5-yI}prop-2-en-1-one (I) [228] 
Synthesised from [207] (2.00 g, 0.86 mmol). 
U-11 N 
'1 
Orange oil (1.79 g, 69%): anal. RP-HPLC: tR 12.0 mm (0-60% MeCN, purity 73%); 
'H NMR (DMSO-d6): 5 2.51 (s, 3H, CH3), 2.85 (bs, 31-I, CH3), 3.12 (bs, 3H, CH3), 
3.51 (s, 3H, CH3), 5.24 (d, J = 12.0 Hz, IH, CH), 7.52 - 7.55 (m, IH, pyrid-H), 7.59 
(d, J = 12.0 Hz, 1H, CM), 8.00 (d, J = 8.0 Hz, IH, pyrid-H), 8.52 (d, J = 5.0 Hz, 1H, 
pyrid-H), 8.79 (bs, 1H, pyrid-H); MS (ESI) mlz: 303.23 [M+H]t 
(2E)- 1- [2- (Benzylamino) .4-methyl -  1,3-thiazol-5-yl]-3-(dimethylamino)prop-2-en-
1-one (I) [229] 
Synthesised from [208] (1.41 g, 0.57 mmol). 
YN 11 
N 
Orange oil (quant.): anal. RP-HPLC: tR 14.6 mm (0-60% MeCN, purity %); 'H NMR 
(CD 30D): ö 2.86 (s, 6H, CH3), 3.05 (s, 3H, CH3), 3.35 (s, 3H, CH3), 4.84 (s, 2H, 
CH2), 5.38 (d, J = 12.0 Hz, IH, CM), 7.26 - 7.36 (m, 511, phe-H), 7.67 (d, J = 12.0 
Hz, IH, CM);  MS (ESI) m/z: 315.98 [M+H]t 
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(2E)- 1- { 2- [(4-Chlorophenyl)amino] -4-methyl -  1,3-thiazol-5-yI}-3-
(dimethylamino)prop-2-en-1-one (I) [230] 
Synthesised from [209] (3.75 g, 1.41 mmol). 
CI 
Orange solid (1.89 g, 40%): anal. RP-HPLC: tR 15.5 mm (0-60% MeCN, purity 
100%); 'H NMR (CD 30D): ö 2.53 (s, 3H, CH3), 2.88 (bs, 3H, CR)), 3.14 (bs, 3H, 
CH3), 3.49 (s, 3H, CR)),  5.30 (d, J = 12.0 Hz, 1H, CH), 7.45 (d, J = 9.0 Hz, 4H, phe-
H), 7.66 (d, J = 12.0 Hz, 1H, CH); MS (ESr) m/z: 336.95 [M+H]. 
(2E)- 1-{2-[(3,5.Dichlorophenyl)amino]-4-methyl- 1,3-thiazol-5-yI}-3-
(dimethylamino)prop-2-en-1-one (I) [231] 




Orange solid (4.12 g, 78%): anal. RP-HPLC: tR 22.7 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): ö 2.49 (bs, 3H, CR)), 2.68 (s, 3H, CL!3), 2.91 (s, 311, 
CL!3), 3.18 (bs, 3H, CR)),  5.34 (d, J = 12.0 Hz, 1H, CH), 7.34 (bs, IH, phe-H), 7.50 
(bs, 2H, phe-H), 7.68 (d, J = 12.0 Hz, I H, CH); MS (ESI) m/z: 371.05 [M+H]t 
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(2E)-3-(dimethylamino)-1-(4-methyl-2-[methyl(phenyl)amino]- 1 ,3-thiazol -5-
yI}prop-2-en-1-one (I) [232] 
.Synthesised from [211] (3.89 g, 1.67 mmol). 
Orange solid (4.49 g, 89%): anal. RP-HPLC: tR 15.0 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): ö 2.56 (s, 3H, CH3), 2.98 (s, 6H, CH3), 3.36 (s, 3H, CH3), 
5.27 (d, J = 12.0 Hz, IH, CH), 7.35 - 7.49 (m, 5H, phe-H), 7.64 (d, J = 12.0 Hz, IH, 
CH); MS (ESI) m/z: 302.16 [M+H]t 
(2E)-3-(Dimethylamino)- 1-{4-methyl-2-[(2-phenylethyl)amino]-1,3-thiazol-5-
yI}prop-2-en-1-one (I) [233] 
Synthesised from [212] (4.50 g, 0.02 mol). 
NH 
NS 
Orange solid (quant.): anal. RP-HPLC: tR 13.3 mm (0-60% MeCN, purity 100%); 'H 
NMR (CD30D): ö 2.49 (s, 3H, CH3), 2.84 (s, 3H, CH3), 2.91 (t, J = 7.5 Hz, 2H, CL!2), 
3.35 (s, 3H, CL!3), 3.51 (m, 2H, NHCH 2), 5.33 (d, J = 12.0 Hz, IH, CL!), 7.19-7.29 
(m, 5H, phe-R), 7.65 (d, J = 12.0 Hz, 1H, CH), 7.96 (bs, IH, NH); MS (ESr) m/z: 
316.21 [M+H]. 
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(2E)-3-(Dimethylamino)- 143-methyl-2-thienyl)prop-2-en-  1-one (I) [234] 
Synthesised from [214] (0.78 g, 0.35 mmol). 
'l 
Orange solid (0.81 g, 83%): anal. RP-HPLC: tR 17.7 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 5 2.62 (s, 3H, CH3), 2.89 (bs, 3H, CH3), 3.16 (bs, 3H, 
CH3), 5.41 (d, J = 12.0 Hz, IH, CH), 7.18 (dd, JA = JB = 4.5 Hz, IH, thio-H), 7.69 - 
7.71 (m, 2H, thio-H and Cl]), 7.75 (d, J = 4.5 Hz, IH, thio-H); MS (ESr) nilz: 279.17 
[M+H] . 
(2E)-3-(Dimethylamino)-1-{ 4-methyl-2-[(2-thienylsulfonyl)methyl]- 1,3-thiazol-5-
yI}prop-2-en-1-one (I) [235] 




Orange solid (0.85 g, 60%): anal. RP-HPLC: tR 14.9 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): ö 2.49 (s, 3H, CH3), 2.83 (bs, 3H, CH3), 2.83 (bs, 3H, 
CH3), 3.27 (s, 2H, CH2), 5.31 (d, J = 12.0 Hz, IH, Cl]), 7.04 (dd, 1A = JB = 4.5 Hz, 
IH, thio-H), 7.41 (d,J=4.5 Hz, 1H, thio-H), 7.61 (d,J= 12.0 Hz, IH, Cl]), 7.78 (d,J 




Synthesised from [216] (1.40 g, 0.59 mmol). 
N 
Orange solid (1.19 g, 69%): anal. RP-HPLC: tR 15.5 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): 8 2.61 (s, 3H, CH3), 2.67 (s, 3H, CH3 ), 2.85 (bs, 3H, 
CH3 ), 3.11 (bs, 3H, CH3), 5.41 (d, J = 12.0 Hz, IFI, CH'), 7.64 (d, J = 12.0 Hz, IH, 
CH), 8.08 (s, 1H, thiaz-H); MS (ESI) m/z: 294.11 [M+H]. 
(2E)-3-(Dimethylamino)- 1-[4-methyl-2-(4-morpholin-4-ylphenyl)- 1,3-thiazol-5-
yI]prop-2-en-1-one (I) [237] 
Synthesised from [217] (1.12 g, 0.37 mmol). 
co) 
Yellow solid (1.04 g, 79%): anal. RP-HPLC: tR 15.3 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 2.63 (s, 3H, CH3), 3.23 (dd, JA = JB = 4.5 Hz, 4H, 
morph-H), 3.32 (s, 6H, CH3), 3.74 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 5.42 (d, J = 
12.0 Hz, 1H, CH), 7.01 (d, J = 9.0 Hz, 2H, phe-H), 7.67 (d, J = 12.0 Hz, IH, CH), 
7.79 (d, J = 9.0 Hz, 2H, phe-H); MS (ESr) mlz: 358.40 [M+H]t 
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(2E)-3-(Dimethylamino)- 1-[2-(2,4-dimethylphenyl)-4-methyl-1,3-thiazol-5-
yl]prop-2-en-1-one (I) [238] 
Synthesised from [213] (0.41 g, 0.17 mmol). 
Orange oil (0.30 g, 60%): anal. RP-HPLC: tR 13.8 mm (0-60% MeCN, purity 59%); 
'H NMR (CD 3OD): ö 2.27 (s, 3H, CH3), 2.60 (s, 3H, CH3), 3.40 (s, 6H, CH3), 3.46 (s, 
3H, CH3), 5.52 (d, J = 12.0 Hz, IH, Cl]), 7.13 (bs, 2H, phe-H), 7.19 (bs, IH, phe-H), 
7.62(d,J= 12.0 Hz, 1H,CH). 
General Procedure for Synthesis of Unmethylated Enaminones (I) [239-240] 
The synthesis of unmethylated derivatives of (I) [229] and (I) [232] was achieved by 
the reaction of the appropriate thiazole precursor, [208] and [211] respectively, with 
N,N-dimethylformamide diethylacetal (3 eq) in place of N,N-dimethyl form amide 
dimethylacetal under the same reaction conditions. 
(2E)-1- [2-(Benzylamino)-4-methyl - 1 ,3-thiazol-5-yI] -3- (dimethylamino)prop-2-en-
1-one [239] 
Synthesised from [208] (4.87 g, 0.02 mol). 
YN H 
N 
Orange solid (4.95 g, 83%): anal. RP-HPLC: tR 13.3 mm (0-60% MeCN, purity 
83%); 'H NMR (DMSO-d 6): 8 2.41 (s, 3H, CH3), 2.80 (bs, 3H, CH3), 3.06 (bs, 3H, 
CH3), 4.45 (d, J = 5.5 Hz, 2H, CH2), 5.57 (d, J = 12.0 Hz, IH, Cl]), 7.24 - 7.36 (m, 
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5H, phe-H), 7.65 (d, J = 12.0 Hz, 1H, CH), 8.48 (t, J = 5.5 Hz, 1H, NH); MS (ESr) 
m/z: 302.34 [M+H]. 
(2E)-3-(Dimethylamino)- 1-[4-methyl-2-(pyridin-3-ylamino)- 1,3-thiazol-5-
yl]prop-2-en-1-one (I) [240] 
Synthesised from [211](0.90  g, 0.39 mmol). 
II 
NH 
Orange solid (0.78 g, 70%): anal. RP-HPLC: tR 13.3 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 2.13 (s, 3H, CH3), 2.45 (bs, 3H, CH3 ), 2.72 (bs, 3H, 
CH3), 4.90 (d, J = 12.0 Hz, IH, CH), 6.60 (t, J = 8.0 Hz, IH, phe-H), 6.94 (dd, JA = JB 
= 8.0 Hz, 2H, phe-H), 7.18 —7.21 (m, 3H, 2 x phe-H and CH); MS (ESI) m/z: 288.06 
[M+H] . 
(2E).3.(Dimethylamino)- 1-(2,4-dimethyl-1,3-thiazol-5-yI)prop-2-en-1-one 	(I) 





Conversion of Nitro-Precursors [242-264] to Guanidine Intermediates (II) [291-
318] 
Synthesis of Nitro-Compounds with Acetamide Substituents 
The appropriate benzylamine starting material (1 eq) was solubilised in pyridine (15 
mL) and the solution cooled to 0 °C in an ice-water bath prior to drop-wise addition 
of acetyl bromide (1.2 eq) [caution: exothermic addition]. The solution was allowed to 
warm to rt and stirred for a further 12 - 16 h. Progress of the reaction was monitored 
by HPLC (0-60% MeCN). When no starting material remained, the RM was 
evaporated under reduced pressure and the residue purified by flash chromatography 
(EtOAc/PE 2:1). Fractions containing products were combined, dried under reduced 
pressure and further dried in vacuo to yield the acetamide products as yellow solids' 21 . 
N-(3-Nitrobenzyl)acetamide [242] 
Synthesised from 3-nitrobenzylamine hydrochloride (5.21 g, 0.03 mol). 
O2N_ç 
HN 
Yellow solid (4.28 g, 80%): anal. RP-HPLC: tR 12.0 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): 8 2.01 (s, 3H, CH3), 4.46 (s, 2H, CH2), 7.56 (dd, JA = JB = 
8.0 Hz, IH, 5-H), 7.69 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 8.11 (dd, J = 2.0 and 8.0 
Hz, lU, phe-H), 8.15 (dd, JA = JB = 2.0 Hz, IH, 2-H); MS (ESI) m/z: 195.08 [M+H]t 
N-(4-Nitrobenzyflacetamide [243] 
Synthesised from 4-nitrobenzylamine hydrochloride (4.22 g, 0.02 mol). 
- 02N-_çJ\ 
Yellow solid (4.24 g, 98%): anal. RP-HPLC: tR 11.6 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): ö 2.02 (s, 3H, CH3), 4.46 (s, 2H, CH2), 7.50 (d, J = 8.5 
Hz, 2H, phe-H), 8.18 (d, J= 8.5 Hz, 2H, phe-H); MS (ESI) m/z: 195.08 [Mi-H]t 
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Synthesis of Nitro-Compounds with Sulfonamide Substituents 
3-Nitrobenzylamine hydrochloride (1 eq) was solubilised in pyridine and the resulting 
solution cooled to 0 °C before addition of either methanesulfonyl chloride or 
trifluoromethanesulfonyl chloride (1.5 eq) [caution: exothermic addition]. The RM 
was allowed to warm to rt and stirred for a further 10 - 16 h. Progress of the reaction 
was monitored by HPLC and when no starting material remained, the RM was 
evaporated under reduced pressure and the resulting residue purified by flash 
chromatography (EtOAc/PE 1:1) to afford the desired sulfonamides' 24 . 
N-(3-Nitrobenzyl)methanesulfonamide [244] 
Synthesised from 3-nitrobenzylamine hydrochloride (10.30 g, 0.05 mol) and 




Yellow solid (12.22 g, 97%): anal. RP-HPLC: tR 13.7 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): 5 2.96 (s, 3H, CH3), 4.38 (s, 2H, CH2), 7.60 (dd, JA = JB = 
8.0 Hz, 1H, 5-H), 7.79 (dd, J = 1.0 and 8.0 Hz, IH, phe-I1), 8.15 (dd, J = 1.0 and 8.0 
Hz, I H, phe-H), 8.27 (dd, JA = JB = 1.0 Hz, 1H, 2-H); MS (ESF) m/z: 229.12 [M-H]. 
1,1,1-Trifluoro-N-(3-nitrobenzyl)methanesulfonamide [245] 
Synthesised from 3-nitrobenzylamine hydrochloride (3.61 g, 0.02 mol) and 
trifluoromethanesulfonyl chloride (3.04 mL, 0.03 mol). 
HN  o 
F3c' 
Yellow solid (4.24 g, 78%): anal. RP-HPLC: tR 19.9 mm (0-60% MeCN, purity 
52%); 'H NMR (CD30D): 8 4.50 (s, 2H, CH2), 7.63 (dd, JA = JB = 7.5 Hz, 1H, 5-H), 
7.76 (dd, J = 2.5 and 7.5 Hz, IH, phe-H), 8.19 (dd, J = 2.5 and 7.5 Hz, IH, phe-H), 
8.25 (dd, JA =J8 = 2.5 Hz, IH, 2-H); MS (ESI) m/z: 283.21 [M-H]. 
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Synthesis of Nitro-Compounds with Acetylated Sulfonamide Substituents 
N- [(3-Nitrophenyl)sulfonyl]acetamide [246] 
O2N_Q 
HN 0 
3-Nitrobenzenesulfonyl chloride (6.35 g, 0.03 mol) was solubilised in pyridine (10 - 
15 mL) and the solution cooled to 0 °C before addition of acetyl bromide (1.2 eq) 
[caution: exothermic addition]. The RM was allowed to warm to rt and stirred for a 
further 10 - 16 h. Progress of the, reaction. was monitored by HPLC (0-60% MeCN) 
and when no remaining starting material was detected, the RM was evaporated under 
reduced pressure. The resultant residue was purified by flash chromatography 
(EtOAcIMeOH 10:1) to yield the desired sulfonamide as a yellow solid 121  (6.29 g, 
90%): Anal. RP-HPLC: tR 12.8 mm (0-60% MeCN, purity 94%); 'H NMR (CD30D): 
1.98 (s, 3H, CH3), 7.86 (dd, JA = JB = 8.0 Hz, IH, 5-H), 8.38 (dd, J = 2.0 and 8.0 
Hz, IH, phe-H), 8.54 (dd, J = 2.0 and 8.0 Hz, 1H, phe-H), 8.79 (dd, JA = JB = 2.0 Hz, 
1H, 2-H); MS (ESI) nilz: 243.06 [M+H]t 
Alkylation of N-[(3-nitrophenyl)sulfonyl]acetamide [247-248] 
N-[(3-Nitrophenyl)sulfonyl]acetamide (I eq) was solubilised in DMF (3 mL) in a 
sealed tube and KOH (I eq) added, followed by either methyl iodide or ethyl iodide 
(10 eq). The RM was then heated, under sealed tube conditions, to 125 °C for approx. 
16 - 20 h until no further depletion of starting material was evident using HPLC 
analysis. The RM was evaporated under reduced pressure and the resulting residue 




Synthesised from [246] (2.80 g, 0.01 mol) and methyl iodide (7.14 mL, 0.11 mol). 
02N-Q 
110 
Orange solid (1.63 g, 55%): anal. RP-HPLC: tR 16.2 mm (0-60% MeCN, purity 
93%); 'H NMR (CD30D): ö 2.23 (s, 3H, CH3), 3.94 (s, 3H, CH3), 7.94 (dd, JA = JB = 
7.5 Hz, IH, 5-H), 8.38 (d, J = 7.5 Hz, IH, phe-H), 8.56 (d, J = 7.5 Hz, IH, phe-H), 
8.60 (bs, 1H, 2-H). 
N-Ethyl-N-[(3-nitrophenyl)sulfonyl]acetamide [248] 
Synthesised from [246] (2.0 g, 0.82 mmol) and ethyl iodide (6.55 mL, 0.82 mol). 
O2N-( 
Orange solid (1.02 g, 46%): anal. RP-HPLC: tR 18.6 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): 5 1.38 (t, J = 7.0 Hz, 3H, CH2CH3), 2.29 (s, 3H, CH3), 
3.97 (q, J = 7.0 Hz, 2H, CH2CH3), 7.88 (dd, JA = JB = 8.0 Hz, lH, 5-H), 8.35 (dd, J = 
2.0 and 8.0 Hz, 1H, phe-H), 8.55 (d, J = 2.0 and 8.0 Hz, 1H, phe-H), 8.75 (dd, JA = JB 
= 2.0 Hz, IH, 2-H); MS (ESf) m/z: 273.80 [M+H]t 
Synthesis of Nitro-Compounds with Benzylated Sulfonamide Substituents [249-
250] 
The appropriate nitrobenzenesulfonyl chloride (1 eq) was solubilised in DCM (20 
mL) and the solution cooled to 0 °C in an ice water-bath prior to the addition of 
benzylamine (1.2 eq) [caution: exothermic addition]. The solution was allowed to 
warm to 11 and stirred for a further 4 - 8 h. Reaction progress was monitored by 
HPLC and when no starting material remained, the RM was evaporated under reduced 
pressure. The resulting residue was purified by flash chromatography (EtOAC/PE 
2:1) to yield the desired sulfonamide products 126 . 
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N-Benzyl-3-nitrobenzenesulfonamide [249] 




Off-white solid (1.30 g, 60%): anal. RP-HPLC: tR 20.1 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 8 4.16 (s, 2H, CH2), 7.11 - 7.18 (m, 5H, phe-H), 7.71 
(dd, JA = JB = 8.0 Hz, IH, 5-11), 8.11 (dd, J = 2.0 and 8.0 Hz, 1H, phe-H), 8.35 (d, J = 
2.0 and 8.0 Hz, lH, phe-H), 8.45 (dd, JA = JB = 2.0 Hz, IH, 2-H); MS (ESI) m/z: 
293.40 [M+H]. 
N-Benzyl-4-nitrobenzenesulfonamide [2501 
Synthesised from 4-nitrobenzenesulfonyl chloride (4.02 g, 0.02 mol). 
02N-Q4°NH 
b 
Yellow solid (3.71 g, 70%): anal. RP-HPLC: tR 21.0 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 5 4.14 (s, 2H, CH2), 7.15 - 7.22 (m, 514, phe-H), 7.97 
(d, J = 9.0 Hz, 2H, phe-H), 8.29 (d, J = 9.0 Hz, 2H, phe-H); MS (EST) m/z: 291.31 
EM-H]. 
Synthesis of Nitro-Compounds with Alkylated Sulfonamide Substituents [251-
254] 
The appropriate nitrobenzenesulfonyl chloride (0.018 mol) was solubilised in DCM 
(20 mL) and the solution cooled to 0 °C in an ice-water bath prior to addition of the 
appropriate alkylamine (0.022 mol, 1.5 eq) [caution: exothermic addition]. The 
solution was allowed to warm to II and stirred for a further 4 - 8 h. Progress of the 
reaction was monitored by HPLC and when no remaining starting material was 
detected, the RM was evaporated under reduced pressure. The resulting residue was 




Synthesised from 3-nitrobenzenesulfonyl chloride (4.79 g, 0.02 mol) and 




Yellow oil (3.87 g, 73%): anal. RP-HPLC: tR 12.5 mm (0-60% MeCN, purity 100%); 
'H NMR (CD30D): 8 3.03 (t, J = 6.0 Hz, 2H, CH2), 3.55 (t, J = 6.0 Hz, 2H, CH2), 
7.84 (dd, JA = JB = 8.0 Hz, 1H, 5-H), 8.24 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 8.46 
(dd, J = 2.0 and 8.0 Hz, III, phe-H), 8.66 (dd, .JA = JB = 2.0 Hz, IH, 2-H); MS (ES!) 
m/z: 245.22 [M-H]. 
N-(2-Hydroxyethyl)-4-nitrobenzenesulfonamide [252] 
Synthesised from 4-nitrobenzenesulfonyl chloride (5.63 g, 0.03 mol) and 





White solid (5.50 g, 88%): anal. RP-HPLC: tR 12.4 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 8 2.82 - 2.87 (m, 4H, Cl!2), 3.58 (t, J = 5.0 Hz, 1H, 




Synthesised from 3-nitrobenzenesulfonyl chloride (5.90 g, 0.03 mol) and 2-




Yellow solid (4.99 g, 72%): anal. RP-HPLC: tR 15.5 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 6 2.99 (dt, JA = JB = 5.5 Hz, 2H, CH2), 3.10 (s, 3H, 
CH3), 3.29 (t, J= 5.5 Hz, 2H, CH2), 7.90 (dd, JA = JB = 8.0 Hz, 1H, 5-H), 8.12 (t, J = 
5.5 Hz, IH, NH), 8.21 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 8.47 (dd, J = 2.0 and 8.0 
Hz, lH, phe-H), 8.55 (dd, JA = JB = 2.0 Hz, 1H, 2-H). 
N-(2-Methoxyethyl)-4-nitrobenzenesulfonamide [254] 
Synthesised from 4-nitrobenzenesulfonyl chloride (5.90 g, 0.03 mol) and 2- 
methoxyethylamine (3.46 mL, 0.04 mL) 127 . 
02N- 4° 
NH 
Yellow solid (4.99 g, 72%): anal. RP-HPLC: tR 12.0 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 6 3.11 (t, J = 5.5 Hz, 2H, CH2), 3.21 (s, 3H, CL!3), 3.37 
(t, J = 5.5 Hz, 2H, CH2), 8.09 (d, J = 9.0 Hz, 2H, phe-H), 8.40 (d, J = 9.0 Hz, 2H, 
phe-H); MS (ESF) m/z: 259.12 [M-H]. 
Synthesis of Nitro-Compounds with Morpholine-Substituted Sulfonamide 
Substituents [255-256] 
The appropriate nitrobenzenesulfonyl chloride starting material (1 eq) was solubilised 
in DCM (20 mL) and the reaction mixture cooled to 0 °C before addition of 
morpholine (1.5 eq) [caution: exothermic addition]. The RM was allowed to warm to 
it and stirred for a further 4 - 8 h. A white precipitate formed during reaction and 
when HPLC analysis of the RM revealed that no starting material remained, the 
precipitate was collected by suction filtration, washed with MeOH (3 x 5 mL), Et 20 
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(3 x 5 mL) and further dried in vacuo to yield the desired products as off-white 
solids' 21 . 
4- [(3-Nitrophenyl)sulfonyljmorpholine [255] 
Synthesised from 3-nitrobenzenesulfonyl chloride (7.90 g, 0.04 mol). 
02N_Q 
Off-white solid (6.10 g, 63%): anal. RP-HPLC: tR 17.0 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 2.96 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.64 (dd, 
JA = JB = 4.5 Hz, 4H, morph-H), 7.97 (dd, JA = JB = 8.0 Hz, 1H, 5-H), 8.18 (dd, J = 
2.0 and 8.0 Hz, 1H, phe-H), 8.37 (dd, JA = JB = 2.0 Hz, III, 2-H), 8.57 (dd, J = 2.0 
and 8.0 Hz, IH, phe-H). 
4-[(2-Methyl-5-nitrophenyl)sulfonyl]morpholine [256] 
Synthesised from 2-methyl-5-nitrobenzenesulfonyl chloride (5.56 g, 0.02 mol). 
Off-white solid (4.80 g, 71%): anal. RP-HPLC: tR 18.2 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 2.69 (s, 3H, CH3), 3.11 (dd, JA = JB = 4.5 Hz, 4H, 
morph-H), 3.62 (dd, JA = .JB = 4.5 Hz, 4H, morph-H), 7.79 (d, J = 8.5 Hz, IH, phe-H), 
8.43 (dd, J = 2.5 and 8.5 Hz, IH, phe-H), 8.49 (d, J = 2.5 Hz, 1H, phe-H); MS (ESI) 
m/z: 285.22 [M+H]. 
General Procedure for Synthesis of Nitro-Compounds from Fluoronitrobenzene 




The appropriately substituted nitrobenzene starting material (1 eq) was solubilised in 
DMSO (20 mL) and K2CO3 (1 eq) added. The resulting mixture was stirred at rt for 
30 min prior to the addition of the appropriate aryl amine (I eq) and then heated at 
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reflux for 4 - 6 h. The RM was cooled and poured over iced water (50 mL). The 
resultant precipitate was collected by suction filtration, washed with water (3 x 10 
mL), Et20 0  x 10 mL) and further dried in vacuo to yield the required nitro-
products 129 
1-(4-Nitrophenyl)piperidine (R3 = piperid, it4 = H) [257] 
Synthesised from l-fluoro-4-nitrobenzene (3.38 g, 0.02 mol) and piperidine (2.37 mL, 
0.02 mol). 
02N-c -- N 
Brown solid (quant.): anal. RP-HPLC: tR 23.2 mm (0-60% MeCN, purity 100%); 'H 
NMR (DMSO-d6): 8 1.54 - 1.58 (m, 4H, piperid-H), 1.60 - 1.64 (m, 2H, piperid-H), 
3.47 - 3.49 (m, 4H, piperid-H), 6.97 (d, J = 9.0 Hz, 2H, phe-H), 8.01 (d, J = 9.0 Hz, 
2H, phe-H); MS (ESI) mlz: 207.29 [M-i-H]. 
4-(4-Nitropheny1)thiomorpholine (R3 = thiomorph, it, = H) [258] 
Synthesised from I -fluoro-4-nitrobenzene (5.46 g, 0.04 mol) and thiomorpholine 




Yellow solid (6.94 g, 80%): anal. RP-HPLC: tR 20.8 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 8 2.64 (dd, JA = JB = 5.0 Hz, 4H, morph-H), 3.87 (dd, 
JA = JB = 5.0 Hz, 4H, morph-H), 7.00 (d, J = 9.5 Hz, 2H, phe-H), 8.04 (d, J = 9.5 Hz, 
2H, phe-H); MS (ESI) m/z: 225.41 [M+H]. 
1-(4-Nitrophenyl)pyrrolidine (R3 = pyrr, R4 = H) [259] 
Synthesised from 1-fluoro-4-nitrobenzene (5.26 g, 0.04 mol) and pyrrolidine (3.11 
mL, 0.04 mol). 
02N---~&NC] 
Yellow solid (quant.): anal. RP-HPLC: tR 22.4 mm (0-60% MeCN, purity 100%); 'H 
NMR (DMSO-d6): 8 1.96 - 1.99 (m, 4H, pyrr-H), 3.34- 3.38 (m, 4H, pyrr-H), 6.59 
(d, J = 9.0 Hz, 2H, phe-H), 8.04 (d, J = 9.0 Hz, 2H, phe-H); MS (ESr) m/z: 193.13 
[M+H]t 
1-(2-Methyl-4-nitrophenyl)piperidine (R3 = piperid, R4 = CH3) [2601 
Synthesised from 2-fluoro-5-nitrotoluene (5.78 g, 0.04 mol) and piperidine (3.68 mL, 
0.04 mol). 
02N-C~ND 
Yellow solid (7.94 g, 97%): anal. RP-HPLC: tR 14.8 mm (0-60%, MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 1.51 - 1.54 (m, 2H, piperid-H), 1.59- 1.63 (m, 4H, 
piperid-H), 2.26 (s, 3H, CL!3), 2.90 (dd, JA = JB = 5.0 Hz, 4H, piperid-H), 7.03 (d, J = 
8.0 Hz, IH, phe-H), 7.94 -7.96 (m, 2H, phe-H); MS (ESI) m/z: 221.27 [M+H]. 
1-(2-Methoxy-4-nitrophenyl)piperidine (R3 = piperid, R4 = OMe) [261] 




Yellow solid (2.42 g, 72%): anal. RP-HPLC: tR 14.9 mm (0-60%, MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 1.56- 1.58 (m, 2H, piperid-H), 1.60- 1.65 (m, 4H, 
piperid-H), 3.15 (dd, JA = JB = 5.0 Hz, 4H, piperid-H), 3.89 (s, 3H, CH3), 6.97 (d, J = 
9.0 Hz, 1H, phe-H), 7.65 (d, J = 2.5 Hz, IH, 2-H), 7.79 - 7.81 (m, lH, phe-H); MS 
(ESi) mlz: 237.15 [M+H]. 
4-(2-Methyl.4-nitrophenyl)morpholine (R3 = morph, R4 = CH3) [262] 
Synthesised from 2-fluoro-5-nitrotoluene (3.35 g, 0.02 mol) and morpholine (1.88 
mL, 0.02 mol). 
O2N-c_N,O 
Yellow solid (5.51 g, 94%): anal. RP-HPLC: tR 21.0 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 8 2.30 (s, 3H, CH3), 2.96 (dd, JA = JB = 4.5 Hz, 4H, 
morph-H), 3.71 (dd, .JA = JB = 4.5 Hz, 4H, morph-H), 7.09 (d, J = 8.5 Hz, IH, phe-H), 
7.98 - 8.00 (m, 2H, phe-H); MS (ESr') mlz 235.31 [M+H]t 
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3-Nitrobenzyl chloride (2.06 g, 0.01 mol) was solubilised in DCM (10 mL) and the 
solution cooled to 0 °C using an ice-water bath before drop-wise addition of 
thiomorpholine (1.37 mL, 0.01 mol) [caution: exothermic addition]. Once addition 
was complete, the RM was allowed to warm to rt and stirred for a further 16 h. 
Progress of the reaction was monitored by HPLC and when no starting material 
remained, the RM was evaporated under reduced pressure and the residue purified by 
flash chromatography (PE/EtOAc 2:1) to afford the product as a light brown solid 121 
(2.86 g, 74%). Anal. RP-HPLC: tR 9.0 mm (0-60% MeCN, purity 100%); 'H NMR 
(CD30D): 8 2.65 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 2.72 (dd, JA = JB = 4.5 Hz, 4H, 
morph-H), 3.63 (s, 2H, CH2), 7.55 (dd, JA = JB = 8.0 Hz, IH, 5-H), 7.72 (dd, J = 2.5 
and 8.0 Hz, 1H, phe-H), 8.12 (dd, J = 2.5 and 8.0 Hz, 111, phe-H), 8.21 (dd, JA = JB = 
2.5 Hz, lH, 2-Il); MS (ESIT) mlz: 239.27 [M+H]. 
1-Methyl-4-(3-nitrobenzyl)piperazine [264] 
C 
3-Nitrobenzyl chloride (3.65 g, 0.02 mol) was solubilised in DMSO (15 mL) and 
K2CO3 (2.94 g, 0.02 mol) added. The resulting mixture was stirred at rt for 20 mm 
prior to addition of methylpiperazine (2.36 mL, 0.02 mol). The RM was heated at 
reflux for 4 - 6 h, cooled, poured over ice/water (25 mL) and the product extracted 
using DCM (3 x 25 mL). The organic extracts were combined, dried (MgSO 4), 
filtered and evaporated under reduced pressure to yield the product as a yellow 
solid 130  (2.45 g, 49%). Anal. RP-HPLC: tR 8.0 mm (0-60% MeCN, purity 100%); 'H 
NMR (DMSO-d6): S 2.10 (s, 3H, CH3), 2.23 - 2.35 (m, 8H, piperaz-H), 3.54 (s, 2H, 
CH2), 7.58 (dd, JA = "B = 8.0 Hz, lH, 5-H), 7.71 (dd, J = 2.0 and 8.0 Hz, III, phe-H), 
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8.07 (dd, J = 2.0 and 8.0 Hz, lH, phe-H), 8.09 (dd, JA = JB = 2.0 Hz, IH, 2-H); MS 
(ESI) m/z: 236.01 [M+H] 4 . 
4-(3-Nitrobenzoyl)morpholine [265] 
C) 
3-Nitrobenzoyl chloride (5.29 g, 0.03 mol) was solubilised in DCM (15 mL) and the 
solution cooled to 0 °C using an ice-water bath before addition of morpholine (3.73 
mL, 0.04 mol) [caution: exothermic addition]. The RM was then warmed to rt and 
stirred for a further 4 - 6 h. When HPLC analysis indicated that no starting material 
remained, the RM was evaporated under reduced pressure and the residue purified by 
flash chromatography (PE/EtOAc 2:1) to give the product as an off-white solid ' 2 ' 
(4.80 g, 71 %).  Anal. RP-HPLC: tR 12.8 mm (0-60% MeCN, purity 100%); 'H NMR 
(CD30D): 8 3.44 (bs, 2H, morph-H), 3.63 (bs, 2H, morph-H), 3.77 (bs, 4H, morph-
H), 7.72 (dd, JA = JB = 8.0 Hz, Ill, 5-H), 7.83 (dd, J = 2.0 and 8.0 Hz, lH, phe-H), 
8.29 (dd, JA = JB = 2.0 Hz, 1H, 2-H), 8.33 (dd, J = 2.0 and 8.0 Hz, IH, phe-H); MS 
(ESi) m/z: 237.29 [M+H]t 
171 
General Procedure for Reduction of Nitro-Intermediates to the Corresponding 
Aniline Derivatives [266-289] 
The nitro-intermediate (I eq) was solubilised in EtOH (10 - 15 mL) and 10% 
palladium catalyst on activated carbon added (0.001 mol, 5%). A hydrogen balloon 
was fitted to the reaction flask and, after careful removal of air from the system by 
vacuum, hydrogen was released into the vessel [caution: risk of explosion] and the 
RM stirred at it for 24 - 36h. Progress of the reaction was monitored by HPLC and 
when no starting material remained, the RM was filtered through celite to remove the 
catalyst, the filtrate evaporated under reduced pressure and further dried in vacuo to 
yield the desired aniline as a solid or oily residue 122 . 
N-(3-Aminobenzyl)acetamide [266] 
Synthesised from [242] (4.28 g, 0.02 mol). 
H2N- 
HN 
Yellow solid (3.16 g, 87%): anal. RP-HPLC: tR 6.0 mm (0-60% MeCN, purity 100%); 
'H NMR (CD30D): ö 1.97 (s, 3H, CH3), 4.24 (s, 2H, CH2), 6.61 - 6.62 (m, 2H, phe-
H), 6.64 (dd, JA = JB = 1.5 Hz, IH, 2-11), 7.02 (dd, JA = JB = 7.5 Hz, IH, 5-H); MS 
(ESI) m/z: 165.00 [M+H]. 
N-(4-Aminobenzyl)acetamide [267] 
Synthesised from [243] (4.10 g, 0.02 mol). 
H2N_c -\ 
Yellow solid (3.22 g, 93%): anal. RP-HPLC: tR 12.0 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): 8 1.94 (s, 3H, CH3), 4.20 (s, 2H, CH2), 6.68 (d, J = 8.0 
Hz, 2H, phe-11), 7.02 (d, J = 8.0 Hz, 2H, phe-H); MS (ESF') m/z: 164.66 [M+H]t 
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N-(3-Aminobenzyl)methanesulfonamide [268] 
Synthesised from [244] (7.30 g, 0.03 mol). 
H2N_( 
Yellow oil (quant.): anal. RP-HPLC: tR 5.4 mm (0-60% MeCN, purity 89%); 'H 
NMR (CD30D): 6 2.81 (s, 3H, CH3), 4.13 (s, 2H, CH2), 6.64 (dd, J = 1.5 and 7.5 Hz, 
IH, phe-H), 6.68 (dd, J = 1.5 and 7.5 Hz, 1H, phe-I1), 6.74 (dd, .JA = JB = 1.5 Hz, IH, 
2-H), 7.07 (dd, JA = JB = 7.5 Hz, 1H, 5-H); MS (ESI) m/z: 203.15 [M+H]t 
N-(3-Aminobenzyl)- 1,1,1-trifluoromethanesulfonamide [269] 





Yellow oil (3.24 g, 9 1%): anal. RP-HPLC: tR 11.3 mm (0-60% MeCN, purity 100%); 
'H NMR (CD30D): 6 4.24 (s, 2H, CH2), 6.65 - 6.67 (m, 2H, phe-H), 6.70 (dd, JA = JB 
= 2.0 Hz, IH, 2-H), 7.08 (dd, JA = JB = 8.0 Hz, 5-H); MS (ESIF)  n7/z: 254.19 [M+H]t 
N-[(3-Aminophenyl)sulfonyi]acetamide [270] 
Synthesised from [246] (3.75 g, 0.02 mol). 
H2N- 
HN 0 
Orange oil (2.79 g, 85%): anal. RP-HPLC: tR 9.8 mm (0-60% MeCN, purity 73%); 
'H NMR (CD 30D): 6 1.69 (s, 3H, CH3), 2.28 (bs, 2H, NH2), 6.57 (dd, J = 2.0 and 8.0 




Synthesised from [247] (2.20 g, 0.85 mmol). 
H2N-Q 
Orange oil (1.85 g, 95%): anal. RP-HPLC: tR 10.2 mm (0-60% MeCN, purity 97%); 
'H NMR (CD30D): 8 2.35 (s, 3H, CH3), 3.26 (s, 3H, CH3), 6.94 (d, J = 8.0 Hz, IH, 
phe-H), 7.10 (d, J = 8.0 H, 1H, phe-H), 7.16 (s, IH, 2-H), 7.28 (dd, JA = JB = 8.0 Hz, 
1H, 5-H); MS (ESIT1 ) nilz: 229.04 [M+H]t 
N-[(3-Aminophenyl)sulfonyl]-N-ethylacetamide [272] 
Synthesised from [248] (1.01 g, 0.37 mmol). 
H2N-ç 
/-)= 
Orange oil (0.80 g, 89%): anal. RP-HPLC: tR 12.5 mm (0-60% MeCN, purity 100%); 
'H NMR (CD30D): 8 1.26 (t, J = 7.0 Hz, 3H, CH2CH3), 2.33 (s, 3H, CH3 ), 3.86 (q, J 
= 7.0 Hz, 2H, CH2CH3), 6.96 (dd, J = 1.5 and 8.0 Hz, 1H, phe-H), 7.12 (dd, J = 1.5 
and 8.0 Hz, 1H, phe-H), 7.19 (dd, JA = JB = 1.5 Hz, 1H, 2-H), 7.29 (dd, JA = JB = 8.0 
Hz, IH, 5-H); MS (ES1) n7/z: 243.29 [M+H]t 
3-Amino-N-benzylbenzenesulfonamide [273] 




Yellow oil (1.52 g, 90%): anal. RP-HPLC: tR 14.2 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): ö 4.04 (s, 2H, CH2), 6.90 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 
7.11 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 7.16 (dd, .1,, = JB = 2.0 Hz, IH, phe-H), 7.21 
- 7.29 (m, 6H, phe-H). 
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4-Amino-N-benzylbenzenesulfonamide [274] 





Orange solid (4.12 g, 90%): anal. RP-HPLC: tR 16.2 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d 6): 8 3.83 (d, J = 6.5 Hz, 2H, CH2), 6.58 (d, J = 8.5 Hz, 
2H, phe-H), 7.17 - 7.26 (m, 5H, phe-H), 7.41 (d, J = 8.5 Hz, 2H, phe-H), 7.59 (t, J = 
6.5 Hz, IH, NH); MS (ES) m/z: 261.13 [M-H]. 
3-Amino-N-(2-hydroxyethyl)benzenesulfonamide [275] 




Yellow solid (3.13 g, 91%): anal. RP-HPLC: tR 5.8 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): ö 2.95 (t, J = 6.0 Hz, 2H, CH2), 3.54 (t, J = 6.0 Hz, 2H, CH2), 
6.88 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 7.09 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 
7.14 (dd, JA = JB = 2.0 Hz, IH, 2-H), 7.23 (dd, JA = JB = 8.0 Hz, lH, 5-H); MS (ESf) 
m/z: 217.02 [M+H]t 
4-Amino-N-(2-hydroxyethyl)benzenesulfonamide [276] 





Yellow oil (3.24 g, 92%): anal. RP-HPLC: tR 6.1 mm (0-60% MeCN, purity 100%); 
'H NMR (CD30D): 8 2.70 (dt, JA = JB = 6.0 Hz, 2H, CH2), 3.33 (t, J = 6.0 Hz, 2H, 
CH2), 6.60 (d, J = 8.5 Hz, 2H, phe-H), 7.03 (t, J = 6.0 Hz, 1H, NH), 7.40 (d, J = 8.5 
Hz, 2H, phe-H); MS (ESI) nilz: 217.12 [M+H]t 
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3-Amino-N-(2-methoxyethyl)benzenesulfonamide [277] 
Synthesised from [253] (4.80 g, 0.02 mol). 
H2N__Q 
HN 0 
Yellow oil (3.96 g, 93%): anal. RP-HPLC: tR 7.9 mm (0-60% MeCN, purity 79%); 'H 
NMR (CD30D): 5 3.03 (t, J = 5.5 Hz, 2H, CH2), 3.27 (s, 3H, CH3), 3.38 (t, J = 5.5 
Hz, 2H, CH2), 6.88 (dd, J= 1.0 and 8.0 Hz, IH, phe-H), 7.09 (dd, J = 1.0 and 8.0 Hz, 
1H, phe-H), 7.14 (dd, JA = JB = 1.0 Hz, 1H, 2-H), 7.24 (dd, .JA = JB = 8.0 Hz, IH, 5-
H). 
4-Amino-N-(2-methoxyethyl)benzenesulfonamide [278] 





Yellow oil (3.61 g, 82%): anal. RP-HPLC: tR 8.7 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): ö 2.96 (t, J = 5.5 Hz, 2H, CH2), 3.25 (s, 3H, Cl!3), 3.36 (t, J = 
5.5 Hz, 2H, CH2), 6.7 (d, J = 9.0 Hz, 2H, phe-H), 7.53 (d, J = 9.0 Hz, 2H, phe-H); MS 
(ESF) n?/z: 229.17 [M-H]. 
3-(Morpholin-4-ylsulfonyl)aniline [279] 
Synthesised from [255] (2.01 g, 0.74 mmol). 
H2N_Q 
Off-white solid (1.01 g, 56%): anal. RP-HPLC: tR 9.9 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 8 2.82 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.62 (dd, 
"A = JB = 4.5 Hz, 4H, morph-H), 5.65 (bs, 2H, NH2), 6.78 (dd, J = 2.5 and 8.0 Hz, IH, 
phe-H), 6.84 (dd, J = 2.5 and 8.0 Hz, 1H, phe-H), 6.90 (dd, JA = JB = 2.5 Hz, IH, 2-
H), 7.25 (dd, JA = JB = 8.0 Hz, IH, 5-H); MS (ESI) m/z: 243.27 [M+H]t 
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4-Methyl-3-(morpholin-4-ylsulfonyl)aniline [280] 




Yellow oil (2.85 g, 89%): anal. RP-HPLC: tR 10.1 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): 6 2.81 (s, 3H, CH3), 2.97 (dd, JA = J8 = 4.5 Hz, 4H, morph-H), 
3.61 (dd, 1A = .1J3 = 4.5 Hz, 4H, morph-H), 6.75 (dd, J = 2.5 and 8.0 Hz, IH, phe-J1), 
7.05 (d, J = 8.0 Hz, IH, phe-H), 7.07 (d, J = 2.5 Hz, 1H, 2-H); MS (ESI 1 ) nilz: 257.00 
[M+H]t 
4-Piperidin-1-ylaniline [281] 
Synthesised from [257] (3.05 g, 0.01 mol). 
H2N-c -N 
Brown oil (2.41 g, 92%): anal. RP-HPLC: tR 5.2 mm (0-60% MeCN, purity 100%); 
'H NMR (CD30D): 8 1.52 (m, 2H, piperid-H), 1.69 - 1.74 (m, 4H, piperid-H), 2.93 - 
2.95 (m, 4H, piperid-H), 6.70 (d, J = 8.0 Hz, 2H, phe-H), 6.86 (d, J = 8.0 Hz, 2H, 
phe-H); MS (ESr) m/z: 177.04 [Mi-H]t 
4-Pyrrolidin-1-ylaniline [282] 
Synthesised from [259] (6.09 g, 0.03 mol). 
H2N-c --Nc1 
Brown oil (4.59 g, 89%): anal. RP-HPLC: tR 7.9 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): 6 1.87 - 1.90 (m, 4H, pyrr-H), 3.07 (dd, JA = JB = 6.5 Hz, 4H, 
pyrr-H), 6.35 (d, J = 8.5 Hz, 2H, phe-H), 6.49 (d, J = 8.5 Hz, 2H, phe-H); MS (ES[) 
m/z: 163.26 [Mi-H]t 
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4-Thiomorpholin-4-ylaniline [283] 
Synthesised from [258] (5.08 g, 0.02 mol). 
/=\ /___\ 
Yellow solid (3.70 g, 84%): anal. RP-HPLC: tR 7.3 mm (0-60% MeCN, purity 100%); 
'H NMR (CD3OD): ö 2.75 (dd, JA = JB = 5.0 Hz, 4H, morph-H), 3.25 (dd, JA = JB 
5.0 Hz, 4H, morph-H), 6.70 (d, J = 8.5 Hz, 2H, phe-H), 6.83 (d, J = 8.5 Hz, 2H, phe-
H); MS (ESI) m/z: 195.15 [M+H]t 
3-Methyl-4-piperidin-1-ylaniline [284] 
Synthesised from [260] (5.99 g, 0.03 mol). 
H2N-c --N3 
Brown oil (3.77 g, 73%): anal. RP-HPLC: tR 11.6 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): 5 1.46- 1.48 (m, 2H, piperid-H), 1.57- 1.60 (m, 4H, piperid-
H), 2.10 (s, 3H, CH3), 2.63 (dd, JA = .JB = 5.0 Hz, 4H, piperid-H), 4.62 (bs, 2H, NH2), 
6.34 (d, J = 8.0 Hz, IH, phe-H), 6.72 (dd, J = 2.5 and 8.0 Hz, 1H, phe-H), 8.02 (d, J = 
2.5 Hz, IH, 2-H); MS (ESI) m/z: 191.16 [M+H]. 
3-Methoxy-4-piperidin-1-ylaniline [285] 
Synthesised from [261] (2.43 g, 0.01 mol). 
H2N-c?--N 
,0 
Brown oil (1.61 g, 76%): anal. RP-HPLC: tR 6.4 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): ö 1.67- 1.68 (m, 2H, pip-H), 1.88- 1.93 (m, 4H, pip-H), 3.28 
(bs, 4H, pip-H), 3.72 (s, 3H, CH3), 6.31 - 6.34 (m, IH, phe-H), 6.48 (bs, IH, 2-H), 
7.11 (d, J= 8.5 Hz, IH, phe-H); MS (ESr) m/z: 193.00 [M+H]. 
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3-Methyl-4-morpholin-4-ylaniline [286] 
Synthesised from [262] (4.30 g, 0.02 mol). 
H2N-( )-N 0 
Brown oil (3.44 g, 93%): anal. RP-HPLC: tR 7.8 mm (0-60% MeCN, purity 100%); 
'H NMR (CD30D): 8 1.06 (s, 3H, CH3), 1.61 (dd, JA = .18 = 4.5 Hz, 4H, morph-H), 
2.62 (dd, JA = J8 = 4.5 Hz, 4H, morph-H), 5.40 (d, J = 8.0 Hz, IH, phe-H), 5.44 (d, J 
= 2.0 Hz, IH, 2-H), 5.70 (dd, J = 2.0 and 8.0 Hz, IH, phe-H); MS (ESI) m/z: 193.00 
[M+H]. 
3-(Thiomorpholin-4-ylmethyl)aniline [287] 
Synthesised from [263] (1.44 g, 0.60 mmol). 
H2N 
KT) 
Off-white solid (1.01 g, 80%): anal. RP-HPLC: tR 11.1 mm (0-60% MeCN, purity 
100%); 'H NMR (CD30D): 8 2.65 (dd, JA = .18 = 4.5 Hz, 4H, thiomorph-H), 2.73 (dd, 
JA = JB = 4.5 Hz, 4H, thiomorph-H), 3.46 (s, 2H, CH2), 6.62 - 6.64 (m, 214, phe-H), 
6.69 (bs, 1H, 2-H), 7.04 (dd, .1,, = JB = 7.5 Hz, 1H, 5-H); MS (ESI) m/z: 209.14 
[M+H]t 
3- [(4-Methylpiperazin -1-yl)methyl]aniline [288] 
Synthesised from [264] (1.20 g, 0.51 mmol). 
p 
Yellow oil (1.02 g, 97%): anal. RP-HPLC: tR 8.2 mm (0-60% MeCN, purity 100%); 
'H NMR (CD 30D): 5 2.26 (s, 3H, CH3), 2.38 - 2.56 (m, 8H, piperaz-H), 3.40 (s, 2H, 
Cl2), 4.86 (bs, 2H, NH2), 6.61 - 6.64 (m, 2H, phe-H), 6.69 (bs, IH, phe-H), 7.03 (dd, 
JA = JB = 8.0 Hz, 1H, 5-H); MS (ESI) m/z: 206.08 [M-i-H]t 
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3-(Morpholin-4-ylcarbonyl)aniline [289] 
Synthesised from [265] (4.50 g, 0.02 mol). 
H2N-.c 
C 
Brown oil (3.35 g, 85%): anal. RP-HPLC: tR 6.1 mm (0-60% MeCN, purity 100%); 
'H NMR (CD30D): ö 3.60 - 3.64 (m, 4H, morph-H), 3.77 (bs, 4H, morph-H), 7.36 - 
7.41 (m, 3H, phe-H), 7.57 (dd, .JA = JB = 8.0 Hz, IH, 5-H). MS (ESr) m/z: 207.47 
[M+H]t 
4-Methoxy-3-methylaniline [290] 
Synthesised from 2-methyl-4-nitroanisole (2.40 g, 0.01 mol). 
H2N_- O\ 
Brown oil (1.80 g, 85%): anal. RP-HPLC: tR 8.5 mm (0-60% MeCN, purity 100%); 
'H NMR (CD 30D): 8 2.11 (s, 3H, CH3), 3.71 (s, 3H, CH3), 6.56 (dd, J = 2.5 and 8.5 
Hz, IH, phe-H), 6.58 (d, J = 2.5 Hz, IH, 2-H), 6.67 (d, J = 8.5 Hz, 2H, phe-H); MS 
(ESr4 ) nilz: 138.22 [M+H]. 
:s 
General Procedure for Synthesis of Guanidines (II) [291-318] from Aniline 
Intermediates 
The aniline (1 eq) was solubilised in EtOH (15 mL) and the resulting solution cooled 
to 0 °C using an ice-water bath before the addition of HNO3 (2eq). The RM was 
stirred at 0 °C for a further 10 min before addition of cyanamide (2 eq), allowed to 
warm tort and heated at reflux (approx. 110 °C) for 16-20 h. Progress of the reaction 
was monitored by HPLC; when the reaction had reached completion the RM was 
evaporated under reduced pressure, the residue washed with Et20 (I x 5 mL) and then 
further dried in vacuo56" 20" 23 . 
N-(3-{ [Amino(imino)methyl]amino}benzyl)acetamide  (II) [291] 




Brown oil (quant.): anal. RP-HPLC: tR 12.0 mm (0-60% MeCN, purity 70%); 'H 
NMR (CD30D): 5 2.00 (s, 3H, CH3), 4.38 (s, 2H, CH2), 7.20 (dd, J = 2.0 and 8.0 Hz, 
IH, phe-H), 7.40 (dd, .JA = JB = 2.0 Hz, IH, 2-H), 7.29 (dd, J = 2.0 and 8.0 Hz, IH, 
phe-H), 7.40 (dd, JA = JB = 8.0 Hz, 1H, 5-H); MS (ESI) n7/z: 207.09 [M+H]. 
N-(4-{[Amino(imino)methyl]amino}benzyl)acetamide (II) [292] 
Synthesised from [267] (0.54 g, 0.33 mmol). 
H2N-(0 N-
NH 
Brown oil (quant.): anal. RP-HPLC: tR 11.5 mm (0-60% MeCN, purity 67%); 'H 
NMR (CD30D): 8 2.00 (s, 3H, CH3), 4.28 (s, 2H, Cl-I2), 4.95 (bs, 2H, NH2), 7.35 (d, J 
= 8.0 Hz, 2H, phe-H), 7.43 (d, J = 8.0 Hz, 2H, phe-H); MS (ESf') m/z: 207.09 
[M+H] . 
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N-(3-{ [Amino(imino)methyl]amino}benzyl)methanesulfonamide (II) [293] 




Orange oil (quant.): anal. RP-HPLC: tR 6.9 mm (0-60% MeCN, purity 82%); 'H 
NMR (CD30D): ö 2.95 (s, 3H, CH3), 4.30 (s, 2H, CH2), 7.21 - 7.25 (m, IH, phe-H), 
7.33 (bs, IH, 2-H), 7.38 (d, J = 8.0 Hz, 1H, phe-H), 7.46 (dd, JA = JB = 8.0 Hz, 1H, 5-
H); MS (ESI) m/z: 243.39 [M+H]t 
N-(3-{ [Amino(imino)methyl]amino}benzyl)- 1,1,1-trifluoromethanesulfonamide 
(II) [294] 




Orange oil (quant.): anal. RP-HPLC: tR 12.2 mm (0-60% MeCN, purity 72%); 'H 
NMR (CD30D): ö 4.42 (s, 2H, CH2), 4.86 (bs, NH2), 7.25 (dd, J = 2.0 and 7.5 Hz, 
IH, phe-H), 7.28 (dd, JA = JB = 2.0 Hz, 1H, 2-H), 7.35 (dd, J = 2.0 and 7.5 Hz, 1H, 
phe-H), 7.49 (dd, JA = JB = 7.5 Hz, IH, 5-H); MS (ESI) ni/z: 301.27 [M+H]t 
N-[(3-{ [Amino(imino)methyl]amino}phenyl)sulfonyl] -N-methylacetamide 	(II) 
[295] 





Orange oil (quant.): anal. RP-HPLC: tR 6.3 mm (0-60% MeCN, purity 100%); 'H 
NMR (CD30D): 8 1.67 (s, 3H, CH3), 7.27 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 7.44 
(dd, JA = J8 = 8.0 Hz, 1H, 5-H), 7.60 (dd, J = 2.0 and 8.0 Hz, 1H, phe-H), 7.64 (dd, JA 
JB = 2.0 Hz, 1H, 2-H); MS (ESr) m/z: 257.65 [M+H]. 
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N-[(3-{ [Amino(imino)methyl]amino}phenyl)sulfonyl] -N-methylacetamide 	(II) 
[296] 








Orange oil (quant.): anal. RP-HPLC: tR 6.4 mm (0-60% MeCN, purity 43%); 'H 
NMR (CD30D): S 2.53 (s, 3H, CH3), 2.99 (s, 3H, CH3), 6.90 (dd, J = 1.5 and 7.5 Hz, 
I H, phe-H), 7.06 (dd, J = 1.5 and 7.5 Hz, IH, phe-H), 7.13 (dd, JA = JB = 1.5 Hz, I H, 
2-H), 7.25 (dd, .JA = JB = 7.5 Hz, 1H, 5-H); MS (ESr) m/z: 271.15 [M+H]. 
N-[(3-{ [Amino(imino)methyl]amino}phenyl)sulfonyl] -N-ethylacetamide (II) [297] 




Orange oil (quant.): anal. RP-HPLC: tR 10.4 mm (0-60% MeCN, purity 100%); 'H 
NMR (CD30D): 5 1.35 (t, J = 7.0 Hz, 311, CH2CH3), 2.31 (q, J = 7.0 Hz, 2H, 
CH2CH3 ), 2.53 (s, 3H, CH3), 7.63 (dd, J = 2.0 and 8.0 Hz, 1H, phe-H), 7.71 (dd, JA 
JB = 8.0 Hz, IH, 5-H), 7.89-7.91 (m, 211, phe-H); MS (ESI) m/z: 285.15 [M+H]. 
3-{ [Amino(imino)methyl]amino)-N.benzylbenzenesulfonamide  (II) [298] 









Orange oil (quant.): anal. RP-HPLC: tR 14.2 mm (0-60% MeCN, purity 75%); 1 H 
NMR (DMSO-d6): 5 4.12 (s, 2H, CH2), 7.19- 7.26 (m, 5H, phe-H), 7.49 (dd, J = 2.0 
and 8.0 Hz, IH, phe-H), 7.60 (dd, JA = JB = 8.0 Hz, IH, 5-H), 7.75 - 7.76 (m, 211, 
phe-H); MS (ESI) m/z: 305.22 [M+H]t 
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4-{ [Amino(imino)methyl]amino}-N-benzylbenzenesulfonamide  (II) [299] 
Synthesised from [274] (3.16 g, 0.01 mol). 
H2N ° H 
NH b 
Orange solid (2.40 g, 65%): anal. RP-HPLC: tR 12.7 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 4.07 (d, J = 6.0 Hz, 2H, CH2), 7.31 - 7.40 (m, 5H, 
phe-H), 7.49 (d, J = 8.5 Hz, 2H, phe-H), 7.72 (bs, 2H, NH2), 7.92 (d, J = 8.5 Hz, 2H, 
phe-H), 8.28 (t, J = 6.0 Hz, IH, NH); MS (ESr) m/z: 305.28 [M+H]. 
3-{ [Amino(imino)methyl]amino}-N-(2-hydroxyethyl)benzenesulfonamide 	(II) 
 






Brown oil (quant.): anal. RP-HPLC: tR 5.8 mm (0-60% MeCN, purity 70%); MS 
(ESI) m/z: 259.41 [M±H]. 
4- [Amino(imino)methyl] amino } -N- (2-hydroxyethyl)benzenesulfonamide 	(II) 
 




Orange oil (quant.): anal. RP-HPLC: tR 5.7 mm (0-60% MeCN, purity 69%); 'H 
NMR (CD 30D): ö 2.70 (m, 2H, CH2), 4.28 (m, 2H, CH2), 5.52 (bs, 2H, NH2), 6.61 (d, 




Synthesised from [277] (3.95 g, 0.02 mol). 
Orange oil (quant.): anal. RP-HPLC: tR 7.8 mm (0-60% MeCN, purity 100%); 'H 
NMR (DMSO-do): ö 3.09 (dt, J = 6.0 Hz, 2H, CH2), 3.33 (s, 3H, CH3), 3.47 (t, J = 6.0 
Hz, 2H, CH2), 7.66 (dd, J = 2.0 and 7.5 Hz, 1H, phe-H), 7.74 (bs, 2H, NH2), 7.78 - 




Synthesised from [278] (1.59 g, 0.69 mmol). 
H2N-' NH 
NH 
Brown oil (quant.): anal. RP-HPLC: tR 6.1 mm (0-60% MeCN, purity 100%); 'H 
NMR (DMSO-d6): 6 2.96 (m, 2H, CH2), 3.14 (s, 3H, CH3), 3.31 (t, J = 5.5 Hz, 2H, 
CH2), 7.95 - 7.97 (m, 2H, phe-H), 8.02 - 8.05 (m, 3H, NH and NH2), 8.09 (d, J = 8.5 
Hz, 2H, phe-H); MS (ESt) m/z: 273.35 [M+H]t 
1-[3-(Morpholin-4-ylsulfonyl)phenyl]guanidine (II) [304] 
Synthesised from [279] (0.79 g, 0.32 mmol). 





Orange oil (quant.): anal. RP-HPLC: tR 8.5 mm (0-60% MeCN, purity 100%); 'H 
NMR (DMSO-d6): 6 3.02 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.11 (dd, JA = JB = 4.5 
Hz, 4H, morph-H), 6.97 (dd, J = 1.5 and 8.0 Hz, I H, phe-H), 7.04 (dd, J = 1.5 and 8.0 
185 
Hz, IH, phe-H), 7.09 (dd, JA = JB = 1.5 Hz, 1H, 2-11), 7.45 (dd, JA = JB = 8.0 Hz, IH, 
5-H); MS (ESI[) m/z: 285.39 [M+H]t 
1- [4-Methyl -3- (morpholin-4-ylsulfonyl)phenyl]guanidine (II) [305] 






Orange oil (quant.): anal. RP-HPLC: tR 10.6 mm (0-60% MeCN, purity 41%); 'H 
NMR (DMSO-d6): 5 2.56 (s, 3H, CH3), 3.13 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
3.17 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 7.2 (d, J = 8.0 Hz, IH, phe-H), 7.34 (d, J = 
8.0 Hz, IH, phe-H), 7.77 (bs, 1H, 2-H); MS (ESI) m/z: 299.14 [M+H]t 
Ethyl (3-{ [amino(imino)methyl]amino}phenyl)acetate  (II) [306] 
Synthesised from 3 -aminophenyl acetic acid (1.00 g, 0.66 mmol). 
H2N - ( 
NHq 
Brown solid (quant.): anal. RP-HPLC: tR 10.4 mm (0-60% MeCN, purity 73%); 'H 
NMR (DMSO-d6): 8 1.19 (t, J = 7.0 Hz, 3H, CH2CH3), 3.69 (s, 2H, CH2), 4.04 -4.10 
(m, 2H, CH2), 5.45 (bs, 2H, NH2), 7.13 - 7.14 (m, 2H, phe-H), 7.19 (d, J = 8.0 Hz, 
IH, phe-H), 7.39 (dd, .JA = JB = 8.0 Hz, 1H, 5-H); MS (ESI) m/z: 222.49 [M+H]t 
1-(4-Piperidin-1-ylphenyl)guanidine (II) [307] 





Purple solid (1.45 g, 5 1%): anal. RP-HPLC: tR 5.5 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): 8 1.50- 1.51 (m, 2H, piperid-H), 1.56- 1.57 (m, 4H, piperid-
H), 3.11 - 3.13 (m, 4H, piperid-H), 6.93 (d, J = 8.5 Hz, 2H, phe-H), 7.02 (d, J = 8.5 
Hz, 2H, phe-H), 7.07 (bs, 2H, NH2), 9.18 (bs, IH, NH); 13C NMR (DMSO-d6): 8 
MR 
24.47, 25.84, 50.02, 116.87, 125.63, 127.26, 151.16, 156.90; MS (ESI) m/z: 219.30 
[M+H]. 
1-(4-Pyrrolidin-1-ylphenyl)guanidine (II) [308] 




Purple solid (3.01 g, 61 %):  anal. RP-HPLC: tR 8.3 mm (0-60% MeCN, purity 100%); 
'H NMR (DM50-d6): ö 1.90- 1.93 (m, 4H, pyrr-H), 3.18 (dd, JA = JB = 6.5 Hz, 411, 
pyrr-H), 6.53 (d, J = 9.0 Hz, 2H, phe-H), 6.97 - 6.70 (m, 4H, NH2 and 2 x phe-H), 
9.07 (bs, 111, NH); ' 3C NMR (DMSO-d6): 8 25.72, 48.09, 112.78, 122.60, 127.99, 
147.64, 157.21; MS (ESI) in/z: 205.13 [M+H]. 
1-(4-Thiomorpholin-4-ylphenyl)guanidine (II) [309] 




Brown solid (quant.): anal. RP-IIPLC: tR 7.9 mm (0-60% MeCN, purity 100%); 'H 
NMR (DMSO-do): 8 2.61 (dd, JA = JB = 5.0 Hz, 411, morph-H), 3.52 (dd, JA = JB = 5.0 
Hz, 4H, morph-H), 6.93 (d, J = 9.0 Hz, 2H, phe-H), 7.04 (d, J = 9.0 Hz, 211, phe-H), 
7.08 (bs, 2H, NH2), 9.18 (bs, 111, NH); MS (ESt) mlz: 236.97 [M+H]. 
1-(3-Methyl-4-piperidin-1-ylphenyl)guanidine (II) [310] 
Synthesised from [284] (3.75 g, 0.02 mol). 
H2N_CC) 
NH 
Purple solid (2.71 g, 59%): anal. RP-HPLC: tR 6.2 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): 8 1.53- 1.54 (m, 211, piperid-H), 1.63- 1.67 (m, 411, piperid-
H), 2.24 (s, 3H, CH3), 2.78 (dd, JA = JB = 4.5 Hz, 4H, piperid-H), 6.90 - 7.03 (m, 3H, 
phe-H), 7.18 (bs, NH); MS (ESI) m/z: 233.01 [M+H]. 
187 
1-(3-Methoxy-4-piperidin-1-ylphenyl)guanidine (II) [311] 





Grey solid (1.52 g, 67%): anal. RP-HPLC: tR 6.0 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): 6 1.47 - 1.48 (m, 2H, piperid-H), 1.58 - 1.59 (m, 4H, piperid-
H), 2.86 (bs, 4H, piperid-H), 3.29 (s, 3H, CH3), 6.70 (dd, J = 2.0 and 8.0 Hz, III, phe-
H), 6.74 (d, J=2.0 Hz, 1H, 2-H), 6.87 (d, J= 8.0 Hz, lH, phe-H), 7.15 (bs, 2H, NH2), 
9.32 (bs, IH, NH); MS (ESr) m/z: 249.10 [M+H]t 
1-(3-Methyl-4-morpholin-4-ylphenyl)guanidine (II) [312] 
Synthesised from [286] (3.33 g, 0.02 mol). 
HN-
NH 
Purple solid (2.55 g, 63%): anal. RP-HPLC: tR 8.0 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): 62.23 (s, 311, CH3), 2.79 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
3.70 (dd, JA = .JB = 4.5 Hz, 4H, morph-H), 6.99-7.05 (m, 311, phe-H), 7.18 (bs, NH2); 
' 3C NMR (DMSO-d6): 6 18.34, 52.47, 67.22, 120.52, 124.02, 128.32, 130.48, 134.04, 
150.47,156.60; MS (ESI) m/z: 235.31 [M+H]t 
1-(4-Methoxy-3-methylphenyl)guanidine (II) [313] 
Synthesised from [290] (2.40 g, 0.01 mol). 
Purple solid (2.40 g, 77%): anal. RP-HPLC: tR 10.3 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 62.11 (s, 3H, CH3), 3.76 (s, 311, CH3), 6.95 (d, J = 8.0 
Hz, 1H, phe-H), 7.00 (d, J = 8.0 Hz, 111, phe-H), 7.10 (bs, 111, phe-H), 9.24 (bs, 1H, 
NH); MS (ESI) m/z: 180.21 [M+H]t 
1-(1,3-Benzodioxol-5-yl)guanidine (II) [314] 
Synthesised from I ,3-benzodioxol-5-amine (3.50 g, 0.03 mol). 
H2N-(Q 
NH 	0 
Dark brown solid (3.80 g, 83%): anal. RP-HPLC: tR 7.4 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 8 2.50 (s, 2H, CH2), 6.71 (dd, J = 2.5 and 8.0 Hz, 2H, 
phe-H), 6.87 (d, J = 2.5 Hz, IH, 2-H), 6.96 (d, J = 8.0 Hz, 2H, phe-H), 7.23 (bs, 2H, 
NH2); MS (E5I) m/z: 180.28 [M+H]t 
1-(2,3-Dihydro-1,4-benzodioxin-6-yl)guanidine (II) [315] 
Synthesised from 1,4-benzodioxan-6-amine (1.99 g, 0.01 mol). 
HN- 
H2NQ1) 
Purple solid (1.88 g, 74%): anal. RP-HPLC: tR 8.0 mm (0-60% MeCN, purity 75%); 
'H NMR (DMSO-d6): 5 1.25 (dd, JA = JB = 7.0 Hz, 2H, CH2), 4.22 - 4.26 (m, 2H, 
CH2), 6.65 (dd, J = 2.5 and 8.5 Hz, lH, phe-H), 6.72 (d, J = 2.5 Hz, IH, 2-H), 6.86 (d, 
J = 8.5 Hz, IH, phe-H), 7.20 (bs, 2H, NH2), 9.36 (bs, IH, NH); MS (ESI) m/z: 
193.95 [M+H]. 
1- [3-(Thiomorpholin -4-ylmethyl)phenyl]guanidine (II) [316] 






Orange oil (quant.): anal. RP-HPLC: tR 5.8 mm (0-60% MeCN, purity 100%); 'H 
NMR (CD30D): 8 2.96 (bs, 4H, morph-H), 3.50 (bs, 4H, morph-H), 4.23 (s, 2H, 
CH2), 6.78 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 6.81 (dd, JA = JB = 2.0 Hz, IH, 2-H), 
7.20 (dd, JA = JB = 8.0 Hz, IH, 5-H), 7.50 (dd, J = 2.0 8.0 Hz, 1H, phe-H); MS (ESr) 
mlz: 251.21 [M+H]. 
1- (3-[(4-Methylpiperazin -1-yl)methyl]phenyl}guanidine (II) [317] 






Orange oil (quant.): anal. RP-HPLC: tR 4.9 mm (0-60% MeCN, purity 100%); MS 
(ESI) m/z: 248.27 [M+H]t 
1-[3-(Morpholin-4-ylcarbonyl)phenyl]guanidine (II) [318] 







Orange oil (quant.): anal. RP-HPLC: tR 6.2 mm (0-60% MeCN, purity 100%); 'H 
NMR (DMSO-d6): 8 3.50 (bs, 4H, morph-H), 3.77 (bs, 4H, morph-H), 7.36 (bs, IH, 
phe-H), 7.40 —7 .41 (m, 2H, phe-H), 7.57 (dd, JA = J8 = 8.0 Hz, IH, 5-H); MS (EST') 
m/z: 249.60 [M--H]t 
The following guanidines were obtained from Ultrafine Chemicals or colleagues at 
Cyclacel. 





1-(4-Morpholin-4-ylphenyl)guamdine (II) [320] 
I- ' 	\ 
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1- [4- (4-Benzylpiperazin-1-yl)phenyl]guanidine (II) [322] 
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1-(3,4,5-Trimethoxyphenyl)guanidine (II) [326] 
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T 	 A2 
N 
N N' 	R4 
(III) 
The appropriate enaminone intermediate (I) (1 eq; 0.10 mmol), guanidine 
intermediate (II) (1 eq; 0.10 mmol) and NaOH (1 eq; 0.10 mmol) were combined in a 
microwave tube and 2-methoxyethanol added (3.5 mL). The resulting RM was heated 
to 190 °C for 20 min in a microwave reactor. The RM was evaporated under reduced 
pressure and the residue purified by solid phase extraction, SPE, (products eluted by 
100% EtOAc). Fractions containing the product were combined, evaporated under 
reduced pressure and the residue further dried in vacuo. The purified product was 
recovered via recrystallisation using DCMIMeOH (1:1), collected by suction 
filtration, washed with MeOH (1 x 5 mL), Et20 (1 x 5 mL) and further dried in vacuo. 
N-(3- 1 [4- (2,4-Dimethyl- 1,3-thiazol-5-yl)pyriniidin-2-ylI amino lbenzyl)acetamide 
(III) [5] 
From (I) [241] (R i = Me) and (H) [291] (R 2 = R3 = H, R4 = CH2NHAc). 
N-( 
N "C )'~' H 
Yield = 10% (yellow solid): mp 206-207 °C; anal. RP-HPLC: tR 13.6 mm (0-60% 
MeCN, purity 98%); 'H NMR (CD30D): 8 2.53 (s, 3H, CH3), 2.65 (s, 3H, CH3), 2.68 
193 
(s, 3H, CH3), 4.38 (s, 2H, CH2), 6.94 (dd, J = 2.5 and 7.5 Hz, IH, phe-H), 7.01 (d, J = 
5.5 Hz, IH, pyr-H), 7.26 (dd, .JA = JB = 7.5 Hz, 1H, phe-J-1), 7.56 (dd, J = 2.5 and 7.5 
Hz, 1H, phe-H), 7.70 (bs, IH, phe-H), 8.40 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR 
(DMSO-d6): ö 18.53, 19.60, 23.30, 43.10, 109.01, 118.30, 118.71, 121.43, 129.11, 
131.59, 140.51, 140.95, 152.60, 158.58, 159.71, 160.25, 167.42, 169.76; HRMS 
(FAB+) m/z calcd for C,8H 1 9N50S 354.13886, obsd 354.13888. 
N- [3- ({ 4- [4-Methyl -2-(methylamino) - 1 ,3-thiazol -5-yI]pyrimidin-2-
yI}amino)benzyl]acetamide (III) [6] 







Yield = 24% (orange solid): mp 253-255 °C; anal. RP-HPLC: tR 11.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD 30D): ö 1.99 (s, 3H, CH3), 2.53 (s, 3H, CH3), 
2.98 (s, 3H, CH3), 4.39 (s, 2H, CH2), 6.92 - 6.94 (m, 2H, phe-H and pyr-H), 7.26 (dd, 
JA = JB = 8.0 Hz, IH, phe-H), 7.51 (dd, J = 2.5 and 8.0 Hz, ill, phe-H), 7.79 (bs, IH, 
phe-H), 8.27 (d, J = 5.5 Hz, 1H, pyr-H), 8.55 (bs, 1H, NH); ' 3C NMR (DMSO-d6): 6 
19.34, 23.30, 31.45, 107.42, 110.00, 118.01, 118.58, 118.70, 120.87, 129.02, 140.37, 
141.34, 153.00, 158.37, 159.21, 160.17, 169.80, 170.05; HRMS (FAB+) mlz calcd for 
C, 8H20N60S 369.14976, obsd 369.14977. 
194 
N- [3- ({ 4- [2-(Ethylamino) ..4-methyl- 1 ,3-thiazol-5-yl]pyrimidin -2-
yl}amino)benzyl]acetamide (III) [7] 




H 	 0 
Yield = 26% (yellow solid): mp 227-228 °C; anal. RP-HPLC: tR 12.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD3OD): 5 1.17 (t, J = 7.5 Hz, 3H, CH 2CH3), 1.85 
(s, 3H, CH3), 2.45 (s, 3H, CH3), 2.49 (s, 2H, CH2), 4.24 (m, 2H, CH2CH3), 6.82 (dd, J 
= 1.5 and 8.0 Hz, 1H, phe-H), 6.88 (d, J = 5.5 Hz, IH, pyr-H), 7.20 (dd, JA = JB = 8.0 
Hz, I H, phe-H), 7.60 (dd, J = 1.5 and 8.0 Hz, 1H, phe-H), 7.74 (dd, JA = JB = 1.5 Hz, 
1H, phe-H), 8.31 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): ö 15.00, 19.33, 
23.29, 43.16, 107.38, 117.97, 118.46, 120.84, 128.99, 140.35, 141.35, 152.96, 158.31, 
159.20, 160.16, 169.09, 169.83; HRMS (FAB+) m/z calcd for C,9H22N60S 
383.16541, obsd 383.16512. 
N-(3-{ [4-(3,4-Dimethyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yI)pyrimidin-2-
yl]amino}benzyl)acetamide [8] 
From (I) [222] (R i = Thiazolone) and (II) [291] (R2 = R3 = H, R4 = CH2NHAc). 
(XL y 
Yield = 32% (pale brown solid): mp 202-203 °C; anal. RP-HPLC: tR 13.0 mm (0-60% 
MeCN, purity 96%); 'H NMR (DMSO-d 6): 8 2.28 (s, 3H, CH3), 2.97 (s, 3H, CH3), 
3.70 (s, 3H, CH3 ) 4.63 (d, J = 6.0 Hz, 2H, CH2), 7.26 (dd, J = 2.0 and 8.0 Hz, IH, 
phe-H), 7.34 (d, J = 5.0 Hz, IH, pyr-H), 7.64 (dd, JA = JB = 8.0 Hz, IH, phe-H), 8.02 
(dd, J = 2.0 and 8.0 Hz, IH, phe-H), 8.05 (bs, IH, phe-H), 8.71 (s, IH, NH), 8.83 (d, J 
= 5.0 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 8 14.89, 23.25, 30.25, 43.04, 109.00, 
110.43, 118.24, 118.67, 121.18, 129.03, 138.52, 140.46, 140.92, 158.45, 159.22, 
195 
160.18, 169.75, 170.39; HRMS (FAB+) m/z calcd for C 1 8H,9N502S 370.13377, obsd 
370.13375. 
N-(4- { [4-(2,4-Dimethyl- 1,3-thiazol-5-yI)pyrimidin-2-yl]amino}benzyl)acetamide 
(III) [9] 
From (I) [241] (R i = Me) and (H) [292] (R2 = H, R3 = CH2NHAc, R 4 = H). 
(N 
LNNI) H 
Yield = 5% (yellow solid): mp 212-213 °C; anal. RP-HPLC: tR 13.5 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): ö 1.99 (s, 3H, CH3), 2.68 (s, 3H, CH3), 
2.70 (s, 3H, CH3), 4.33 (s, 2H, CH2), 4.58 (s, IH, NH) 7.05 (d, J = 5.0 Hz, IH, pyr-
H), 7.25 (d, J = 8.5 Hz, 2H, phe-H), 7.67 (d, J = 8.5 Hz, 2H, phe-H), 8.43 (d, J = 5.0 
Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 8 18.59, 19.69, 23.32, 42.49, 109.98, 119.56, 
128.29, 131.54, 133.31, 139.70, 152.65, 158.57, 159.78, 160.36, 167.13, 169.68; 
HRMS (FAB+) in/z calcd for C 1 8H,9N50S 354.13886, obsd 354.13833. 
N-(4-{ [4-(2-Amino-4-methyl- 1,3-thiazol-5-yI)pyrimidin-2-
yl]aminojbenzyl)acetamide (III) [10] 




(N 	 N' 
LNN)) H 
Yield = 8% (yellow solid): mp 270-271 °C; anal. RP-HPLC: tR 10.9 mm (0-60% 
MeCN, purity 90%); 'H NMR (CD 30D): ö 1.35 (s, 3H, CH3), 2.50 (s, 3H, CH3), 4.32 
(s, 2H, CH2), 4.51 (bs, 2H, NH2) 6.92 (d, J = 5.5 Hz, IH, pyr-H), 7.23 (d, J = 8.5 Hz, 
2H, phe-H), 7.68 (d, J = 8.5 Hz, 2H, phe-H), 8.28 (d, J = 5.5 Hz, IH, pyr-H); 13C 
NMR (DMSO-d6): 6 19.13, 23.32, 42.51, 107.43, 118.86, 119.26, 128.25, 132.85, 
140.10, 152.68, 158.34, 159.29, 160.14, 169.53, 169.71; HRMS (FAB+) mlz calcd for 
C 17H 1 8N60S 355.13411, obsd 355.13409. 
196 
N- [4- ({ 4-[4-Methyl-2-(methylamino) - 1 ,3-thiazol -5-yl]pyrimidin-2-
yi}amino)benzyl]acetamide (Ifl) [11] 





Yield = 12% (yellow solid): mp 252-253 °C; anal. RP-HPLC: tR 11.6 mm (0-60% 
MeCN, purity 73%); 'H NMR (CD30D): 8 1.99 (s, 3H, CH3), 2.57 (s, 3H, CL!3), 2.97 
(s, 3H, CH3), 4.32 (s, IH, NH), 4.57 (s, 2H, CH2), 6.91 (d, J = 5.5 Hz, IH, pyr-H), 
7.23 (d, J = 8.5 Hz, 2H, phe-H), 7.66 (d, J = 8.5 Hz, 2H, phe-H), 8.26 (d, J = 5.5 Hz, 
IH, pyr-H); ' 3C NMR (DMSO-d6): ö 19.36, 23.31, 31.39, 42.52, 107.38, 118.61, 
119.29, 128.27, 132.86, 140.09, 152.95, 158.31, 159.26, 160.15, 169.67, 169.89; 
FIRMS (FAB+) m/z calcd for C,8H20N60S 369.14976, obsd 369.14971. 
N- [4- ({ 4- [2- (Ethylamino) -4-methyl - 1 ,3-thiazol-5-yI]pyrimidin -2. 
yI}amino)benzyl]acetamide (III) [12] 





Yield = 24% (yellow solid): mp 210-212 °C; anal. RP-HPLC: tR 12.3 mm (0-60% 
MeCN, purity 92%); 'H NMR (CD30D): 5 1.28 (t, J = 7.0 Hz, 3H, CH2CH3), 1.99 (s, 
3H, CL!3), 2.52 (s, 3H, CH3), 3.36 (q, J = 7.0 Hz, 2H, CH2CH3), 4.31 (s, 2H, CH2), 
6.90 (d, J = 5.5 Hz, 1H, pyr-H), 7.22 (d, J = 8.5 Hz, 2H, phe-J-1), 7.66 (d, J = 8.5 Hz, 
2H, phe-H), 8.25 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): S 14.95, 19.33, 
23.27, 42.49, 60.41, 107.34, 118.30, 119.25, 128.23, 132.80, 140.06, 152.85, 158.24, 
159.22, 160.10, 168.92, 169.64; HRMS (FAB+) in/z calcd for C,9H22N60S 
383.16541, obsd 383.16491. 
197 
N-(4-{ [4-(3,4-Dimethyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yI)pyrimidin-2-
yl]amino}benzyl)acetamide (III) [13] 
From (I) [222] (Ri = Thiazolone) and (H) [292] (R 2 = H, R3 = CH 2NHAc, R, = H). 
(N 	 NAI 
H 
LNN)  
Yield = 27% (orange solid): mp 229-231 °C; anal. RP-HPLC: tR 12.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): 6 2.29 (s, 3H, CH3), 2.99 (s, 3H, CH3), 
4.62 (d, J = 6.0 Hz, 2H, CH2), 7.36 (d, J = 5.5 Hz, 1H, pyr-H), 7.60 (d, J = 8.5 Hz, 
2H, phe-H), 8.10 (d, J= 8.5 Hz, 2H, phe-H), 8.68 (t, J= 6.0 Hz, IH, NH), 8.49 (d, J= 
5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): 6 14.90, 23.27, 30.23, 42.45, 108.86, 
110.53, 119.65, 128.21, 133.28, 138.47, 139.63, 158.41, 159.19, 160.16, 169.66, 
170.40; HRMS (FAB+) ,n/z calcd for C 181-1 1 9N502S 370.13370, obsd 370.13289. 
General Procedure for Removal of the Acetyl Moiety 
The appropriate acetamide-substituted pyrimidine {(llI) [5], [6], [7], or [13]} was 
solubilised in a 4:1 mixture of HCI:MeOH (5 mL) and the solution heated to 125 °C 
for 16 - 20 h, until no starting material was detected via HPLC analysis. The RM was 
cooled, evaporated under reduced pressure and the residue purified by SPE (product 
eluted by 10:1 EtOAcIMeOH). Fractions containing the product were combined, dried 
under reduced pressure and the product ((III) [14-17] } isolated by crystallisation of 
the resulting residue(]: I MeOHIDCM). 
N- [3- (Aminomethyl)phenyl] -4- (2,4-dimethyl -1 ,3-thiazol -5-yI)pyrimidin -2-amine 
(III) [14] 
From (III) [5] (RI = Me, R2 = R3 = H, R 4 = CH2NH2). 
LNNIZ ..- 1NH2 
H 
Yield = 98% (yellow solid): mp 183-184 °C; anal. RP-HPLC: tR 12.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.82 (s, 3H, CL!3), 2.84 (s, 3H, CH3 ), 
4.17 (t, J = 6.0 Hz, 2H, CH2), 7.29 - 7.30 (m, 2H, phe-H and pyr-H), 7.54 (dd, JA = J8 
= 8.0 Hz, 1H, phe-H), 7.92 (dd, J = 1.5 and 8.0 Hz, IH, phe-H), 8.01 (dd, JA = J8 = 
1.5 Hz, IH, phe-H), 8.50 (bs, 2H, NH2), 8.71 (d, J = 5.0 Hz, lH, pyr-R); ' 3C NMR 
(DMSO-d6): 8 17.96, 19.24, 43.14, 109.24, 120.27, 120.82, 123.27, 129.63, 131.64, 
135.14, 140.49, 151.80, 158.54, 158.90, 159.22, 168.95; HRMS (FAB+) m/z calcd for 
C 16H 17N5S 312.12829, obsd312.12827. 
N-[3-(Aminomethyl)phenyl]-4-[4-methyl-2-(methylamino)-1,3-thiazol-5-
yl]pyrimidin-2-amine (III) [15] 




Yield = 75% (yellow solid): mp 287-289 °C; anal. RP-HPLC: tR 10.1 mm (0-60% 
MeCN, purity 92%); 'H NMR (CD30D): 8 2.68 (s, 3H, CH3), 3.17 (s, 3H, CH3), 4.17 
(s, 2H, CH2), 7.23 (d, J = 6.0 Hz, IH, pyr-H), 7.27 (d, J = 7.5 Hz, IH, phe-H), 7.41 
(dd, JA = JB = 7.5 Hz, IH, phe-H), 7.70 (dd, J = 1.5 and 7.5 Hz, IH, phe-H), 7.75 (dd, 
JA = JB = 1.5 Hz, IH, phe-H), 8.44 (d, J = 6.0 Hz, 1H, pyr-H'); ' 3C NMR (DMSO-do): 
ö 16.21, 32.39, 42.23, 107.89, 118.16, 120.39, 120.80, 123.38, 129.54, 129.62, 
135.15, 140.27, 142.50, 157.45, 157.90, 159.36; HRMS (FAB+) m/z calcd for 
C 1 6H,8N6S 327.13919, obsd 327.13919. 
199 
N-[3- (Aminomethyl)phenyl} -4- [2- (ethylamino) -4-methyl -  1,3-thiazol-5-
yl]pyrimidin -2-amine (III) [16] 




C LN JZLNH2 
Yield = 81% (yellow solid): mp 290-292 °C; anal. RP-HPLC: tR 10.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): ö 1.38 (t, J = 7.0 Hz, 3H, CH2CH3), 2.66 
(s, 3H, CH3), 3.51 (q, J = 7.0 Hz, 2H, CH2CH3), 4.14 (s, 2H, CH2), 7.15 (d, J = 6.0 
Hz, IH, pyr-H), 7.19 (dd, J = 1.5 and 8.0 Hz, IH, phe-H), 7.45 (dd, JA = JB = 8.0 Hz, 
IH, phe-H), 7.73 - 7.76 (m, 214, phe-H), 8.45 (d, J = 6.0 Hz, IH, pyr-H); HRMS 
(FAB+) ink calcd for C 17H20N6S 341.15484, obsd 341.15483. 
5-(2-{ [4-(Aminomethyl)phenyl]amino}pyrimidin-4-yl)-3,4-dimethyl-  1,3-thiazol-
2(311)-one (III) [17] 





Yield = 78% (yellow solid): mp 210-211 °C; anal. RP-HPLC: tR 17.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): ö 2.80 (s, 3H, CH3), 3.54 (s, 3H, CH3 ), 
4.17 - 4.20 (m, 2H, Cl-I2), 7.24 (d, J = 5.5 Hz, IH, pyr-H), 7.64 (d, J = 8.5 Hz, IH, 
2H, phe-H), 8.00 (d, J = 8.5 Hz, 2H, phe-H), 8.46 (bs, 2H, NH2), 6.87 (d, J = 5.5 Hz, 
IH, pyr-H); ' 3C NMR (DMSO-d6): 8 15.07, 30.37, 42.56, 109.11, 110.47, 119.76, 
127.86, 130.11, 139.50, 140.83, 158.25, 158.97, 159.33, 170.44; HRMS (FAB+) m/z 
calcd for C, 6H, 7N50S 328.1232 1, obsd 328.12326. 
200 
N-(3-{ [4-(2,4-Dimethyl- 1,3-thiazol-5-yI)pyrimidin-2- 
yl]amino}benzyl)methanesulfonamide (III) [18] 
From (I) [241] (R, = Me) and (II) [293] (R2 = R3 = H, R4 = CH2NHS02Me). 
N 
N Vf:::~~ N'S:~ H 	cr0 
Yield = 32% (yellow solid): mp 163-164 °C; anal. RP-HPLC: tR 14.8 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): 8 2.68 (s, 3H, CH3), 2.70 (s, 3H, C!!3), 
2.88 (s, 3H, CH3), 4.28 (s, 2H, CH2), 7.04 (dd, J = 1.5 and 8.0 Hz, IH, phe-H), 7.08 
(d, J = 5.5 Hz, IH, pyr-H), 7.30 (dd, .1,, = JB = 8.0 Hz, 1H, phe-H), 7.53 (dd, J = 1.5 
and 8.0 Hz, IH, phe-H), 7.94 (dd, JA = JB = 1.5 Hz, IH, phe-H), 8.45 (d, J = 5.5 Hz, 
IH, pyr-H); ' 3C NMR (DMSO-d6): 8 18.61, 19.66, 47.18, 109.05, 118.67, 118.92, 
121.67, 129.20, 131.58, 139.14, 141.09, 152.66, 158.58, 159.79, 160.35, 167.29; 
HRMS (FAB+) m/z calcd for C 17H,9N502S2 390.10585, obsd 390.10586. 
N-(3-{ [4-(2-Amino-4-methyl-1,3-thiazol-5-yI)pyrimidin-2-
yl]amino}benzyl)methanesulfonamide (III) [19] 




N N H 	cr'o 
Yield = 26% (yellow solid): anal. RP-HPLC: tR 12.4 mm (0-60%, purity 92%); 'H 
NMR (CD30D): 5 2.49 (s, 3H, CH3), 2.90 (s, 3H, CH3), 4.29 (s, 2H, CH2), 6.94 (d, J 
= 5.5 Hz, IH, pyr-H), 7.01 (dd, J= 1.5 and 8.0 Hz, IH, phe-H), 7.28 (dd, .1,, = JB = 8.0 
Hz, IH, phe-H), 7.49 (dd, J = 1.5 and 8.0 Hz, 1H, phe-H), 7.96 (dd, .1,, = JB = 1.5 Hz, 
IH, phe-H), 8.29 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): ö 19.14, 47.11, 
107.65, 118.38, 118.81, 121.23, 129.11, 139.05, 141.40, 152.78, 158.32, 159.35, 
160.16, 169.55; MS (ESI 4 ) ,Wz: 391.06 [M+H]t 
201 
N-[3-({4- [4-Methyl -2- (methylamino) -1 ,3-thiazol-5-yI]pyrimidin-2-
yl}amino)benzyl]methanesulfonamide (III) [20] 




N N'J::) 	'S;~ H 	cro 
Yield = 26% (yellow solid): mp 216-218 °C; anal. RP-HPLC: tR 12.8 mm (0-60% 
MeCN, purity 98%); 'H NMR (CD30D): 8 2.53 (s, 311, CH3), 2.88 (s, 3H, CH3), 2.98 
(s, 3H, CH3), 4.28 (s, 211, CH2), 6.94 (d, J= 5.5 Hz, IH, pyr-H), 7.02 (dd, J = 1.5 and 
8.0 Hz, IH, phe-H), 7.29 (dd, JA = JB = 8.0 Hz, IH, phe-H), 7.52 (dd, J = 1.5 and 8.0 
Hz, 1H, phe-H), 7.91 (dd, JA = JB = 1.5 Hz, 1H, phe-H), 8.28 (d, J = 5.5 Hz, IH, pyr-
H); ' 3C NMR (DMSO-d6): ö 19.35, 31.47, 47.12, 107.49, 118.38, 118.59, 118.80, 
122.19, 129.12, 139.00, 141.37, 153.11, 158.32, 159.25, 160.15, 170.08; HRMS 
(FAB+) m/z calcd for C, 7H20N602S2 405.11674, obsd 405.11670. 
N-[3-({4-[2-(Ethylamino)-4-methyl- 1 ,3-thiazol.5.yI]pyrimidin-2-
yl}amino)benzyl]methanesulfonamide (III) [21] 




N N H 	cr° 
Yield = 25% (yellow solid): mp 198-200 °C; anal. RP-HPLC: tR 13.7 mm (0-60% 
MeCN, purity 92%); 'H NMR (CD30D): S 1.28 (t, J = 7.5 Hz, 3H, CH2CH3), 2.52 (s, 
314, CH3), 2.88 (s, 3H, Cl!3), 3.38 (q, J = 7.5 Hz, 2H, CH2CH3), 4.28 (s, 2H, CH2), 
6.94 (d, J = 5.5 Hz, 1H, pyr-H), 7.03 (dd, J = 2.0 and 7.5 Hz, 1H, phe-J1), 7.28 (dd, JA 
= JB = 7.5 Hz, 1 H, phe-H), 7.51 (dd, J = 2.0 and 7.5 Hz, IH, phe-H), 7.91 (dd, JA = JB 
= 2.0 Hz, IH, phe-H), 8.27 (d, J = 5.5 Hz, IH, pyr-h); ' 3C NMR (DMSO-do): S 
14.96, 19.36, 47.13, 107.53, 118.32, 118.41, 118.84, 121.19, 129.13, 139.03, 141.39, 
202 
153.06, 158.03, 159.27, 160.16, 169.16; HRMS (FAB+) m/z calcd for C 1 8H22N602S2 
419.13239, obsd419.13239. 
N-(3-{ [4-(3,4-Dimethyl-2-oxo-2,3-dihydro- 1,3-thiazol-5-yl)pyrimidin-2-
yl]amino}benzyl)methanesulfonamide (III) [22] 
From (I) [222] (R, = Thiazolone) and (II) [293] (R2 = R3 = H, R4 = CH2NHS02Me). 
11 N "JCJ~,H 
	
H 	 cr0 
Yield = 29% (yellow solid): mp 189-190 °C; anal. RP-HPLC: tR 14.0 mm (0-60% 
MeCN, purity 100%): 'H NMR (CD 30D): ö 2.64 (s, 3H, CH3 ), 2.91 (s, 3H, CH3 ), 
3.39 (s, 3H, CH3), 4.28 (s, 2H, CH2), 6.93 (d, J = 5.5 Hz, IH, pyr-H), 7.06 (dd, J = 2.0 
and 8.0 Hz, 1H, phe-H), 7.33 (dd, JA = JB = 8.0 Hz, 1H, phe-H), 7.64 (dd, J = 2.0 and 
8.0 Hz, lH, phe-H), 7.79 (dd, JA = JB = 2.0 Hz, 1H, phe-H), 8.41 (d, J = 5.5 Hz, 1H, 
pyr-H); ' 3C NMR (DMSO-d6): 8 14.95, 30.25, 47.05, 109.12, 110.34, 118.72, 119.09, 
121.63, 129.21, 138.63, 139.16, 141.02, 158.55, 159.25, 160.21, 170.39; HRMS 
(FAB+) mlz calcd for C 17H, 9N503S2 406.10076, obsd 406.09989. 
N-(3-{ [4-(2,4-Dimethyl-1,3-thiazol-5-yI)pyrimidin-2-yl]amino}benzyl)- 1,1,1-
trifluoromethanesulfonamide (III) [23] 
From (I) [241] (R i = Me) and (II) [294] (R2 = R3 = H, R4 = CH2NHS02CF3). 
N 
(N 
II 	I 	 H 
NN NS..CF3 
H cr0 
Yield = 22% (yellow solid): mp 110-112 °C; anal. RP-HPLC: tR 20.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): ö 2.26 (s, 3H, CH3), 2.68 (s, 3H, CH3), 
4.39 (s, 211, CH2) 7.01 (dd, J = 1.5 and 8.0 Hz 1H, phe-H), 7.05 (d, J = 5.5 Hz, 1H, 
pyr-H), 7.31 (dd, JA = JB = 8.0 Hz, IH, phe-H), 7.55 (dd, J = 1.5 and 8.0 Hz, I H, phe-
H), 7.91 (dd, JA = JB = 1.5 Hz, 111, phe-H), 8.43 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR 
(DMSO-d6): 8 18.59, 19.62, 47.84, 109.15, 118.75, 119.16, 121.54, 129.42, 131.54, 
137.70, 141.28, 152.70, 158.57, 159.79, 160.31, 167.19 (CF3 too weak to be 
203 
observed); HRMS (FAB+) ink calcd for C 17H, 6F3N502S2 444.07758, obsd 
444.07772. 
N-(3-{ [4-(2-Amino-4-methyl- 1,3-thiazol-5.yI)pyrimidin-2-yl]amino}benzyl)-1,1,1-
trifluoromethanesulfonamide (ifi) [24] 





I 	 H N_CF3 
H 	 c3"O 
Yield = 29% (yellow solid): mp 183-184 °C; anal. RP-HPLC: tR 16.4 mm (0-60% 
MeCN, purity 82%); 'H NMR (CD 30D): 6 2.50 (s, 311, CH3), 4.39 (s, 2H, CH2), 6.93 
(d, J = 5.5 Hz, IH, pyr-I1), 7.00 (dd, J = 1.5 and 8.0 Hz, 1H, phe-H), 7.31 (dd, .1,, = JB 
= 8.0 Hz, lH, phe-H), 7.65 (dd, J= 1.5 and 8.0 Hz, 1H, phe-H), 7.74 (bs, IH, phe-H), 
8.29 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): 6 19.15, 47.74, 107.83, 
112.50, 118.78, 120.97, 129.34, 137.72, 141.58, 152.86, 158.38, 159.42, 160.14, 
169.53, 171.19, 188.92 (CF3 too weak to be observed); HRMS (FAB+) m/z calcd for 
C , 6H 15F3N602S2 445 .07283, obsd 445.07298. 
1 ,1 ,1-Trifluoro-N- [3- ({4- [4-methyl -2- (methylamino) -1 ,3-thiazol-5-yl]pyrimidin -2-
yI}amino)benzyl]methanesulfonamide (III) [25] 




II 	I 	 H 
NN NsCF3 
H 	 cro 
Yield = 21% (yellow solid): mp 258-259 °C; anal. RP-HPLC: tR 16.9 mm (0-60% 
MeCN, purity 81 %);  'H NMR (CD30D): 62.53 (s, 3H, CH3), 2.97 (s, 3H, CH3), 4.40 
(s, 2H, CH2), 6.93 (d, J = 5.5 Hz, IH, pyr-H), 7.01 (dd, J = 2.0 and 8.0 Hz, 1H, phe-
H), 7.31 (dd, .JA = JB = 8.0 Hz, 1H, phe-H), 7.62 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 
7.80 (bs, IH, phe-H), 8.44 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 6 19.35, 
31.48, 47.79, 107.60, 118.54, 118.70, 118.88, 120.91, 121.67, 129.36, 137.69, 141.57, 
204 
153.22, 158.33, 159.27, 160.13, 170.20 (CF3 too weak to be observed); HRMS 
(FAB+) mlz calcd for C 1 7H,7F3N602S2 459.08848, obsd 459.08830. 
N- [3- ({ 4- [2-(Ethylamino) -4-methyl- 1 ,3-thiazol-5-yl]pyrimidin -2-
yI)amino)benzylj- 1,1,1-trifluoromethanesulfonamide (HI) [26] 






Yield = 22% (yellow solid): mp 182-183 °C; anal. RP-HPLC: tR 17.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): ö 1.34 (t, J = 7.5 Hz, 311, CH2CH3), 2.60 
(s, 3H, CH3), 3.46 (q, J = 7.5 Hz, 2H, CH2CH3), 4.41 (s, 2H, CH2), 7.05 (d, J = 5.5 
Hz, 111, pyr-H), 7.08 (d, J = 8.0 Hz, 1H, phe-H), 7.35 (dd, JA = JB = 8.0 Hz, IH, phe-
H), 7.56 (d, J = 8.0 Hz, 1H, phe-H), 7.75 (bs, IH, phe-H), 8.35 (d, J = 5.5 Hz, 1H, 
pyr-H); 13C NMR (DMSO-d6): ö 14.89, 19.36, 47.80, 48.69, 107.67, 118.26, 118.68, 
118.88, 119.26, 120.88, 129.36, 137.70, 141.58, 153.15, 158.25, 159.28, 160.11, 
169.26 (CF3 too weak to be observed); HRMS (FAB+) m/z calcd for C 18H, 9F3N602S2 
473.10413, obsd 473.10418. 
N-(3- {[4-(3,4-Dimethyl -2-oxo -2,3-dihydro -  1,3-thiazol-5-yI)pyrimidin-2-
yI]amino}benzyl)-1,1,1-trifluoromethanesulfonamide (III) [27] 





I, '' H 
Yield = 19% (colourless solid): mp 200-210 °C; anal. RP-HPLC: tR 18.9 mm (0-60% 
MeCN, purity 90%); 'H NMR (DMSO-d6): 6 0.02 (s, 3H, CH3), 2.57 (s, 3H, CH3), 
4.33 (s, 2H, CH2), 6.95 - 6.97 (m, 2H, phe-H and pyr-H), 7.32 (dd, JA = JB = 8.0 Hz 
1H, phe-H), 7.72 (d, J = 8.0 Hz, 1H, phe-H), 7.74 (bs, 1H, phe-H), 8.44 (d, J = 5.0 
Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 6 14.94, 30.30, 47.71, 109.22, 110.37, 118.90, 
205 
119.19, 121.36, 121.67, 129.43, 137.79, 138.64, 141.23, 158.55, 159.23, 160.17, 
170.39 (CF3 too weak to be observed); HRMS (FAB+) m/z calcd for C 17H, 6F3N503S2 
460.07249, obsd 460.07248. 
3-1[4- (2,4-Dimethyl- 1,3-thiazol-5-yI)pyrimidin-2-yI] amino }-N-( 2-
hydroxyethyl)benzenesulfonamide (III) [28] 







 N 	SZNOH 
H d(o 
Yield = 21% (yellow solid): mp 184-186 °C; anal. RP-HPLC: tR 13.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.64 (s, 3H, CH3), 2.84 (m, 2H, CH2), 
3.31 (s, 3H, CH3), 3.38 (m, 2H, CH2), 4.66 (t, J = 6.5 Hz, IH, NH), 7.15 (d, J = 5.0 
Hz, lH, pyr-H), 7.50 (dd, J = 2.0 and 7.5 Hz, 1H, phe-H), 7.50 - 7.53 (m, 2H, phe-H 
and NH), 7.97 (dd, J = 2.0 and 7.5 Hz, 1H, phe-H), 8.32 (dd, JA = .18 = 2.0 Hz, IH, 
phe-H), 8.56 (d, J = 5.0 Hz, lH, pyr-H'); ' 3C NMR (DMSO-d6): ö 18.59, 19.67, 45.83, 
60.67, 109.87, 117.29, 119.86, 122.88, 130.05, 131.21, 141.63, 141.73, 153.00, 
158.79, 159.83, 160.11, 167.27; HRMS (FAB+) m/z calcd for C 17H,9N503S2 
406.10076, obsd 406.10059. 
3-{ [4-(2-Amino-4-methyl- 1,3-thiazol-5-yl)pyrimidin-2-yI]amino}-N-(2-
hydroxyethyl)benzenesulfonamide (III) [29] 
From (I) [218] (R, = NH2) and (II) [300] (R 2 = R3 = H, R4 = S02NH(CH2)20H). 
NH 2 
N= 
(LNJ3N  	SN._OH 
H 6 -0 
Yield = 18% (yellow solid): mp 150-151 °C; anal. RP-HPLC: tR 11.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.71 (s, 3H, CH3), 3.09 (dt, JA = JB = 
6.5 Hz, 2H, CH2), 3.63 (dt, JA = JB = 6.5 Hz, 2H, CH2), 7.18 (d, J = 5.5 Hz, 1H, pyr-
H), 7.60 (dd, J = 1.5 and 8.0 Hz, 1H, phe-H), 7.73 (dd, JA = J5 = 8.0 Hz, 1H, phe-H), 
7.75 - 7.77 (m, 2H, phe-H and NH), 8.42 (dd, JA = JB = 1.5 Hz, 111, phe-H), 8.61 (d, J 
= 5.5 Hz, IH, pyr-H'); ' 3C NMR (DMSO-d6): 8 19.19, 45.79, 60.66, 108.48, 117.23, 
118.28, 119.45, 122.60, 129.92, 141.59, 141.97, 153.24, 158.28, 159.61, 159.93, 
169.93; HRMS (FAB+) m/z calcd for C, 6H,8N603S2 407.0960 1, obsd 407.09606. 
N- (2-Hydroxyethyl) -3- ({4- [4-methyi -2- (methylamino) - 1 ,3-thiazol-5-yI]pyrimidin-
2-yI}amino)benzenesulfonamide (III) [30] 






H 6 "0 
Yield = 13% (yellow solid): mp 189-190 °C; anal. RP-HPLC: tR 11.8 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.71 (s, 3H, CH3), 3.06 (m, 2H, CH2), 
3.09 (d, J = 5.0 Hz, 3H, CH3), 3.58 - 3.62 (m, 2H, CH2), 7.18 (d, J = 5.5 Hz, IH, pyr-
H), 7.58 (dd, J = 1.0 and 8.0 Hz, IH, phe-H), 7.69— 7.72 (m, 2H, phe-H and NH), 
8.19 (dd, J = 1.0 and 8.0 Hz, IH, phe-H), 8.28 (q, J= 5.0 Hz, lH, NH), 8.56 (dd, JA = 
JB = 1.0 Hz, IH, phe-H), 8.59 (d, J = 5.5 Hz, lH, pyr-H); ' 3C NMR (DMSO-d6): 
19.39, 31.67, 45.82, 60.64, 108.12, 117.00, 118.34, 119.45, 122.64, 129.92, 141.65, 
141.98, 153.58, 158.32, 159.44, 159.91, 170.52; HRMS (FAB+) m/z calcd for 
C, 7H20N603 S2 421.11166, obsd421.11169. 
N- (2-Hydroxyethyl) -3- ({4- [2- (ethylamino) .4-methyl) - 1 ,3-thiazol-5-yI]pyrimidin-
2-yI}amino)benzenesulfonamide (III) [31] 
From (I) [220] (RI = NHEt) and (II) [300] (R2 = R3 = H, R4 = S0 2NH(CH 2) 20H). 
(H 
N 
Ilk NSZN 	0H 
H 
Yield = 11% (yellow solid): mp 124-125 °C; anal. RP-HPLC: tR 12.5 mm (0-60%, 
purity 100%); 'H NMR (DMSO-d6): 8 1.41 (t, J = 7.0 Hz, 311, CH2CH3), 2.71 (s, 3H, 
CH3), 3.07 (dt, JA = .JB = 6.5 Hz, 2H, CH2), 3.48 - 3.53 (m, 2H, CH2), 3.61 (q, J = 7.0 
207 
Hz, 2H, CH2CH30 .19 (d, J = 5.5 Hz, 1H, pyr-H), 7.58 (dd, J = 1.5 and 7.5 Hz, IH, 
phe-H), 7.69 - 7.73 (m, 214, phe-H and NH), 8.21 (dd, JA = JB = 7.5 Hz, IH, phe-H), 
8.35 (t, J= 6.5 Hz, IH, NH), 8.55 (dd, JA = JB = 1.5 Hz, IH, phe-H), 8.60 (d, J = 5.5 
Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): ö 14.98, 19.40, 45.81, 60.64, 108.16, 117.02, 
118.00, 119.43, 122.62, 129.91, 141.64, 141.99, 153.51, 158.28, 159.46, 159.91, 
169.51; HRMS (FAB+) m/z calcd for C 1 8H22N603S2 435.1273 1, obsd 435.12739. 
3-{ [4-(3,4-Dimethyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yI)pyrimidin-2-yl]amino}-N-
(2-hydroxyethyl)benzenesulfonamide (III) [32] 




Yield = 8% (pale brown solid): mp 222-223 °C; anal. RP-HPLC: tR 13.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 5 2.64 (s, 314, CH3), 2.89 (dt, JA = J8 = 
6.5 Hz, 2H, CH2), 3.36 (s, 3H, CH3), 3.42 - 3.45 (m, 214, CH2), 7.07 (d, J = 5.5 Hz, 
IH, pyr-H), 7.43 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 7.55 - 7.59 (m, 2H, phe-H and 
NH), 8.04 (dd, J = 2.0 and 8.0 Hz, 1H, phe-H), 8.31 (dd, JA = JB = 2.0 Hz, IH, phe-
H), 8.54 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): ö 14.97, 30.31, 45.84, 
60.66, 109.81, 110.20, 117.30, 119.80, 122.89, 130.03, 138.87, 141.63, 141.69, 
158.73, 159.26, 159.95, 170.44; HRMS (FAB+) m/z: calcd for C 1714 19N504S2 
422.09567, obsd 422.09529. 
3- [4-(2,4-Dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yI]amino}-N-(2-
methoxyethyl)benzenesulfonamide (III) [33] 




Yield = 9% (yellow solid): mp 197-198 °C; anal. RP-HPLC: tR 16.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.64 (s, 3H, CH3 ), 2.65 (s, 3H, CH3), 
2.95 (dt, JA = JB = 6.0 Hz, 2H, CH2), 3.16 (s, 3H, CH3), 3.30 - 3.31 (m, 2H, CH2), 
7.15 (d, J = 5.5 Hz, 1H, pyr-H), 7.38 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 7.51 (dd, JA 
= JB = 8.0 Hz, 111, phe-H), 7.65 (t, J = 6.0 Hz, 1H, NH), 7.96 (dd, J = 2.0 and 8.0 Hz, 
IH, phe-H), 8.32 (dd, JA = JB = 2.0 Hz, 1H, phe-H), 8.56 (d, J = 5.5 Hz, IH, pyr-H); 
' 3C NMR (DMSO-d6): 8 19.37, 31.67, 42.90, 58.56, 71.23, 108.12, 116.95, 118.33, 
119.43, 122.60, 129.90, 141.72, 141.98, 153.57, 158.33, 158.93, 159.91, 170.51; 
HRMS (FAB+) m/z calcd for C 18H21 N503 S2 420.11641, obsd 420.11630. 
3-{ [4-(2-Amino-4-methyl- 1,3-thiazol-5-yl)pyrimidin-2-yl]amino}-N-( 2 -
methoxyethyl)benzenesulfonamide (III) [34] 




Yield = 21% (yellow solid): mp 179-180 °C; anal. RP-HPLC: tR 12.5 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.71 (s, 311, CH3), 3.20 (dt, JA = JB = 
6.0 Hz, 211, CH2), 3.42 (s, 3H, Cl!3), 3.56– 3.57 (m, 2H, Cl!2), 7.18 (d, J = 5.5 Hz, 
IH, pyr-H), 7.60 (dd, J = 2.0 and 7.5 Hz, 1H, phe-H), 7.73 (dd, JA = JB = 7.5 Hz, IH, 
phe-H), 7.78 (dd, JA = JB = 2.0 Hz, 1H, phe-H), 7.88 (t, J = 6.0 Hz, IH, NH), 8.35 (dd, 
J = 2.0 and 7.5 Hz, 1H, phe-H), 8.42 (s, 1H, NH), 8.62 (d, J = 5.5 Hz, IH, pyr-H); 13C 
NMR (DMSO-d 6): 5 19.18, 42.88, 58.56, 71.25, 108.50, 117.20, 118.27, 119.43, 
122.60, 129.91, 141.66, 141.97, 153.20, 158.28, 159.61, 159.94, 169.63; HRMS 
(FAB+) mlz calcd for C 17H20N603S2 421.11166, obsd 421.11155. 
209 
3-{ [4-(4-Methyl-2-(methylamino)- 1,3-thiazol-5-yl)pyrimidin-2-yI]amino}-N-( 2-
methoxyethyl)benzenesulfonamide (III) [35] 





i N' 	 0 
H cr0 
Yield = 21% (yellow solid): mp 205-206 °C; anal. RP-HPLC: tR 13.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.71 (s, 3H, CH3), 3.10 (d, J = 4.5 Hz, 
3H, CH3), 3.17 (dt, JA = JB = 6.0 Hz, 2H, Cl2), 3.39 (s, 3H, Cl3), 3.52-3.54 (m, 2H, 
Cl2), 7.19 (d, J= 5.5 Hz, IH, pyr-H), 7.58 (d, J= 8.0 Hz, 1H, phe-H), 7.70 (dd, JA = 
JB = 8.0 Hz, 1H, phe-H), 7.83 (t, J = 6.0 Hz, 1H, NH), 8.19 (d, J = 8.0 Hz, 1H, phe-
H), 8.29 (q, J = 4.5 Hz, 1H, NH), 8.57 (bs, IH, phe-H), 8.60 (d, J = 5.5 Hz, IH, pyr-
H); ' 3C NMR (DMSO-d6): 8 19.18, 42.88, 58.56, 71.25, 108.50, 117.20, 118.27, 
119.43, 122.60, 129.91, 141.66, 141.97, 153.20, 158.28, 159.61, 159.94, 169.63; 
HRMS (FAB+) m/z calcd for C 18H22N603S2 435.1273 1, obsd 435.12729. 
3-t [4-(2-(Ethylamino)-4-methyl)-1,3-thiazol-5-yI)pyrimidin-2-yl]amino}-N-(2-
methoxyethyl)benzenesulfonamide (III) [36] 
From (I) [220] (R, = NHEt) and (II) [302] (R2 = R3 = H, R 4 = S02NH(CH2)2OMe). 
(H 
N=< 
II 	I H 
NN 
H po 
Yield = 13% (yellow solid): mp 180-181 °C; anal. RP-HPLC: tR 13.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD 30D): ö 1.29 (t, J = 7.5 Hz, 3H, CH2CH3), 2.53 
(s, 3H, CH3), 3.09 (t, J = 6.0 Hz, 2H, CH2), 3.24 (s, 3H, Cl3), 3.36 - 3.41 (m, 4H, 
Cl2 and CH2CH3), 6.99 (d, J = 5.5 Hz, 1H, pyr-H), 7.46 - 7.47 (m, 2H, phe-H), 7.76 
- 7.79 (m, IH, phe-H), 8.32 (d, J = 5.5 Hz, 1H, pyr-H), 8.53 (bs, IH, phe-H); 13C 
NMR (DMSO-d6): 8 14.97, 19.39, 42.90, 58.58, 71.26, 108.17, 112.50, 116.97, 
210 
117.99, 119.40, 122.62, 129.90, 141.71, 141.98, 153.51, 158.28, 159.47, 159.92, 
169.51; HRMS (FAB+) m/z C,9H24N603S2 449.14296, obsd 449.14280. 
[4-(3,4-Dimethyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yI)pyrimidin-2-yI]amino}-N-
(2-methoxyethyl)benzenesulfonamide (III) [37] 




11 x NSZNO 
H 	d"o 
Yield = 18% (colourless solid): mp 122-123 °C; anal. RP-HPLC: tR 15.8 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.64 (s, 3H, CH3), 3.00 (dt, JA = JB = 
6.0 Hz, 2H, CH2), 3.23 (s, 3H, CH3), 3.31 - 3.38 (m, 5H, CH2 and CH3), 7.07 (d, J = 
5.5 Hz, IH, pyr-H), 7.44 (d, J = 7.5 Hz, 1H, phe-H), 7.57 (dd, JA = JB = 7.5 Hz, 1H, 
phe-H), 7.71 (t, J = 6.0 Hz, 1H, NH), 8.02 (d, J = 7.5 Hz, 1H, phe-H), 8.33 (bs, IH, 
phe-H), 8.54 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): ö 14.96, 30.31, 42.89, 
58.56, 71.25, 108.81, 110.21, 117.26, 119.79, 122.91, 130.03, 138.87, 141.61, 141.74, 
158.72, 159.72, 159.95, 170.44; HRMS (FAB+) m/z calcd for C 181-121 N 504S2 
436.11132, obsd 436.11278. 
[4- (2,4-Dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl] amino }-N-(2-
hydroxyethyl)benzenesulfonamide (III) [38] 




SN . OH 
H 
N "'), NIa 
H 
Yield = 5% (orange solid): mp 261-263 °C; anal. RP-HPLC: tR 10.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.52 (s, 6H, CH3), 2.65 (dt, JA = JB = 
6.5 Hz, 2H, CH2), 4.54 (t, J = 6.5 Hz, 2H, CH2), 7.06 (d, J = 5.0 Hz, lH, pyr-H), 7.26 
(t, J = 6.5 Hz, IH, NH), 7.59 (d, J = 9.0 Hz, 2H, phe-H), 7.84 (d, J = 9.0 Hz, 2H, phe-
H), 8.46 (d, J = 5.0 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): ö 18.62, 19.70, 45.77, 
211 
60.60, 110.12, 118.78, 128.21, 131.25, 132.99, 144.64, 153.04, 158.70, 159.89, 
159.94, 167.44; HRMS (FAB+) mlz calcd for C 1 7H,9N503S2 405.09294, obsd 
405.09176. 
4-{ [4-(2-Amino-4-methyl- 1,3-thiazol-5-yI)pyrimidin-2-yI]amino}-N-( 2-
hydroxyethyl)benzenesulfonamide (III) [39] 








Yield = 4% (orange solid): mp 297-298 °C; anal. RP-HPLC: tR 11.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.54 (s, 3H, CH3 ), 2.85 (dt, JA = JB = 
6.5 Hz, 2H, CH2), 4.75 (t, J = 6.5 Hz, 2H, CH2), 7.07 (d, J = 5.5 Hz, IH, pyr-H), 7.45 
(t, J = 6.5 Hz, IH, NH), 7.65 (s, IH, NH), 7.76 (d, J = 9.0 Hz, 2H, phe-H'), 8.05 (d, J 
= 9.0 Hz, 2H, phe-H), 8.47 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): ö 
19.19, 45.75, 60.60, 108.52, 118.54, 128.12, 132.52, 145.00, 153.35, 158.42, 159.38, 
159.72, 169.71; HRMS (FAB+) m/z calcd for C 16H 1 8N603S2 407.09601, obsd 
407.09633. 
N-(2-Hydroxyethyl) -4- ({4- [4-methyl-2- (methylamino) -  1,3-thiazol.5-yl]pyrimidin-
2-yl}amino)benzenesulfonamide (III) [40] 







Yield = 6% (yellow solid): mp 292-293 °C; anal. RP-HPLC: tR 11.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 8 2.58 (s, 3H, CH3), 2.86 (dt, JA = JB = 
6.0 Hz, 2H, CH2NH), 2.97 (d, J = 5.0 Hz, 3H, CH3), 4.75 (t, J = 6.0 Hz, 2H, CH2), 
7.09 (d, J = 5.5 Hz, 1H, pyr-H), 7.45 (t, J = 6.0 Hz, IH, NH), 7.77 (d, J = 9.0 Hz, 2H, 
phe-H), 8.06 (d, J= 9.0 Hz, 214, phe-H), 8.17-8.20 (m, IH, NH), 8.48 (d, J = 5.5 Hz, 
1H, pyr-H); ' 3C NMR (DMSO-d6): ö 19.39, 31.44, 45.75, 60.60, 108.44, 118.29, 
212 
118.57, 128.13, 132.53, 144.99, 153.60, 158.38, 159.35, 159.73, 170.11; HRMS 
(FAB+) mlz calcd for C 17H20N603S2 421.11166, obsd 421.11167. 
N-(2-Hydroxyethyl) -4- ({4- [2- (ethylamino) -4-methyl)- 1 ,3-thiazol-5-yI]pyrimidin-
2-yl }amino)benzenesulfonamide (III) [41] 






Yield = 4% (yellow solid): mp 253-254 °C; anal. RP-HPLC: tR 12.2 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 6 1.27 (t, J = 6.5 Hz, 3H, CH2CH3), 2.57 
3H, CH3), 2.86 (dt, JA = JB = 6.5 Hz, 3H, CH2), 3.35 - 3.41 (m, 2H, CH2CH3), 4.75 
J = 6.5 Hz, 2H, CH2), 7.09 (d, J = 5.5 Hz, IH, pyr-H), 7.45 (t, J = 6.5 Hz, I H, NH), 
7.77 (d, J = 9.0 Hz, 2H, phe-H), 8.06 (d, J = 9.0 Hz, 2H, phe-H), 8.24 (t, J = 6.5 Hz, 
IH, NH), 8.48 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 6 14.97, 19.42, 
45.75, 60.60, 108.47, 118.03, 118.56, 128.12, 132.53, 145.00, 153.56, 158.35, 159.36, 
159.73, 169.15; HRMS (FAB+) in/z calcd for C18H22N603S2 435.12731, obsd 
435.12735. 
4-1 [4-(3,4-Dimethyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yI)pyrimidin-2-yI]amino}-N-
(2-hydroxyethyl)benzenesulfonamide (III) [42] 









Yield = 40% (pale brown solid): mp >300 °C; anal. RP-HPLC: tR 13.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 6 2.52 (s, 3H, CH3), 2.71 (dt, .1,, = JB = 
6.5 Hz, 2H, CH2), 3.25 (s, 3H, CH3), 4.61 (t, J = 6.5 Hz, 2H, CH2), 7.00 (d, J = 5.5 
Hz, 1H, pyr-H), 7.31 (t, J = 6.5 Hz, IH, NH), 7.65 (d, J = 8.5 Hz, 2H, phe-H), 7.87 (d, 
213 
J = 8.5 Hz, 2H, phe-H), 8.44 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): 
15.00, 30.32, 45.77, 60.61, 110.10, 110.21, 118.87, 128.15, 133.02, 139.06, 144.63, 
158.64, 159.31, 159.78, 170.37; HRMS (FAB+) m/z calcd for C 17H,9N504S2 
422.09567, obsd 422.09577. 
4-{ [4-(2,4-Dimethyl-1,3-thiazol-5-yi)pyrimidin-2-yI]amino)-N-(2-
methoxyethyl)benzenesulfonamide (III) [43] 
From (I) [241] (R, = Me) and (II) [303] (R2 = H, R3 = S0 2NH(CH2)2OMe, R4 = H). 
N 
O 
I 	 H 
NNJz;X 
H 
Yield = 14% (yellow solid): mp 181-183 °C; anal. RP-HPLC: tR 16.3 mm (0-60% 
MeCN, purity 100%); 1 11 NMR (DMSO-d6): 5 2.52 (s, 3H, CH3 ), 2.53 (s, 311, GIl3 ), 
2.75 (dt, JA = JB = 6.5 Hz, 2H, CH2), 3.04 (s, 311, CH3), 3.15 - 3.17 (m, 2H, Gil2), 
7.06 (d, J = 5.0 Hz, 1H, pyr-H), 7.37 (t, J = 6.5 Hz, lH, NH), 7.59 (d, J = 9.0 Hz, 2H, 
phe-H), 7.84 (d, J = 9.0 Hz, 214, phe-H), 8.46 (d, J = 5.0 Hz, 111, pyr-H); ' 3C NMR 
(DMSO-d6): ö 18.57, 19.65, 31.35, 42.78, 58.53, 71.20, 110.09, 118.72, 128.12, 
131.20, 133.03, 144.61, 153.01, 158.66, 159.26, 159.90, 160.46, 167.40; HRMS 
(FAB+) m/z calcd for C, 8H21 N503S2 420.1164 1, obsd 420.11643. 
4-1[4- (2-Amino-4-methyl- 1,3-thiazol-5-yl)pyrimidin-2-yl] amino }-N-( 2-
methoxyethyl)benzenesulfonamide (III) [44] 




Yield = 16% (yellow solid): mp 224-226 °C; anal. RP-HPLC: tR 12.5 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.54 (s, 3H, CH3), 2.96 (dt, JA = J13 = 
6.0 Hz, 2H, CH2), 3.25 (s, 3H, CH3), 3.36 - 3.38 (m, 2H, CH2), 7.08 (d, J = 5.5 Hz, 
IH, pyr-H), 7.57 (t, J = 6.0 Hz, 1H, NH), 7.65 (bs, 211, NH2), 7.76 (d, J = 9.0 Hz, 2H, 
phe-H), 8.05 (d, J = 9.0 Hz, 2H, phe-H), 8.48 (d, J = 5.5 Hz, 111, pyr-H); ' 3C NMR 
214 
(DMSO-d6): 5 19.40, 31.44, 42.80, 58.59, 71.24, 108.45, 118.29, 118.54, 128.11, 
132.61, 145.00, 153.63, 158.37, 159.35, 159.73, 170.10; HRMS (FAB+) rn/z calcd for 
C, 7H20N603S2 421.11166, obsd 421.11184. 
4-{ [4-(4-Methyl-2-(methylamino-1,3-thiazol-5-yi)pyrimidin.2.yl)]amino}-N.(2-
methoxyethyl)benzenesulfonamide (III) [45] 









Yield = 9% (yellow solid): mp 260-261 °C; anal. RP-HPLC: tR 13.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.59 (s, 3H, CH3), 2.97 (dt, JA = JB = 
6.5 Hz, 2H, CH2), 3.26 (s, 3H, CH3 ), 3.37 - 3.39 (m, 2H, CH2), 3.40 (s, 3H, CH3), 
7.09 (d, J = 5.5 Hz, 1H, pyr-H), 7.57 (t, J = 6.5 Hz, 1H, NH), 7.77 (d, J = 9.0 Hz, 2H, 
phe-H), 8.06 (d, J = 9.0 Hz, 2H, phe-H), 8.19 (d, J = 5.0 Hz, NH), 8.48 (d, J = 5.5 Hz, 
IH, pyr-H); ' 3C NMR (DMSO-d6): 8 19.40, 31.44, 42.80, 58.59, 71.24, 108.45, 
118.29, 118.54, 128.11, 132.61, 145.00, 153.61, 158.37, 159.35, 159.73, 170.10; 
HRMS (FAB+) mlz calcd for C 1 8H22N603S2 435.1273 1, obsd 435.12650. 
4-{ [4- (2-(Ethylamino)-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino}-N-(2-
methoxyethyl)benzenesulfonamide (III) [46] 









Yield = 12% (yellow solid): mp 221-222 °C; anal. RP-HPLC: tR 14.7 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.27 (t, J = 7.0 Hz, 311, CH2CH3), 2.57 
(s, 3H, CH3), 2.97 (dt, JA = JB = 5.0 Hz, 2H, CH2), 3.26 (s, 3H, CH3), 3.36 - 3.40 (m, 
411, CH2 and CH2CH3 ), 7.09 (d, J = 5.5 Hz, IH, pyr-H), 7.58 (t, J = 7.0 Hz, 1H, NH), 
215 
7.78 (d, J = 9.0 Hz, 2H, phe-H), 8.06 (d, J = 9.0 Hz, 214, phe-H), 8.25 (t, J = 5.0 Hz, 
IH, NH), 8.48 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): 6 14.98, 19.37, 
23.31, 42.53, 107.39, 118.34, 119.29, 128.27, 132.84, 140.10, 152.89, 158.28, 159.27, 
160.15, 168.96, 169.68; HRMS (FAB+) mlz calcd for C, 9H24N603S2 449.14296, obsd 
449.14294. 
4-{[4-(3,4.Dimethyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yI)pyrimidin-2-yI]amino}-N-
(2-methoxyethyl)benzenesulfonamide (III) [47] 








Yield = 20% (off-white solid): mp 238-239 °C; anal. RP-HPLC: tR 16.7 mm (0-60% 
MeCN, purity 100%); 1 11 NMR (DMSO-d6): 6 2.52 (s, 3H, CH3), 2.82 (dt, JA = JB = 
6.0 Hz, 211, CH2), 3.10 (s, 3H, CH3), 3.23 (t, J = 6.0 Hz, 2H, CH2), 3.25 (s, 3H, CH3), 
7.00 (d, J = 5.5 Hz, 1H, pyr-H), 7.43 (t, J = 6.0 Hz, lH, NH), 7.65 (d, J = 9.0 Hz, 2H, 
phe-H), 7.87 (d, J = 9.0 Hz, 2H, phe-H), 8.44 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR 
(DMSO-d6): 6 14.95, 30.29, 42.78, 58.53, 71.19, 110.05, 110.18, 118.80, 128.09, 
133.04, 139.01, 144.58, 158.57, 159.27, 159.72; HRMS (FAB+) m/z calcd for 
C,81421 N504S2 436.11132, obsd 436.11051. 
3- ({4- [4-Methyl-2- (methylamino) -1 ,3-thiazol-5-yI]pyrimidin-2-
yI}amino)benzenesulfonamide (III) [48] 




ft_ L.. .JZI1S.NH2 N N 
H 	cr0 
Yield = 27% (yellow solid): mp 276-278 °C; anal. RP-HPLC: tR 11.8 mm (0-60% 
MeCN, purity 84%); 'H NMR (DMSO-d6): 6 2.73 (s, 3H, CH3), 3.12 (d, J = 5.0 Hz, 
216 
3H, Cl-I3), 7.20 (d, J = 6.0 Hz, 1H, pyr-H), 7.52 (s, 2H, NH2), 7.65 (dd, J = 2.0 and 8.0 
Hz, I H, phe-H), 7.70 (dd, JA = JB = 8.0 Hz, 1H, phe-H), 8.18 (dd, J = 2.0 and 8.0 Hz, 
IH, phe-H), 8.29 (q, J = 5.0 Hz, IH, NH), 8.59 (dd, JA = JB = 2.0 Hz, 1H, phe-H), 
8.61 (d, J = 6.0 Hz, 1H, pyr-H); 13C NMR (DMSO-d6): 8 19.80, 31.91, 107.98, 
112.50, 116.33, 118.32, 119.01, 122.22, 129.64, 141.77, 145.20, 153.52, 158.28, 
159.45, 159.95; HRMS (FAB+) mlz calcd for C 15H 16N602S2 377.08544, obsd 
377.08571. 
3-({4- [2-(Ethylamino)-4-methyl-1,3-thiazol-5-yl]pyrimidin-2-
yI}amino)benzenesulfonamide (III) [49] 





Yield = 5% (yellow solid): mp 148-150 °C; anal. RP-HPLC: tR 12.6 mm (0-60% 
MeCN, purity 93%); 'II NMR (CD30D): 8 1.28 (t, J = 7.0 Hz, 3H, CH2CH3), 2.52 (s, 
3H, CH3), 3.38 (q, J = 7.0 Hz, 2H, CH2CH3), 6.98 (d, J = 5.5 Hz, 1H, pyr-H), 7.45 
(dd, JA = JB = 8.0 Hz, IH, phe-H), 7.52 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 7.78 (dd, 
J = 2.0 and 8.0 Hz, 1H, phe-H), 8.31 (d, J = 5.5 Hz, IH, pyr-H), 8.51 (dd, JA = JB = 
2.0 Hz, 111, phe-H); ' 3C NMR (DMSO-d6): ö 14.98, 19.39, 108.13, 116.27, 117.98, 
118.89, 122.22, 129.64, 141.78, 145.19, 153.46, 158.25, 159.48, 159.96, 169.45; 
HRMS (FAB+) mlz calcd for C 16H 1 8N602S2 391.10109, obsd 39 1.10080. 
217 
3-{ [4-(3,4-Dimethyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yI)pyrimidin-2- 
yl]amino}benzenesulfonamide (III) [50] 
From (I) [222] (RI = Thiazolone) and (H) [295] (R2 = R3 = H, R, = S0 2N}T2). 
\ 0 
N-q 
LNN I1 S NH2 
H 
Yield = 5% (pale brown solid): mp 226-228 °C; anal. RP-HPLC: tR 13.7 mm (0-60% 
MeCN, purity 94%); 1 H NMR (DMSO-d6): ö 2.66 (s, 3H, CH3), 3.38 (s, 3H, CH3), 
7.07 (d, J = 5.5 Hz, 114, pyr-H), 7.38 (s, 2H, NH2), 7.50 (dd, J = 2.0 and 8.0 Hz, 1H, 
phe-H), 7.56 (dd, JA = JB = 8.0 Hz, 1H, phe-H), 8.02 (dd, J = 2.0 and 8.0 Hz, 1H, phe-
H), 8.35 (dd, JA = JB = 2.0 Hz, IH, phe-H), 8.55 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR 
(DMSO-d6): 8 14.97, 30.32, 109.74, 110.16, 116.46, 119.26, 122.50, 129.78, 138.86, 
141.42, 145.22, 158.74, 159.24, 160.00, 170.43; HRMS (FAB+) mlz calcd for 
C , 5H 15N 503S2 378.06946, obsd 378.06931. 
3-{ [4-(2,4-Dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino}-N-
methylbenzenesulfonamide (III) [51] 




Yield = 24% (yellow solid): mp 174-175 °C; anal. RP-HPLC: tR 12.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD 30D): ö 2.50 (s, 314, CH3), 2.58 (s, 3H, CH3), 
3.31 (s, 3H, CH3), 6.98 (d, J = 5.5 Hz, 1H, pyr-H), 7.43 (dd, J = 2.0 and 8.0 Hz, IH, 
phe-H), 7.49 (dd, JA = JB = 8.0 Hz, IH, phe-H), 7.89 (dd, J = 2.0 and 8.0 Hz, 1H, phe-
H), 8.33 (d, J = 5.5 Hz, IH, pyr-H), 8.37 (dd, JA = JB = 2.0 Hz, IH, phe-H); ' 3C NMR 
(DMSO-d6): 8 19.19, 29.47, 108.51, 112.50, 117.38, 118.27, 119.55, 122.67, 129.94, 
140.33, 142.05, 153.25, 158.28, 159.62, 159.94, 169.63; HRMS (FAB+) mlz calcd for 
C 16H 1 7N502S2 377.09802, obsd 377.09801. 
218 
3-1[4- (2-Amino-4-methyl- 1,3-thiazol-5-yl)pyrimidin-2-yl] amino }-N-
methylbenzenesulfonamide (III) [52] 
From (I) [218] (RI = NH2) and (H) [296] (R2 = R3 = H, R4 = S02NHMe). 
NH2 
'I 	 I 	HN . 
	
N N 	SZ 
H 
Yield = 10% (colourless solid): mp 206-208 °C; anal. RP-HPLC: tR 12.7 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): 6 2.51 (s, 3H, CH3), 2.57 (s, 3H, CH3), 
6.99 (d, J = 5.5 Hz, IH, pyr-H), 7.43 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 7.49 (dd, JA 
= JB = 8.0 Hz, IH, phe-R), 7.90 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 8.34 (d, J = 5.5 
Hz, IH, pyr-H), 8.37 (dd, JA = JB = 2.0 Hz, 1H, phe-H); ' 3C NMR (DMSO-d6): 6 
18.54, 19.65, 29.43, 109.85, 117.40, 119.91, 122.89, 130.02, 131.14, 140.40, 141.65, 
152.98, 158.74, 160.07, 167.22; HRMS (FAB+) m/z calcd for C 15H 16N602S2 
376.07762, obsd 376.07737. 
N-Methyl -3- ({4- [4-methyl -2- (methylamino) - 1 ,3-thiazol -5-yI]pyrimidin-2-
yI)amino)benzenesulfonamide (III) [53] 




N N-aS -, HN' 
H 	cr0 
Yield = 7% (yellow solid): mp 243-245 °C; anal. RP-HPLC: tR 13.0 mm (0-60% 
MeCN, purity 98%); 'H NMR (DMSO-d6): 6 2.67 (d, J = 5.0 Hz, 3H, CH3), 2.70 (s, 
3H, CH3), 3.09 (d, J = 5.0 Hz, 3H, CH3), 7.18 (d, J = 5.5 Hz, IH, pyr-I1), 7.53 - 7.55 
(m, 2H, NH and phe-R), 7.71 (dd, JA = JB = 8.0 Hz, 1H, phe-H), 8.19 (dd, J = 2.0 and 
8.0 Hz, IH, phe-H), 8.28 (d, J = 5.0 Hz, IH, NH), 8.56 (dd, JA = JB = 2.0 Hz, IH, phe-
H), 8.59 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): 6 19.34, 29.46, 31.63, 
108.08, 117.12, 118.29, 119.51, 122.66, 129.89, 140.35, 142.01, 153.54, 158.28, 
159.40, 159.87, 170.47; HRMS (FAB+) m/z calcd for C 16H 1 8N602S2 391.10109, obsd 
39 1.10065. 
219 
3-({4- [2-(Ethylamino) -4-methyl -1 ,3-thiazol -5-yl]pyrimidin-2-yl}amino) -N-
methylbenzenesulfonamide (III) [54] 




NC SZ N 
H 	cr0 
Yield = 11% (yellow solid): mp 175-176 °C; anal. RP-HPLC: tR 14.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): ö 1.29 (t, J = 7.5 Hz, IH, CH2CH3), 2.53 
(s, 3H, CH3), 2.58 (s, 3H, CH3), 3.39 (q, J = 7.5 Hz, 2H, CH2CH3), 6.99 (d, J = 5.5 
Hz, IH, pyr—H), 7.42 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 7.48 (dd, JA = JB = 8.0 Hz, 
IH, phe-H), 7.80 (dd, J = 8.0 Hz, IH, phe-H), 8.32 (d, J = 5.5 Hz, 111, pyr-H), 8.52 
(dd, JA = JB = 2.0 Hz, 1H, phe-H); ' 3C NMR (DMSO-d6): 8 14.94, 19.34, 29.44, 
108.13, 117.13, 117.91, 119.51, 122.64, 127.30, 129.87, 140.35, 142.00, 153.46, 
158.23, 159.43, 159.87, 169.45; HRMS (FAB+) m/z calcd for C 17H20N602S2 
405.11674, obsd 405.11623. 
3-t [4- (2-Amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino}-N-
ethylbenzenesulfonamide (III) [55] 




Yield = 12% (yellow solid): mp 176-177 °C; anal. RP-HPLC: tR 13.5 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): ö 1.08 (t, J = 7.5 Hz, 314, CH2CH3), 2.51 
(s, 3H, CH3), 2.95 (q, J = 7.5 Hz, 2H, CH2CH3), 6.98 (d, J = 5.5 Hz, IH, pyr-H), 7.44 
—7.49 (m, 2H, phe-H), 7.89 (dd, J = 1.5 and 7.5 Hz, IH, phe-J1), 8.34 (d, J = 5.5 Hz, 
IH, pyr-H), 8.37 (dd, JA = JB = 1.5 Hz, 1H, phe-H); ' 3C NMR (DMSO-d6): 5 15.54, 
19.18, 38.29,108.50, 117.21, 118.27, 119.44, 122.57, 129.91, 141.60, 141.99, 153.24, 
159.62, 159.94, 169.63, 171.20; HRMS (FAB+) m/z calcd for C 16H,8N602S2 
391.10109, obsd 391.10073. 
220 
N-Ethyl-3- ({4- [4-methyl -2- (methylamino)-1 ,3-thiazol -5-yl]pyrimidin-2-
yl)amino)benzenesuifonamide (III) [56] 
From (I) [219] (R I = NI-IMe) and (II) [297] (R2 = R 3 = H, R, = S02NHEt). 
NH 
N=< 
II 	I 	 H 
NN 
H 	cr0 
Yield = 25% (yellow solid): mp 246-248 °C; anal. RP-HPLC: tR 14.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): 8 1.08 (t, J = 7.5 Hz, 3H, CH2CH3), 2.54 
3H, CH3), 2.96 (q, J = 7.5 Hz, 2H, CH2CH3), 3.00 (s, 3H, CH3), 7.00 (d, J = 5.5 
Hz, IH, pyr-H), 7.45 - 7.48 (m, 2H, phe-H), 7.79 (dd, J = 2.0 and 7.5 Hz, IH, phe-H), 
8.33 (d, J = 5.5 Hz, 1H, pyr-H), 8.51 (dd, JA = JB = 2.0 Hz, IH, phe-H); ' 3C NMR 
(DMSO-d6): 5 15.47, 19.34, 31.63, 38.28, 108.08, 116.98, 118.29, 119.39, 122.56, 
129.86, 141.63, 141.96, 153.53, 158.27, 159.41, 159.88, 170.46; HRMS (FAB+) mlz 
calcd for C 17H20N602S2 405.11674, obsd 405.11675. 
N-Ethyl-3- ({4- [2- (ethylamino) -4-methyl-1 ,3-thiazol-5-yl]pyrimidin-2-
yI}amino)benzenesulfonamide (III) [57] 






Yield = 29% (yellow solid): mp 217-218 °C; anal. RP-HPLC: tR 15.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): ö 1.07 (t, J = 7.5 Hz, 3H, CH2CH3), 1.29 
J = 7.0 Hz, 3H, CH2CH3), 2.95 (q, J = 7.5 Hz, 2H, CH2CH3 ), 3.39 (q, J = 7.0 Hz, 
2H, CH2CH3), 6.99 (d, J = 5.5 Hz, IH, pyr-I1), 7.43 - 7.49 (m, 2H, phe-H), 7.79 (dd, 
J = 2.0 and 8.0 Hz, lH, phe-H), 8.32 (d, J = 5.5 Hz, IH, pyr-H), 8.51 (dd, JA = 
2.0 Hz, 1H, phe-H); ' 3C NMR (DMSO-d6): 6 14.93, 15.44, 19.35, 38.27, 108.14, 
117.94, 119.37, 122.54, 129.86, 141.62, 141.96, 153.46, 158.23, 159.43, 159.87, 
169.47; HRMS (FAB+) m/z calcd for C,8H22N 602S2 419.13239 obsd 419.13231. 
221 
3-{ [4-(3,4-Dimethyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yl)pyrimidin-2-yI]amino}-N-
ethylbenzenesulfonamide (III) [58] 






Yield = 11% (colourless solid): mp 188-189 °C; anal. RP-HPLC: tR 16.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.05 (t, J = 7.0 Hz, 3H, CH 2CH3), 2.64 
(s, 3H, CH3), 2.85 - 2.91 (m, 2H, CH2CH3), 3.37 (s, 3H, CH3), 7.07 (d, J = 5.5 Hz, 
1H, pyr-H), 7.42 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 7.53 - 7.59 (m, 2H, NH and 
phe-H), 8.02 (dd, J = 2.0 and 8.0 Hz, 1H, phe-H), 8.32 (dd, .JA = JB = 2.0 Hz, IH, phe-
H), 8.54 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): ö 14.97, 15.50, 30.32, 
38.31, 109.80, 110.22, 117.32, 119.79, 122.88, 130.04, 138.85, 141.63, 141.69, 
158.71, 159.25, 159.95, 170.44; HRMS (FAB+) m/z calcd for C 17H 19N503 S2 
406.10076, obsd 406.10097. 
N-Benzyl-3- ({ 4- [4-methyl -2- (methylamino) -1 ,3-thiazol -5-yl]pyrimidin -2-
yl}amino)benzenesulfonamide (III) [59] 




.101S, N,, 6 0 
H 
Yield = 9% (yellow solid): mp 233-234 °C; anal. RP-HPLC: tR 16.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.71 (s, 3H, CL!3), 3.06 (d, J = 3.5 Hz, 
3H, CH3), 4.25 (d, J = 6.5 Hz, 2H, CH2), 7.19 (d, J = 5.0 Hz, 1H, pyr-H), 7.43 —7.52 
(m, 5H, phe-H), 7.59 (dd, J = 1.5 and 8.0 Hz, 1H, phe-H), 7.70 (dd, .JA = JB = 8.0 Hz, 
IH, phe-H), 8.18 (dd, J = 1.5 and 8.0 Hz, 1H, phe-H), 8.28-8.29 (m, 2H, NH and pyr-
H), 8.59-8.60 (m, 2H, NH and phe-H); ' 3C NMR (DMSO-d6): 6 19.21, 32.00, 46.87, 
105.41, 108.13, 110.0, 116.98, 118.33, 119.42, 122.64, 127.80, 128.24, 128.90, 
222 
129.95, 138.54, 141.81, 142.03, 153.59, 159.92, 170.51; HRMS (FAB+) mlz calcd for 
C22H22N602S2 467.13239, obsd 467.13183. 
N-Benzyl-3-({4-[2-(ethylamino)-4-methyl- 1,3-thiazol-5-yI]pyrimidin-2- 
yI}amino)benzenesulfonamide (III) [60] 
From (I) [220] (R I = NHEt) and (II) [298] (R2 = R3 = H, R4 = S02NHBn). 
NI-i 
N=< 
L N N)O1S NJJ 
H 	cr° 
Yield = 4% (yellow solid): mp 204-205 °C; anal. RP-HPLC: tR 17.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.39 (t, J = 7.0 Hz, 3H, CH2CH3), 2.71 
(s, 3H, CH3), 3.45 - 3.51 (m, 2H, CH2CH3), 4.25 (s, 2H, CH2), 7.19 (d, J = 5.5 Hz, 
IH, pyr-H), 7.45 - 7.61 (m, 5H, phe-H), 7.60 (dd, J = 1.0 and 8.0 Hz, 1H, phe-H), 
7.70 (dd, JA = JB = 8.0 Hz, 1H, phe-H), 8.20 (dd, J = 1.0 and 8.0 Hz, I H, phe-H), 8.29 
(bs, IH, NH), 8.34 (t, J = 7.0 Hz, 1H, NH), 8.59 - 8.60 (m, 1H, phe-H and pyr-H); 
' 3C NMR (DMSO-d6): ö 14.95, 19.39, 46.89, 108.19, 117.01, 118.01, 119.41, 122.66, 
127.80, 128.23, 128.90, 129.94, 138.55, 141.82, 142.04, 153.51, 158.28, 159.48, 
159.93, 169.53; HRMS (FAB+) m/z calcd for C23H24N602S2 481.14804, obsd 
481.14864. 
N-Benzyl- 3-{[4- (3,4-dimethyl -2-oxo-2,3-dihydro-1,3-thiazol-5-yl)pyrimidin -2-
yl]amino}benzenesulfonamide (III) [61] 






Yield = 4% (yellow solid): mp 185-186 °C; anal. RP-HPLC: tR 19.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 8 2.64 (s, 3H, CH3), 3.36 (s, 3H, CH3), 
4.08 (s, 2H, CH2), 7.07 (d, J = 5.5 Hz, IH, pyr-H), 7.28 - 7.35 (m, 5H, phe-H), 7.45 
(dd, J = 1.0 and 8.0 Hz, I H, phe-H), 7.56 (dd, JA = JB = 8.0 Hz, I H, phe-H), 8.03 (dd, 
223 
J = 1.0 and 8.0 Hz, 1H, phe-J1), 8.15 (bs, IH, NH), 8.36 (dd, JA = J5 = 1.0 Hz, IH, 
phe-H), 8.55 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): 6 14.98, 30.04, 46.90, 
109.82, 110.16, 117.29, 119.79, 122.98, 127.79, 128.23, 128.88, 130.06, 138.48, 
138.89, 141.81, 158.74, 159.25, 159.97, 170.42; HRMS (FAB+) in/z calcd for 
C22142 1 N503S2 468.1164 1, obsd 468.11642. 
N-Benzyl-4-1 [4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-
yl]amino}benzenesulfonamide (III) [62] 






Yield = 17% (off-white solid): mp 192-193 °C; anal. RP-HPLC: tR 20.7 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.52 (s, 3H, CH3 ), 3.17 (s, 3H, CH3), 
3.82 (d, J = 7.0 Hz, 2H, CH2), 7.06 - 7.16 (m, 8H, 7 x phe-H and pyr-H), 7.60 (d, J = 
9.0 Hz, 2H, phe-H), 7.80 (t, J = 7.0 Hz, 1H, NH), 7.83 (d, J = 9.0 Hz, 2H, phe-H), 
8.46 (d, J = 5.0 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): ö 18.63, 19.71, 46.84, 110.16, 
112.50, 118.79, 124.15, 127.80, 128.28, 128.92, 131.25, 133.10, 138.54, 144.69, 
153.06, 158.72, 159.94, 167.44; HRMS (FAB+) m/z calcd for C 22H21 N502S2 
452.12150, obsd452.12154. 
N-Benzyl-4-1 [4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-
yl]amino}benzenesulfonamide (III) [63] 







Yield = 14% (yellow solid): mp 206-208 °C; anal. RP-HPLC: tR 16.2 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): ö 2.53 (s, 3H, CH3), 4.03 (d, J = 6.5 Hz, 
2H, CH2), 7.07 (d, J = 5.5 Hz, III, pyr-H), 7.29 - 7.38 (m, 5H, phe-H), 7.64 (s, IH, 
NH), 7.78 (d, J = 9.0 Hz, 2H, phe-H), 8.00 (t, J = 6.5 Hz, 1H, NH), 8.04 (d, J = 9.0 
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Hz, 2H, phe-H), 8.47 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-do): 8 42.82, 
58.58, 71.26, 109.67, 118.51, 118.75, 121.02, 128.25, 129.31, 130.93, 132.95, 135.23, 
136.31, 139.54, 144.88, 160.02, 160.44, 163.37; HRMS (FAB+) m/z calcd for 
C21 H20N602S2 453.11674, obsd 453.11621. 
N-Benzyl-4- ({4- [4-methyl -2- (methylamino) -1 ,3-thiazol-5-yl]pyrimidin-2-
yl}amino)benzenesulfonamide (III) [64] 





Yield = 14% (yellow solid): mp 220-222 °C; anal. RP-HPLC: tR 16.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.57 (s, 3H, CH3), 2.95 (d, J = 4.5 Hz, 
3H, CH3), 4.02 (d, J = 6.0 Hz, CH2), 7.08 (d, J = 5.5 Hz, IH, pyr-H), 7.28 - 7.37 (m, 
5H, phe-H), 7.78 (d, J = 9.0 Hz, 2H, phe-H), 8.00 (t, J = 6.0 Hz, IH, NH), 8.04 (d, J = 
9.0 Hz, 2H, phe-H), 8.17 - 8.19 (m, IH, NH), 8.47 (d, J = 5.5 Hz, IH, pyr-H); 13C 
NMR (DMSO-d6): ö 49.98, 66.89, 107.79, 116.32, 118.50, 120.91, 121.05, 129.08, 
130.91, 133.62, 135.68, 136.30, 139.32, 146.92, 159.82, 161.04, 163.03; HRMS 
(FAB+) ink calcd for C22H22N602S2 467.13239, obsd 467.13 195. 
N-Benzyl -4- ({ 4- [4-methyl -2- (ethylamino) - 1 ,3-thiazol-5-yl]pyrimidin -2-
yI}amino)benzenesulfonamide (III) [65] 
From (I) [220] (R 1 = NHEt) and (II) [299] (R 2 = H, R3 = S02NHBn, R4 = H). 
NH 
N=< 
EL CrrC N N 
H 
Yield = 12% (yellow solid): mp 216-217 °C; anal. RP-HPLC: tR 17.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.26 (t, J = 7.0 Hz, 3H, CH2CH3), 2.57 
(s, 3H, CH3), 3.36 - 3.38 (m, 2H, CH2CH3), 4.04 (d, J = 6.5 Hz, 2H, CH2), 7.09 (d, J 
= 5.5 Hz, IH, pyr-H), 7.29 - 7.39 (m, 5H, phe-H), 7.79 (d, J = 9.0 Hz, 2H, phe-H), 
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8.01 (t, J = 7.0 Hz, 1H, NH), 8.05 (d, J = 9.0 Hz, 2H, phe-H), 8.24 (t, J = 6.5 Hz, IH, 
NH), 8.48 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): ö 14.97, 19.42, 46.8 1, 
108.48, 118.03, 118.58, 127.80, 128.18, 128.28, 128.92, 132.62, 138.54, 145.05, 
153.57, 158.35, 159.37, 159.73, 169.16; HRMS (FAB+) m/z calcd for C 23H24N602S2 
48 1.14804, obsd 481.14863. 
N-Benzyl-4-{ [4-(3,4-dimethyl-2-oxo-2,3-dihydro-1,3-thiazol-5-yI)pyrimidin-2-
yl]amino}benzenesulfonamide (III) [66] 
From (I) [222] (R, = Thiazolone) and (II) [299] (R2 = H, R3 = S02NHBn, R4 = H). 
\ 0 
N-q _rs 
cXN 1N C 
Yield = 14% (colourless solid): mp 211-212 °C; anal. RP-HPLC: tR 20.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.51 (s, 3H, CH3), 3.24 (s, 3H, CH3), 
3.89 (d, J = 6.0 Hz, 2H, CH2), 7.00 (d, J = 5.0 Hz, 111, pyr-H), 7.14 - 7.30 (m, 5H, 
phe-H), 7.65 (d, J = 9.0 Hz, 2H, phe-H), 7.86 (d, J = 9.0 Hz, 2H, phe-H), 8.44 (d, J 
5.0 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): ö 15.01, 30.34, 33.52, 46.83, 110.13, 
110.22, 118.88, 127.81, 128.29, 128.92, 133.14, 138.56, 139.10, 144.66, 158.66, 
159.35 159.79, 170.39; HRMS (FAB+) mlz calcd for C 22H21 N503S2 468.11641, obsd 
468.11630. 
4.(2-Amino-4-methyi-1,3-thiazol-5-y1)-N-[(3-(morpholin- 4-
ylsulfonyl)phenyl]pyrimidin-2.amine (III) [67] 
From (I) [218] (R, = NH2) and (H) [304] (R2 = R3 = H, R 4 = S02-morph). 
NH2 
-s 
(N ( o 
II L N L N }.. S..N) 
H 	d"o 
Yield = 13% (yellow solid): mp 215-217 °C; anal. RP-HPLC: tR 17.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 8 2.57 (s, 3H, CH3), 2.88 - 2.90 (m, 411, 
morph-H), 3.62 - 3.64 (m, 4H, morph-H), 7.04 (d, J = 5.0 Hz, IH, pyr-H), 7.29 (dd, J 
= 2.0 and 8.0 Hz, 1H, phe-H), 7.58 (dd, JA = JB = 8.0 Hz, IH, phe-H), 8.06 (dd, J 
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2.0 and 8.0 Hz, IH, phe-H), 8.23 (dd, JA = JB = 2.0 Hz, IH, phe-H), 8.49 (d, J = 5.0 
Hz, 1H, pyr-H); HRMS (FAB+) mlz calcd for C 1 8H20N603S2 429.11166, obsd 
429.11080. 
3-({4- [4-Methyl-2-(methylamino)-1,3-thiazol-5-yl]-N-[3-(morpholin-4-
ylsulfonyl)phenyl]pyrimidin-2-amine (III) [68] 








LN N 	S,  
H cr0 
Yield = 11% (yellow solid): mp 273-275 °C; anal. RP-HPLC: tR 14.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 2.63 (s, 3H, CH3), 3.01 (d, J = 4.5 Hz, 
lH, NH), 3.05 (dd, JA = J8 = 4.5 Hz, 4H, morph-H), 3.41 (s, 3H, CH3), 3.78 (dd, JA = 
JB = 4.5 Hz, 4H, morph-H), 7.13 (d, J = 5.5 Hz, 1H, pyr-H), 7.42 (dd, J = 2.0 and 8.0 
Hz, IH, phe-H), 7.70 (dd, JA = JB = 8.0 Hz, IH, phe-H), 8.19 (dd, J = 2.0 and 8.0 Hz, 
IH, phe-H), 8.22 - 8.26 (m, 1H, NH), 8.50 (dd, JA = JB = 2.0 Hz, IH, phe-H), 8.53 (d, 
J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): ö 19.20, 21.92, 46.29, 49.95, 50.36, 
107.07, 117.11, 120.97, 125.06, 138.82, 142.42, 146.53, 148.05, 152.12, 160.25, 
168.94, 168.98; HRMS (FAB+) m/z calcd for C 1 9H22N603S2 447.12731, obsd 
447.12740. 
3-({4-[4-Methyl-2-(ethylamino)- 1,3-thiazol-5-yI]-N-[3-(morpholin- 4-
ylsulfonyl)phenyl]pyrimidin -2-amine (III) [691 






Yield = 5% (orange solid): mp 216-217 °C; anal. RP-HPLC: tR 14.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.34 (t, J = 6.0 Hz, 3H, CH2CH3), 2.63 
(s, 3H, CH3), 3.05 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.38 - 3.44 (m, 2H, 
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CH2CH3), 3.79 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 7.14 (d, J = 5.5 Hz, IH, pyr-H), 
7.43 (dd, J = 2.0 and 8.0 Hz, 1H, phe-I1), 7.71 (dd, .JA = JB = 8.0 Hz, 1H, phe-H), 8.21 
(dd, J = 2.0 and 8.0 Hz, 1H, phe-H), 8.31 (t, J = 6.0 Hz, 1H, NH), 8.49 (dd, JA = JB = 
2.0 Hz, 1H, phe-H), 8.54 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): ö 14.97, 
19.42, 46.69, 65.99, 109.49, 117.38, 117.97, 120.50, 121.92, 123.48, 130.14, 135.44, 
142.36, 151.99, 153.63, 159.47, 159.85, 169.61; HRMS (FAB+) m/z calcd for 
C20H24N603S2 461.14296, obsd 461.14290. 
3-{ [4-(3,4-Dimethyl-2-oxo-2,3-dihydro- 1,3-thiazol-5-yl)-N-[3-(morpholin- 4-
ylsulfonyl)phenyl]pyrimidin -2-amine (III) [70] 
From (I) [222] (R, = Thiazolone) and (II) [304] (R2 = R 3 = H, R4 = S02-morph). 
LNN)S N) 
H 	cr0 
Yield = 3% (brown solid): mp 82-84 °C; anal. RP-HPLC: tR 17.4 mm (0-60% MeCN, 
purity 100%); 'H NMR (DMSO-d6): ö 2.57 (s, 3H, CH3 ), 2.89 (bs, 4H, morph-H), 
3.30 (s, 3H, CH3 ), 3.63 (bs, 4H, morph-H), 7.04 (d, J = 5.0 Hz, lH, pyr-H), 7.29 (d, J 
= 8.0 Hz, IH, phe-H), 7.58 (dd, JA = JB = 8.0 Hz, 1H, phe-H), 8.05 (d, J = 8.0 Hz, ill, 
phe-H), 8.23 (bs, IH, phe-H), 8.49 (d, J = 5.0 Hz, iH, pyr-H); HRMS (FAB+) m/z 
calcd for C,9H 21 N504S2 448.11132, obsd 448.11129. 
4-(2,4-Dimethyl- 1,3-thiazol-5-yl)-N-[4-methyl-3- (morpholin -4-ylsulfonyl)phenyl] 
pyrimidin-2-amine (III) [71] 




Yield = 12% (orange solid): mp 100-101 °C; anal. RP-HPLC: tR 18.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.58 (s, 3H, CH3), 2.71 (s, 6H, Cl-I3), 
3.13 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.70 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
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7.20 (d, J = 5.5 Hz, IH, pyr-H), 7.46 (d, J = 8.0 Hz, 1H, phe-H), 8.08 (dd, J = 2.5 and 
8.0 Hz, 1H, phe-H), 8.29 (d, J= 2.5 Hz, 1H, phe-H), 8.61 (d, J = 5.5 Hz, IH, pyr-H); 
' 3C NMR (DMSO-d6): ö 18.57, 19.69, 20.36, 46.01, 66.30, 109.73, 120.24, 123.75, 
130.26, 131.20, 133.82, 135.44, 139.37, 152.93, 158.80, 159.77, 160.13, 167.21; 
HRMS (FAB+) tnlz calcd for C 20H23N503S2 446.13206, obsd 446.13211. 
3-{ [4-(2-Amino-4-methyl-1,3-thiazol-5-yI)pyrimidin-2-yl]amino}-N-[4-methyl-3-
(morpholin-4-ylsulfonyl)phenyl]pyrimidin-2-amine (III) [72] 
From (I) [218] (R, = NH 2) and (H) [305] (R2 = H, R3 = Me, R4 = S02-morph). 
NH2 
(N 
NN SZ N 
H 
Yield = 12% (orange solid): mp 183-184 °C; anal. RP-HPLC: tR 14.7 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 8 2.76 (s, 3H, CL!3), 3.38 (dd, JA = JB = 
4.5 Hz, 4H, morph-H), 3.62 (s, 3H, CL!3), 3.95 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
7.23 (d, J = 5.5 Hz, IH, pyr-H), 7.66 (dd, J = 2.0 and 8.5 Hz, IH, phe-H), 7.83 (s, 2H, 
NH2), 8.40 - 8.42 (m, 2H, phe-H), 8.66 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR 
(DMSO-d6): ö 19.16, 20.33, 46.03, 66.32, 108.31, 118.33, 120.11, 123.47, 129.70, 
133.66, 135.41, 139.72, 153.12, 158.24, 159.63, 159.95, 169.62; HRMS (FAB+) m/z 
calcd for C,9H22N603S2 447.1273 1, obsd 447.12713. 
3-({4- [4-Methyl-2-(methylamino)-1,3-thiazol-5-yl]-N- [4-methyl-3-(morpholin-4-
ylsulfonyl)phenyl]pyrimidin -2-amine (III) [73] 





Yield = 24% (pale brown solid): mp 237-238 °C; anal. RP-HPLC: tR 15.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.77 (s, 3H, CH3), 3.16 (d, J= 4.5 Hz, 
3H, CH3), 3.36 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.61 (s, 3H, CL!3), 3.93 (dd, JA = 
229 
JB = 4.5 Hz, 4H, morph-H), 7.24 (d, J = 5.5 Hz, IH, pyr-H), 7.65 (d, J = 8.5 Hz, IH, 
phe-H), 8.30 (dd, J = 2.0 and 8.5 Hz, 1H, phe-H), 8.34 - 8.37 (m, IH, NH), 8.53 (d, J 
= 2.0 Hz, 1H, phe-H), 8.65 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 
19.38, 20.38, 31.61, 46.03, 66.30, 108.02, 118.29, 119.89, 123.51, 129.75, 133.71, 
135.34, 139.74, 153.47, 158.27, 159.50, 159.94, 170.38; HRMS (FAB+) m/z calcd for 
C20H24N603S2 461.14296, obsd 461.14332. 
3-({4- [4-Methyl-2-(ethylamino)-1,3-thiazol-5-yI]-N-[ 4-methyl-3-(morpholin-4-
ylsulfonyl)phenyl]pyrimidin -2-amine (III) [74] 




N N -'"S N) 
H 	cr0 
Yield = 16% (yellow solid): mp 217-219 °C; anal. RP-HPLC: tR 16.7 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.48 (t, J = 7.5 Hz, 3H, CH2CH3 ), 2.39 
(s, 3H, CH3), 2.77 (s, 3H, CH3 ), 3.36 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.56 (q, J 
= 7.5 Hz, 2H, CH2CH3), 3.93 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 7.24 (d, J = 5.5 
Hz, IH, pyr-H), 7.65 (d, J = 8.5 Hz, 1H, phe-H), 8.32 (dd, J = 2.0 and 8.5 Hz, IH, 
phe-H), 8.42 (q, J = 7.5 Hz, 1H, NH), 8.52 (d, J = 2.0 Hz, LH, phe-H), 8.65 (d, J = 
5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 5 14.98, 19.39, 20.38, 46.03, 66.30, 
108.06, 112.50, 117.98, 119.90, 123.51, 129.74, 133.73, 135.33, 139.75, 153.40, 
158.23, 159.52, 159.94, 169.42; HRMS (FAB+) mlz calcd for C2 1 H26N603S2 
475.15861, obsd 475.15845. 
230 
5-{ [4-(3,4-Dimethyl-2-oxo-2,3-dihydro- 1,3-thiazol-5-yI)-N-[4-methyl- 3-
(morpholin-4-ylsulfonyl)phenyl]pyrimidin -2-amine (III) [75] 
From (I) [222] (R, = Thiazolone) and (II) [305] (R2 = H, R3 = Me, R 4 = S02-morph). 
('L N 
t! 
N N'al S N.) 
	
H 	cr0 
Yield = 5% (colourless solid): mp 202-204 °C; anal. RP-HPLC: tR 18.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.69 (s, 3H, CH3), 3.19 (bs, 4H, 
morph-H), 3.43 (s, 3H, CH3), 3.76 (bs, 4H, morph-H), 7.12 (d, J= 5.5 Hz, I  pyr-H), 
7.52 (d, J = 8.5 Hz, IH, phe-H), 8.12 (d, J = 8.5 Hz, lH, phe-H), 8.31 (bs, IH, phe-
H), 8.59 (d, J = 5.5 Hz, lH, pyr-H); ' 3C NMR (DMSO-do): 5 14.97, 20.35, 30.34, 
46.02, 66.31, 109.66, 110.00, 110.27, 120.30, 123.84, 130.25, 133.83, 135.47, 138.84, 
139.36, 158.73, 159.30, 159.98, 170.46; HRMS (FAB+) nilz calcd for C20H23N504S2 
462.12697, obsd 462.12689. 
4-(2,4-Dimethyl- 1,3-thiazol-5-yI)-N-(4-thiomorpholin-4-ylphenyl)pyrimidin-2-
amine (III) [89] 






Yield = 37% (yellow solid): mp 173-174 °C; anal. RP-HPLC: tR 13.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.62 (s, 3H, CH3), 2.64 (s, 3H, CH3 ), 
2.69 (dd, JA = JB = 5.0 Hz, 4H, thiomorph-H), 3.40 (dd, JA = JB = 5.0 Hz, 4H, 
thiomorph-H), 6.90 (d, J = 9.0 Hz, 2H, phe-H), 7.00 (d, J = 5.0 Hz, IH, pyr-H), 7.61 
(d, J = 9.0 Hz, 2H, phe-H), 8.45 (d, J = 5.0 Hz, 1H, pyr-H), 9.42 (bs, IH, NH); 13C 
NMR (DMSO-d6): ö 18.53, 19.64, 26.75, 52.67, 108.29, 117.79, 121.02, 131.58, 
133.33, 146.92, 152.43, 158.51, 159.61, 160.45, 166.88; HRMS (FAB+) m/z calcd for 








Yield = 29% (yellow solid): mp 177-179 °C; anal. RP-HPLC: tR 12.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.49— 1.53 (m, 2H, piperid-H), 1.61 - 
1.65 (m, 4H, piperid-H), 2.61 (s, 3H, CH 3), 2.64 (s, 3H, CH3), 3.04 (dd, JA = J8 = 5.5 
Hz, 4H, piperid-H), 6.88 (d, J = 9.0 Hz, 2H, phe-H), 6.98 (d, J = 5.0 Hz, IH, pyr-H), 
7.57 (d, J = 9.0 Hz, 2H, phe-H), 8.44 (d, J = 5.0 Hz, IH, pyr-H), 9.37 (bs, IH, NH); 
' 3C NMR (DMSO-d6): ö 18.56, 19.66, 24.58, 26.15, 51.17, 108.30, 117.11, 121.02, 
131.64, 132.83, 147.83, 152.44, 158.54, 159.63, 160.53, 166.89; HRMS (FAB+) tn/z 
calcd for C 20H23N5S 366.17524, obsd 366.17465. 
4-(2,4-Dimethyl-1,3-thiazol-5-yI)-N-(4-pyrrolidin-1-ylphenyl)pyrimidin-2-amine 
(III) [91] 
From (I) [241] (R i = Me) and (II) [308] (R2 = H, R3 = pyrrol, R 4 = H). 
N 	
ND 
N N fa 
Yield = 31% (yellow solid): mp 193-194 °C; anal. RP-FIPLC: tR 12.5 mm (0-60% 
MeCN, purity 100%); 1 H NMR (DMSO-d6): 8 1.93 - 1.96 (m, 4H, pyrrol-H), 2.61 (s, 
3H, CH3), 2.64 (s, 311, CH3), 3.20 (dd, JA = JB = 6.5 Hz, 4H, pyrrol-H), 6.51 (d, J = 
9.0 Hz, 2H, phe-H), 6.94 (d, J = 5.0 Hz, IH, pyr-H), 7.51 (d, J = 9.0 Hz, 2H, phe-H), 
8.40 (d, J = 5.0 Hz, IH, pyr-H), 9.22 (bs,• 1H, NH); ' 3C NMR (DMSO-d6): 8 18.56, 
19.67, 25.60, 48.28, 107.92, 112.21, 121.94, 129.70, 131.70, 144.45, 152.32, 158.53, 




ylphenyl)pyrimidin-2-amine (ifi) [92] 





Yield = 29% (yellow solid): mp 173-174 °C; anal. RP-HPLC: tR 15.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.23 (s, 3H, CH3), 2.59 (s, 3H, Cl-I3), 
2.61 (s, 3H, CH3), 2.76 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.69 (dd, JA = JB = 4.5 
Hz, 4H, morph-H), 6.95 (d, J = 9.0 Hz, 1H, phe-H), 6.99 (d, J = 5.0 Hz, IH, pyr-H), 
7.51 (dd, J = 2.5 and 9.0 Hz, 1. H, phe-H), 7.56 (d, J= 2.5 Hz, IH, phe-H), 8.43 (d, J = 
5.0 Hz, 1H, pyr-H), 9.43 (bs, IH, NH); ' 3C NMR (DMSO-d 6): 8 18.34, 18.53, 19.63, 
52.89, 67.31, 108.60, 118.01, 119.58, 122.45, 131.55, 132.61, 136.31, 146.17,152.53, 
158.46, 159.65, 160.37, 166.95; HRMS (FAB+) m/z calcd for C 20H23N50S 
382.17016, obsd 382.17033. 
4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-(3-methyl-4-piperidin-1-ylphenyl)pyrimidin-
2-amine (III) [93] 
From (I) [241] (R i = Me) and (II) [3 10] (R2 = H, R3 = piperid, R 4 = Me). 
N Na 
Yield = 40% (yellow solid): mp 159-160 °C; anal. RP-HPLC: tR 12.8 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.51 - 1.52 (m, 2H, piperid-H), 1.62-
1.66 (m, 4H, piperid-H), 2.24 (s, 3H, CH3), 2.62 (s, 3H, CH3), 2.64 (s, 3H, CH3), 2.74 
(dd, JA = ii,, = 4.5 Hz, 4H, piperid-H), 6.95 (d, J = 8.5 Hz, 1H, phe-H), 7.01 (d, J = 5.0 
Hz, IH, pyr-H), 7.51 (dd, J = 2.0 and 8.5 Hz, IH, phe-H), 7.56 (d, J = 2.0 Hz, IH, 
phe-H), 8.46 (d, J = 5.0 Hz, lH, pyr-H), 9.42 (bs, 1H, NH); ' 3C NMR (DMSO-d 6): 
18.26, 18.53, 19.63, 24.56, 26.91, 53.87, 108.50, 117.99, 119.51, 122.41, 131.59, 
132.53, 135.84, 147.62, 152.50, 158.46, 159.62, 160.41, 166.91; HRMS (FAB+) m/z 
calcd for C2 1 H25N5S 380.19089, obsd 380.19093. 
233 
4-(2,4-Dimethyl.1,3-thiazol-5-yl)-N-[3-(thiomorpholin- 4-
ylmethyl)phenyl]pyrimidin -2-amine (III) [94] 




Yield = 17% (yellow solid): mp 153-154 °C; anal. RP-HPLC: tR 12.8 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.86 - 2.87 (m, 4H, thiomorph-H), 
2.97 - 2.98 (m, 4H, thiomorph-H), 3.00 (s, 3H, CH3), 3.02 (s, 3H, CH3), 3.84 (s, 211, 
CH2), 7.26 (d, J= 7.5 Hz, 1H, phe-H), 7.44 (d, J= 5.0 Hz, IH, pyr-H), 7.60 (dd, JA = 
JB = 7.5 Hz, 1H, phe-H), 7.98 (dd, J = 2.0 and 7.5 Hz, IH, phe-H), 8.16 (d, J = 2.0 
Hz, IH, phe-H), 8.88 (d, J = 5.0 Hz, IH, pyr-H); ' 3C NMR (DMSO-d 6): 8 18.57, 
19.63, 27.84, 55.22, 63.66, 109.00, 118.36, 120.03, 122.79, 128.86, 131.52, 139.08, 
140.89, 152.65, 158.47, 159.74, 160.34, 167.00; HRMS (FAB+) mlz calcd for C-
20H23N5 S2 398.14732, obsd 398.14714. 
4-(2,4-Dimethyl- 1,3-thiazol-5-yI)-N-[3-(morpholin- 4-
ylcarbonyl)phenyl]pyrimidin -2-amine (III) [95] 
From (I) [241] (R i = Me) and (II) [318] (R2 = R 3 = H, R4 = CO-morph). 
LNNZIN 
Yield = 15% (off-white solid): mp 216-217 °C; anal. RP-HPLC: tR 14.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): ö 2.80 (s, 3H, CH3 ), 2.82 (s, 3H, CH3), 
3.53 - 3.84 (bs, 8H, morph-H), 7.15 (d, J = 8.0 Hz, IH, phe-H), 7.28 (d, J = 5.0 Hz, 
IH, pyr-H), 7.54 (dd, JA = JB = 8.0 Hz, 1H, phe-H), 7.97 (dd, J = 2.0 and 8.0 Hz, 1H, 
phe-H), 8.08 (d, J = 2.0 Hz, IH, phe-H), 8.71 (d, J = 5.0 Hz, IH, pyr-H); 13C NMR 
(DMSO-d6): 8 18.54, 19.65, 66.83, 109.47, 117.86, 120.44, 120.51, 129.34, 131.30, 
136.53, 141.05, 152.83, 158.58, 159.78, 160.20, 167.04, 169.87; HRMS (FAB+) m/z 
calcd for C201-12 1 N502S 396. 14942, obsd 396.14946. 
234 
4-(2-Amino-4-methyl-1,3-thiazol-5-yI)-N-(4-thiomorpholin-4-ylphenyl)pyrimidin-
2-amine (III) [96] 






Yield = 21% (yellow solid): mp 180-182 °C; anal. RP-HPLC: tR 10.4 mm (0-60% 
MeCN, purity 100%); 1 H NMR (DMSO-d6): 6 2.08 (s, 3H, CH3), 2.69 (dd, JA = JB = 
5.0 Hz, 4H, thiomorph-H), 3.37 - 3.39 (m, 4H, thiomorph-H), 6.80 (d, J =. 5.5 Hz, 1H, 
pyr-H), 6.86 (d, J = 9.0 Hz, 211, phe-H), 7.45 (bs, 214, NH2), 7.61 (d, J = 9.0 Hz, 2H, 
phe-H), 8.26 (d, J = 5.5 Hz, IH, pyr-H), 9.18 (bs, IH, NH); MS (ESI) m/z: 385.43 
[M+H]t 
4-(2-Amino-4-methyl-1,3-thiazol-5-yl)-N-(4-piperidin-1-ylphenyl)pyrimidin-2-
amine (III) [97] 





Yield = 7% (yellow solid): mp 202-203 °C; anal. RP-HPLC: tR 10.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 1.48 - 1.53 (m, 2H, piperid-H), 1.60 - 
1.66 (m, 4H, piperid-H), 2.42 (s, 3H, CH3), 3.03 (dd, JA = JB = 5.5 Hz, 4H, piperid-H), 
6.79 (d, J = 5.0 Hz, IH, pyr-H), 6.85 (d, J = 9.0 Hz, 2H, phe-H), 7.44 (bs, 2H, NH2), 
7.57 (d, J = 9.0 Hz, 2H, phe-H), 8.26 (d, J = 5.0 Hz, IH, pyr-H), 9.13 (bs, 1H, NH); 
' 3C NMR (DMSO-d6): 6 19.10, 25.58, 26.20, 51.29, 106.87, 117.12, 118.96, 120.75, 
133.32, 147.54, 152.36, 159.30, 160.32, 169.41, 171.19; HRMS (FAB+) m/z calcd for 
C 19H22N6S 367.17049, obsd 367.17071. 
235 
4-(2-Amino-4-methyl-1,3-thiazol-5-yI)-N-(4-pyrrolidin-1-ylphenyl)pyrimidin-2-
amine (HI) [98] 
From (I) [218] (R I = NH2) and (II) [308] (R2 = H, R3 = pyrrol, R4 = H). 
NH2 
N O 
Yield = 24% (brown solid): mp 234-236 °C; anal. RP-HPLC: tR 10.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-do): 6 1.94 (dd, JA = JB = 6.5 Hz, 4H, pyrrol-
H), 2.41 (s, 3H, Cl-I3), 3.19 (dd, JA = JB = 6.5 Hz, 4H, pyrrol-H), 6.48 (d, J = 8.5 Hz, 
2H, phe-H), 6.75 (d, J = 5.0 Hz, 1H, pyr-H), 7.42 (bs, 2H, NH2), 7.52 (d, J = 8.5 Hz, 
2H, phe-H), 8.27 (d, J = 5.0 Hz, 1H, pyr-H), 8.98 (bs, IH, NH); ' 3C NMR (DMSO-
d6): 6 10.09, 25.60, 48.30, 106.49, 112.18, 119.04, 121.59, 130.21, 144.17, 152.16, 
158.23, 159.28, 160.46, 169.34; HRMS (FAB+) mlz calcd for C 18H20N6S 415.17049, 
obsd 415.17064. 
4-(2-Amino-4-methyl-1,3-thiazol-5-yl)-N-(3-methyl-4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [99] 





Yield = 21% (yellow solid): mp 256-257 °C; anal. RP-HPLC: tR 11.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.23 (s, 3H, CH3), 2.39 (s, 3H, CH3), 
2.75 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.69 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
6.79 (d, J = 5.5 Hz, IH, pyr-H), 6.91 (d, J = 9.0 Hz, IH, phe-H), 7.44 (bs, 2H, NH2), 
7.51 (dd, J = 2.5 and 9.0 Hz, 1H, phe-H), 7.55 (d, J = 2.5 Hz, I H, phe-H), 8.24 (d, J = 
5.5 Hz, IH, pyr-H'), 9.18 (bs, lH, NH); ' 3C NMR (DMSO-d6): 6 18.40, 19.13, 52.98, 
67.41, 107.19, 117.19, 118.91, 119.50, 122.25, 132.64, 136.78, 145.85, 152.54, 
158.28, 159.28, 160.21, 169.46; HRMS (FAB+) m/z calcd for C,9H22N 60S 
383.16541, obsd 383.16518. 
236 
4-(2-Amino-4-methyl-1,3-thiazol-5-yI)-N-(4-methyl-4-piperidin-1-
ylphenyl)pyrimidin-2-amine (III) [100] 






Yield = 41% (yellow solid): mp 221-223 °C; anal. RP-HPLC: tR 10.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 5 1.51 - 1.52 (m, 2H, piperid-H), 1.62-
1.65 (m, 4H, piperid-H), 2.39 (s, 3H, CH3), 2.43 (s, 3H, CH3), 2.74 (dd, JA = JB = 5.0 
Hz, 4H, piperid-H), 6.82 (d, J = 5.5 Hz, 1H, pyr-H), 6.91 (d, J = 8.5 Hz, 1H, phe-H), 
7.47 (bs, 2H, NH2), 7.51 (dd, J= 2.5 and 8.5 Hz, 1H, phe-H), 7.56 (d, J= 2.5 Hz, 1H, 
phe-H), 8.28 (d, J = 5.5 Hz, IH, pyr-H), 9.18 (bs, 1H, Nil); ' 3C NMR (DMSO-d6): 
18.31, 19.11, 24.61, 26.97, 53.96, 107.07, 117.72, 118.96, 119.43, 122.22, 132.54, 
136.29, 147.30, 152.49, 158.26, 159.27, 160.24, 169.46; HRMS (FAB+) m/z calcd for 
C20H24N6S 381.18614, obsd 381.18611. 
4-(2-Amino-4-methyl- 1,3-thiazol-5-yl)-N-(3-methoxy-4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [101] 





Yield = 32% (yellow solid): mp 243-245 °C; anal. RP-HPLC: tR 10.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.42 (s, 3H, CH3), 2.90 (dd, JA = J8 = 
4.5 Hz, 4H, morph-H), 3.71 (dd, JA = JB = 4.5 Hz, morph-H), 3.81 (s, 3H, OCH3), 
6.79 (d, J = 8.5 Hz, IH, phe-H), 6.85 (d, J = 5.0 Hz, 1H, pyr-H), 7.28 (dd, J = 2.0 and 
8.5 Hz, IH, phe-H), 7.43 (d, J = 2.0 Hz, 1H, phe-H), 7.48 (bs, 2H, NH2), 8.29 (d, J = 
5.0 Hz, 1FI, pyr-H), 9.23 (bs, IH, NH); ' 3C NMR (DMSO-d6): ö 19.15, 51.71, 56.2 1, 
67.17, 104.70, 107.19, 111.58, 118.37, 118.86, 135.96, 136.86, 152.51, 152.64, 
158.30, 159.32, 160.20, 169.45; HRMS (FAB+) m/z calcd for C 1 9H22N602S 
399.16032, obsd 399. 16035. 
237 
4-(2-Amino-4-methyl- 1,3-thiazol-5-yl)-N-(4-methoxy-3-methylphenyl)pyrimidin-
2-amine (III) [102] 
From (I) [218] (RI = NH2) and (II) [313] (R2 = H, R3 = OMe, R 4 = Me). 
N=' NH2 
(N 	 01, 
L N L N) ) 
Yield = 12% (yellow solid): mp 178-180 °C; anal. RP-HPLC: tR 13.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.16 (s, 3H, CH3), 2.42 (s, 3H, CH3), 
3.74 (s, 3H, OCH3), 6.80 (d, J = 5.5 Hz, 1H, pyr-H), 6.83 (d, J = 8.5 Hz, 1H, phe-H), 
7.46 (bs, 214, NH2), 7.50 (dd, J = 2.5 and 8.5 Hz, 1H, phe-H), 7.55 (d, J = 2.5 Hz, IH, 
phe-H), 8.27 (d, J = 5.5 Hz, 1H, pyr-H), 9.14 (bs, IH, NH); ' 3C NMR (DMSO-d6): 
17.04, 19.10, 56.05, 106.98, 110.87, 118.09, 118.94, 122.61, 125.84, 134.09, 152.45, 
152.88, 158.29, 159.26, 160.31, 169.42; HRMS (FAB+) m/z calcd for C 16H 1 7N50S 
328.1232 1, obsd 328.12321. 
4-(2-Amino-4-methyl-1,3-thiazol-5-yl)-N-(3,5-dimethoxyphenyl)pyrimidin-2-
amine (III) [103] 
From (I) [218] (R, = NH 2) and (II) [325] (R2 = OMe, R3 = H, R4 = OMe). 
N=' NH2 
Yield = 20% (pale brown solid): mp 269-271 °C; anal. RP-HPLC: tR 13.5 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.43 (s, 3H, CH3), 3.74 (s, 6H, CH3), 
6.10 (dd, JA  =JB = 2.5 Hz, 1H, phe-H), 6.90 (d, J= 5.5 Hz, lH, pyr-H), 7.05 (dd, JA = 
JB = 2.5 Hz, 2H, phe-H), 7.51 (bs, 2H, NH2), 8.33 (d, J = 5.5 Hz, 1H, pyr-H), 9.35 
(bs, 1H, NH); ' 3C NMR (DMSO-d6): 8 19.16, 55.88, 94.28, 97.70, 107.77, 118.65, 
143.02, 152.75, 158.26, 159.37, 160.14, 161.13, 169.54; HRMS (FAB+) m/z calcd for 
C, 6H17N502S 344.11812, obsd 344.11810. 
238 
4-(2-Amino-4-methyl-1,3-thiazol-5-yI)-N-[3-(morpholin-4-
ylcarbonyl)phenyl]pyrimidin-2-amine (III) [104] 
From (I) [218] (RI = NI-12) and (II) [318] (R2 = R3 = H, R4 = CO-morph). 
NH2 
—s 
KN 	 (o 
N 	NI 
Yield = 14% (pale brown solid): mp 243-244 °C; anal. RP-HPLC: tR 11.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.87 (s, 3H, CH3), 3.79 –4.08 (bs, 8H, 
morph-H), 7.33 (d, J = 5.5 Hz, IH, pyr-H), 7.37 (dd, J = 1.0 and 7.5 Hz, 1H, phe-H), 
7.56 (dd, JA = J!J = 7.5 Hz, IH, phe-H), 7.94 (bs, 2H, NH2), 8.24 (dd, JA = JB = 1.0 Hz, 
IH, phe-H), 8.30 (dd, J = 1.0 and 7.5 Hz, 1H, phe-H), 8.73 (d, J = 5.5 Hz, 1H, pyr-H); 
' 3C NMR (DMSO-d6): ö 19.17, 66.84, 108.10, 117.64, 117.69, 118.46, 120.20, 
120.28, 129.29, 136.48, 141.39, 152.97, 158.31, 159.48, 160.07, 169.52, 169.93; 
HRMS (FAB+) m/z calcd for C 1 9H20N602S 397.14467, obsd 397.14477. 
4-(2-Amino-4-methyl-1,3-thiazol-5-yl)-N-[3-(thiomorpholin- 4-
ylmethyl)phenyl]pyrimidin -2-amine (III) [105] 
From (I) [218] (R, = NH 2) and (H) [316] (R2 = R 3 = H, R4 = CH2-thiomorph). 
NH 2 
(NTh 	(S 
Yield = 14% (pale brown solid): mp 227-228 °C; anal. RP-HPLC: tR 10.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): ö 2.40 (s, 3H, CH3), 2.56 - 2.57 (m, 4H, 
thiomorph-H), 2.59 - 2.60 (m, 411, thiomorph-H), 3.44 (s, 2H, CH2), 6.82 - 6.84 (m, 
2H, phe-H and pyr-H), 7.16 (dd, JA = JB = 8.0 Hz, IH, phe-H), 7.45 (bs, 2H, NH2), 
7.64 - 7.66 (m, 211, phe-H), 8.28 (d, J = 5.5 Hz, 1H, pyr-H), 9.35 (bs, IH, NH); 13C 
NMR (DMSO-d6): 6 19.16, 27.90, 55.15, 63.64, 107.80, 118.10, 118.75, 119.98, 
122.38, 128.82, 138.98, 141.25, 152.74, 158.33, 159.34, 160.19, 169.51; HRMS 




From (I) [218] (Ri = NH2) and (II) [314] (R 2 = H, R3 and R4 fused = OCH20). 
N=( NH2 
(N ( :7 ) O 
Yield = 36% (brown solid): mp 211-213 °C; anal. RP-HPLC: tR 12.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.42 (s, 3H, CH3), 5.96 (s, 2H, CH2), 
6.81 (d, J = 8.0 Hz, 1H, phe-H), 6.84 (d, J = 5.5 Hz, IH, pyr-H), 7.09 (dd, J = 2.0 and 
8.0 Hz, IH, phe-H), 7.50 (bs, 2H, NH2), 7.54 (d, J = 2.0 Hz, 1H, phe-H), 8.29 (d, J = 
5.5 Hz, IH, pyr-H), 9.31 (bs, IH, NH); ' 3C NMR (DMSO-d6): ö 19.81, 101.32, 
101.80, 103.61, 107.32, 108.53, 111.83, 112.08, 118.72, 135.93, 142.13, 147.65, 
152.63, 160.15, 169.45; HRMS (FAB+) mlz calcd for C 15H, 3N502S 328.08682, obsd 
328.08685. 
4-[4-Methyl-2-(ethylamino)-1,3-thiazol-5-yl]-N-( 4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [107] 





Yield = 29% (yellow solid): mp 253-254 °C; anal. RP-HPLC: tR 11.8 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.69 (t, J = 7.0 Hz, CH2CH3), 2.45 (s, 
3H, CH3), 3.03 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.24 - 3.28 (m, 2H, CH2CH3 ), 
3.73 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 6.81 (d, J = 5.5 Hz, IH, pyr-H), 6.87 (d, J = 
9.0 Hz, 2H, phe-H), 7.61 (d, J = 9.0 Hz, 2H, phe-H), 8.05 (t, J = 7.0 Hz, IH, NH), 
8.27 (d, J = 5.5 Hz, IH, pyr-H), 9.17 (bs, IH, NH); ' 3C NMR (DMSO-d6): 8 15.00, 
19.33, 50.04, 66.89, 106.90, 116.27, 118.41, 120.74, 133.85, 146.65, 152.62, 158.21, 




ylphenyl)pyrimidin-2-amine (ifi) [108] 






Yield = 9% (yellow solid): mp 207-209 °C; anal. RP-HPLC: tR 11.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 1.17 (t, J = 7.5 Hz, 3H, CH3CH3), 2.45 
311, CH3), 2.69 (dd, JA = JB = 5.0 Hz, 4H, thiomorph-H), 3.24 - 3.30 (m, 2H, 
CH2CH3), 3.38 (dd, JA = JB = 5.0 Hz, 4H, thiomorph-H), 6.82 (d, J = 5.5 Hz, IH, pyr-
H), 6.87 (d, J = 9.0 Hz, 2H, phe-H), 7.61 (d, J = 9.0 Hz, 2H, phe-H), 8.05 (t, J = 5.0 
Hz, IH, NH), 8.27 (d, J = 5.5 Hz, IH, pyr-H), 9.17 (bs, 1H, NH); ' 3C NMR (DMSO-
d6): 6 15.00, 19.33, 26.86, 52.81, 106.92, 117.97, 118.40, 120.84, 133.89, 146.75, 
152.63, 158.21, 159.28, 160.29, 168.92, 174.77; HRMS (FAB+) in/z calcd for 
C20H24N6S2 413.15822, obsd 413.15832. 
N-{4-[2-(Ethylamino)-4-methyl-1,3-thiazol-5-yI]-4-(4-piperidin- 1-
ylphenyl)pyrimidin-2-amine (III) [109] 






Yield = 27% (yellow solid): mp 193-194 °C; anal. RP-HPLC: tR 11.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 1.17 (t, J = 7.0 Hz, 3H, CH2CH3), 1.48 
- 1.53 (m, 2H, piperid-H), 1.60 - 1.65 (m, 411, piperid-H), 2.45 (s, 311, CH3), 3.03 
(dd, JA = J8 = 5.5 Hz, 4H, piperid-H), 3.24 - 3.30 (m, 2H, CH2CH3), 6.80 (d, J = 5.5 
Hz, 1H, pyr-H), 6.85 (d, J = 9.0 Hz, 2H, phe-H), 7.57 (d, J = 9.0 Hz, 2H, phe-H), 8.04 
J = 5.5 Hz, IH, NH), 8.26 (d, J = 5.5 Hz, IH, pyr-H), 9.13 (bs, 1H, NH); ' 3C NMR 
(DMSO-d6): 6 14.99, 19.32, 24.58, 26.18, 51.30, 106.80, 113.50, 117.21, 118.45, 
241 
120.78, 133.33, 147.56, 152.56, 158.21, 159.28, 160.32, 168.91; HRMS (FAB+) m/z 
calcd for C2 1 H26N6S 395.20 179, obsd 395.20 175. 
4-[2-(Ethylamino)-4-methyl- 1,3-thiazol-5-yl]-N-(3-methyl-4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [110] 




Yield = 24% (yellow solid): mp 213-214 °C; anal. RP-HPLC: tR 13.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): ö 1.12— 1.15 (m, 3H, CH2CH3), 2.23 (s, 
3H, CH3), 2.41 (s, 3H, CH3), 2.74 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.20 - 3.26 
(m, 2H, CH2CH3), 3.68 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 6.80 (d, J = 5.0 Hz, 1H, 
pyr-H), 6.91 (d, J = 8.5 Hz, IH, phe-H), 7.44 (dd, J = 2.0 and 8.5 Hz, IH, phe-H), 
7.64 (d, J = 2.0 Hz, IH, phe-H), 8.05 (t, J = 5.0 Hz, IH, NH), 8.24 (d, J = 5.0 Hz, IH, 
pyr-H), 9.19 (bs, 1H, NH); ' 3C NMR (DMSO-d6): ö 14.90, 18.33, 19.28, 52.93, 60.4 1, 
67.37, 106.96, 117.74, 118.48, 119.48, 122.17, 132.55, 136.75, 145.79, 152.73, 
158.23, 160.15, 169.01, 170.99; HRMS (FAB+) m/z calcd for C2,H26N60S 
411.1967 1, obsd41 1.19670. 
4-[2-(Ethylamino)-4-methyl-1,3-thiazol-5-yI]-N-(3-methyl- 4-piperidin-1-
ylphenyl)pyrimidin-2-amine (III) [111] 







Yield = 35% (yellow solid): mp 213-214 °C; anal. RP-HPLC: tR 11.2 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.18 (t, J = 7.0 Hz, 3H, CH2CH3), 1.51 
- 1.52 (m, 2H, piperid-H), 1.62— 1.66 (m, 4H, piperid-H), 2.24 (s, 3H, CH3), 2.45 (s, 
242 
3H, CH3), 2.74 (dd, JA = JB = 5.0 Hz, 4H, piperid-H), 3.24 - 3.29 (m, 2H, CH2CH3 ), 
6.83 (d, J = 5.5 Hz, IH, pyr-H), 6.92 (d, J = 8.5 Hz, IH, phe-H), 7.45 (dd, J = 2.5 and 
8.5 Hz, H, phe-H), 7.65 (d, J = 2.5 Hz, 1H, phe-H), 8.08 (t, J = 5.0 Hz, IH, NH), 8.28 
(d, J = 5.5 Hz, 1H, pyr-H), 9.19 (bs, IH, NH); ' 3C NMR (DMSO-d6): 8 14.91, 18.24, 
19.27, 24.57, 26.93, 53.91, 60.41, 106.87, 117.71, 118.51, 119.42, 122.15, 132.46, 
136.26, 147.25, 152.68, 158.23, 159.11, 160.18, 169.00; HRMS (FAB+) m/z calcd for 
C22H28N6S 409.21744, obsd 409.21702. 
N-(3-Methoxy-4-morpholin-4-ylphenyl)-4-(2-ethylamino- 1,3-thiazol-5-
yl)pyrimidin-2-amine (III) [112] 
From (I) [220] (R I = NI-lEt) and (II) [319] (R2 = H, R 3 = morph, R4 = OMe). 
<H 
N=< 
Yield = 22% (yellow solid): mp 224-226 °C; anal. RP-HPLC: tR 10.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.17 (t, J= 7.0 Hz, 3H, CH2CH3), 2.45 
(s, 311, CH3), 2.90 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.22 - 3.26 (m, 2H, 
CH2CH3), 3.71 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.82 (s, 3H, OCH3), 6.80 (d, J = 
8.5 Hz, 111, phe-H), 6.86 (d, J = 5.5 Hz, IH, pyr-H), 7.26 (dd, J = 2.5 and 8.5 Hz, IH, 
phe-H), 7.50 (d, J = 2.5 Hz, IH, phe-H), 8.09 (t, J = 5.0 Hz, IH, NH), 8.29 (d, J = 5.5 
Hz, IH, pyr-H), 9.24 (bs, IH, NH); ' 3C NMR (DMSO-d6): ö 14.95, 19.37, 51.71, 
56.16, 67.17, 104.61, 107.06, 111.60, 112.50, 118.36, 118.43, 135.94, 136.88, 152.64, 
158.26, 159.24, 160.19, 169.02; HRMS (FAB+) mlz calcd for C 21 H26N602S 
427.19 162, obsd 427.19147. 
243 
N-(3-Chloro- 4-morpholin-4-ylphenyl) -4- [2-(ethylamino)-4-methyl -  1,3-thiazol-5- 
yl]pyrimidin-2-amine (III) [113] 
From (I) [220] (RI = NHEt) and (H) [323] (R2 = H, R3 = morph, R 4 = Cl). 
(I  NH 
( o N) 
N 01 CI 
H 
Yield = 23% (off-white solid): mp 273-274 °C; anal. RP-HPLC: tR 13.4 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 6 1.18 (t, J = 7.0 Hz, CH2CH3), 2.46 (s, 
3H, CH3), 2.91 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.24 - 3.29 (m, 2H, CH2CH3 ), 
3.73 (dd, .1,, = .JB = 4.5 Hz, 4H, morph-H), 6.90 (d, J = 5.5 Hz, IH, pyr-H), 7.10 (d, J = 
9.0 Hz, IH, phe-H), 7.58 (dd, J = 2.5 and 9.0 Hz, 1H, phe-H), 8.09 (d, J = 2.5 Hz, IH, 
phe-H), 8.14 (t, J = 5.5 Hz, 1H, NH), 8.33 (d, J = 5.5 Hz, 1H, pyr-H), 9.50 (bs, IH, 
NH); ' 3C NMR (DMSO-d6): 6 14.93, 19.36, 52.37, 67.14, 107.60, 118.25, 118.79, 
120.87, 121.34, 128.32, 137.77, 143.05, 153.20, 158.32, 159.24, 159.89; HRMS 
(FAB+) m/z calcd for C 20H23C1N60S 431.14209, obsd 431.14193. 
N-(3 ,5-Dichloro-4-morpholin-4-ylphenyl)-442-(ethylamino) -4-methyl-1 ,3-thiazol -
5-yI]pyrimidin -2-amine (III) [114] 
From (I) [220] (R I = NHEt) and (II) [324] (R2 = Cl, R3 = morph, R 4 = Cl). 
<H 
(N 
LN J CI 
Yield = 16% (off-white solid): mp >300 °C; anal. RP-HPLC: tR 17.1 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 1.45 (t, J = 7.0 Hz, 3H, CH2CH3 ), 2.74 
(s, 3H, CH3), 3.36 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.51 - 3.53 (m, 2H, CH2CH3), 
3.96 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 7.23 (d, J = 5.5 Hz, 1H, pyr-H), 8.20 (s, 
2H, phe-H), 8.47 (t, J = 5.0 Hz, IH, NH), 8.63 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR 
(DMSO-d6): 6 14.87, 19.39, 50.22, 67.75, 108.22, 118.10, 119.04, 135.01, 137.56, 
244 
140.10, 153.68, 158.39, 159.19, 159.55, 169.40; HRMS (FAB+) in/z calcd for 
C20H22C12N60S 465.10311, obsd 465.10361. 
4-[2-(Ethylamino)-4-methyl-1,3-thiazol-5-yl]-N-(4-methoxy-3-
methylphenyl)pyrimidin-2-amine (III) [115] 
From (I) [220] (R, = NHEt) and (H) [313] (R2 = H, R3 = OMe, R 4 = Me). 
<I 
NH 
(N 	rY 0••• 
Yield = 12% (yellow solid): mp 206-208 °C; anal. RP-HPLC: tR 15.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.17 (t, J = 7.0 Hz, 3H, CH2CH3), 2.16 
(s, 3H, CH3), 2.45 (s, 311, CH3), 3.24 - 3.29 (m, 2H, CH2CH3), 3.74 (s, 3H, OCH3), 
6.81 - 6.84 (m, 2H, phe-H and pyr-I1), 7.45 (dd, J = 2.0 and 9.0 Hz, 111, phe-H), 7.62 
(d, J = 2.0 Hz, IH, phe-H), 8.08 (t, J = 5.5 Hz, 1H, NH), 8.27 (d, J = 5.0 Hz, IH, pyr-
H), 9.15 (bs, IH, NH); ' 3C NMR (DMSO-d6): 8 14.96, 17.01, 19.31, 56.05, 106.82, 
110.93, 118.14, 118.52, 122.63, 125.78, 134.10, 152.68, 152.88, 157.68, 158.28, 
159.16, 160.29, 168.98; HRMS (FAB+) m/z calcd for C 1 8H2 1 N50S 356.1545 1, obsd 
356.15475. 
N-(3,5-Dimethoxyphenyl) -4- [2- (ethylamino) -4-methyl-1 ,3-thiazol -5-yI]pyrimidin-
2-amine (III) [116] 
From (I) [220] (R, = NI-lEt) and (II) [325] (R2 = OMe, R 3 = H, R4 = OMe). 
(H 
1,4, , 6~111, 
Yield = 44% (white solid): mp 226-228 °C; anal. RP-HPLC: tR 15.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.17 (t, J = 7.0 Hz, 3H, CH 2CH3), 2.46 
(s, 3H, CH3), 3.22— 3.26 (m, 2H, CH2CH3), 3.75 (s, 6H, CH3), 6.10 (dd, JA = JB = 2.0 
Hz, III, phe-H), 6.91 (d, J= 5.5 Hz, IH, pyr-H), 7.07 (d, J= 2.0 Hz, 2H, phe-H), 8.14 
245 
(t, J = 5.5 Hz, IH, NH), 8.33 (d, J = 5.5 Hz, IH, pyr-H), 9.36 (bs, 1H, NH); ' 3C NMR 
(DMSO-d6): ö 14.92, 19.38, 55.83, 94.38, 97.64, 107.58, 118.21, 143.5, 153.03, 
158.25, 159.25, 160.13, 161.12, 169.13; HRMS (FAB+) m/z calcd for C 1 81-12 1 N502S 
372.14942, obsd 372.14895. 
N- 1 ,3-Benzodioxol-5-yl- 4-[2-(ethylamino) -4-methyl-1 ,3-thiazol-5-yI]pyrimidin-2-
amine (III) [117] 




LNN 1 )O 
Yield = 38% (brown solid): mp 194-195 °C; anal. RP-HPLC: tR 13.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 5 1.17 (t, J = 7.5 Hz, 3H, CH2CH3), 2.45 
(s, 3H, CH3), 3.24 - 3.28 (m, 2H, CH2CH3), 5.96 (s, 2H, CH2), 6.81 (d, J = 8.5 Hz, 
IH, phe-H), 6.85 (d, J = 5.0 Hz, IH, pyr-H), 7.19 (dd, J = 2.0 and 8.5 Hz, IH, phe-H), 
7.54 (d, J = 2.0 Hz, IH, phe-H), 8.10 (t, J = 5.0 Hz, 1H, NH), 8.29 (d, J = 5.0 Hz, IH, 
pyr-H), 9.30 (bs, 1H, NH); ' 3C NMR (DMSO-d6): ö 14.96, 19.34, 101.33, 101.86, 
107.23, 108.54, 112.12, 118.26, 135.92, 142.14, 147.66, 152.83, 158.23, 159.27, 
160.15, 168.93; HRMS (FAB+) mlz calcd for C 17H 17N502S 356.11812, obsd 
356.11797. 
N-(2,3-Dihydro-1,4-benzodioxin-6-yI)-4- [2-(ethylamino) -4-methyl -  1,3-thiazol-5-
yl]pyrimidin -2-amine (III) [118] 




(N ° rY 
Yield = 38% (yellow solid): mp 220-221 °C; anal. RP-HPLC: tR 13.8 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.17 (t, J = 7.0 Hz, 311, CH2CH3), 2.45 
246 
(s, 3H, Cl-I3), 3.24— 3.30 (m, 2H, CH2CH3), 4.20-4.21 (m, 411, CH2), 6.74 (d, J = 9.0 
Hz, 1H, phe-H), 6.84 (d, J = 5.5 Hz, IH, pyr-H), 7.15 (dd, J = 2.5 and 9.0 Hz, 1H, 
phe-H), 7.43 (d, J = 2.5 Hz, 1H, phe-H), 8.05 (t, J = 5.0 Hz, IH, NH), 8.28 (d, J = 5.5 
Hz, IH, pyr-H), 9.21 (bs, 1H, NH); ' 3C NMR (DMSO-d6): 8 14.97, 19.35, 64.61, 
64.94, 107.21, 108.56, 112.92, 117.13, 118.30, 135.11, 138.62, 143.55, 152.74, 
158.20, 159.30, 160.16, 168.99; HRMS (FAB+) m/z calcd for C 1 8H 1 9N5020 
370.13377, obsd 370.13366. 
4-[4-Methyl-2-(methylamino)-1,3-thiazol-5-yl] -N-(4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [119] 









Yield = 23% (yellow solid): mp >300 °C; anal. RP-HPLC: tR 7.8 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.46 (s, 3H, CH3), 2.86 (d, J = 4.5 Hz, 
3H, CH3), 3.02 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.73 (dd, JA = JB = 4.5 Hz, 4H, 
morph-H), 6.82 (d, J = 5.5 Hz, 1H, pyr-H), 6.88 (d, J = 9.0 Hz, 211, phe-H), 7.61 (d, J 
= 9.0 Hz, 2H, phe-H), 7.99 (q, J = 4.5 Hz, 1H, NH), 8.27 (d, J = 5.5 Hz, IH, pyr-H), 
9.17 (bs, 1H, NH); ' 3C NMR (DMSO-d6): 5 19.32, 31.43, 50.03, 66.89, 106.85, 
116.27, 118.69, 120.78, 133.83, 146.65, 152.70, 158.25, 159.28, 160.30, 169.88; 
HRMS (FAB+) mlz calcd for C 19H22N60S 383.16541, obsd 383.16502. 
247 
(4-Methyl-5-{2-[(4-morpholin-4-ylphenyl)amino]pyrimidin-4-yI }-1,3-thiazol-2-
yI)methanol (III) [120] 





Yield = 25% (brown solid): mp 181-182 °C; anal. RP-HPLC: tR 11.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.63 (s, 3H, CH3), 3.04 (dd, JA = JB = 
4.5 Hz, 4H, morph-H), 3.73 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 4.70 (d, J = 6.0 Hz, 
2H, CH2), 6.13 (t, J = 6.0 Hz, IH, OH), 6.90 (d, J = 9.0 Hz, 2H, phe-H), 7.02 (d, J = 
5.0 Hz, IH, pyr-H), 7.62 (d, J = 9.0 Hz, 2H, phe-H), 8.46 (d, J = 5.0 Hz, IH, pyr-H), 
9.41 (bs, IH, NH); ' 3C NMR (DMSO-d6): 8 18.75, 49.93, 61.77, 66.88, 108.55, 
116.23, 121.01, 131.40, 133.36, 146.97, 152.59, 158.75, 159.66, 160.54, 175.19; 
HRMS (FAB+) m/z calcd for C 1 9H2 1 N502S 384.14942, obsd 384.14970. 
N44- [4.Methyl -2- (2-thienyi)-1 ,3-thiazol-5-yl] -4- (4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [121] 




Yield = 62% (yellow solid): mp 247-249 °C; anal. RP-HPLC: tR 16.7 mm (20-70% 
MeCN, purity 100%); 'H NMR (DMSO): ö 2.68 (s, 3H, CH3), 3.05 (dd, JA = JB = 4.5 
Hz, 4H, morph-H), 3.74 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 6.94 (d, J = 9.0 Hz, 2H, 
phe-H), 7.08 (d, J = 5.5 Hz, IH, pyr-H), 7.21 (dd, JA = JB = 4.0 Hz, IH, thio-H), 7.63 
(d, J = 9.0 Hz, 2H, phe-H), 7.76 (d, J = 4.0 Hz, 1H, thio-H), 7.79 (d, J = 4.0 Hz, IH, 
thio-H), 8.49 (d, J= 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 5 18.74, 49.95, 66.88, 
108.31, 116.32, 121.01, 128.95, 129.44, 130.57, 131.95, 133.31, 137.01, 147.00, 
153.58, 158.04, 159.81, 160.48, 161.24; HRMS (FAB+) m/z calcd for C22H2 1 N50S2 
436.12658, obsd 436.126 10. 
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N-(2',4-Dimethyl-2,4'-bi-1,3-thiazol-5-yI)-4-(4-morpholin-4-ylphenyl)pyrimidifl-
2-amine (III) [122] 




Yield = 23% (yellow solid): mp 262-263 °C; anal. RP-HPLC: tR 13.8 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 5 2.72 (s, 3H, CH3), 2.75 (s, 3H, CH3), 
3.06 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.74 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
6.92 (d, J = 9.0 Hz, 2H, phe-H), 7.09 (d, J = 5.0 Hz, 1H, pyr-H), 7.62 (d, J = 9.0 Hz, 
2H, phe-H), 8.17 (s, 1H, thiaz-H), 8.49 (d, J= 5.0 Hz, 1H, pyr-H), 9.44 (bs, IH, NH); 
' 3C NMR (DMSO-d6): ö 18.89, 19.52, 49.92, 66.88, 108.70, 116.27, 118.58, 121.07, 
132.41, 133.30, 147.03, 148.34, 154.07, 158.48, 159.76, 160.56, 162.07, 168.04; 
HRMS (FAB+) m/z calcd for C 22H22N60S 2 451.13748, obsd 451.13748. 
N-(4-{4-Methyl-2-[(2-thienylsulfonyl)methyl]- 1,3-thiazol-5-yl}-4-(4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [123] 





Yield = 12% (orange solid): mp 187-189 °C; anal. RP-HPLC: tR 15.5 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.60 (s, 3H, CH3), 3.05 (dd, JA = J8 = 
4.5 Hz, 4H, morph-H), 3.75 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 5.30 (s, 2H, CH2), 
6.90 (d, J = 9.0 Hz, 2H, phe-H), 7.05 (d, J = 5.0 Hz, IH, pyr-H), 7.28 (dd, JA = JB = 
4.5 Hz, lH, thio-H), 7.59 (d, J = 9.0 Hz, 2H, phe-H), 7.76 (d, J = 4.5 Hz, lH, thio-H), 
8.12 (d, J = 4.5 Hz, 1H, thio-H), 8.49 (d, J = 5.0 Hz, 1H, pyr-H), 9.48 (bs, IH, NH); 
' 3C NMR (DMSO-d6): 8 18.46, 49.93, 60.43, 66.95, 108.51, 110.93, 116.24, 129.12, 
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133.21, 135.34, 134.89, 136.16, 136.95, 139.13, 152.71, 156.98, 158.00, 160.00, 
160.52; HRMS (FAB+)m/z calcd for C23H23N503S3 514. 10413, obsd 5 14.10441. 
N-[4-(4-Methyl-2-pyridin-3-yI-1,3-thiazol-5-yl)-4-(4-morpholin-4-
ylphenyl)]pyrimidin-2-amine (III) [124] 
From (I) [224] (R I = 3-pyrid) and (H) [320] (R2 = H, R3 = morph, R 4 = H). 
N= 
N0('U N  
N 1,1,:~  N 
 or 
Yield = 47% (yellow solid): mp 240-242 °C; anal. RP-HPLC: tR 13.5 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.75 (s, 3H, CH3), 3.05 (dd, JA = JB = 
4.5 Hz, 4H, morph-H), 3.74 (dd, JA = JB = 4.5 Hz, 4H, morph-H'), 6.95 (d, J = 9.0 Hz, 
2H, phe-H), 7.11 (d, J = 5.0 Hz, IH, pyr-H), 7.57 (dd, J = 5.0 and 8.0 Hz, 1H, pyrid-
H), 7.65 (d, J = 9.0 Hz, 2H, phe-H), 8.35 (dd, J = 1.5 and 8.0 Hz, IH, pyrid-H), 8.52 
(d, J= 5.0 Hz, IH, pyr-H), 8.71 (dd, J= 1.5 and 5.0 Hz, Ill, pyrid-H), 9.17 (dd, JA = 
JB = 1.5 Hz, IH, pyrid-H); ' 3C NMR (DMSO-d6): 8 18.86, 49.95, 66.88, 108.52, 
116.34, 121.01, 125.02, 129.38, 133.27, 134.37, 134.39, 147.03, 147.66, 152.00, 
154.08, 157.99, 159.94, 160.52, 164.17; HRMS (FAB+) in/z calcd for C23H22N60S 
431.16541, obsd430.17120. 
N-{ 4- [2- (2-Ethylpyridin-4-yI)-4-methyl-1 ,3-thiazol-5-yl] -4- (4-morpholin-4-
ylphenyl)}pyrimidin-2-amine (III) [125] 





Yield = 18% (yellow solid): mp 214-215 °C; anal. RP-HPLC: tR 11.2 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.77 (t, J = 7.5 Hz, 3H, CH2CH3), 3.25 
(s, 3H, CH3), 3.35 (q, J = 7.5 Hz, 2H, CH2CH3), 3.54 (dd, JA = JB = 5.0 Hz, 4H, 
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morph-H), 4.23 (dd, .JA = JB = 5.0 Hz, 4H, morph-H), 7.44 (d, J = 9.0 Hz, 2H, phe-H), 
7.61 (d, J = 5.5 Hz, 1H, pyr-H), 8.12 (d, J = 9.0 Hz, 2H, phe-H), 8.21 (dd, J = 1.5 and 
5.0 Hz, 1H, pyrid-H), 8.27 (d, J = 1.5 Hz, IH, pyrid-H), 9.02 (d, J = 5.5 Hz, IH, pyr-
H), 9.12 (d, J = 5.0 Hz, 1H, pyrid-J-I); ' 3C NMR (DMSO-d6): ö 14.33, 18.85, 31.25, 
49.93, 66.88, 108.69, 116.33, 118.32, 118.66, 121.08, 133.22, 134.46, 134.46, 140.23, 
147.06, 150.95, 154.26, 160.55, 164.74, 164.91; HRMS (FAB+) m/z calcd for 
C25H26N60S 459.1967 1, obsd 458.18581. 
N- {4- [4-Methyl -2- (6-methylpyridin -3-yl)-1 ,3-thiazol-5-yI] -4- (4-morpholin-4-
ylphenyl)}-pyrimidin-2-amine (III) [126] 




Yield = 77% (yellow solid): mp 244-245 °C; anal. RP-HPLC: tR 13.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.55 (s, 3H, CH3), 2.74 (s, 3H, CH3 ), 
3.05 (dd, JA = J8 = 4.5 Hz, 4H, morph-H), 3.74 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
6.95 (d, J = 9.0 Hz, 2H, phe-H), 7.10 (d, J = 5.5 Hz, IH, pyr-H), 7.42 (d, J = 8.0 Hz, 
1H, pyrid-H), 7.64 (d, J = 9.0 Hz, 2H, phe-H), 8.23 (dd, J = 2.5 and 8.0 Hz, IH, 
pyrid-H), 8.51 (d, J= 5.5 Hz, 1H, pyr-H), 9.04 (d, J= 2.5 Hz, IH, pyrid-H), 9.49 (bs, 
IH, NH); ' 3C NMR (DMSO-d6): ö 18.87, 24.75, 49.95, 66.88, 108.47, 116.32, 
121.02, 124.29, 126.83, 133.02, 134.56, 134.58, 147.01, 153.97, 158.06, 159.88, 
160.52, 161.02, 164.49; HRMS (FAB+) m/z calcd for C 24H24N60S 444.18 106, obsd 
444.17611. 
251 
N-{4-Methyl- 2-[methyl(pyridin -3-yl)amino]-1 ,3-thiazol -5-yl} -4- (4-morpholin-4-
ylphenyl)pyrimidin-2-ainine (III) [127] 
From (I) [228] (R, = N(Me)-3-pyrid) and (II) [320] (R2 = H, R3 = morph, R4 = H). 
QN 
ro 
Yield = 12% (yellow solid): mp 194-195 °C; anal. RP-HPLC: tR 11.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.51 (s, 3H, CH3), 3.01 (dd, JA = JB = 
4.5 Hz, 4H, morph-H), 3.52 (s, 311, CH3), 3.74 (dd, JA = JB = 4.5 Hz, 411, morph-H), 
6.82 (d, J = 9.0 Hz, 2H, phe-H), 6.89 (d, J = 5.5 Hz, IH, pyr-H), 7.53 - 7.56 (m, 311, 2 
x phe-H and pyrid-H), 8.01 (dd, J = 2.5 and 8.0 Hz, 1H, pyrid-H), 8.32 (d, J = 5.5 Hz, 
1H, pyr-H), 8.53 (dd, J = 2.5 and 5.0 Hz, 1H, pyrid-H), 8.80 (dd, JA = JB = 2.5 Hz, 
IH, pyrid-H), 9.21 (bs, IH, NH); ' 3C NMR (DMSO-d6): 6 19.16, 49.95, 66.88, 
107.01, 116.15, 121.00, 121.83, 125.03, 133.45, 142.43, 146.77, 147.49, 148.05, 
148.65, 152.09, 158.72, 158.77, 160.27, 168.97; HRMS (FAB+) m/z calcd for 
C24H25N70S 460.19196, obsd 460.19195. 
N-(4- {4-Methyl-2-[methyl(pyridin-2-yi)amino]- 1,3-thiazol-5-yIJ-4-(4-morpholin-
4-ylphenyl)pyrimidin-2-amine (III) [128] 
From (I) [227] (R 1 = N(Me)-2-pyrid) and (II) [320] (R2 = H, R 3 = morph, R4 = H). 
N 
ro 
Yield = 4% (orange solid): mp 183-185 °C; anal. RP-HPLC: tR 15.8 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.61 (s, 3H, CH3), 3.11 (bs, 4H, 
morph-H), 3.78 (dd, JA = JB = 4.5 Hz, 411, morph-H), 3.80 (s, 3H, CH3), 6.95 - 6.99 
(m, 3H, 2 x phe-H and pyr-H), 7.16 (dd, J= 6.0 and 8.0 Hz, IH, pyrid-H), 7.38 (d, J = 
8.0 Hz, 1H, pyrid-H), 7.65 - 7.68 (m, 2H, phe-H), 7.92 (dd, JA = JB = 6.0 Hz, IH, 
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pyrid-H), 8.35 (d, J = 6.0 Hz, 1H, pyrid-H), 8.46 (d, J = 5.5 Hz, 1H, pyr-H), 9.42 (bs, 
IH, NH); HRMS (FAB+) m/z calcd for C2 4H25N70S 460.19196, obsd 460.19219. 
N-(4-{2-[(4-Chlorophenyl)(methyl)amino] -4-methyl -1 ,3-thiazol -5-yI }-4-(4-
morpholin-4-ylphenyl)pyrimidin-2-amine (III) [129] 





Yield = 51 % (yellow solid): mp 245-246 °C; anal. RP-HPLC: tR 16.8 mm (20-70% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 8 2.50 (s, 3H, CH3), 3.02 (dd, JA = JR = 
5.0 Hz, 411, morph-H), 3.48 (s, 3H, CH3), 3.75 (dd, JA = JR = 5.0 Hz, 4H, morph-H), 
6.79 (d, J = 9.0 Hz, 211, phe-H), 6.82 (d, J = 5.5 Hz, IH, pyr-H), 7.53 (d, J = 9.0 Hz, 
2H, phe-H), 7.58 (s, 4H, phe-H), 8.30 (d, J = 5.5 Hz, 1H, pyr-H), 9.20 (bs, IH, NH); 
' 3C NMR (DMSO-d6): 8 19.16, 49.96, 66.89, 106.78, 116.06, 120.95, 121.52, 128.00, 
130.43, 131.71, 133.56, 144.92, 146.70, 152.08, 158.70, 160.18, 169.13; HRMS 
(FAB+) mlz calcd for C 25H25C1N60S 493.15774, obsd 493.15745. 
253 
N-{ 2- [(3 ,5-Dichlorophenyl)(methyl)amino] -4-methyl -1 ,3-thiazol-5-yI }-4-(4-
morpholin-4-ylphenyl)pyrimidin-2-amine (Ifl) [130] 




Yield = 51% (yellow solid): mp 216-218 °C; anal. RP-HPLC: tR 18.8 mm (20-70% 
MeCN, purity 100%); 1 H NMR (DMSO-d6): 6 2.52 (s, 3H, CH3), 3.02 (dd, JA = JB = 
5.0 Hz, 4H, morph-H), 3.51 (s, 3H, CH3), 3.74 (dd, JA = JB = 5.0 Hz, 4H, morph-H), 
6.84 (d, J = 9.0 Hz, 2H, phe-H), 6.91 (d, J = 5.0 Hz, 1H, pyr-H), 7.56 - 7.58 (m, 3H, 
phe-H), 7.72 (d, J = 2.0 Hz, 2H, phe-H), 8.34 (d, J = 5.0 Hz, IH, pyr-H), 9.26 (bs, IH, 
NH); ' 3C NMR (DMSO-d6): 6 19.17, 50.02, 66.87, 107.04, 116.19, 120.88, 122.22, 
124.14, 126.37, 133.56, 135.31, 146.77, 147.80, 151.77, 158.61, 160.24, 168.05; 
HRMS (FAB+) m/z calcd for C 25H24C12N60S 527.11876, obsd 527.11932. 
4-{ [4-(4-Methyl-2-pyridin-3-yI-1,3-thiazol-5-yl)pyrimidin-2-yl]amino}-N-(2-
methoxyethyl)benzenesulfonamide (III) [131] 








Yield = 26% (light brown solid): mp 252-254 °C; anal. RP-HPLC: tR 16.5 mm (0-
60% MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.79 (s, 3H, CH3 ), 2.90 (dt, J = 
6.0 Hz, 2H, CH2), 3.17 (s, 3H, CH3), 3.29 - 3.31 (m, 2H, CH2), 7.32 (d, J = 5.5 Hz, 
1H, pyr-H), 7.51 (t, J = 6.0 Hz, 1H, NH), 7.59 (dd, J = 5.0 and 8.0 Hz, 1H, pyrid-H), 
7.78 (d, J = 9.0 Hz, 2H, phe-H), 8.01 (d, J = 9.0 Hz, 2H, phe-H), 8.38 (dd, J = 2.0 and 
254 
8.0 Hz, IH, pyrid-H), 8.67 (d, J = 5.5 Hz, IH, pyr-H), 8.72 (dd, J = 2.0 and 5.0 Hz, 
IH, pyrid-H), 9.21 (dd, JA = J8 = 2.0 Hz, IH, pyrid-H); ' 3C NMR (DMSO-d6): 
18.92, 42.83, 58.58, 71.26, 110.23, 118.82, 125.00, 128.32, 129.29, 133.17, 134.40, 
144.55, 147.72, 152.09, 154.58, 158.14, 159.97, 160.15, 164.57; HRMS (FAB+) mlz 
calcd for C 22H22N603S2 483.1273 1, obsd 483. 12738. 
N-(4-{ [4-(4-Methyl-2-pyridin-3-yl-1,3-thiazol-5-yI)pyrimidin-2-
yl]amino}benzyl)acetamide (III) [132] 
From (I) [224] (R, = 3-pyrid) and (lU) [292] (R2 = H, R3 = CH 2NHCOCH3, R4 = H). 
('LN 
H 
Yield = 45% (orange solid): mp 199-201 °C; anal. RP-HPLC: tR 14.3 mm (0-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.87 (s, 3H, CH3), 2.76 (s, 3H, CH3), 
4.21 (d, J = 6.0 Hz, 2H, CH2), 7.18 (d, J = 5.0 Hz, 1H, pyr-H), 7.23 (d, J = 9.0 Hz, 
2H, phe-H), 7.57 (dd, J = 5.0 and 8.0 Hz, IH, pyrid-H), 7.74 (d, J = 9.0 Hz, 2H, phe-
11), 8.27 (t, J = 6.0 Hz, 1H, NH), 8.34 (dd, J = 2.0 and 8.0 Hz, 1H, pyrid-H), 8.56 (d, J 
= 5.0 Hz, 1H, pyr-H), 8.71 (dd, J = 2.0 and 5.0 Hz, IH, pyrid-H), 9.17 (dd, JA = JB = 
2.0 Hz, 114, pyrid-H); ' 3C NMR (DMSO-d6): 6 18.88, 23.31, 42.55, 109.14, 119.67, 
125.03, 128.41, 129.35, 133.41, 134.37, 139.61, 147.65, 152.04, 154.24, 158.03, 
160.03, 164.31, 169.71; HRMS (FAB+) m/z calcd for C 22H20N60S 417.14976, obsd 
417. 15021. 
255 
N-(3- { [4-(4-Methyl-2-pyridin-3-yl- 1,3-thiazol-5-yI)pyrimidin-2- 
yI]amino}benzyl)acetamide (III) [133] 
From (I) [224] (R, = 3-pyrid) and (Ell) [291] (R2 = R3 = H, R4 = CH 2NHCOCH3). 
0 
N=( -es 
zztl- 	NY N N C)" 
H 0 
Yield = 44% (yellow solid): mp 209-211 °C; anal. RP-HPLC: tR 14.3 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 5 1.85 (s, 3H, CH3), 2.77 (s, 314, CH3), 
4.28 (d, J = 6.0 Hz, 2H, CH2), 6.89 (dd, J = 1.0 and 8.0 Hz, lH, phe-H), 7.20 (d, J = 
5.0 Hz, IH, pyr-H), 7.28 (dd, JA = JB = 8.0 Hz, lH, phe-H), 7.57 (dd, J = 4.5 and 8.0 
Hz, lH, pyrid-H), 7.73 (dd, J = 1.0 and 8.0 Hz, IH, phe-H), 7.76 (dd, JA = JB = 1.0 
Hz, 1H, phe-H), 8.33 (t, J = 6.0 Hz, IH, NH), 8.38 (dd, J = 2.0 and 8.0 Hz, lH, pyrid-
H), 8.58 (d, J = 5.0 Hz, IH, pyr-H), 8.70 (dd, J = 2.0 and 4.5 Hz, 1H, pyrid-H), 9.19 
(dd, JA = JB = 2.0 Hz, 1H, pyrid-H); ' 3C NMR (DMSO-d6): 8 18.90, 23.27, 43.15, 
109.20, 118.37, 118.77, 121.47, 125.01, 129.19, 129.35, 133.53, 134.42, 140.54, 
140.89, 147.67, 152.02, 154.26, 157.99, 160.09, 160.42, 164.39, 169.75; HRMS 
(FAB+) nilz calcd for C 221420N60S 417.14976, obsd 417. 14970. 
N-[3-(Aminomethyl)phenyl] -4- (4-methyl-2-pyridin-3-yl-  1,3-thiazol-5-
yI)pyrimidin-2-amine (III) [134] 
From (III) [133] (R i = 3-pyrid, R2 = R3 = H, R4 = CH2NH2). 
IN 
N---p 
N NH 2 
Compound (III) [133] (0.03 g, 0.007 mmol) was solubilised in a 4:1 solution of 
HCIJMeOH (5 mL) and the RM heated to approx. 125 °C for 16 - 20 h. Progress of 
the reaction was monitored using HPLC and when no remaining starting material was 
detected the RM was cooled. The resultant precipitate was collected by suction 
filtration, washed with MeOH (3 x 5 mL), Et20 (5 mL) and recrystallised (1:1 
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MeOHJDCM) to give the deacetylated product (HI) [134] as a yellow solid (0.017 g, 
63%): mp 211-213 °C; anal. RP-HPLC: tR 12.2 mm (10-70% MeCN, purity 100%); 
'H NMR (DMSO-d6): 6 2.79 (s, 3H, CH3), 4.02 (t, J = 6.0 Hz, 2H, CH2), 7.16 (dd, J = 
2.0 and 8.0 Hz, 1H, phe-R), 7.26 (d, J = 5.0 Hz, 1H, pyr-H), 7.40 (dd, JA = JB = 8.0 
Hz, 1H, phe-H'), 7.73 (dd, J = 2.0 and 8.0 Hz, 1H, phe-H), 7.79 (dd, J = 6.0 and 8.0 
Hz, IH, pyrid-H), 7.93 (dd, JA = JB = 2.0 Hz, 1H, phe-H), 8.46 (bs, 2H, NH2), 8.59 
(dd, J = 2.0 and 8.0 Hz, 1H, pyrid-H), 8.62 (d, J = 5.0 Hz, 1H, pyr-H), 8.80 (dd, J = 
2.0 and 6.0 Hz, IH, pyrid-H), 9.27 (dd, JA = JB = 2.0 Hz, lH, pyrid-H); ' 3C NMR 
(DMSO-d6): 6 18.89, 43.33, 109.46, 119.96, 120.38, 122.80, 126.87, 129.68, 130.69, 
134.56, 135.06, 138.59, 140.96, 145.53, 147.79, 154.63, 157.94, 160.04, 160.11, 
162.71; HRMS (FAB+) m/z calcd for C22H18N6S 375.13919, obsd 375.13911. 
N- [4-(4-Methyl -2-pyridin-3-yl-  1,3-thiazol-5-yl)-4-(3,4,5-
trimethoxyphenyl)]pyrimidin-2-amine (III) [135] 






Yield = 58% (brown solid): mp 210-211  °C; anal. RP-HPLC: tR 12.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.76 (s, 3H, CH3), 3.64 (s, 3H, CH3), 
3.83 (s, 6H, CH3), 7.20 (d, J = 5.0 Hz, IH, pyr-H), 7.22 (s, 2H, phe-H), 7.58 (dd, J = 
5.0 and 8.0 Hz, IH, pyrid-H), 8.28 (dd, J = 2.0 and 8.0 Hz, IH, pyrid-H), 8.58 (d, J = 
5.0 Hz, IH, pyr-H), 8.71 (dd, J = 2.0 and 5.0 Hz, IH, pyrid-H), 9.11 (dd, JA = JB = 2.0 
Hz, 1H, pyrid-H); ' 3C NMR (DMSO-d6): 6 19.51, 56.48, 60.82, 97.49, 108.98, 
125.08, 129.32, 133.10, 133.44, 134.17, 137.04, 152.02, 153.39, 154.08, 154.19, 
157.80, 160.02, 160.29, 164.17; HRMS (FAB+) m/z calcd for C22H2 1 N503S 
436.14434, obsd 436.14456. 
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N-[4-(4-Methyl-2-pyridin-3-yI-1,3-thiazol-5-yI)-4-(3,5-
dimethoxyphenyl)]pyrimidin -2-amine (HI) [136] 
From (I) [224] (RI = 3-pyrid) and (H) [325] (R2 = OMe, R3 = H, R4 = OMe). 
N= 
0 
Yield = 54% (brown solid): mp 229-230 °C; anal. RP-HPLC: tR 17.8 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.77 (s, 3H, CH3), 3.77 (s, 6H, CH3), 
6.16 (dd, .JA = JB = 2.0 Hz, 1H, phe-H), 7.12 (d, J = 2.0 Hz, 2H, phe-H), 7.22 (d, J = 
5.5 Hz, 1H, pyr-H), 7.58 (dd, J = 5.0 and 8.0 Hz, 1H, pyrid-H), 8.29 (dd, J = 2.0 and 
8.0 Hz, 1H, pyrid-H), 8.60 (d, J = 5.5 Hz, 1H, pyr-H), 8.71 (dd, J = 2.0 and 5.0 Hz, 
1H, pyrid-H), 9.12 (dd, 1A = JB = 2.0 Hz, 1H, pyrid-f1); ' 3C NMR (DMSO-d6): 6 
18.86, 55.81, 94.76, 97.91, 109.31, 125.09, 129.35, 133.36, 134.25, 142.63, 147.54, 
152.07, 154.29, 157.93, 160.07, 160.34, 161.17, 164.27; HRMS (FAB+) ni/z calcd for 
C21 H 19N502S 406.13377, obsd 406.13367. 
N-(4-Methoxy-3-methylphenyl)-4-(4-methyl-2-pyridin-3-yI- 1,3-thiazol-5-
yI)pyrimidin-2-amine (III) [137] 




Yield = 43% (yellow solid): mp 169-170 °C; anal. RP-HPLC: tR 17.5 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.18 (s, 3H, CH3), 2.75 (s, 3H, CH3), 
3.77 (s, 3H, OCH3), 6.91 (d, J = 8.0 Hz, IH, phe-H), 7.11 (d, J = 5.0 Hz, IH, pyr-H), 
7.52 - 7.58 (m, 3H, 2 x phe-H and 1 x pyrid-H), 8.32 (dd, J = 2.0 and 8.0 Hz, IH, 
pyrid-H), 8.52 (d, J = 5.0 Hz, 1H, pyr-H), 8.70 (dd, J = 2.0 and 4.5 Hz, IH, pyrid-H), 
9.15 (dd, JA = JB = 2.0 Hz, IH, pyrid-H), 9.47 (bs, IH, NH); ' 3C NMR (DMSO-d6): 6 
16.99, 18.85, 56.08, 108.50, 111.07, 118.61, 122.98, 125.03, 129.38, 133.56, 133.66, 
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134.25, 147.58, 151.99, 153.27, 154.09, 157.88, 159.97, 160.53, 164.11; HRMS 
(FAB+) m/z calcd for C 21 11 1 9N50S 390.13886, obsd 390.13883. 
N-[4-(4-Methyl-2-pyridin-3-yI-1,3-thiazol-5-yl)-4-(3-chloro-4-morpholin-4-
ylphenyl)]pyrimidin-2-amine (III) [138] 




I NNO CI 
H 
Yield = 44% (yellow solid): mp 230-231 °C; anal. RP-HPLC: tR 18.7 mm (20-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.77 (s, 3H, CH3), 2.94 (dd, JA = JR = 
4.5 Hz, 4H, morph-H), 3.74 (dd, JA = JR = 4.5 Hz, 4H, morph-H), 7.18 (d, J = 9.0 Hz, 
IH, phe-H), 7.21 (d, J = 5.5 Hz, 1H, pyr-H), 7.59 (dd, J = 5.0 and 8.0 Hz, Ill, pyrid-
H), 7.64 (dd, J = 2.0 and 9.0 Hz, 1H, phe-H), 8.08 (d, J = 2.0 Hz, 1H, phe-H), 8.32 
(dd, J = 2.0 and 8.0 Hz, IH, pyrid-H), 8.59 (d, J = 5.5 Hz, 1H, pyr-H), 8.71 (dd, J = 
2.0 and 5.0 Hz, IH, pyrid-H), 9.16 (dd, JA = JR = 2.0 Hz, IH, pyrid-H); ' 3C NMR 
(DMSO-d6): 8 18.88, 52.35, 67.14, 109.26, 109.11, 121.20, 121.57, 125.06, 128.28, 
129.33, 133.49, 134.22, 134.83, 137.25, 143.50, 147.58, 151.47, 152.07, 152.66, 
154.36, 157.89, 160.07, 164.30; HRMS (FAB-i-) m/z calcd for C23H2 1 C1N60S 
465.12644, obsd 465.12671. 
N-[4-(4-Methyl-2-pyridin-3-yI-1,3-thiazol-5-yI)-4-(3,5-dichloro-4-morpholin-4- 
ylphenyl)]pyrimidin -2-amine (III) [139] 





Yield = 37% (pale brown solid): mp 211-213 °C; anal. RP-HPLC: tR 24.5 mm (20- 
70% MeCN, purity 100%); 'H NMR (DMSO-do): 5 2.77 (s, 3H, CH3), 3.11 (dd, JA = 
259 
JR = 4.5 Hz, 4H, morph-H), 3.70 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 7.27 (d, J = 5.0 
Hz, 1H, pyr-H), 7.59 (dd, J = 5.0 and 8.0 Hz, 1H, pyrid-H), 7.95 (s, 2H, phe-H), 8.28 
(dd, J = 2.0 and 8.0 Hz, IH, pyrid-H), 8.63 (d, J = 5.0 Hz, 1H, pyr-H), 8.71 (dd, J = 
2.0 and 5.0 Hz, IH, pyrid-H), 9.12 (dd, JA = JR = 2.0 Hz, 1H, pyrid-H); ' 3C NMR 
(DMSO-d6): 5 18.90, 50.22, 60.66, 67.74, 109.90, 119.35, 125.14, 129.26, 133.32, 
134.15, 135.04, 137.96, 139.62, 143.19, 152.12, 154.60, 159.68, 160.25, 164.37; 
HRMS (FAB+) mJz calcd for C 23H20C12N60S 499.08746, obsd 499.08730. 
N- [4-(4-Methyl-2.pyridin-3-yl-1 ,3-thiazol-5-yl)-4- (3-methoxy-4-morpholin-4-
ylphenyl)]pyrimidin -2-amine (III) [140] 




Yield = 19% (yellow solid): mp 212-214 °C; anal. RP-HPLC: tR 12.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.77 (s, 3H, CH3), 2.92 (dd, .1,, = JB = 
4.5 Hz, 4H, morph-H), 3.72 (dd, JA = JR = 4.5 Hz, 4H, morph-H), 3.84 (s, 3H, OCH3), 
6.88 (d, J = 8.5 Hz, 1H, phe-H), 7.17 (d, J = 5.0 Hz, I H, pyr-H), 7.31 (dd, J = 2.0 and 
8.5 Hz, IH, phe-H), 7.52 (d, J = 2.0 Hz, IH, phe-H), 7.58 (dd, J = 5.0 and 8.0 Hz, IH, 
pyrid-H), 8.32 (dd, J = 2.5 and 8.0 Hz, IH, pyrid-H), 8.56 (d, J = 5.0 Hz, IH, pyr-H), 
8.71 (dd, J = 2.5 and 5.0 Hz, 1H, pyrid-H), 9.15 (dd, JA = JB = 2.5 Hz, IH, pyrid-H); 
' 3C NMR (DMSO-d6): 8 18.87, 51.70, 56.08, 67.11, 104.76, 108.76, 111.89, 118.62, 
125.07, 129.35, 133.54, 134.30, 136.37, 147.58, 151.43, 152.03, 152.64, 154.13, 
157.92, 160.03, 160.40, 164.19; HRMS (FAB+) mlz calcd for C24H24N602S 
461.17597, obsd 461.17606. 
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N-[4-(4-Methyl-2-pyridin-3-yl-1,3-thiazol-5-yI)-4-(4-acetylpiperazin-1-
yl)phenyl]pyrimidin-2-amine (III) [141] 
From (I) [224] (R I = 3-pyrid) and (II) [321] (R2 = H, R3 = piperaz-Ac, R4 = H). 
CN 
(N 
(i NJZX N 
H 
Yield = 18% (orange solid): mp 123-125 °C; anal. RP-HPLC: tR 13.2 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.04 (s, 3H, CH3), 2.76 (s, 3H, CH3), 
3.03 (dd, JA = JB = 5.0 Hz, 2H, piperaz-H), 3.09 (dd, JA = JB = 5.0 Hz, 2H, piperaz-H), 
3.58 (dd, JA = JB = 5.0 Hz, 4H, piperaz-H), 6.98 (d, J = 9.0 Hz, 2H, phe-H), 7.13 (d, J 
= 5.0 Hz, 1H, pyr-H), 7.58 (dd, J = 5.0 and 8.0 Hz, IH, pyrid-H), 7.65 (d, J = 9.0 Hz, 
2H, phe-H), 8.35 (dd, J = 2.0 and 8.0 Hz, IH, pyrid-H), 8.53 (d, J = 5.0 Hz, 1H, pyr-
H), 8.71 (dd, J = 2.0 and 5.0 Hz, 1H, pyrid-H), 9.18 (dd, JA = JB = 2.0 Hz, IH, pyrid-
H); ' 3C NMR (DMSO-d6): 6 18.86, 21.90, 41.47, 46.30, 49.90, 50.31, 108.5 8, 117.28, 
120.98, 125.04, 129.38, 133.54, 133.63, 134.40, 146.77, 147.65, 152.02, 154.10, 
160.50, 164.18, 168.95; HRMS (FAB+) m/z calcd for C 25H25N70S 472.19196, obsd 
472. 19 199. 
N-[4-(4-Methyl-2-pyridin-3-yI-1,3-thiazol-5-yI)-4-(4-thiomorpholin-4-
ylphenyl)]pyrimidin-2.amine (III) [142] 




Yield = 15% (orange solid): mp 191-193 °C; anal. RP-HPLC: tR 13.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.70 (dd, JA = JB = 5.0 Hz, 4H, 
thiomorph-H), 2.76 (s, 3H, CH3 ), 3.42 (dd, JA = JB = 5.0 Hz, 4H, thiomorph-H), 6.94 
(d, J = 9.0 Hz, 2H, phe-H), 7.12 (d, J = 5.0 Hz, IH, pyr-H), 7.57 (dd, J = 4.5 and 8.0 
Hz, 1H, pyrid-H), 7.64 (d, J = 9.0 Hz, 2H, phe-H), 8.35 (dd, J = 2.5 and 8.0 Hz, 1H, 
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pyrid-I1), 8.52 (d, J = 5.0 Hz, 1H, pyr-H), 8.71 (dd, J = 2.5 and 4.5 Hz, IH, pyrid-H), 
9.18 (dd, JA = J8 = 2.5 Hz, 1H, pyrid-H); ' 3C NMR (DMSO-d6): ö 18.82, 26.75, 
52.67, 108.52, 117.94, 121.08, 124.98, 129.34, 133.23, 133.57, 134.33, 147.01, 
147.63, 151.97, 154.04, 157.96, 159.91, 160.48, 164.14; HRMS (FAB+) m/z calcd for 
C23H22N6S 2 447.14257, obsd 447.14252. 
N-[4-(4-Methyl-2-pyridin-3-yI-1,3-thiazol-5-yl)-4-(4-pyrrolidin-1-
ylphenyl)]pyrimidin-2-amine (III) [143] 







Yield = 39% (brown solid): mp 212-214 °C; anal. RP-HPLC: tR 12.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.93 (m, 4H, pyrrol-H), 2.74 (s, 3H, 
CH3), 3.20 (dd, JA = JB = 6.5 Hz, 4H, pyrrol-H), 6.54 (d, J = 9.0 Hz, 2H, phe-H), 7.05 
(d, J = 5.0 Hz, IH, pyr-H), 7.53 (d, J = 9.0 Hz, 2H, phe-H), 7.57 (dd, J = 4.5 and 8.0 
Hz, IH, pyrid-H), 8.33 (dd, J = 2.0 and 8.0 Hz, 1H, pyrid-H), 8.47 (d, J = 5.0 Hz, IH, 
pyr-H), 8.70 (dd, J = 2.0 and 4.5 Hz, li-I, pyrid-H), 9.16 (dd, JA = JB = 2.0 Hz, IH, 
pyrid-H), 9.30 (bs, IH, NH); ' 3C NMR (DMSO-d6): ö 18.84, 25.55, 48.30, 108.50, 
112.26, 122.04, 124.99, 129.40, 129.58, 133.71, 134.34, 144.53, 147.62, 151.94, 
153.93, 157.99, 159.86, 160.73, 164.03; HRMS (FAB+) m/z calcd for C 23H22N6S 
415.17049, obsd 415.17053. 
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N-[4-(4-Methyl-2.pyridin-3-yl-1,3-thiazol-5-yI)-4-(4-piperidin-1-
ylphenyl)]pyriniidin-2-amine (III) [144] 




Yield = 22% (orange solid): mp 165-166 °C; anal. RP-HPLC: tR 12.8 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): S 1.48- 1.54 (m, 2H, piperid-H), 1.60-
1.66 (m, 4H, piperid-H), 2.75 (s, 3H, CH3), 3.05 (dd, JA = JB = 5.0 Hz, 4H, piperid-H), 
6.93 (d, J = 9.0 Hz, 2H, phe-H), 7.10 (d, J = 5.0 Hz, 1H, pyr-H), 7.57 (dd, J = 4.5 and 
8.0 Hz, IH, pyrid-H), 7.60 (d, J = 9.0 Hz, 2H, phe-H), 8.36 (dd, J = 2.5 and 8.0 Hz, 
1H, pyrid-H), 8.51 (d, J = 5.0 Hz, IH, pyr-H), 8.70 (dd, J = 2.5 and 4.5 Hz, IH, pyrid-
H), 9.17 (dd, JA = JB = 2.5 Hz, IH, pyrid-H'), 9.46 (bs, 1H, NH); ' 3C NMR (DMSO-
d6): S 18.86, 24.58, 26.16, 51.17, 108.44, 117.20, 121.05, 125.02, 129.39, 132.74, 
133.64, 134.37, 147.66, 147.92, 151.99, 154.05, 157.99, 159.92, 160.55, 164.15; 
HRMS (FAB+) m/z calcd for C 24H24N6S 429.18614, obsd 429.18611. 
N-[4-(4-Methyl-2-pyridin-3-yI-1,3-thiazol-5-yI)-4-(3-methyl-4-piperidin-1-
ylphenyl)]pyrimidin-2-amine (III) [145] 
From (I) [224] (R, = 3-pyrid) and (lU) [3 10] (R2 = H, R 3 = piperid, R4 = Me). 
N= P  
I NNc 
H 
Yield = 44% (orange solid): mp 200-201 °C; anal. RP-HPLC: tR 13.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 5 1.51 - 1.52 (m, 2H, piperid-H), 1.62-
1.66 (m, 4H, piperid-H), 2.27 (s, 3H, CH3), 2.50 (s, 3H, CH3), 2.75 (dd, JA = .JB = 4.5 
Hz, 4H, piperid-H), 6.98 (d, J = 8.5 Hz, 1H, phe-H), 7.12 (d, J = 5.0 Hz, IH, pyr-H), 
7.50 (dd, J = 2.5 and 8.5 Hz, 1H, phe-R), 7.57 (dd, J = 5.0 and 8.0 Hz, IH, pyrid-H), 
7.63 (d, J = 2.5 Hz, 1H, phe-H), 8.32 (dd, J = 1.5 and 8.0 Hz, IH, pyrid-H), 8.52 (d, J 
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= 5.0 Hz, IH, pyr-H), 8.70 (dd, J = 1.5 and 5.0 Hz, 1H, pyrid-H), 9.15 (dd, JA = JR = 
1.5 Hz, 1H, pyrid-H); ' 3C NMR (DMSO-d6): ö 18.30, 18.86, 24.63, 26.95, 53.91, 
108.60, 118.11, 119.65, 122.48, 125.04, 129.38, 132.57, 133.70, 134.30, 135.78, 
147.59, 147.75, 152.00, 154.12, 157.88, 159.98, 160.46, 164.15; HRMS (FAB+) m/z 
calcd for C 25H26N6S 443.20 179, obsd 443.20176. 
N-1,3-Benzodioxol-5-yI-4-(4-methyl-2-pyridin-3-yI-1,3-thiazol-5-yI)pyrimidin-2-
amine (III) [146] 
From (I) [224] (R, = 3-pyrid) and (ifi) [314] (R 2 = H, R3 and R4 fused = OCH20). 
N- P IN 
I NNO0 
Yield = 52% (brown solid): mp 187-188 °C; anal. RP-HPLC: tR 16.0 mm (0-60% 
MeCN, purity 100%; 'H NMR (DMSO-d6): ö 2.75 (s, 3H, CH3), 5.98 (s, 2H, CH2), 
6.90 (d, J = 8.5 Hz, IH, phe-H), 7.15 (d, J = 5.0 Hz, IH, pyr-H), 7.21 (dd, J = 2.0 and 
8.5 Hz, 1H, phe-H), 7.46 (d, J= 2.0 Hz, IH, phe-R), 7.57 (dd, J= 4.5 and 8.0 Hz, IH, 
pyrid-H), 8.32 (dd, J = 2.0 and 8.0 Hz, lH, pyrid-H), 8.54 (d, J = 5.0 Hz, IH, pyr-H), 
8.70 (dd, J = 2.0 and 4.5 Hz, 1H, pyrid-H), 9.14 (dd, JA = JB = 2.0 Hz, 111, pyrid-R); 
' 3C NMR (DMSO-d6): 8 18.84, 101.48, 102.22, 108.66, 108.94, 112.62, 125.03, 
129.34, 133.43, 134.31, 135.34, 142.62, 147.61, 147.71, 152.03, 154.21, 158.00, 




yl)pyrimidin-2-amine (III) [147] 
From (I) [224] (R I = 3-pyrid) and (ifi) [315] (R2 = H, R3 and R4 = O(CH2)20). 
rN 	rY• ° 
Yield = 42% (yellow solid): mp 183-184 °C; anal. RP-HPLC: tR 16.2 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.81 (s, 3H, Cl-I3), 4.27 -4.31 (m, 4H, 
CH2), 6.86 (d, J = 9.0 Hz, 1H, phe-H), 6.98 - 7.01 (m, 2H, phe-H and pyr-H), 7.40 - 
7.44 (m, 2H, phe-H and pyrid-H), 8.31 (dd, J = 1.0 and 8.0 Hz, IH, pyrid-H), 8.41 (d, 
J = 5.5 Hz, 1H, pyr-H), 8.70 (dd, J = 1.0 and 5.0 Hz, IH, pyrid-H), 9.22 (dd, JA = JB = 
1.0 Hz, 1H, pyrid-I1); ' 3C NMR (DMSO-d6): 8 18.83, 64.64, 64.96, 108.88, 108.98, 
113.28, 117.30, 125.03, 129.36, 133.45, 134.30, 134.58, 139.06, 143.59, 147.61, 
152.01, 154.17, 158.01, 159.91, 160.39, 164.18; HRMS (FAB+) m/z calcd for 
C2 1 H 17N502S 404.11812, obsd 404.11822. 
N-(2',4-Dimethyl-2,4'-bi-1,3-thiazol-5-yi)-4-(3-chloro-4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [148] 





Yield = 31% (yellow solid): mp 228-229 °C; anal. RP-HPLC: tR 22.7 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.98 (s, 3H, CH3 ), 2.99 (s, 3H, CH3 ), 
3.18 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.99 (dd, JA = J8 = 4.5 Hz, 4H, morph-H), 
7.39 (d, J = 9.0 Hz, IH, phe-H), 7.42 (d, J = 5.0 Hz, IH, pyr-H), 7.88 (dd, J = 2.5 and 
9.0 Hz, 1H, phe-H), 8.30 (d, J = 2.5 Hz, IH, phe-H), 8.42 (s, IH, thiaz-H), 8.80 (d, J 
= 5.0 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): ö 18.92, 19.53, 52.35, 67.14, 109.54, 
118.67, 119.07, 121.16, 121.47, 128.33, 132.19, 137.33, 143.49, 148.27, 154.38, 
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158.52, 159.87, 160.12, 162.30, 168.01; HRMS (FAB+)mIzcalcd for C22H2iClN6OS2 
485.0985 1, obsd 485.09862. 
N-{2-[(3,5-Dichlorophenyl)(methyl)amino]-4-methyl- 1,3-thiazoi.5-yI }-4-(3-
chioro-4-morpholin-4-ylphenyl)pyrimidin-2-amine (III) [149] 
From (I) [231] (R, = N(Me)-3,5-dichlorophenyl) and (II) [323] (R2 = H, R 3 = morph, 
R4 = CD- 
:  
0 
Yield = 48% (yellow solid): mp 224-225 °C; anal. RP-HPLC: tR 22.7 mm (20-70% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 6 2.95 (s, 3H, CH3), 3.31 (dd, JA = JB = 
4.5 Hz, 4H, morph-H), 3.92 (s, 3H, CH3), 4.15 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
7.42 (d, J = 5.5 Hz, IH, pyr-H), 7.48 (d, J = 9.0 Hz, 1H, phe-H), 7.90 (dd, J = 2.5 and 
9.0 Hz, IH, phe-H), 7.98 (dd, JA = JB = 2.0 Hz, 1H, phe-H), 8.13 (d, J = 2.0 Hz, 2H, 
phe-H), 8.46 (d, J = 2.5 Hz, IH, phe-H), 8.81 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR 
(DMSO-d6): 6 19.24, 52.34, 67.11, 107.72, 118.90, 121.03, 121.23, 122.17, 124.54, 
126.66, 128.27, 135.40, 137.46, 143.18, 147.68, 152.29, 158.55, 158.96, 159.82, 
168.31; HRMS (FAB+) mlz calcd for C25H23C13N60S 561.07979, obsd 561.07954. 
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N-[4-Methyl-2-(4-morpholin-4-ylphenyl)- 1,3-thiazol-5-yl]- 4-(3-chloro-4-
morpholin-4-ylphenyl)pyrimidin-2-amine (III) [150] 
From (I) [237] (R I = 4-(morpholino)phenyl) and (H) [323] (R2 = H, R3 = morph, R4 = 
Cl). 
Yield = 44% (yellow solid): mp 231-232 °C; anal. RP-HPLC: tR 24.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.81 (s, 3H, CH3), 3.07 (dd, JA = JB = 
4.5 Hz, 411, morph-H), 3.31 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.88 - 3.92 (m, 8H, 
morph-H), 6.95 (d, J = 9.0 Hz, 2H, phe-H), 7.04 (d, J = 6.0 Hz, 1H, pyr-H), 7.07 (d, J 
= 8.5 Hz, IH, phe-H), 7.37 (dd, J = 2.0 and 8.5 Hz, IH, phe-H), 7.95 (d, J = 9.0 Hz, 
211, phe-H), 8.05 (d, J = 2.0 Hz, 1H, phe-H), 8.29 (d, J = 6.0 Hz, 1H, pyr-H); 13C 
NMR (DMSO-d6): 6 19.03, 47.90, 52.36, 66.60, 67.15, 109.00, 115.03, 115.10, 
119.07, 121.10, 121.53, 123.60, 128.05, 128.32, 130.55, 143.39, 153.31, 154.20, 
158.34, 160.04, 167.86; HRMS (FAB+) m/z calcd for C 281129C1N602S 549.18395, 
obsd 549.18324. 
N-(2' ,4-Dimethyl-2,4'-bi-1,3-thiazol-5-yI)-4-(3,5-dichloro-4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [151] 







Yield = 29% (yellow solid): mp >300 °C; anal. RP-HPLC: tR (10-70% MeCN, purity 
100%); 'H NMR (DMSO-d6): 6 2.75 (s, 3H, CH3), 2.76 (s, 3H, CH3), 3.12 (dd, JA = 
JB = 4.5 Hz, 4H, morph-H), 3.71 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 7.27 (d, J = 5.0 
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Hz, III, pyr-H), 7.96 (s, 2H, phe-H), 8.20 (s, III, thiaz-H), 8.62 (d, J = 5.0 Hz, IH, 
pyr-H); HRMS (FAB+) mlz calcd for C 22H20C1 2N60S2 5 19.05954, obsd 519.05959. 
N-{4-Methyl-2- [(2-phenylethyl)amino]- 1,3-thiazol-5-yI }-4..(3,4,5-
trimethoxyphenyl)pyrimidin-2-amine (III) [152] 




(N 	 01, 
N N,&O 
Yield = 23% (yellow solid): mp 174-175 °C; anal. RP-HPLC: tR 17.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.46 (s, 3H, CH3), 2.89 (t, J = 7.0 Hz, 
2H, CH2), 3.45 (dt, J = 5.5 and 7.0 Hz, 2H, CH2), 3.61 (s, 3H, CH3), 3.78 (s, 6H, 
CH3), 6.91 (d, J = 5.5 Hz, 1H, pyr-H), 7.16 (s, 2H, phe-H), 7.18 - 7.33 (m, 5H, phe-
H), 8.25 (t, J = 5.5 Hz, 1H, NH), 8.32 (d, J = 5.5 Hz, IH, pyr-H), 9.28 (bs, IH, NH); 
13 NMR (DMSO-d6): ö 19.41, 35.18, 56.61, 60.83, 97.25, 107.34, 118.47, 126.93, 
129.07, 129.39, 132.78, 137.45, 139.88, 152.86, 153.34, 158.36, 159.16, 160.12, 
169.00; HRMS (FAB+) m/z calcd for C 25H27N503S 478.19129, obsd 478.19 180. 
N-{4-Methyl -2- [(2-phenylethyl)amino] -1 ,3-thiazol -5-yI}-4- (3,5-
dimethoxyphenyl)pyrimidin-2-amine (III) [153] 




Yield = 7% (colourless solid): mp 201-202 °C; anal. RP-HPLC: tR 18.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.47 (s, 3H, CH3), 2.89 (t, J = 7.5 Hz, 
2H, CH2), 3.46 (dt, J = 5.0 and 7.5 Hz, 2H, CH2), 3.73 (s, 6H, CH3), 6.10 (dd, JA = JB 
= 2.0 Hz I H, phe-H), 6.92 (d, J = 5.5 Hz, I H, pyr-H), 7.06 (d, J = 2.0 Hz, 2H, phe-H), 
7.20— 7.33 (m, 5H, phe-H), 8.26 (t, J = 5.0 Hz, 1H, NH), 8.33 (d, J = 5.5 Hz, IH, pyr-
H), 9.36 (bs, 1H, NH); 13C NMR (DMSO-d6): ö 19.42, 35.21, 55.86, 94.38, 97.68, 
105.79, 107.65, 118.40, 126.93, 129.00, 129.40, 139.89, 143.01, 152.96, 158.37, 
159.23, 160.13, 161.12; HRMS (FAB+) mlz calcd for C24HN502S 448.18072, obsd 
448.18077. 
N- { 4-Methyl -2- [(2-phenylethyl)amino] -  1,3-thiazol-5-yI }-4-(4-morpholin.4-
ylphenyl)pyrimidin-2-amine (III) [154] 




Yield = 8% (yellow solid): mp 226-228 °C; anal. RP-HPLC: tR 14.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.46 (s, 3H, CH3 ), 2.88 (t, J = 7.5 Hz, 
2H, CH2), 3.02 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.47 - 3.51 (m, 2H, CH2), 3.73 
(dd, JA = J8 = 4.5 Hz, 4H, morph-H), 6.82 (d, J = 5.5 Hz, 1Ff, pyr-H), 6.87 (d, J = 9.0 
Hz, 2H, phe-H), 7.20-7.33 (m, 5H, phe-H), 7.61 (d, J = 9.0 Hz, 2H, phe-H), 8.18 (t, 
J = 5.0 Hz, IH, NH), 8.27 (d, J = 5.5 Hz, IH, pyr-H), 9.18 (bs, IH, NH); ' 3C NMR 
(DMSO-d6): 8 19.35, 35.26, 50.05, 66.89, 106.88, 116.26, 118.65, 120.75, 126.90, 
129.08, 129.39, 133.83, 139.92, 146.65, 152.55, 154.05, 158.26, 159.22, 160.29, 
168.89; HRMS (FAB+) mlz calcd for C 26H28N60S 473.21236, obsd 473.21209. 
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N-{4-Methyl-2. [(2-phenylethyl)amino]- 1,3-thiazol-5-yl}-4-(4-acetylpiperazin- 1-
yl)phenyl)pyrimidin-2-amine (III) [155] 







Yield = 7% (orange solid): mp 211-213 °C; anal. RP-HPLC: tR 14.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.04 (s, 3H, CH3), 2.46 (s, 3H, CH3), 
2.89 (t, J = 7.0 Hz, 2H, CH2), 2.99 (dd, .JA = JB = 4.5 Hz, 2H, piperaz-H), 3.06 (dd, JA 
= JB = 4.5 Hz, 2H, piperaz-H), 3.49 (dt, J = 5.0 and 7.0 Hz, 2H, CH2), 3.57 - 3.59 (m, 
4H, piperaz-H), 6.83 (d, J = 5.5 Hz, lH, pyr-H), 6.90 (d, J = 9.0 Hz, 2H, phe-H), 7.20 
- 7.33 (m, 511, phe-H), 7.62 (d, J = 9.0 Hz, 2H, phe-H), 8.19 (t, J = 5.0 Hz, 1H, Nil), 
8.27 (d, J = 5.5 Hz, lH, pyr-H), 9.20 (bs, IH, NH); ' 3C NMR (DMSO-d6): 6 19.4 1, 
35.18, 56.61, 60.83, 97.25, 107.34, 118.47, 126.93, 129.07, 129.39, 132.78, 137.45, 
139.88, 152.86, 153.34, 158.36, 159.16, 160.12, 169.00; HRMS (FAB+) in/z calcd for 
C28H3 1 N70S 514.23891, obsd 5 14.23896. 
N-{4-Methyl- 2- [(2-phenylethyl)amino] -1 ,3-thiazol-5-yl}-4- (4-benzylpiperazin-1-
yl)phenyl)pyrimidin-2-amine (III) [156] 





Yield = 20% (light brown solid): mp 191-192 °C; anal. RP-HPLC: tR 14.9 mm (0- 
60% MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.45 (s, 3H, CH3), 2.88 (t, J = 7.5 
Hz, 2H, CH2), 3.05 (dd, JA = JB = 5.0 Hz, 4H, piperaz-H), 3.30 - 3.33 (m, 4H, 
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piperaz-H), 3.48 (dt, J = 5.5 and 7.5 Hz, 2H, CH2), 3.52 (s, 2H, CH2), 6.81 (d, J = 5.5 
Hz, IH, pyr-H), 6.85 (d, J = 9.0 Hz, 2H, phe-H), 7.18 - 7.34 (m, IOH, phe-H), 7.58 
(d, J = 9.0 Hz, 2H, phe-H), 8.18 (t, J = 5.5 Hz, 1H, NH), 8.26 (d, J = 5.5 Hz, IH, pyr-
H), 9.15 (bs, 1H, NH); ' 3C NMR (DMSO-d6): ö 19.35, 35.24, 46.39, 49.78, 53.36, 
62.79, 106.80, 116.51, 118.69, 120.77, 126.88, 127.66, 128.90, 129.07, 129.38, 
129.59, 133.54, 138.83, 139.91, 146.70, 152.52, 158.28, 159.20, 160.29, 168.90; 
HRMS (FAB+) ni/z calcd for C33H35N7S 562.27529, obsd 562.27532. 
N- { 4-Methyl-2-[(2-phenylethyl)amino] -1,3-thiazol -5-yl }-4-(2,3-dihydro- 1,4-
benzodioxin-6-yl) pyrimidin-2-amine (III) [157] 
From (I) [233] (R I = NH(CH2)2Ph) and (H) [315] (R2 = H, R3 and R, fused = 
O(CH2)20). 
NH 
Yield = 15% (orange solid): mp 174-175 °C; anal. RP-HPLC: tR 17.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.46 (s, 3H, CH3 ), 2.89 (t, J = 7.5 Hz, 
2H, CH2), 3.48 (dt, J = 5.5 and 7.5 Hz, 2H, CH2), 4.19 (m, 4H, 2 x OCH2), 6.74 (d, J 
= 9.0 Hz, IH, phe-H), 6.84 (d, J = 5.5 Hz, 1H, pyr-H), 7.14 (dd, J = 2.5 and 9.0 Hz, 
1H, phe-H), 7.20 - 7.33 (m, 5H, phe-H), 7.43 (d, J = 2.5 Hz, IH, phe-H), 8.22 (t, J = 
5.5 Hz, 1H, NH), 8.28 (d, J = 5.5 Hz, 1H, pyr-H), 9.22 (bs, 111, NH); ' 3C NMR 
(DMSO-d6): ö 19.37, 35.24, 46.45, 64.60, 64.93, 107.17, 108.55, 112.89, 117.17, 
118.53, 126.91, 129.08, 129.39, 135.09, 138.62, 139.91, 143.55, 152.69, 158.24, 




methylphenyl)pyrimidin-2-amine (III) [158] 
From (I) [233] (R, = NH(CH2)2Ph) and (III) [317] (R2 = R3 = H, R4 = Me). 
NH 
N Nja 
Yield = 8% (yellow solid): mp 202-204 °C; anal. RP-HPLC: tR 19.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.26 (s, 3H, CH3), 2.44 (s, 3H, CH3), 
2.86 (t, J = 7.5 Hz, 2H, CH2), 3.45 (dt, J = 5.5 and 7.5 Hz, 211, CH2), 6.72 (dd, J = 2.5 
and 8.0 Hz, IH, phe-H), 6.85 (d, J = 5.5 Hz, IH, pyr-H), 7.10 (dd, JA = JB = 8.0 Hz, 
lH, phe-H), 7.16 - 7.29 (m, 5H, phe-R), 7.45 (dd, J = 2.5 and 8.0 Hz, IH, phe-H), 
7.68 (dd, JA = .18 = 2.5 Hz, 1H, phe-H), 8.20 (t, J = 5.5 Hz, 1H, NH), 8.28 (d, J = 5.5 
Hz, 111, pyr-H), 9.31 (bs, 1H, NH); ' 3C NMR (DMSO-d6): 8 19.37, 22.09, 35.24, 
46.48, 107.35, 116.66, 118.63, 120.03, 122.54, 126.91, 128.87, 129.07, 129.38, 
138.13, 139.89, 141.25, 152.87, 158.36, 159.14, 160.18, 169.04; HRMS (FAB+) m/z 
calcd for C 23H23N5 S 402.17524, obsd 402.17531. 
4-{4-Methyl-2- [(2-phenylethyl)amino] -  1,3-thiazol-5-yI}-N-[3-(morpholin- 4-
ylcarbonyl)phenyl]pyrimidin -2-amine (III) [159] 




Yield = 17% (yellow solid): mp 192-194 °C; anal. RP-HPLC: tR 15.7 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 2.89 (s, 311, CH3), 3.31 (t, J = 7.5 Hz, 
211, CH2), 3.90 (dt, J = 5.0 and 7.5 Hz, 211, CH2), 3.96 (bs, 811, morph-H), 7.34 (d, J = 
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5.5 Hz, IH, pyr-H), 7.36 (dd, J = 2.0 and 8.0 Hz, 114, phe-H), 7.63 (dd, JA = JB = 8.0 
Hz, IH, phe-H), 7.69 - 7.76 (m, 5H, phe-H), 8.24 (dd, J = 2.0 and 8.0 Hz, IH, phe-
H), 8.29 (bs, IH, phe-H), 8.66 (t, J = 5.0 Hz, IH, NH), 8.76 (d, J = 5.5 Hz, IH, pyr-
H); ' 3C NMR (DMSO-d6): S 19.41, 35.21, 66.84, 107.94, 117.71, 118.28, 120.22, 
126.92, 129.07, 129.23, 129.42, 136.50, 139.87, 141.32, 141.42, 153.15, 158.33, 
159.34, 159.97, 160.05, 169.12, 169.92; HRMS (FAB+) mlz calcd for C 27H28N602S 
501.20727, obsd 501.20695. 
N-(2-Anilino-4-methyl-1,3-thiazol-5-yl)-4-[(4-acetylpiperazin-1-
yl)phenyl]pyrimidin-2-amine (III) [160] 






Yield = 21% (orange solid): mp 245-246 °C; anal. RP-HPLC: tR 14.5 mm (0-60% 
MeCN, purity 100%); 1 H NMR (DMSO-d6): 5 2.16 (s, 3H, CL!3), 2.62 (s, 3H, CL!3), 
3.11 - 3.16 (m, 4H, piperaz-H), 3.64 (dd, JA = JR = 5.0 Hz, 2H, piperaz-H), 3.80 (dd, 
JA = JB = 5.0 Hz, 2H, piperaz-H), 6.86 (d, J = 5.5 Hz, 1H, pyr-H), 6.94 (d, J = 9.0 Hz, 
2H, phe-H), 7.18 (bs, IH, NH), 7.39 - 7.44 (m, 5H, phe-H), 7.52 (d, J = 9.0 Hz, 2H, 
phe-H), 8.27 (d, J = 5.5 H, 1H, pyr-H); ' 3C NMR (DMSO-d6): 5 19.26, 21.92, 41.49, 
46.31, 49.94, 50.37, 107.46, 117.18, 118.32, 120.55, 120.88, 122.70, 129.75, 133.92, 
141.27, 146.53, 151.55, 158.74, 158.94, 160.33, 164.10, 168.93; HRMS (FAB+) mlz 
calcd for C 26H27N70S 486.2076 1, obsd 486.20673. 
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N- { 4- [2-(Benzylamino) -4-methyl - 1 ,3-thiazol -5-yI] -4-(acetylpiperazin -1-
yI)phenylpyrimidin-2-mine [161] 





Yield = 33% (yellow solid): mp 197-198 °C; anal. RP-HPLC: tR 13.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.04 (s, 3H, CH3), 2.45 (s, 3H, CH3), 
3.00 (dd, JA = JB = 5.0 Hz, 2H, piperaz-H), 3.06 (dd, JA = J8 = 5.0 Hz, 2H, piperaz-H), 
3.56 - 3.59 (dd, JA = JB = 5.0 Hz, 4H, piperaz-H), 4.49 (d, J = 6.0 Hz, 2H, CH2), 6.82 
(d, J = 5.5 Hz, IH, pyr-H), 6.89 (d, J = 9.0 Hz, 2H, phe-H), 7.26 - 7.37 (m, 5H, phe-
H), 7.60 (d, J = 9.0 Hz, 2H, phe-H), 8.27 (d, J = 5.5 Hz, III, pyr-H), 8.59 (t, J = 6.0 
Hz, IH, NH), 9.20 (bs, IH, NH); ' 3C NMR (DMSO-d6): 8 19.27, 21.90, 41.49, 46.3 1, 
48.15, 50.00, 50.43, 106.93, 117.19, 119.09, 120.72, 127.81, 128.09, 129.09, 134.08, 
139.29, 146.40, 152.37, 158.32, 159.17, 160.25, 168.95, 169.14; HRMS (FAB+) m/z 
calcd for C 27H29N70S 500.22326, obsd 500.55325. 
N-(2-Anilino-4-methyl-1,3-thiazol-5-yI)-4-(4-morpholin-4-ylphenyl)pyrimidin-2-
amine (III) [162] 
From (I) [240] (R I = NHPh) and (II) [320] (R2 = H, R3 = morph, R 4 = H). 
, c'- Ir 
Yield = 49% (yellow solid): mp 290-291 °C; anal. RP-HPLC: tR 13.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 8 2.57 (s, 3H, CH3), 3.04 (dd, JA = JB = 
4.5 Hz, 4H, morph-H), 3.74 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 6.89 (d, J = 8.5 Hz, 
2H, phe-H), 6.93 (d, J = 5.5 Hz, IH, pyr-H), 7.01 (t, J = 7.5 Hz, IH, phe-H), 7.35 - 
7.65 (m, 6H, phe-H), 8.35 (d, J = 5.5 Hz, 1H, pyr-H), 9.28 (bs, IH, NH); ' 3C NMR 
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(DMSO-d6): ö 19.26, 50.00, 66.89, 107.40, 116.24, 118.32, 120.92, 122.69, 129.74, 
133.65, 141.30, 146.79, 151.52, 158.93, 160.35, 164.10; HRMS (FAB+) m/z calcd for 
C24H24N60S 445.18106, obsd 445.18109. 
4- [2- (Benzylamino) -4-methyl -  1,3-thiazol-5-yI)]-N-( 4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [163] 
From (I) [239] (R I = NHCH2Ph) and (II) [320] (R2 = H, R3 = morph, R4 = H). 
NH 
ro 
Yield = 42% (off-white solid): mp 236-237 °C; anal. RP-HPLC: tR 14.1 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.45 (s, 3H, CH3), 3.03 (dd, JA = JB = 
4.5 Hz, 4H, morph-H), 3.74 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 4.49 (d, J = 6.0 Hz, 
2H, CH2), 6.82 (d, J = 5.0 Hz, lH, pyr-H), 6.86 (d, J = 9.0 Hz, 2H, phe-H), 7.26 - 
7.37 (m, 5H, phe-H), 7.60 (d, J = 9.0 Hz, 2H, phe-H), 8.27 (d, J = 5.0 Hz, lH, pyr-H), 
8.59 (t, J = 6.0 Hz, 1H, NH), 9.18 (bs, IH, NH); ' 3C NMR (DMSO-d6): ö 19.29, 
48.15, 50.05, 66.89, 106.87, 116.25, 119.11, 120.75, 127.81, 128.09, 129.09, 133.80, 
139.30, 146.65, 152.34, 158.32, 159.15, 160.27, 169.12; HRMS (FAB+) mlz calcd for 
C25H26N60S 459.1967 1, obsd 459.19661. 
N-{4-Methyl-2- [methyl(phenyl)amino]-1,3-thiazol-5-yl}-4-[(4-acetylpiperazin-  1-
yI)phenyl]pyrimidin-2-amine (III) [164] 





Yield = 17% (yellow solid): mp 177-178 °C; anal. RP-HPLC: tR 12.8 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.05 (s, 3H, CH3), 2.51 (s, 3H, CH3), 
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2.97 (dd, JA = JB = 5.0 Hz, 2H, piperaz-H), 3.04 (dd, JA = JB = 5.0 Hz, 2H, piperaz-H), 
3.49 (s, 3H, CH3), 3.58 (m, 4H, piperaz-H), 6.81 (d, J = 9.0 Hz, 2H, phe-H), 6.85 (d, J 
= 5.5 Hz, 111, pyr-H), 7.34 - 7.39 (m, 2H, phe-H), 7.52 - 7.54 (m, 5H, phe-H), 8.29 
(d, J = 5.5 Hz, IH, pyr-H), 9.18 (bs, 1H, NJ]); ' 3C NMR (DMSO-d6): ö 19.21, 21.92, 
41.46, 46.29, 49.95, 50.37, 106.97, 117.05, 120.96, 121.23, 126.15, 127.75, 130.60, 
133.88, 146.18, 146.45, 152.17, 158.94, 160.23, 168.93, 169.44; HRMS (FAB+) m/z 
calcd for C 27H29N70S 500.22326, obsd 500.22332. 
N- { 4-Methyl -2- [methyl(phenyl)amino] -  1,3-thiazoi-5-yl}-4-(4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [165] 
From (I) [232] (R I = N(Me)Ph) and (TI) [320] (R2 = H, R3 = morph, R4 = H). 
9 
ro 
Yield = 24% (yellow solid): mp 192-193 °C; anal. RP-HPLC: tR 15.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.51 (s, 3H, CH3), 3.00 (dd, JA = JB = 
4.5 Hz, 4H, morph-H), 3.49 (s, 3H, CH3), 3.74 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
6.78 (d, J = 9.0 Hz, 2H, phe-H), 6.85 (d, J = 5.0 Hz, IH, pyr-H), 7.35 - 7.38 (m, 2H, 
phe-H), 7.51 - 7.53 (m, 5H, phe-H), 8.28 (d, J = 5.0 Hz, 1H, pyr-H), 9.15 (bs, 1H, 
NH); ' 3C NMR (DMSO-d6): 6 19.20, 50.00, 66.88, 106.91, 116.10, 120.89, 121.00, 
121.93, 126.14, 127.75, 130.59, 133.59, 146.19, 146.70, 152.14, 158.52, 158.92, 
160.24, 169.44; HRMS (FAB+) nilz calcd for C25H26N60S 459.19671, obsd 
459. 19676. 
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N- { 2- [Benzyl(methyl)amino] -4-methyl-  1,3-thiazol-5-yl }-4-[(4-acetylpiperazin-1-
yI)phenyl] pyrimidin-2-amine (III) [166] 




(i NC N> 
H 
Yield = 10% (orange solid): mp 177-179 °C; anal. RP-HPLC: tR 16.7 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.04 (s, 314, CH3), 2.51 (s, 3H, CH3 ), 
3.06 (bs, 2H, piperaz-H), 3.13 (bs, 5H, 2 x piperaz-H and CH3), 3.60 (bs, 4H, piperaz-
H), 4.77 (s, 2H, CH2), 6.91 (d, J = 5.5 Hz, IH, pyr-H), 6.98 (d, J = 9.0 Hz, 2H, phe-
H), 7.29— 7.39 (m, 5H, phe-H), 7.59 (d, J = 9.0 Hz, 2H, phe-H), 8.26 (d, J = 5.5 Hz, 
lU, pyr-H), 9.48 (bs, 1H, NH); ' 3C NMR (DMSO-d6): ö 19.51, 21.88, 39.00, 41.2 1, 
46.01, 50.30, 50.69, 106.74, 117.63, 119.84, 121.49, 128.05, 128.09, 129.38, 137.17, 
158.53, 158.83, 159.11, 159.94, 168.95, 170.48; HRMS (FAB+) m/z calcd for 
C28H31 N70S 514.23891, obsd 514.23814. 
N- [3- ({4- [4-Methyl -2- (2-thienyl) -1 ,3-thiazol -5-yl]pyrimidin-2-
y1}amino)benzy1]acetamide (III) [167] 
From (I) [234] (R i = 2-thio) and (II) [291] (R 2 = R3 = H, R4 = CH2NHAc). 
Q 
N=( 
N N'Ic~, H 
0 
Yield = 67% (yellow solid): mp 223-225 °C; anal. RP-HPLC: tR 17.5 mm (20-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.15 (s, 3H, CH3), 2.99 (s, 3H, CH3), 
4.56 (d, J = 6.0 Hz, 2H, CH2), 7.18 (d, J = 7.5 Hz, lH, phe-H), 7.45 (d, J = 5.5 Hz, 
IH, pyr-H), 7.50 (dd, JA = JB = 3.5 Hz, lH, thio-H), 7.56 (dd, JA = "B = 7.5 Hz, 1H, 
phe-H), 7.90 (d, J = 7.5 Hz, IH, phe-H), 8.04 (bs, IH, phe-H), 8.07 - 8.10 (m, 211, 
thio-H), 8.61 (t, J = 6.0 Hz, 114, NH), 8.84 (d, J = 5.5 Hz, 1H, pyr-H); ' 3C NMR 
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(DMSO-d6): 8 18.79, 23.28, 43.15, 108.98, 118.34, 118.75, 121.43, 129.07, 129.16, 
129.47, 130.62, 131.85, 137.00, 140.51, 140.93, 153.78, 158.04, 159.32, 159.92, 
160.37, 161.44; HRMS (FAB+) m/z calcd for C 21 11 19N50S2 422.11093, obsd 
422.1 1098. 
N- [4-Methyl -2- (2-thienyl) -1,3-thiazol -5-yI] -4- [(4-acetylpiperazin -1-
yI)phenyl]pyrimidin-2-amine (III) [168] 
From (I) [234] (Ri = thio) and (H) [321] (R2 = H, R3 = piperaz-Ac, R4 = H). 




Yield = 13% (orange solid): mp 134-136 °C; anal. RP-HPLC: tR 14.9 mm (20-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.04 (s, 314, Cl3), 2.68 (s, 3H, CH3 ), 
3.02 (dd, JA = JB = 5.0 Hz, 4H, piperaz-H), 3.09 (dd, JA = JB = 5.0 Hz, 4H, piperaz-H), 
6.97 (d, J = 9.0 Hz, 211, phe-H), 7.09 (d, J = 5.5 Hz, 1H, pyr-H), 7.21 (dd, JA = JB = 
4.5 Hz, 1H, thio-H), 7.64 (d, J = 9.0 Hz, 2H, phe-H), 7.76 (d, J = 4.5 Hz, 1H, thio-H), 
7.79 (d, J = 4.5 Hz, 1H, thio-H), 8.49 (d, J = 5.5 Hz, lH, pyr-H), 9.49 (bs, IH, NH); 
' 3C NMR (DMSO-d6): ö 18.77, 21.92, 46.32, 49.92, 50.33, 108.39, 117.29, 120.99, 
129.01, 129.48, 130.63, 131.96, 133.58, 137.00, 146.77, 153.61, 158.06, 159.88, 




acetylpiperazin -1-yI)phenyl]pyrimidin -2-amine (III) [169] 









Yield = 7% (orange solid): mp 205-206 °C; anal. RP-HPLC: tR 11.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.05 (s, 3H, CH3), 2.51 (s, 3H, Cl3), 
2.99 (dd, JA = JB = 5.0 Hz, 2H, piperaz-H), 3.05 (dd, JA = JB = 5.0 Hz, 2H, piperaz-H), 
3.52 (s, 3H, Cl?3), 3.58 (dd, JA = JB = 5.0 Hz, 4H, piperaz-H), 6.84 (d, J = 9.0 Hz, 2H, 
phe-H), 6.89 (d, J = 5.5 Hz, IH, pyr-H), 7.53 - 7.56 (m 3H, 2 x phe-H and pyrid-H), 
8.01 (dd, J = 2.5 and 7.0 Hz, 1H, pyrid-H), 8.32 (d, J = 5.5 Hz, IH, pyr-H), 8.53 (d, J 
= 4.5 Hz, IH, pyrid-H), 8.80 (d, J = 2.5 Hz, 1H, pyrid-H), 9.22 (bs, 1H, NR); 13C 
NMR (DMSO-d6): ö 19.16, 21.88, 21.91, 46.29, 49.95, 50.36, 107.06, 117.10, 120.97, 
121.80, 125.05, 133.46, 133.50, 142.42, 146.53, 147.49, 148.05, 152.12, 158.73, 
160.25, 168.94, 168.98; HRMS (FAB+) m/z calcd for C 26H28N80S 501.2185 1, obsd 
501.21863. 
(4-Methyl- 5-{ 2-[(4-piperidin-1-ylphenyl)amino]pyrimidin -4-yI}-1 ,3-thiazol-2-
yl)methanol (III) [170] 
From (I) [221] (R i = CH20H) and (H) [307] (R2 = H, R3 = piperid, R4 = H). 
HO 
N N'ja 
Yield = 22% (brown solid): mp 194-195 °C; anal. RP-HPLC: tR 11.5 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d 6): 5 1.48 - 1.53 (m, 2H, piperid-H), 1.60 - 
1.65 (m, 4H, piperid-H'), 2.63 (s, 3H, Cl 3), 3.05 (dd, JA = JB = 5.5 Hz, 4H, piperid-H), 
4.70 (d, J = 6.0 Hz, 2H, CH2), 6.12 (t, J = 6.0 Hz, IH, OH), 6.88 (d, J = 9.0 Hz, 2H, 
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phe-H), 7.01 (d, J = 5.0 Hz, III, pyr-H), 7.58 (d, J = 9.0 Hz, 2H, phe-H), 8.45 (d, J = 
5.0 Hz, 1H, pyr-H), 9.37 (bs, 1H, Nil); HRMS (FAB+) m/z calcd for C 20H23N50S 
382.17016, obsd 382.17024. 
(4-Methyl-5- {2- [(3-methoxy-4-morpholin-4-ylphenyl)amino]pyrimidin -4-yI }- 1,3-
thiazol-2-yl)methanol (III) [171] 
From (I) [221] (R, = CH 20H) and (II) [319] (R 2 = H, R3 = morph, R, = OMe). 
HO 
(o 
Yield = 21% (yellow solid): mp 179-180 °C; anal. RP-HPLC: tR 11.4 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.63 (s, 3H, C!!3), 2.91 (dd, JA = JR = 
4.5 Hz, 4H, morph-H), 3.71 (dd JA = JB = 4.5 Hz, 4H, morph-H), 3.82 (s, 3H, OCH3), 
4.70 (d, J = 6.0 Hz, 2H, CH2), 6.14 (t, J = 6.0 Hz, IH, OH), 6.82 (d, J = 8.5 Hz, IH, 
phe-H), 7.06 (d, J = 5.0 Hz, 1H, pyr-H), 7.26 (dd, J = 1.5 and 8.5 Hz, 1H, phe-H), 
7.53 (d, J = 1.5 Hz, III, phe-H), 8.49 (d, J = 5.0 Hz, 1H, pyr-H), 9.49 (bs, 1H, NH); 
' 3C NMR (DMSO-d6): ö 18.76, 51.67, 56.16, 61.76, 65.62, 67.16, 104.82, 108.68, 
111.85, 118.45, 131.41, 136.28, 136.51, 152.65, 158.66, 159.75, 160.39, 175.50; 
HRMS (FAB+) in/z calcd for C201-123N503S 414.15999, obsd 414.15900. 
(4-Methyl -5- {2- [(3-methoxy-4-piperidin -  1-ylphenyl)amino]pyrimidin -4-yI }-1,3-
thiazol-2-yl)methanol (III) [172] 




Yield = 34% (brown oily residue): anal. RP-HPLC: tR 12.0 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): 1.56 - 1.59 (m, 2H, piperid-H), 1.72 - 1.76 (m, 4H, 
piperid-H), 2.68 (s, 3H, CH3), 2.91 - 2.94 (m, 4H, piperid-H), 3.94 (s, 3H, OCH3), 
4.80 (s, 2H, CH2), 6.96 (d, J = 8.5 Hz, 1H, phe-H), 7.05 (d, J = 5.0 Hz, IH, pyr-H), 
WE 
7.14 (dd, J = 2.0 and 8.5 Hz, 1H, phe-H), 7.54 (d, J = 2.0 Hz, 1H, phe-H), 8.42 (d, J = 
5.0 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 5 18.76, 24.75, 26.70, 52.63, 56.20, 61.76, 
104.89, 108.61, 111.90, 118.79, 131.44, 136.11, 137.77, 152.62, 152.74, 158.67, 
159.80, 160.42, 175.48; HRMS (FAB+) nilz calcd for C 21 1-1N502S 412.18072, obsd 
412. 17997. 
(4-Methyl -5- { 2- [(3-methyl -4-morpholin-4-ylphenyl)amino]pyrimidin-4-yl }- 1,3-
thiazol-2-yl)methanol (III) [173] 






Yield = 31% (brown solid): mp 93-94 °C; anal. RP-HPLC: tR 13.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.23 (s, 3H, CH3), 2.60 (s, 3H, CH3), 
2.75 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.68 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
4.67 (d, J = 6.0 Hz, 2H, CH2), 6.10 (t, J = 6.0 Hz, IH, OH), 6.94 (d, J = 9.0 Hz, 1H, 
phe-H), 7.01 (d, J = 5.0 Hz, 1H, pyr-H), 7.49 (dd, J = 2.0 and 9.0 Hz, 1H, phe-H), 
7.60 (d, J = 2.0 Hz, 1H, phe-H), 8.44 (d, J = 5.0 Hz, 111, pyr-H), 9.43 (bs, lH, NH); 
' 3C NMR (DMSO-d6): 8 18.34, 18.71, 52.89, 61.73, 67.35, 108.68, 118.03, 119.55, 
122.50, 131.40, 132.66, 136.34, 146.18, 152.64, 158.63, 159.68, 160.39, 175.36; 
HRMS (FAB+) mlz calcd for C20H23N502S 398.16507, obsd 398.16457. 
(4-Methyl-5-{2-[(3-methyl-4-piperidin-1-ylphenyl)amino]pyrimidin-4-yI }-1,3-
thiazol-2-yI)methanol (III) [174] 




Yield = 41% (brown solid): mp 142-144 °C; anal. RP-HPLC: tR 11.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.50 - 1.52 (m, 2H, piperid-H), 1.62 - 
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1.66 (m, 4H, piperid-H), 2.24 (s, 3H, CH3), 2.64 (s, 3H, CH3), 2.75 (dd, JA = JB = 5.0 
Hz, 4H, piperid-H), 4.71 (d, J = 6.0 Hz, 2H, CH2), 6.13 (t, J = 6.0 Hz, IH, OH), 6.94 
(d, J = 8.5 Hz, IH, phe-H), 7.04 (d, J = 5.0 Hz, IH, pyr-H), 7.49 (dd, J = 2.0 and 8.5 
Hz, IH, phe-H), 7.61 (d, J = 2.0 Hz, 1H, phe-H), 8.47 (d, J = 5.0 Hz, IH, pyr-H), 9.43 
(bs, IH, NH); ' 3C NMR (DMSO-d6): 8 18.29, 18.76, 24.60, 26.95, 53.91, 61.77, 
108.63, 112.50, 118.05, 119.53, 122.50, 132.58, 135.90, 147.67, 152.65, 158.66, 
159.71, 160.47, 175.38; HRMS (FAB+) m/z calcd for C2 1 HN50S 396.18581, obsd 
396.18606. 
N- (4-Methoxy-3.methylphenyl) -4- [4-methyl -2- (methylamino) -1 ,3-thiazol-5-
yl]pyrimidin..2-amine (III) [175] 




(N rY °' 
Yield = 38% (yellow solid): mp 208-209 °C; anal. RP-HPLC: tR 14.2 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.16 (s, 3H, CH3 ), 2.46 (s, 3H, CH3 ), 
2.85 (d, J = 5.0 Hz, 3H, NHCH3), 3.74 (s, 3H, OCH3), 6.82 - 6.84 (m, 2H, phe-H and 
pyr-H), 7.84 (dd, J = 2.0 and 8.5 Hz, 1H, phe-H), 7.62 (d, J = 2.0 Hz, IH, phe-H), 
8.02 (q, J = 5.0 Hz, 1H, NH), 8.27 (d, J = 5.5 Hz, 1H, pyr-H), 9.16 (bs, 1H, NH); ' 3C 
NMR (DMSO-d6): ö 16.99, 19.30, 31.44, 56.05, 106.79, 110.93, 118.15, 118.81, 
122.64, 125.79, 134.09, 152.75, 152.88, 158.32, 159.15, 160.29, 169.94; HRMS 
(FAB+) m/z calcd for C 17H, 9N50S 342.13886, obsd 342.13880. 
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N-{ 4- [2-(2-Ethylpyridin-4-yI) -4-methyl -1 ,3-thiazol-5-yI]pyrimidin -2-
yI}aminobenzylacetamide (III) [176] 





Yield = 9% (orange solid): mp 180-181 °C; anal. RP-HPLC: tR 10.2 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 1.51 (t, J = 7.5 Hz, 3H, CH2CH3), 2.06 
(s, 3H, CH3), 3.00 (s, 3H, CH3), 3.14 (q, J = 7.5 Hz, 2H, CH2CH3), 4.51 (d, J = 6.0 
Hz, 2H, CH2), 7.12 (d, J = 8.0 Hz, IH, phe-H), 7.45 (d, J = 5.0 Hz, IH, pyr-H), 7.50 
(dd, JA = JB = 8.0 Hz, 1H, phe-H), 7.79 (dd, J = 2.0 and 8.0 Hz, IH, phe-H), 8.02 (d, J 
= 2.0 Hz, 1H, phe-H), 8.16 (dd, J = 2.0 and 5.0 Hz, IH, pyrid-H), 8.24 (d, J= 2.0 Hz, 
IH, pyrid-H), 8.56 (t, J = 6.0 Hz, 1H, NH), 8.82 (d, J = 5.0 Hz, 1H, pyr-H), 8.92 (d, J 
= 5.0 Hz, 1H, pyrid-H); 13C NMR (DMSO-d6): 8 14.15, 18.89, 23.27, 29.67, 43.15, 
109.31, 118.41, 118.43, 118.77, 119.37, 120.38, 121.59, 129.21, 136.01, 140.58, 
140.81, 154.81, 157.54, 158.77, 159.06, 160.37, 163.16, 163.17, 169.77; HRMS 
(FAB+) 'n/z calcd for C 24H24N60S 445.18106, obsd 445.18100. 
N-({ 4-[2-(2-Ethylpyridin-4-yJ) -4-methyl-1 ,3-thiazol -5-yl]pyrimidin -2-yI}amino-4-
(2-hydroxyethyl)benzenesulfonamide (III) [177] 
From (I) [223] (R, = 4-(2-ethyl)-pyrid) and (II) [301] (R2 = H, R 3 = 







Yield = 3% (orange solid): mp 233-234 °C; anal. RP-HPLC: tR 14.6 mm (0-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.06 (t, J = 7.0 Hz, 3H, CH2CH3), 2.57 
(s, 3H, CH3), 2.61 —2.68 (m, 2H, CH2), 3.04-3.06 (m, 2H, CH2), 3.14 (q, J = 7.0 Hz, 
2H, CH2CH3), 4.43 (t, J = 6.0 Hz, 1H, OH), 7.11 (d, J = 5.5 Hz, IH, pyr-H), 7.16 (t, J 
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= 6.0 Hz, IH, NH), 7.52 - 7.53 (m, 1H, pyrid-H), 7.54 (d, J = 9.0 Hz, 2H, phe-H), 
7.59 (bs, IH, pyrid-H), 7.77 (d, J = 9.0 Hz, 2H, phe-H), 8.42 (d, J = 5.5 Hz, 1H, pyr-
H), 8.45 (d, J = 5.0 Hz, 1H, pyrid-H); ' 3C NMR (DMSO-d6): 8 14.39, 31.26, 60.60, 
110.67, 117.25, 118.13, 118.38, 118.72, 118.81, 118.88, 128.36, 133.18, 133.99, 
139.89, 144.52, 150.99, 154.03, 158.11, 160.03, 164.99, 165.19; HRMS (FAB+) in/z 
calcd for C23H 24N603S2 497.14296, obsd 497.14306. 
N-{4-[2-(2-Ethylpyridin-4-yI)-4-methyi- 1,3-thiazol-5-yI]pyrimidin-2-
yl}aminobenzylacetamide (III) [178] 








Yield = 39% (yellow solid): mp 224-225 °C; anal. RP-HPLC: tR 14.3 mm (10-70% 
MeCN, purity 97%); 'H NMR (DMSO-d6): 8 1.56 (t, J = 7.5 Hz, 3H, CH2CH3 ), 2.14 
(s, 314, CH3), 3.05 (s, 3H, CH3), 3.14 (q, J = 7.5 Hz, 2H, CH2CH3), 4.48 (d, J = 6.0 
Hz, 2H, CH2), 7.47-7.51 (m, 3H, 2 x phe-H and pyr-H), 7.99-8.01 (m, 3H, 2 x phe-
H and pyrid-H), 8.06 (bs, IH, pyrid-H), 8.54 (d, J = 6.0 Hz, 1H, NH), 8.86 (d, J = 4.5 
Hz, 1H, pyrid-H), 8.92 (d, J = 5.0 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): ö 14.36, 
18.87, 23.31, 31.26, 42.54, 109.30, 118.28, 118.70, 119.68, 128.40, 133.46, 134.32, 
139.58, 140.21, 150.95, 154.42, 157.92, 160.13, 160.42, 164.87, 169.71; HRMS 
(FAB+) mlz calcd for C24H24N60S 445.18106, obsd 445.18131. 
N-{2-[3-(2-Methoxyethoxy)-5-(trifluoromethyl)pyridin-2-yI]-4-methyl- 1,3-
thiazol-5-yl}-4-(4-morpholin-4-ylphenyl)pyrimidin-2-amine (III) [179] 
From (1) [225] (Ri =2-(3-MeO(CH2)20-5-CF3)-pyrid) and (H) [320] (R2 = H, R 3 = 
morph, R4 = H). 
CF3 
S 	 ro 
IN 
I  NN O 
H 
Yield = 14% (orange solid): mp 175-178 °C; anal. RP-HPLC: tR 18.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.77 (s, 3H, CH3), 2.50 (s, 314, CH3), 
3.06 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.75 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 
3.84 (t, J = 4.5 Hz, 214, CH2), 4.53 (t, J = 4.5 Hz, 2H, CH2), 6.93 (d, J = 8.5 Hz, 2H, 
phe-H), 7.13 (d, J = 5.0 Hz, IH, pyr-H), 7.65 (d, J = 8.5 Hz, 2H, phe-H), 8.10 (d, J = 
1.0 Hz, 1H, pyrid-H), 8.53 (d, J = 5.0 Hz, 1H, pyr-H), 8.69 (d, J = 1.0 Hz, IH, pyrid-
H), 9.49 (bs, 1H, NH); ' 3C NMR (DMSO-d6): 8 18.94, 49.92, 59.10, 70.16, 70.8 1, 
109.0, 116.27, 119.82, 121.04, 122.90, 125.08, 126.73, 126.99, 13129, 135.04, 
138.38, 143.10, 147.03, 153.08, 153.63, 158.43, 159.96, 160.58, 161.73; HRMS 
(FAB+) m/z calcd for C 271427173N603S 573.18957, obsd 573.18935. 
4-{2-[3-Chloro-5-(trifluoromethyl)pyridin-2-yI] -4-methyl-1,3-thiazol-5-yI }-
pyrimidin-2-ylaminobenzylacetamide (III) [180] 







Yield = 6% (yellow solid): mp 217-218 °C; anal. RP-HPLC: tR 21.8 mm (0-60% 
MeCN, purity 100 %); 'H NMR (DMSO-d6): ö 1.86 (s, 3H, CH3), 2.80 (s, 3H, Cl3), 
4.25 (d, J = 6.0 Hz, 2H, Cl2), 6.89 (d, J = 7.5 Hz, IH, phe-H), 7.23 - 7.27 (m, 2H, 
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phe-H and pyr-H), 7.68 - 7.70 (m, 211, phe-H and pyrid-H), 8.30 (t, J = 6.0 Hz, IH, 
NH), 8.61 (d, J = 5.0 Hz, 1H, pyr-H), 8.65 (bs, 1H, phe-H), 9.07 (d, J = 1.0 Hz, IH, 
pyrid-H); ' 3C NMR (DMSO-d6): 5 19.10, 23.27, 43.12, 109.77, 118.28, 118.94, 
121.44, 122.18, 128.88, 129.12, 136.59, 138.63, 140.51, 140.84, 149.92, 154.58, 
158.02, 160.45, 165.11, 169.82; HRMS (FAB+) mlz calcd for C 23 1-1 180173N60S 
519.09817, obsd 519.09807. 
N-(4- [4-Methyl -2- (6-methylpyridin-3-yI)-1 ,3-thiazol -5-yI] -pyrimidin -2-
yl}aminobenzylacetamide (III) [181] 
From (I) [226] (R 1 = 3-(6-Me)-pyrid) and (II) [291] (R2 = R3 = H, R4 = CH 2NHAc). 
0 
Yield = 35% (yellow solid): mp 227-229 °C; anal. RP-HPLC: tR 14.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.85 (s, 3H, CH3), 2.54 (s, 3H, CH3), 
2.75 (s, 3H, CH3), 4.27 (d, J = 6.0 Hz, 2H, CH2), 6.89 (d, J = 8.0 Hz, IH, pyrid-H), 
7.18 (d, J = 5.5 Hz, lH, pyr-H), 7.28 (dd, JA = JB = 8.0 Hz, IH, phe-H), 7.41 (dd, J = 
2.0 and 8.0 Hz, 1H, phe-H), 7.62 (dd, J = 2.0 and 8.0 Hz, 1H, phe-H), 7.76 (dd, JA = 
JB = 2.0 Hz, IH, phe-H), 8.25 (dd, J = 2.5 and 8.0 Hz, IH, pyrid-H), 8.32 (t, J = 6.0 
Hz, IH, NH), 8.57 (d, J = 5.5 Hz, IH, pyr-H), 9.05 (d, J = 2.5 Hz, IH, pyrid-H); 13C 
NMR (DMSO-d6): 8 18.89, 23.27, 24.74, 43.15, 109.13, 118.37, 118.78, 121.42, 
124.47, 126.79, 129.17, 132.92, 134.62, 140.51, 140.91, 147.02, 154.16, 158.05, 
159.99, 160.39, 161.04, 164.70, 169.78; HRMS (FAB+) m/z calcd for C 23H22N60S 
43 1.16541, obsd 431.16552. 
N- { 2- [Benzyl(methyl)amino] -4-methyl -  1,3-thiazol-5-yI }-pyrimidin-2-
ylaminobenzylacetamide (III) [182] 
From (I) [229] (R i = NMeBn) and (H) [291] (R2 = R3 = H, R 4 = CH2NIHAc). 
NY 
N N"O', 
Yield = 3% (yellow solid): mp 181-183 °C; anal. RP-HPLC: tR 12.6 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.37 (s, 3H, CH3), 3.02 (s, 3H, CH3), 
2.99 (s, 3H, CH3), 4.00 (s, 2H, CH2), 4.57 (d, J = 6.0 Hz, 2H, CH2), 7.29 (d, J = 8.0 
Hz, 1H, phe-H), 7.45 (d, J = 5.5 Hz, 1H, pyr-H), 7.63 (dd, JA = JB = 8.0 Hz, lH, phe-
H), 7.83 - 7.86 (m, 2H, phe-H), 7.95 (d, J = 8.0 Hz, 1H, phe-H), 7.98 - 8.03 (m, 3H, 
phe-H), 8.18 (bs, IH, phe-H), 8.73 (d, J = 6.0 Hz, 1H, NH), 8.83 (d, J = 5.5 Hz, IH, 
pyr-H); HRMS (FAB+) m/z calcd for C 25H26N60S 459.1967 1, obsd 459.19610. 
N- { 2- [(3,5-Dichlorophenyl)(methyl)amino] -4-methyl-1 ,3-thiazol-5-yl}-4-
(pyrimidin-2-yI)aminobenzylacetamide (III) [183] 







Yield = 33% (off-white solid): mp 213-214 °C; anal. RP-HPLC: tR 17.8 mm (20-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.36 (s, 3H, CH3), 3.03 (s, 3H, CH3), 
4.00 (s, 3H, CH3), 4.64 (d, J = 6.0 Hz, 214, CH2), 7.31 (dd, J = 1.0 and 8.0 Hz, 1H, 
phe-H), 7.48 (d, J = 5.5 Hz, IH, pyr-H), 7.68 (dd, JA = JB = 8.0 Hz, IH, phe-H), 8.02 
(dd, JA = JB = 2.0 Hz, IH, phe-H), 8.06 (dd, J = 1.0 and 8.0 Hz, IH, phe-H), 8.17 (dd, 
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JA = JB = 1.0 Hz, 1H, phe-H), 8.21 (d, J = 2.0 Hz, 214, phe-H), 8.76 (t, J = 6.0 Hz, 1H, 
NH), 8.89 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO- d6): ö 19.23, 23.28, 43.02, 
107.73, 118.04, 118.57, 120.88, 122.15, 124.31, 126.52, 128.96, 135.32, 140.50, 
141.09, 147.66, 152.14, 158.65, 158.91, 160.15, 168.24, 169.67; HRMS (FAB+) mlz 
calcd for C24H22C12N60S 513.10311, obsd 513.10301. 
N-(4-{4-Methyl-2-[(3-thienylsulfonyl)methyl]- 1,3-thiazol-5-yl}-4-[(4-
acetylpiperazin-1-yI)phenyl]pyrimidin-2-amine (III) [184] 




N=( 	 0 
N N'Ja 
H 
Yield = 6% (brown oil): anal. RP-HPLC: tR 14.9 mm (0-60% MeCN, purity 100%); 
'H NMR (DMSO-d6): 5 2.42 (s, 314, CH3), 2.97 (s, 314, CH3), 3.51 (bs, 2H, piperaz-
H), 3.58 (bs, 2H, piperaz-H), 4.00 (bs, 4H, piperaz-H), 5.67 (s, 2H, CH2), 7.43 - 7.46 
(m, 3H, 2 x phe-H and pyr-H), 7.65 (dd, JA = JB = 4.5 Hz, 1H, thio-H), 8.03 (d, J = 9.0 
Hz, 2H, phe-H), 8.12 (d, J = 4.5 Hz, IH, thio-H), 8.49 (d, J = 4.5 Hz, 1H, thio-H), 
8.88 (d, J = 5.0 Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): ö 18.46, 21.85, 45.66, 60.48, 
109.00, 112.54, 114.83, 117.13, 118.70, 120.89, 129.13, 134.89, 136.12, 136.95, 
139.12, 152.94, 157.14, 158.88, 159.19, 160.24, 169.05; HRMS (FAB+) inJz calcd for 
C25H26N603S3 555.13068, obsd 555.13063. 
N-[2-(2,4-Dimethylphenyl)-4-methyl-1,3-thiazol-5-yl]-4-( 4-morpholin-4-
ylphenyl)pyrimidin-2-amine (ifi) [185] 




Yield = 15% (yellow solid): mp 191-192 °C; anal. RP-HPLC: tR 18.4 mm (10-70% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.17 (s, 311, CH3), 2.34 (s, 3H, CH3), 
2.99 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.37 (s, 311, CH3), 3.74 (dd, JA = JB = 4.5 
Hz, 4H, morph-H), 6.75 (d, J = 9.0 Hz, 2H, phe-H), 6.82 (d, J = 5.5 Hz, IH, pyr-H), 
7.18 (d, J = 7.5 Hz, IH, phe-H), 7.19— 7.26 (m, 2H, phe-H), 7.50 (d, J = 9.0 Hz, 211, 
phe-H), 8.26 (d, J = 5.5 Hz, 1H, pyr-H), 9.11 (bs, lH, NH); ' 3C NMR (DMSO-d6): 6 
17.61, 19.31, 21.35, 50.05, 66.88, 106.73, 110.00, 116.14, 120.86, 128.52, 129.24, 
132.97, 133.72, 136.11, 138.98, 142.12, 146.64, 152.65, 158.42, 159.06, 160.20, 
170.24; HRMS (FAB+) mlz calcd for C26H27N50S 457.19363, obsd 457.19381. 
N-[4-Methyl-2-(4-morpholin-4-ylphenyl)-1,3-thiazol-5-yI]-4-(4-morpholin-4-
ylphenyl)pyrimidin-2-amine (III) [186] 






Yield = 82% (yellow solid): mp 273-274 °C; anal. RP-HPLC: tR 16.5 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.70 (s, 3H, CH3), 3.05 (dd, JA = JB = 
4.5 Hz, 4H, morph-H), 3.25 (dd, JA = JB = 4.5 Hz, 4H, morph-H), 3.75 (m, 8H, 
morph-H), 6.94 (d, J = 9.0 Hz, 2H, phe-H), 7.04 - 7.06 (m, 3H, 2 x phe-H and pyr-H), 
RM 
7.65 (d, J = 9.0 Hz, 2H, phe-H), 7.84 (d, J = 9.0 Hz, 2H, phe-H), 8.46 (d, J = 5.0 Hz, 
IH, pyr-H), 9.42 (bs, IH, NH); ' 3C NMR (DMSO-d6): 6 19.01, 47.96, 49.97, 66.6 1, 
66.89, 108.36, 115.09, 116.30, 120.95, 123.72, 128.13, 133.43, 146.95, 153.27, 
153.89, 155.27, 157.32, 158.49, 160.50; HRMS (FAB+) m/z calcd for C 281130N602S 
5 15.22292, obsd 5 15.22296. 
N-[4-Methyl-2-(4-morpholin-4-ylphenyl)-1,3-thiazol-5-yI]-4-(4-acetylpiperazin-1-
yI)phenyl)pyrimidin-2-amine (III) [187] 
From (I) [237] (R I = 4-morpholinophenyl) and (II) [321] (R2 = H, R3 = piperaz-Ac, R4 
=H). 
=c 	 0 
N 
NN ) 
Yield = 42% (orange solid): mp 250-252 °C; anal. RP-HPLC: tR 15.9 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 6 2.16 (s, 3H, CL!3), 2.77 (s, 3H, CL!3 ), 
3.13 - 3.18 (m, 4H, piperaz-H), 3.29 (dd, JA = .1i9 = 5.0 Hz, 4H, morph-H), 3.65 (dd, 
JA = JB = 5.0 Hz, 2H, piperaz-H), 3.81 (dd, JA = JB = 5.0 Hz, 2H, piperaz-H), 3.89 (dd, 
JA = JB = 5.0 Hz, 4H, morph-H), 6.93 - 6.99 (m, 5H, 4 x phe-H and pyr-H), 7.36 (bs, 
1H, NH), 7.57 (d, J = 9.0 Hz, 2H, phe-H), 7.91 (d, J = 9.0 Hz, 2H, phe-H), 8.36 (d, J 
= 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 6 19.01, 21.90, 41.47, 46.30, 47.95, 
49.94, 50.35, 66.60, 108.38, 115.07, 117.29, 120.93, 123.71, 128.13, 130.60, 133.72, 
146.70, 153.26, 153.90, 158.49, 159.56, 160.49, 167.67, 168.90; HRMS (FAB+) mlz 
calcd for C30H33N702S 556.24947, obsd 556.24924. 
290 
N-(2-Anilino-4-methyl-1,3-thiazol- 5-yD-4-(3,5-dimethoxyphenyl)pyrimidifl-2-
amine (III) [188] 
From (I) [240] (R I = NHPh) and (H) [325] (R2 = OMe, R3 = H, R4 = OMe). 
Q 
s 	•••. 
Yield = 23% (yellow solid): mp 191-193 °C; anal. RP-HPLC: tR 17.0 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 2.61 (s, 3H, CH3 ), 3.78 (s, 6H, CH3 ), 
6.19 (dd, JA = J8 = 2.0 Hz, IH, phe-H), 6.89 (d, J = 2.0 Hz, 2H, phe-H), 6.92 (d, J = 
5.5 Hz, 1H, pyr-H), 7.19 (bs, 1H, NH), 7.36 - 7.44 (m, 5H, phe-H), 8.33 (d, J = 5.5 
Hz, 1H, pyr-H); ' 3C NMR (DMSO-d6): 8 19.29, 55.76, 94.30, 97.79, 108.23, 118.53, 
120.19, 122.92, 129.77, 141.17, 142.87, 151.84, 158.76, 158.96, 160.18, 161.15, 
164.38; HRMS (FA-B+) mlz calcd for C 22H21 N502S 420.14942, obsd 420. 14955. 
N-(2-Anilino-4-methyl-1,3-thiazol-5-yl)-4-[(4-benzylpiperazin- 1 -
yI)phenyl]pyrimidin -2-amine (III) [189] 






Yield = 18% (yellow solid): mp 227-229 °C; anal. RP-HPLC: tR 15.2 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): 8 2.57 (s, 3H, CH3 ), 3.08 (bs, 2H, 
piperaz-H), 3.33 (bs, 6H, piperaz-H), 3.53 (s, 2H, CH2), 6.88 (d, J = 8.0 Hz, 2H, phe-
H), 6.93 (d, J = 5.5 Hz, 1H, pyr-H), 7.02 (t, J = 7.5 Hz, 1H, phe-H), 7.26 - 7.35 (m, 
7H, phe-H), 7.59 - 7.66 (m, 4H, phe-H), 8.35 (d, J = 5.5 Hz, IH, pyr-H), 9.26 (bs, 
lH, NH); ' 3C NMR (DMSO-d6): 8 19.27, 49.78, 53.38, 62.81, 107.38, 116.53, 
118.33, 120.94, 122.68, 127.62, 128.84, 129.65, 129.76, 133.36, 138.84, 141.28, 
291 
146.83, 151.00, 159.00, 160.37, 164.10; HRMS (FAB+) mlz calcd for C3 1 H3 1 N7S 
534.24399, obsd 534.24380. 
4-[2-(Ethylamino) -4-methyl- 1 ,3-thiazol-5-yI] -N- (3-methylphenyl)pyrimidin -2-
amine (III) [190] 




Yield = 26% (yellow solid): mp 238-239 °C; anal. RP-HPLC: tR 16.2 mm (0-60% 
MeCN, purity 100%); 'H NMR (DMSO-d6): ö 1.18 (t, J = 7.0 Hz, 3H, CH2CH3), 2.30 
(s, 3H, CH3), 2.46 (s, 3H, CH3), 3.24 - 3.28 (m, 2H, CH2CH3), 6.75 (dd, J = 2.5 and 
8.0 Hz, lH, phe-H), 6.88 (d, J = 5.5 Hz, lH, pyr-H), 7.13 (dd, JA = JB = 8.0 Hz, 1H, 
phe-H), 7.47 (dd, J = 2.5 and 8.0 Hz, phe-H), 7.73 (dd, JA = JB = 2.5 Hz, IH, phe-H), 
8.11 (t, J = 5.0 Hz, 1H, NH), 8.32 (d, J = 5.5 Hz, 1H, pyr-H), 9.34 (bs, lH, NH); ' 3C 
NMR (DMSO-d6): 8 14.95, 19.34, 22.10, 107.32, 112.50, 116.66, 118.44, 120.03, 
122.52, 128.88, 138.12, 141.26, 152.93, 158.29, 159.17, 160.18, 169.09; HRMS 
(FAB+) mlz calcd for C 17H,9N5S 326. 14394, obsd 326.14396. 
4-[4-Methyl-2-(methylamino)- 1,3-thiazol-5-y1] -N-(3-methylphenyl)pyrimidin-2-
amine (III) [191] 






Yield = 40% (yellow solid): mp 239-240 °C; anal. RP-HPLC: tR 15.0 mm (0-60%, 
purity 100%); 'H NMR (DMSO-d6): ö 2.30 (s, 3H, CH3), 2.47 (s, 3H, CH3), 2.86 (d, J 
= 5.0 Hz, 3H, Cl-I3), 6.75 (dd, J = 2.5 and 7.5 Hz, 1H, phe-H), 6.88 (d, J = 5.0 Hz, 
pyr-H), 7.13 (dd, .JA = JB = 7.5 Hz, 1H, phe-H), 7.47 (dd, J = 2.5 and 7.5 Hz, IH, phe-
H), 7.73 (dd, JA = JB = 2.5 Hz, IH, phe-H), 8.05 (q, J = 5.0 Hz, IH, NH), 8.32 (d, J = 
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5.0 Hz, 1H, pyr-H), 9.35 (bs, 1H, NH); ' 3C NMR (DMSO-d6): 8 19.33, 22.07, 31.44, 
107.28, 116.67, 118.75, 120.04, 122.55, 128.88, 138.13, 141.25, 153.01, 158.34, 
159.16, 160.19, 170.04; HRMS (FAB+) m/z calcd for C 16H 17N5S 312.12829, obsd 
312.12809. 
2-Methoxyethyl-(3-{ [4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-
yI]amino}phenyl)acetate (III) [192] 
From (I) [218] (R, = NH2) and (H) [306] (R2 = R 3 = H, R4 = CH2CO2(CH2)2OMe). 
NH2 
(X 
Yield = 5% (orange solid): mp 180-182 °C; anal. RP-HPLC: tR 13.8 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): 8 2.59 (s, 3H, CH3), 3.33 (s, 311, Cl3), 
3.60 (t, J = 4.5 Hz, 2H, Cl2), 3.71 (s, 211, CH2), 4.24 (t, J= 4.5 Hz, 211, CH2), 7.02 
(dd, J = 2.0 and 7.5 Hz, IH, phe-H), 7.06 (d, J = 5.5 Hz, IH, pyr-H), 7.30 (dd, .JA = JB 
= 7.5 Hz, 1H, phe-H), 7.55 (dd, J = 2.0 and 7.5 Hz, IH, phe-H), 7.62 (dd, JA = JB = 
2.0 Hz, 111, phe-H), 8.40 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 8 16.78, 
41.25, 58.74, 64.17, 70.40, 107.90, 115.36, 118.39, 118.51, 120.92, 123.50, 129.16, 
135.28, 140.72, 158.94, 159.22, 159.54, 169.51, 171.83; HRMS (FAB+) ink calcd for 
C, 9H2 ,N503S 400.14434, obsd 400.14439. 
2-Methoxyethyl - [3- ({ 4- [4-methyi-2- (methylamino)-1 ,3-thiazol-5-yl]pyrimidifl-2-
yI}amino)phenyl]acetate (III) [193] 
From (I) [219] (R, = NHMe) and (H) [306] (R 2 = R3 = H, R4 = CH2CO2(CH2)2OMe). 
\ 
NH 
-N JUO o 
Yield = 7% (yellow solid): mp 179-180 °C; anal. RP-HPLC: tR 11.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD30D): ö 2.52 (s, 3H, CH3), 2.97 (s, 3H, CH3), 
3.30 (s, 3H, CH3), 3.58 (t, J = 4.5 Hz, 211, CH2), 3.68 (s, 211, CH2), 4.30 (t, J = 4.5 Hz, 
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2H, CH2), 6.93 (m, 2H, phe-H and pyr-H), 7.24 (dd, JA = JB = 8.0 Hz, 1H, phe-H), 
7.52 (dd, J = 1.5 and 8.0 Hz, I H, phe-H), 7.79 (dd, JA = JB = 1.5 Hz, I H, phe-H), 8.27 
(d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR (DMSO-d6): 8 58.76, 60.46, 64.16, 70.40, 
118.02, 118.64, 122.78, 126.66, 127.77, 129.03, 135.11, 139.10, 141.40, 153.13, 
158.35, 159.20, 160.13, 170.15, 171.05, 171.85; HRMS (FAB+) mlz calcd for 
C20H23N503S 414.15999, obsd 414.15997. 
2-Methoxyethyl - [3- ({ 4- [4-methyl -2- (ethylamino) - 1 ,3-thiazol-5-yl]pyrimidin -2-
yljamino)phenyl]acetate (III) [194] 




Yield = 5% (yellow solid): mp 187-188 °C; anal. RP-HPLC: tR 12.3 mm (0-60% 
MeCN, purity 100%); 'H NMR (CD 30D): 8 1.36 (t, J = 7.0 Hz, 3H, CH 2CH3), 2.61 
(s, 3H, CH3), 3.32 (s, 3H, CH3), 3.49 (q, J = 7.0 Hz, 2H, CH2CH3 ), 3.60 (t, J = 4.5 Hz, 
2H, CH2), 3.71 (s, 2H, CH2), 4.24 (t, J= 4.5 Hz, 2H, CH2), 7.06 (m, 2H, phe-H and 
pyr-H), 7.32 (dd, JA = JB = 8.0 Hz, 1H, phe-H), 7.48 (dd, J = 1.5 and 8.0 Hz, Ill, phe-
H), 7.66 (dd, JA = JB = 1.5 Hz, IH, phe-H), 8.32 (d, J = 5.5 Hz, IH, pyr-H); ' 3C NMR 
(DMSO-d6): ö 14.94, 23.27, 30.27, 43.07, 109.00, 110.43, 114.89, 118.37, 118.79, 
121.31, 129.08, 138.76, 140.52, 140.86, 158.63, 158.84, 158.98, 159.14, 160.04, 
169.80, 170.42; HRMS (FAB+) m/z calcd for C 21 H25N503S 428.17564, obsd 
429.08477. 
General Procedure for Amide Bond Formation 133 
The appropriate pyrimidine precursor {(HI) [17] or (III) [14]} (2 eq, 0.10 mmol) was 
partially solubilised in dry 3:1 DMF/DCM solution (4 mL). 2-Picolinic acid (2 eq) 
was added followed by DMAP (4 eq). The RBF was flushed with argon and EDAC (1 
eq) added (a colour change from yellow to orange was noted) and the RM stirred at 11 
for 3 - 4 h' 33 . Progress of the reaction was monitored by HPLC; when no remaining 
starting material was detected, the RM was poured over H20 (3 mL) and extracted 
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using EtOAc (3 x 3 mL). The organic extracts were combined, washed (sat NaC1), 
dried (MgSO4), filtered and the filtrate evaporated under reduced pressure to yield the 
product as a light brown solid. The purified product was obtained via recrystallisation 
using a 1:1 mixture of MeOHJDCM' 33 . 
N-(4-{[4-(3,4-Dimethyl-2-oxo-2,3-dihydro- 1,3-thiazol-5-yI)pyrimidin-2-
yI]amino}benzylpyridine-2-carboxamide (III) [195] 
From (III) [17] (R, = Thiazolone, R 2 = H, R3 = CH2NHCO-2-pyrid, R4 = H). 
Yield = 7% (pale brown solid): anal. RP-HPLC: tR 16.8 mm (0-60% MeCN, purity 
100%); 'H NMR (DMSO-d6): ö 2.55 (s, 3H, CH3), 3.29 (s, 3H, CH3), 4.44 (d, J = 6.5 
Hz, 2H, CH2), 6.93 (d, J = 5.5 Hz, 1H, pyr-I1), 7.26 (d, J = 9.0 Hz, 2H, phe-H), 7.60 
(dd, J = 5.0 and 7.0 Hz, IH, pyrid-H), 7.66 (d, J = 9.0 Hz, 2H, phe-H), 8.00 (dd, JA = 
JB = 7.0 Hz, IH, pyrid-H), 8.06 (d, J = 7.0 Hz, IH, pyrid-H), 8.40 (d, J = 5.5 Hz, IH, 
pyr-H), 8.65 (d, J = 5.0 Hz, 1H, pyrid-H), 9.23 (t, J = 6.5 Hz, IH, NH); MS (ESI) 
mlz: 433.41 [M+H]. 
N-(3- { [4-(2,4-Dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yI]amino}benzyl)pyridine -2-
carboxamide (III) [196] 




' 	 11 
H 0 
Yield = 24 % (pale brown solid): anal. RP-HPLC: tR 17.8 mm (0-60% MeCN, purity 
100%). 'H NMR (DMSO-d6): ö 2.62 (s, 3H, CH3), 2.63 (s, 3H, CH3), 4.52 (d, J = 6.5 
Hz, 2H, CH2), 6.62 (dd, J = 1.5 and 8.5 Hz, 1H, phe-H), 7.06 (d, J = 5.5 Hz, IH, pyr-
H), 7.25 (dd, .JA = J8 = 8.5 Hz, 1H, phe-H), 7.41 (dd, J = 1.5 and 8.5 Hz, IH, phe-H), 
7.60 (dd, J = 4.5 and 8.0 Hz, 1H, pyrid-H), 7.64 (dd, JA = JB = 8.0 Hz, 11-1, pyrid-H), 
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7.75 (dd, JA = JB = 1.5 Hz, IH, phe-H), 8.06 (d, J = 8.0 Hz, 1H, pyrid-H), 8.48 (d, J = 
5.5 Hz, IH, pyr-H), 8.64 (d, J = 4.5 Hz, 1H, pyrid-II), 9.22 (t, J = 6.5 Hz, IH, NH); 
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